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Abstract 
 
Hepatitis C is a blood borne virus affecting the liver. In the UK, 
approximately 214,000 people are infected with the hepatitis C virus. 
Hepatitis C disproportionally affects marginalised populations and in the UK 
sharing equipment used to inject drugs is the main risk factor for hepatitis C 
infection. Despite there being treatments for hepatitis C, many do not access 
it or indeed get tested, leading to deaths from complications of hepatitis C 
such as end stage liver disease or hepatocarcinoma. 
 
The World Health Organization’s target to eliminate viral hepatitis as a 
major public health threat by 2030, has led to calls for action to increase 
access to hepatitis C testing and treatment. To increase uptake of testing 
and treatment, an understanding of the current barriers to access is 
required. Historically, alcohol and injecting drug use have been barriers to 
receiving treatment. 
 
Alcohol is also regarded as problematic as it expedites the progression of 
hepatitis C. There is however a paucity of research on experiences of alcohol 
use in People Who Inject Drugs (PWID) who have hepatitis C. 
 
The aim of this research was to gain an understanding of the experiences, 
practices and meanings of alcohol for people living with hepatitis C and to 
understand their needs and support requirements. Being qualitative in 
nature, this research took an explorative, inductive approach, allowing 
emerging themes to lead the direction of the research. The starting point 
was observation of hepatitis C support groups and interviews with people 
who have/had hepatitis C (services users, n=21), leading onto interviews 
with professionals (n=12) working in drug, alcohol and hepatitis C services. 
 
A multi-methods approach was used. Service user interviews were life history 
interviews, using a calendar method, and for the interviews with 
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professionals, vignettes about hypothetical services users and semi 
structured interviews were used. 
 
Data were analysed using a combination of approaches. For the interviews 
using the calendar method, the individual calendars were studied to 
ascertain the sequence of events in a participant’s life. More generally, an 
ongoing constant comparative approach occurred throughout the various 
stages of the research and interview transcripts were analysed using 
thematic analysis. 
 
This research has explored alcohol use in PWID who have hepatitis C, 
however the methods employed have afforded wider findings, giving an 
insight into barriers and challenges to hepatitis C support. 
Barriers/challenges were found at service user, service and strategic levels. 
For service users, barriers were to accessing support (incorporating, testing, 
treatment, advice, information and peer support) and for service providers 
and commissioners, challenges were to providing support services for people 
with the hepatitis C virus. Alcohol fits in to this picture as a barrier to support 
from the PWID community, due to the stigma of becoming ‘a drinker’ and as 
an exclusion to receiving hepatitis C treatment. 
 
There is a paucity of qualitative research on alcohol use and hepatitis C in 
PWID. To our knowledge this research is the first study exploring the lived 
experience of alcohol use for PWID who have hepatitis C in England. The 
findings from this study therefore contribute to the current limited body of 
knowledge on this topic. Although on completing this thesis some of the 
findings are out dated as hepatitis C treatment is now being provided out of 
the hospital setting, other barriers to providing and accessing hepatitis C 
support are still relevant. These findings will be of interest to those working 
both in practice and public health policy who are working towards the 
elimination of hepatitis C by 2030.  
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Glossary 
 
AUDIT 
Alcohol Use Disorders Identification Test. 
 
Alcohol dependence 
A cluster of behavioural, cognitive and physiological factors that typically 
include a strong desire to drink alcohol and difficulties in controlling its use. 
Someone who is alcohol-dependent may persist in drinking, despite harmful 
consequences. They will also give alcohol a higher priority than other 
activities and obligations. 
 
BBV 
Blood-borne virus. 
 
Brief intervention 
A technique used to initiate change for an unhealthy or risky lifestyle 
behaviour. 
 
CAGE 
A screening test for problem drinking and potential alcohol problems. 
 
DBS 
Dry blood spot testing. 
 
GUM  
Genitourinary medicine. 
 
Harmful drinking 
A pattern of alcohol consumption that is causing mental or physical damage. 
 
Hazardous drinking 
xii 
 
A pattern of alcohol consumption that increases someone's risk of harm. 
Some would limit this definition to the physical or mental health 
consequences (as in harmful use). Others would include the social 
consequences. The term is currently used by WHO to describe this pattern 
of alcohol consumption. It is not a diagnostic term. 
 
HCV 
Hepatitis C Virus. 
 
Hep C  
Hepatitis C. 
 
Higher-risk drinking 
Regularly consuming over 50 alcohol units per week (adult men) or over 35 
units per week (adult women). 
 
Increasing-risk drinking 
Regularly consuming between 15 and 50 units per week (adult men) or 
between 15 and 35 units per week (adult women). 
 
Lower-risk drinking 
No more than 14 units a week on a regular basis. 
 
NICE 
National Institute for Health and Care Excellence (formerly known as 
National Institute for Clinical Excellence or National Institute for Health and 
Clinical Excellence). 
 
ODN 
Operational Delivery Network.  
 
OST 
Opioid Substitution Therapy (prescribed to reduce heroin use). 
xiii 
 
 
PHE 
Public Health England. 
 
RCGP 
Royal College of General Practitioners. 
 
SIGN 
Scottish Intercollegiate Guidelines Network. 
 
WHO 
World Health Organization. 
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Chapter 1 Introduction 
 
1.1 Introduction 
 
This thesis explores the topic of hepatitis C in the Merseyside region of the 
UK. Hepatitis C is a virus affecting the liver and in the UK the main route of 
transmission is sharing equipment used to inject drugs, therefore the 
population of interest for this research is People Who Inject Drugs (PWID) 
who have hepatitis C. 
 
Despite there being tests and treatments available to diagnose and cure the 
virus, historically hepatitis C has been under diagnosed and undertreated, 
meaning many who live with the virus risk further liver deterioration over 
time. Whilst living with the virus, people are advised to ‘look after their 
livers’. Alcohol and hepatitis C together are considered a double insult to 
the liver as alcohol can expedite the progression of hepatitis C, therefore 
people are advised to consider their level of alcohol consumption. There is 
however a paucity of research on alcohol use among PWID who have 
hepatitis C. This research used qualitative methods to explore this topic 
with a view to informing services of service users’ needs. The research 
identified barriers (and to a lesser degree, facilitators) to PWID receiving 
hepatitis C support. 
 
1.2 Background to the hepatitis C virus 
 
Discovered in 1989, hepatitis C is a virus predominantly affecting the liver. 
Known as the ‘silent epidemic’, hepatitis C is largely asymptomatic, 
meaning many individuals who have the virus do not know they are infected 
(Hawkes, 2013). Approximately 20% of people exposed to hepatitis C will 
spontaneously clear the virus within the first 6 months after transmission 
(Hepatitis C Trust, 2017a) however others will go onto develop chronic 
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hepatitis C. In this chronic phase individuals can remain asymptomatic for 
many years (Department of Health, 2002; Athwal and Prince, 2017) or have 
symptoms that are nonspecific and are thought to be other illnesses such 
as influenza, fatigue, insomnia, gastrointestinal symptoms, poor 
concentration (“brain fog”) and pain (Athwal and Prince, 2017; Hepatitis C 
Trust, 2017c; World Health Organization (WHO), 2017b). Some people with 
hepatitis C remain undiagnosed until they present late to healthcare 
services with complications such as cirrhosis, end stage liver disease or 
hepatocarcinoma, (Lancet, 2013; Athwal and Prince, 2017) which have high 
mortality rates (Public Health England (PHE), 2017d). 
 
Prior to 1989 hepatitis C was known as ‘non A non B hepatitis’ and since 
that time further learning about the virus has discovered there are 6 major 
genetic variations, named genotype 1-6. The virus is further differentiated 
by subtypes such as genotype 1a and 1b. Different countries have different 
predominant genotypes and in the UK the majority of hepatitis C is 
genotype 1 and 3. It is possible to be infected with more than one genotype 
of the virus at the same time and treatment choices differ based on the 
genotype (Hepatitis C Trust, 2017a). 
 
Hepatitis C is a blood borne virus (BBV), meaning transmission is through 
blood to blood contact with a person who has the hepatitis C virus. 
Approximately 90% (92.3% Department of Health, 2002; 91.1% between 
1992-2002, Department of Health, 2004; 92% PHE, 2017e) of hepatitis C 
cases in England are transmitted through sharing injecting drug 
paraphernalia (equipment used in preparing and administering drugs for 
injection, such as needles, syringes, filters and spoons). Therefore in 
England sharing injecting drug equipment is the biggest risk factor for 
transmission of hepatitis C, and hepatitis C is the most common blood-borne 
infection among PWID (PHE, 2017e). 
 
Worldwide other common routes of transmission include reusing un-
sterilised medical/dental equipment and transfusions of unscreened blood 
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and blood products (WHO, 2017). Since September 1991 blood and blood 
products have been screened for hepatitis C in the UK, and UK healthcare 
standards stipulate sterilisation or single use of medical/dental equipment. 
Other routes of transmission include sharing razors or toothbrushes with 
someone who has the virus, tattooing, piercing, acupuncture, electrolysis, 
clippers, razors, scissors where equipment is unsterile, needlestick injury 
amongst healthcare staff, sharing straws or rolled notes for snorting drugs 
such as cocaine, vertical transmission (from mother to baby during birth – 
3% risk of transmission) (Athwal and Prince, 2017) and sexual transmission 
(2% risk of transmission), (Athwal and Prince, 2017) by having sex with 
someone who has the virus and where exposure to blood occurs (NHS 
Choices, 2018; Hepatitis C Trust 2017b; WHO, 2017b). 
 
Over recent years, hepatitis has attracted global attention, seeing the WHO 
produce the first estimates of prevalence both globally and regionally and 
developing a Global Health Sector Strategy (GHSS) to reduce infections 
(WHO, 2016; WHO, 2017a). WHO (2017a) estimated in 2015 there was a 
similar number of deaths from viral hepatitis (1.34 million) as tuberculosis 
(1.37 million), and a higher number of deaths than HIV (1.06 million) and 
malaria (0.44 million). Of the viral hepatitis deaths, the majority (96%) 
were due to hepatitis C and hepatitis B (WHO, 2017a). Furthermore an 
estimated 71 million people worldwide (1% of global population) were living 
with chronic hepatitis C in 2015, with 1.75 million new infections that year 
(WHO, 2017a). However, within the WHO European Region, a higher 
prevalence of 1.5% of the population was estimated (14 million people), 
with 565,000 new infections (WHO, 2017a). 
 
In the UK, liver disease is currently the third most common cause of 
premature death (Williams et al, 2014). Whereas mortality from other 
diseases (diabetes, cancer, respiratory, road, heart, stroke) has decreased 
over the last few decades, death rates from liver disease are increasing. 
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In addition to this, the Chief Medical Officer for England noted, “liver 
disease…is the only major cause of mortality and morbidity which is on the 
increase in England whilst decreasing among our European neighbours” 
(Davies, 2012, p. 11). These deaths are largely preventable, as the main 
contributors are lifestyle factors; harmful alcohol consumption, obesity 
(causing non-alcoholic fatty liver disease) and viral hepatitis (hepatitis B 
and C) (Royal College of Nursing, 2015; PHE, 2017f). Furthermore, of the 
liver diseases, hepatitis C related deaths are rising the fastest (Hepatitis C 
Trust, 2013b), seeing deaths from liver disease attributed to hepatitis C 
double between 2008 to 2014 (PHE, 2016b). 
 
It is estimated that there are approximately 214,000 people living with 
hepatitis C in the UK (PHE, 2015). Monitoring is conducted yearly in the 
PWID population of the UK, finding, a prevalence of antibodies to the 
hepatitis C virus in 53% of survey participants from England, Wales and 
Northern Ireland in 2016. By individual country, prevalence was 52% for 
Wales, 22% Northern Ireland and 54% England (PHE, 2017g). Scotland’s 
prevalence was at 58% for 2015-2016 (Health Protection Scotland, 2017). 
Within England, the prevalence of hepatitis C among PWID varies between 
regions, with prevalence in 2016 ranging from 39% in the West Midlands to 
67% in the North West (PHE, 2017a). Figures from 2016 showed that 
prevalence amongst PWID in the North West is consistently higher than 
England overall (PHE, 2018b). Within the North West there is variation in 
prevalence. 2013 figures showed prevalence of hepatitis C in PWID at over 
60% in Liverpool and Sefton, two local authority areas of Merseyside (PHE, 
2013). 
 
Admissions to hospital due to end stage liver disease in Liverpool (as well 
as Rochdale and Manchester) are higher than the average admission rates 
for England and the rest of the North West (PHE, 2016a) and deaths from 
liver disease attributed to hepatitis C are highest in the North West and 
London. 
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These statistics show hepatitis C to be a significant health concern within 
the Merseyside region of the UK, justifying the need for research within this 
region. 
 
1.3 Explanation of terms used in this thesis 
 
This section explains the key terms used in this thesis, with the intention 
to bring clarity to the topics discussed and interpretation of findings but 
also in recognition that ‘language shapes beliefs and may influence 
behaviours’ (UNAIDS, 2015, p.3). 
 
People who inject drugs is the preferred terminology for people who inject 
psychoactive drugs (such as heroin or crack cocaine) into veins (UNAIDS, 
2015; PHE, 2017e). Terms such as injecting drug users (IDU) and intravenous 
drug users (IVDU) are now defunct in favour of ‘people who inject drugs’ as 
it places the emphasis on people and not the behaviour (UNAIDS, 2015). 
UNAIDS (2015) also suggest abbreviations should not be used as they are 
dehumanising. Whilst this research is in full agreement with this view, as it 
has a research philosophy that aims to challenge traditional power dynamics 
and views people who inject drugs as the experts in this research, the 
acronym PWID has been used for ease of reading and in keeping with current 
academic literature and UK Government reports. However the term PWID 
requires clarification. Do we mean people who are currently injecting, have 
recently injected or have injected at some point in their life but have 
stopped? Furthermore what time frame is classed as current or recent 
injecting? ‘Lifetime PWID’ (people who have injected at some point in their 
life) is another term used in the literature, however it requires further 
explanation as to whether this refers to those who have stopped injecting 
or those who currently inject. Unfortunately criteria of ‘PWID’ in studies 
and reports is not always specified (Larney et al, 2015). For this research 
the term PWID is used to mean both people who were injecting at the time 
of the research and people who had stopped injecting but had injected at 
some point in their life. The reason for this criteria was that this research’s 
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focus was predominantly on experiences of living with hepatitis C and not 
a focus on injecting behaviour. 
 
The term ‘service user’ is used as a general term throughout discussions in 
this research, referring to people who attend drug, alcohol or hepatitis C 
services. Whilst this includes PWID who have hepatitis C, it may also include 
people attending drug and alcohol services who do not have hepatitis C, or 
people attending for help with non-injectable drugs such as cannabis or 
cocaine. However ‘service user’ interviews were conducted in this research 
(see Chapter 3 for service user interviews method and Chapter 5 findings). 
In this context ‘service users’ refers to people who met the inclusion 
criteria of the research, which was PWID who have hepatitis C. Interviews 
were also conducted with ‘professionals’ which for this research meant 
people who have a professional interest in the topics of the research, thus 
they work in drug, alcohol and/or hepatitis C services. Although some 
people who work in these services may also have hepatitis C and or personal 
experiences of drug and/or alcohol use, it is their professional experience 
that is explored in the ‘interviews with professionals’, as opposed to the 
lived experience which is explored in the service user interviews. It is 
important to note that whilst the term ’professional’ suggests a qualified 
and therefore not amateur understanding of alcohol, drugs and hepatitis C, 
the term is not intended to place the views of those working in services 
above those who use services, as it is the service users that are viewed as 
the experts in this research, which ultimately seeks to understand their 
experiences in order to inform services. 
 
Participants in the service user interviews were PWID who ‘have hepatitis 
C’. The term ‘have hepatitis C’ included people who had hepatitis C at the 
time of the interviews and people who previously had hepatitis C, thus they 
had the virus at some point in their lives. Previous infection includes people 
who had cleared the virus via treatment, or who had spontaneously cleared 
the virus. People with either current or previous hepatitis C infections were 
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included in the interviews as both experiences of hepatitis C were of 
interest in this study. 
 
Throughout the thesis, the term ‘support’ is used. This term is used in a 
general sense and for people with hepatitis C this support could include: 
advice, information, getting tested, being referred to a hepatitis C 
specialist, management of their hepatitis C virus, receiving hepatitis C 
treatment and receiving peer support. 
 
Language on alcohol use is inconsistent throughout the literature, with 
researchers using terms such as ‘heavy drinkers’, ‘high risk drinkers’, 
‘alcohol excess’, ‘problem drinkers’ ‘addicted’ to describe people who 
drink above government recommendations. Often explanations are 
provided on the amount of alcohol the used terminology refers to, but this 
is not always the case, making findings and comparisons between studies 
difficult to interpret. The preferred terminology of use in this thesis is in 
line with the National Institute for Health and Care Excellence (NICE, 
2010b) and the Department of Health’s Chief Medical Officers 
recommendations (Department of Health, 2016) (see glossary for definition 
of terms). 
 
1.4 What is not covered in this research 
 
Prevention of hepatitis C, along with increasing testing and treatment, is a 
key area of focus to reach the WHO (2016) target of eliminating viral 
hepatitis as a public health threat (defined as achieving a 90% reduction in 
new chronic infections and a 65% reduction in mortality) before 2030. Whist 
understanding the importance of preventing new infections, this thesis does 
not focus on hepatitis C prevention, but rather focuses on those who have 
the virus. 
 
Due to the route of transmission for hepatitis C, PWID are at risk of 
contracting other blood borne viruses such as hepatitis B and HIV. Being co-
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infected with these other viruses as well as hepatitis C, complicates 
management of the hepatitis C virus and increases the risk of cirrhosis and 
hepatocarcinoma (Lim, 2001). Whilst research into co-infection is 
important, this research focuses on hepatitis C only, as it is possible that 
the lived experience of having co-infections will be different to that of 
having hepatitis C alone. 
 
1.5 Personal reasons for doing this research 
 
My reasons for undertaking this PhD have come from a professional not 
personal position, thus it is my career in health that has driven me to pursue 
this topic and not one of personal experience of myself, friends or family 
having hepatitis C. I qualified as a nurse 18 years ago and have continued 
to work as a nurse on a part time basis throughout the course of this PhD. 
My current role is a clinical research nurse, which has led to my decision to 
conduct my own research and to undertake a PhD. 
 
By definition of being ‘a nurse’, my interests lie in health and helping 
people who are sick or injured. Although I have not worked specifically in 
drug, alcohol or hepatitis services, I have worked in acute settings (an 
accident and emergency department and Glastonbury Music Festival) with 
people who have taken or are withdrawing from alcohol and/or drugs and 
on general hospital wards where there has been patients with a variety of 
health issues including for some patients alcohol and/or drug dependencies. 
I have also worked on a research studies that considered whether genetics 
impacted on the amount of methadone (opioid substitution therapy (OST)) 
a person required. This involved attending drug services to recruit 
participants (people on methadone) onto the research. I also have a long 
term professional interest in infectious diseases, leading me to study 
tropical medicine and work in South Sudan where the majority of the work 
was to prevent or treat infectious diseases. 
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Outside of nursing, I have previously volunteered for a local Merseyside HIV 
charity. My role there, was not to work as a nurse but to provide support 
such as gardening or driving people to hospital appointments. From this 
volunteering, I learnt some of the ‘social’ issues rather than the ‘medical’ 
issues, of living with HIV, a disease that like hepatitis C, is highly 
stigmatised. Clearly this volunteering experience has also influenced my 
choice of PhD topic. 
 
1.6 Capturing the lived experience 
 
This research considers the lived experience of people who have hepatitis 
C. ‘Lived experience’ refers to understanding the experience of a 
phenomenon from those who have lived it, exploring not only the 
experience but also how people respond, live through and perceive the 
experience (Given, 2008). As someone who does not have first-hand 
experience of hepatitis C, it was important for me to attempt to capture 
the experiences of those with the virus, in order to access their knowledge 
of living with the disease and gain an understanding of issues they faced. 
Capturing the lived experience of service users is valuable as it aims to seek 
understanding of a topic from the service users point of view, which could 
be of value to those working at all levels within that field, such as 
researchers, policy makers, commissioners and front line staff. The 
Department of Health and National Institute of Health Research value the 
lived experience and recommend the involvement of service users, patients 
and public in health research. Patient and public involvement (PPI) differs 
from ‘participation’ in research. ‘Involvement’ refers to patients, service 
users and the public being involved in every step of the research process 
including the design, management, conduct and dissemination of the 
research (Health Research Authority, 2017; National Institute for Health 
Research, 2019). Thus “research being carried out ‘with’ or ‘by’ members 
of the public rather than ‘to’, ‘about’ or ‘for’ them” (National Institute of 
Health Research, 2019).  
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The original vision for the research undertaken in this thesis was to have 
service user involvement throughout the research. Service user involvement 
occurred to some degree but proved to be challenging and is discussed in 
more detailed in section 3.5.3. Despite service user involvement being to a 
lesser degree than hoped, the lived experience of people with hepatitis C 
was explored in depth. Also in contrast to capturing the lived experience of 
service users, the ‘professional experiences’ of people working in the field 
of drug, alcohol and hepatitis C were obtained. Their professional 
experiences of working within services as opposed to their personal 
experiences and views was captured and provided data to compare and 
contrast with the lived experiences of services users. 
 
1.7 Conceptual Framework 
 
A conceptual framework has been developed for this research (Figure 1). 
This framework was informed by existing research and my own experiences 
and knowledge prior to data collection. The framework provides a visual 
representation of the key concepts with further points discussed in more 
detail in the literature review Chapter 2. 
 
1.7.1 Experiential knowledge  
 
From my nursing and volunteering experiences I have gained an awareness 
of some of the difficulties that people with infectious diseases and/or drug 
and alcohol use face when accessing and receiving healthcare. One such 
issue is stigmatisation and discrimination.  
 
I have heard accounts from people who are HIV positive about their 
experiences of discrimination from healthcare staff, such as staff wearing 
two pairs of gloves when they would wear one pair to see patients without 
HIV. These experiences led to ongoing fear and reluctance when seeking 
healthcare in the future. 
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I have also unfortunately witnessed staff expressing negative attitudes 
towards patients who use alcohol or drugs. Terminology such as ‘druggies’ 
or ‘junkies’ was used to discuss patients who used drugs and some staff 
would also expect patients to act in a certain way because they used drugs, 
such as noncompliance with medical advice. This grouping together of 
people based on lifestyle behaviours rather than treating patients as 
individuals is stereotyping and discriminatory. Similar experiences of 
stigmatisation and discrimination in healthcare are also evident in the 
existing literature on hepatitis C. 
 
1.7.2 Existing theory 
 
There are many theories that could be discussed in relation to this thesis, 
such as models of addiction, behavioural change models, theories on how 
people perceive and manage risk, theories on access to health care, 
theoretical approaches to stigma and so on, however as the population 
being studied, PWID with hepatitis C, are generally a hard to reach group it 
is not known if these theories are helpful as their efficacy has not been 
ascertained for this population group. Neale (1997) argues the case for 
reconsidering theory in homelessness. Although she discusses homelessness 
and not PWID who have hepatitis C, there is overlap between the groups as 
both populations are largely marginalised and hard to reach. She suggests 
theories (feminism, post structuralism, postmodernism, critical theory) are 
somewhat incompatible and instead draws upon a range of theoretical 
perspectives to conclude with eight theoretical assumptions, many of which 
are relevant to the population considered in this thesis. Two notable 
assumptions are ‘the differences between homeless individuals are multiple 
and are not adequately explained by theory’ and ‘shared experiences of, 
and beliefs about, homelessness, are nevertheless common’. These points 
can be related to PWID who have hepatitis C as although sometimes ‘tarred 
with the same brush’ people with hepatitis C are not a homogeneous group 
but are individuals with different experiences and outcomes. 
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As this research does not conform to any particular theory but is pragmatic 
in its approach to exploring the topic, a generic qualitative approach is 
used. This approach gives methodological flexibility, allowing choice of 
methods which are best placed to explore the perspectives of participants 
and the topics under consideration (Cooper and Endacott, 2007; Kahlke, 
2014). Innovative methods of calendar and vignettes interviews were used. 
Calendars were used with service users as a visual aid to assist with their 
narratives of alcohol/drug use and hepatitis C and vignettes with staff to 
seek their professional actions rather than personal views on services 
provided. Further to this semi structured interviews were conducted with 
public health commissioners to explore the system factors involved. 
 
1.7.3 Existing empirical research 
 
The existing research shows that little is currently known about the lived 
experience of alcohol and hepatitis C in PWID as there is a paucity of 
qualitative research on this topic. There has been one study (Harris, 2010) 
conducted in Australia and New Zealand which found people drank for a 
variety of reasons but negative judgments could cause people with hepatitis 
C to hide their drinking, become isolated, and limit their opportunities for 
receiving appropriate medical care.  
 
Other barriers to accessing care were evident throughout the literature. 
Barriers were found to getting tested, linking into hepatitis C specialists 
and getting treated as well as barriers to getting support from peers. 
Drinking alcohol (at certain levels) was also a barrier to receiving hepatitis 
C treatment.  
 
The literature also identified facilitators to accessing care, such as having 
engaged, trusted and knowledgeable staff and the importance of a good 
patient /staff relationship. Furthermore, there were system factors which 
impacted on accessing (and providing) care, such as having a pathway to 
link into specialist hepatitis C care.  
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Further discussion of the existing literature is in Chapter 2. 
 
Figure 1 Conceptual framework 
 
 
1.8 Organisation of the thesis 
 
This thesis consists of eight chapters. Chapter 2 is a review of the literature, 
analysing previous research conducted and providing background to the 
topics explored in this thesis. Chapter 3 is the methodology, explaining the 
aims of the research, the theoretical perspectives, the researcher’s 
philosophy underpinning the research, methods used and analytic 
approach. Methods employed were participant observation of hepatitis C 
support groups, life history interviews using a calendar approach with 
service users and semi structured interviews (including the use of vignettes 
of hypothetical service users) with people working in the field of drug, 
alcohol and/or hepatitis C. For the observation, the method as well as the 
researchers role within this method are discussed. For the interviews, the 
design and application of the calendar and vignettes are explained and 
analysed. Chapters 4 to 6 present the research findings. Chapter 4 discusses 
the findings from the period of observation, Chapter 5 presents the service 
user interview findings, and Chapter 6, the findings from the interviews 
with professionals. Chapter 7 is the discussion chapter, comparing and 
contrasting the results from Chapters 4 to 6.Chapter 8, the final chapter, is 
the conclusion, consisting of a summary of the main findings, the strengths 
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and limitations of the research, the contribution to knowledge and future 
recommendations. 
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Chapter 2 Literature review 
 
2.1 Introduction 
 
This chapter presents background information and analysis of the current 
literature on hepatitis C support namely, testing, linkage to specialist 
hepatitis C care, hepatitis C treatment, and peer support. It also reviews 
the literature on alcohol use for PWID who have hepatitis C and stigma, two 
issues that can affect people living with hepatitis C, and affect access to 
support. 
 
2.2 Diagnosis, treatment and linkage to specialist hepatitis C care 
 
Historically, statistics about hepatitis C presented a gloomy picture. 
Approximately 50% of those with hepatitis C in England knew they had the 
virus (PHE, 2014a) and of those diagnosed, only 3% received treatment 
(PHE, 2014b). Thus approximately half of people with chronic hepatitis C 
were aware of their diagnosis but the majority did not access treatment. 
Furthermore of those who did access treatment, few cleared the virus (see 
Section 2.2.2). A similar picture was seen across the whole UK (PHE, 2014b), 
consequently, the UK deaths of hepatitis C related end stage liver disease 
and hepatocarcinoma rose year on year, with 98 deaths in 1996 rising to 
428 deaths in 2012 (PHE, 2014b). However 2015 saw an upturn, with the 
first decrease in deaths from hepatitis C in the UK in over a decade (PHE, 
2016b); a trend continuing in 2016 (PHE, 2017d). This reduction in hepatitis 
C related mortality is thought to be due to the increasing availability of new 
treatments, known as Direct-Acting Antiviral (DAA) drugs (PHE, 2017d; PHE, 
2017e). This is discussed in more detail in Section 2.2.2.  
 
2.2.1 Diagnosis 
 
Hepatitis C testing is a two stage process. Firstly a simple, fast and 
relatively inexpensive (Carlson, 2005; Jefferys, 2017) antibody test is 
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conducted. If antibodies to the hepatitis C virus are present, this indicates 
the person has been infected with hepatitis C at some point in their life. As 
around 20% of people exposed to hepatitis C can spontaneously clear the 
virus (within the first 6 months of being exposed to the virus), the presence 
of antibodies therefore does not necessarily indicate a current infection, 
requiring a second (more expensive) test (Carlson, 2005; Jefferys, 2017) to 
be conducted. This second test is known as HCV (hepatitis C) RNA test or 
PCR (polymerase chain reaction) test and confirms if the infection is 
current, the amount of virus in the blood (viral load) and establishes which 
genotype of the hepatitis C virus is present (National Institute for Health 
and Care Excellence (NICE), 2016b; Hepatitis C Trust, 2017d). 
 
After exposure to the hepatitis C virus, it takes between 6 and 12 weeks for 
the immune system to produce the antibodies to the virus. However for 
some people it could take as long as 6 months (Hepatitis C Trust, 2017d). 
This time frame is known as the ‘window period’ and if antibody testing is 
conducted within this window period it is possible for the person to have 
the virus but get a negative result. Those testing negative for the antibody 
test (conducted at the correct time, thus outside of the window period) do 
not require the second (PCR) test, saving the person being called back for 
a second sample, and reducing costs by only conducting PCR testing on 
those who require it. 
 
Whilst some services do conduct the antibody test and then if necessary 
recommend attending for the second test, Hepatitis C Trust and NICE 
suggest that the two tests could be taken at the same time reducing the 
number of times blood samples are required (NICE 2016c; Hepatitis C Trust, 
2017d). Further guidance on testing is provided by NICE (NICE, 2012c) who 
recommend that hepatitis C (and B) testing is offered to all service users 
attending drug services and that drug services have access to Dried Blood 
Spot testing (DBS) (finger prick test for antibodies) for those who have 
difficult venous access. A further recommendation is for drug services to 
have access to specialist phlebotomy services, with view to enabling 
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hepatitis C treatment to be provided in the community (NICE, 2012c), 
thereby reducing the need to attend secondary care for the second test 
(PCR test) and treatment. 
 
Further recommendations concern staff at drug services, requiring them to 
have the skills and knowledge to promote testing and treatment for 
hepatitis C (and hepatitis B) and also to ensure they are trained and 
competent in performing the DBS test as well as pre and post-test 
discussions (NICE, 2012c). 
 
To note, generally discussions on ‘testing’ and figures on hepatitis C testing 
in PWID, in reports and literature, are related to the antibody test; 
throughout this thesis ‘testing’ is used to mean the antibody test unless 
otherwise stated. 
 
An annual survey, known as the voluntary Unlinked Anonymous Monitoring 
(UAM) survey, is conducted with PWID attending specialist agencies 
(agencies providing a range of services to those who inject illicit drugs, 
from medical treatment to needle and syringe programmes and outreach 
work) in England and Northern Ireland. Amongst the data reported, is the 
prevalence of hepatitis C, as well as the number and proportion (of PWID 
taking survey) who are aware of their positive hepatitis C status. The 
proportion of PWID in England that are aware of their hepatitis C antibody 
positive status has remained relatively stable over the years. In 2003, 47% 
were aware of their hepatitis C positive status (PHE, 2014a), 52% in 2005, 
55% in 2010 and 53% in 2015 (PHE, 2017b). 2016 figures showed that across 
England, Northern Ireland and Wales, 52% of PWID with hepatitis C were 
aware of their positive status (PHE 2017e). Thus roughly half of the people 
surveyed were aware that they have hepatitis C, which evidently means 
half were unaware they have the virus. Furthermore of those that were 
unaware of their positive status, many reported they had never been tested 
or had not received a test recently. 22% said they had never received a test 
and of those tested 44% said their last test was over 2 years ago (PHE, 
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2017e). Retesting is recommended once or twice a year when the risk of 
exposure continues (such as continued sharing of injecting equipment) (NICE 
2012a b or c; Scottish Intercollegiate Guidelines Network (SIGN), 2013; NICE, 
2016c; PHE, 2017e), indicating current testing is insufficient. However, 
amongst PWID that are in treatment for their drug use, there has been an 
increase in hepatitis C testing, from 53% in 2010 to 65% in 2016 (PHE, 2017e). 
Further data on hepatitis C testing in PWID, showed at the start of treatment 
for drug use, 96% were offered a hepatitis C test, however only 67% of PWID 
accepted the offer.  
 
There are a number of studies researching why uptake of testing is low 
amongst PWID (Craine et al, 2004; Khaw, Stobbart and Murtagh, 2007; 
Harris, McDonald and Rhodes, 2014). Considering the UK based studies, 
reasons for low test acceptance include: fear and lack of knowledge on 
hepatitis C, (Craine et al, 2004; Khaw, Stobbart and Murtagh, 2007; Harris, 
McDonald and Rhodes, 2014)) including lack of awareness of disease 
progression and treatment available (Khaw, Stobbart and Murtagh, 2007); 
concerns about the testing procedure including phlebotomy (Craine et al 
2004; Khaw, Stobbart and Murtagh, 2007; Harris, McDonald and Rhodes, 
2014); inadequate pre- and post-test discussions (Craine et al, 2004; Khaw, 
Stobbart and Murtagh, 2007); thinking testing is unnecessary as not at risk 
of having hepatitis C (Craine et al, 2004; Harris, McDonald and Rhodes, 
2014) and concerns around institutional stigma and confidentiality (Khaw, 
Stobbart and Murtagh, 2007), especially in hospitals (Harris, McDonald and 
Rhodes, 2014). People feared breaches of confidentiality regarding their 
positive hepatitis C status, and were fearful of potential discrimination due 
to this diagnosis (PHE, 2017e). 
 
Considering literature from other countries, (mainly Australia and USA) 
(Aitken, Kerger and Crofts, 2002; Day et al, 2008; Lally et al, 2008; Strauss 
et al, 2008; Swan et al, 2010) found the same barriers as the UK, but also 
found other barriers, namely: lack of knowledge on location of testing 
centres (Strauss et al, 2008; Swan et al, 2010) and lack of accessible testing 
(Lally et al, 2008); having not considered testing for hepatitis C (Aitken, 
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Kerger and Crofts, 2002); hepatitis C not thought to be worth worrying 
about (Aitken, Kerger and Crofts, 2002; Swan et al, 2010); feeling well 
(Swan et al, 2010); fear of investigations (Swan et al, 2010); difficulty 
keeping appointments (Day et al, 2008); prioritisation of obtaining/taking 
drugs (Lally et al, 2008) and doubt over healthcare staffs’ knowledge of 
hepatitis C (Swan et al, 2010). 
 
The literature also noted some facilitators to getting tested. Service users 
at drug treatment centres noted that support from staff facilitated testing. 
Explaining the importance of being tested and helping service users to 
understand and cope with test results were seen as supportive measures. 
(Strauss et al, 2008). Lally et al (2008) found a personal facilitator to getting 
tested, which was an interest from service users to improve their own 
health. 
 
Whilst the new DAA treatments are providing opportunities to reduce 
hepatitis C morbidity and mortality, these opportunities are limited if rates 
of diagnosis are not improved, requiring efforts to increase the offer and 
uptake of hepatitis C testing (PHE, 2017d; PHE, 2017e). 
 
2.2.2 Treatment 
 
The aim of treatment for hepatitis C is to ‘cure’ the virus, defined as an 
undetectable level of the virus (HCV RNA) in the blood and known as 
sustained virologic response (SVR) (Pearlman and Traub, 2011). Hepatitis C 
treatments have evolved over the years since the virus was first discovered. 
Initially chronic hepatitis C was treated with interferon alpha, achieving 
SVR rates between 6% and 19% (McHutchinson et al, 1998; Poynard et al 
1998; Manns et al, 2001). Then in the late 1990’s there was ‘a major 
breakthrough for treating HCV’ (Franciscus, 2017, p.3) as ribavarin (tablets) 
were introduced and given in combination with interferon alpha, increasing 
SVR rates to between 38% and 52% (McHutchinson et al, 1998; Poynard et al 
1998; Mannes et al 2001; McHutchinson et al, 2002; Manns et al, 2001). 
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A further development in early 2000s saw the introduction of pegylated 
interferon (NICE, 2004). As interferon alpha is metabolised rapidly in the 
body, the virus could multiply between the thrice weekly injections. 
Pegylation (attaching a molecule chain to the interferon) meant interferon 
was metabolised at a slower rate in the body, enabling drug levels to remain 
more constant and therefore be more effective at treating the virus. This 
also meant pegylated interferon injections were not required as frequently 
as the interferon alpha injections, requiring weekly administration only 
(Hepatitis C Trust, 2018a). 
 
Until recently, ribavirin and pegylated interferon taken for 24 or 48 weeks 
(depending on genotype) have been the standard treatment for hepatitis C 
(European Association for the Study of the Liver, 2011; Burstow et al, 2017). 
These treatments saw a SVR rate of 80% for genotype 2,3,5 and 6, a lower 
SVR rate for genotype 4 and the lowest SVR rate of approximately 40% for 
genotype 1 (the main genotype worldwide) (Burstow et al, 2017). In 2012, 
NICE (2012a; 2012b) approved two further medications (boceprevir and 
telaprevir) for adults with genotype 1 who had compensated liver disease 
(earlier stages of liver disease where the liver is still able to perform most 
of its functions and people do not experience symptoms) (Thornton, 2016; 
Hepatitis C Trust, 2018b). The addition of either boceprevir or telaprevir to 
ribavirin and pegalyted interferon saw SVR rates improve to between 64% 
and 75% (Burstow et al, 2017). It is worth noting that boceprevir and 
telaprevir, are no longer used in the UK (as newer DAAs have a shorter 
treatment duration, achieve better SVR and have less side effects; see 
Section 2.2.2.1) (NICE, 2012a and 2012b). 
 
Despite treatments being available to cure hepatitis C, in 2014 only 3% of 
people diagnosed with hepatitis C in England accessed treatment (PHE, 
2014b). Uptake of treatment is not only a concern for England, but a topic 
of international concern, with the majority of research to ascertain the 
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reasons for the low uptake of treatment being conducted in the USA and 
Australia. 
The majority of research considered found fear of side effects 
(physiological and psychological) to hepatitis C treatment to be a barrier to 
starting treatment (Doab, Treloar and Dore, 2005; Grebely et al, 2008; Swan 
et al, 2010; Jordan et al, 2013; Mravčík et al, 2013; Treloar et al, 2014a; 
Lewis et al, 2016). Side effects reported for interferon based treatments 
include: flu-like symptoms such as fatigue, headache and pyrexia; 
gastrointestinal symptoms including nausea, vomiting, constipation, 
diarrhoea; loss of appetite and weight loss; anaemia; rashes and itchy skin; 
insomnia and depression (NICE, 2010c; NHS Choices, 2015). 
Other commonly noted barriers were concerns over the efficacy of the 
treatment (Mravčík et al, 2013; Treloar et al 2014a), the length of 
treatment (Jordan et al, 2013) and not having symptoms from the hepatitis 
C (Doab, Treloar and Dore, 2005; 
 et al 2008; Treloar et al 2014a). In Jordan et al’s (2013) study there was a 
common perception amongst participants that the treatment was worse 
than the disease itself. This was echoed by participants in Treloar et al’s 
(2014a) study, who felt they would only have treatment when they were 
unwell enough from the hepatitis C, and as one participant (Gary) 
explained, hepatitis C treatment would be the ‘last step to take’. Other 
barriers included: not wanting a liver biopsy (Doab, Treloar and Dore, 
2005); fear of needles (blood tests/interferon) after stopping injecting drug 
use (Swan et al, 2010); a lack of knowledge about hepatitis C (Grebely et 
al, 2008) and lack of knowledge of availability of treatment (Grebely et al, 
2008; Jordan et al, 2013). Studies also found participants had competing 
priorities, such as other health concerns, (Doab, Treloar and Dore, 2005), 
family responsibilities, unstable housing (Treloar et al, 2014a), addiction, 
education (Swan et al, 2010), employment (Swan et al 2010; Treloar et al, 
2014a), as well as an overall sense that hepatitis C was not a priority in 
their lives at the current time (Treloar et al, 2014a). 
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Employment affected participants in many ways, including difficulty 
keeping clinic appointments (Swan et al, 2010), fear of reduced income 
from being unable to work whilst on treatment (Swan et al 2010; Treloar et 
al, 2014a), and a reticence to discuss sick pay in fear of the response to 
disclosing hepatitis C status (Treloar et al, 2014a).The later demonstrates 
another barrier for people with hepatitis C: reluctance to disclose a positive 
status, due to fear of discrimination and stigma of the virus (Hopwood, 
Nakamura and Treloar, 2010). 
 
Some participants in the studies had tried to access treatment but had been 
declined. The main reasons for this were: that their liver disease was not 
advanced enough to receive treatment (Doab, Treloar and Dore 2005; 
Jordan et al, 2013); there were long waiting lists for treatment (Doab, 
Treloar and Dore, 2005); treatment providers’ concerns of the 
complications due to comorbidities; risk of reinfection post treatment 
(Harris and Rhodes, 2013a); injecting drug use (Doab, Treloar and Dore 
2005; Jordan et al, 2013), adherence to treatment and ‘heavy’ alcohol use 
(Doab, Treloar and Dore, 2005, Harris and Rhodes, 2013a). There is however 
evidence to suggest that drinking may not affect interferon treatment. A 
study in France considered interferon based treatment with a population of 
‘alcohol dependent patients with ongoing abuse’. Analysis showed SVR rates 
of 48% versus 49% in control group (lower-risk drinkers) (Le Lan et al, 2012). 
 
Relationships with healthcare providers also influenced participants’ access 
and engagement with treatment (Swan et al, 2010; Jordan et al 2013, 
Treloar et al, 2014a). Participants expressed a lack of trust and confidence 
in healthcare providers motivations and knowledge (Swan et al, 2010; 
Jordan et al 2013). A study conducted in the USA found participants felt 
that healthcare providers dissuaded them from pursuing treatment and felt 
the lack of effective treatment choices was due to the marginalisation and 
stigmatisation of PWID (Jordan et al, 2013). Stigma and discrimination as a 
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barrier to hepatitis C support is discussed further in Section 4.2.6 and 
5.2.3.3. 
 
A study in Australia interviewed staff and clients at opioid substitution 
clinics and considered factors that facilitated engagement with hepatitis C 
treatment, finding there was a ‘crucial interplay between system, provider 
and personal factors’ (Treloar et al, 2014, p.563). Provider factors were 
having an engaged and trusted clinician. System factors were having an 
accessible treatment pathway and associated support structures, which are 
discussed further in Section 2.2.3, linkage to care. 
 
2.2.2.1 The era of direct acting antivirals 
 
In considering patients’ reasons for not accessing hepatitis C treatment 
(interferon based), these are largely centred around the treatment itself, 
namely the efficacy, length of course, route of administration (injection) 
and side effects of the treatment. However since 2014 hepatitis C 
treatment entered a new era, seeing the invention of new drugs known as 
Direct Acting Antivirals (DAAs), such as sofosbuvir, daclatasvir, dasabuvir, 
ledipasvir, ombitasvir, paritaprevir, ritonavir, elbasvir, grazoprevir and 
velpatasvir (NICE, 2015a; NICE, 2015b; NICE, 2015c; NICE, 2016a; NICE 
2017; Hepatitis C Trust, 2018a). 
 
These drugs are orally administered as opposed to injections, the course of 
treatment is shorter than interferon therapy (8-12 weeks), they have fewer 
side effects and are more efficacious at treating hepatitis C (rates of SVR 
80-90%) (Harris et al, 2016; PHE, 2017d; PHE, 2017e). Thus these drugs have 
the potential to transform the treatment landscape for hepatitis C, 
providing a faster and more effective cure to the majority who receive 
them, without many of the complications associated with previous 
interferon based treatments (Innes et al, 2015; Harris et al, 2016). 
However, initially the new drugs raised ‘real issues of affordability for UK 
health services’ (PHE, 2015, p.12), seeing delays in access to these 
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medications for many (Gornall, Hoey and Ozieranski, 2016). The Early 
Access Programme was set up in 2014 by NHS England, which allowed people 
with compensated and decompensated cirrhosis to benefit from the drugs 
whilst they proceeded through the NICE approval and NHS England 
implementation processes (PHE, 2015), explained by Gornall, Hoey and 
Ozieransk (2016), as ‘Before the NICE process was complete, NHS England 
took care to ensure that the sickest patients—people with liver failure who 
might die before the guidelines were issued—were treated’ (Gornall, Hoey 
and Ozieranski, 2016, p. 2). 
 
The first drug approved by NICE in February 2015 was Sovaldi (sofosbuvir), 
however, due to concerns over cost, NHS England delayed access to this 
medication until August 2015 (Gornall, Hoey and Ozieranski, 2016). 
Furthermore the next drugs to be considered by NICE in early 2015, Harvoni 
(combination-ledipasvir-sofosbuvir), Viekirax (ombitasvir-paritaprevir-
ritonavir) and Daklinza (daclatasvir), were challenged by NHS England 
amidst fears of cost effectiveness and the impact on the NHS budget. This 
led the British Society of Gastroenterology, the British Association for the 
Study of the Liver, the British Viral Hepatitis Group and the Royal College 
of Pathologists to provide a joint submission to NICE contesting the budget 
impact claimed by NHS England. NICE finally recommended these 
medications in November 2015, to be available for all indicated patients by 
the end of February 2016. In March 2016 NHS England announced numbers 
treated would be doubled (to 10,000) in 2016 -2017 through 22 operational 
delivery networks (main regional sites that would allocate treatment). 
Gornall, Hoey and Ozieranski (2016) argue that this was actually a way to 
ration treatment to patients, as clinicians had a maximum number of 
patients they were allowed to treat each month, and going over this 
allocation would see the provider paying for treatment. As NHS England had 
for the first time placed a cap on drugs that NICE recommended to be 
effective, cost effective and to be available, the Hepatitis C Trust 
responded, “It is truly ironic that NHS England should chose to start 
rationing drugs that are so effective they cure almost everyone who is 
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treated. It feels like people with hepatitis C are being picked on” (Charles 
Gore, Chief Executive of the Hepatitis C Trust, cited in Hepatitis C Trust, 
2016). Since the controversy over these initial drugs NICE have approved 
further DAAs for use (NICE 2016a; NICE 2017). According to PHE (2017d) 
‘while the high price of these new drugs represents a major barrier to 
access in most countries worldwide, these medicines are now being rolled 
out, in accordance with national recommendations, in all UK countries’ 
(PHE, 2017d, p.17). 
 
Globally, the introduction of DAAs has been controversial, raising questions 
on drug pricing and who should and should not be treated. Whilst the 
Australian government announced DAAs would be available for every 
Australian with hepatitis C (Australian Minister for Health, 2015), Grebely 
et al (2015) noted the USA and ‘other countries’ were excluding people 
from accessing treatment (interferon or DAAs) based on their alcohol and 
drug use, despite USA, European and WHO clinical guidelines recommending 
all people with any stage/severity of the disease receive treatment 
(European Association for the Study of the Liver, American Association for 
the Study of Liver diseases / Infectious Diseases Society of America, cited 
in Grebely et al, 2015; WHO, 2014). The restrictions based on drug and 
alcohol use were also highlighted in the hep-CORE study which in 2016 asked 
liver patient groups in 27 countries (26 in WHO European region including 
United Kingdom, plus Egypt) ‘in practice what restrictions are there on 
access to direct acting antivirals for the treatment of HCV infection in your 
country?’ Findings showed 52% of hep-CORE countries restricted DAA 
treatment for those currently injecting drugs, with restrictions also shown 
to alcohol use and previous injecting in some countries (Lazarus et al, 
2017).  
 
Reasons for excluding PWID, people who use drugs (non-injecting) or people 
who use alcohol from hepatitis C treatments are: non adherence to 
treatment regimes; poorer outcomes from the treatment than people with 
the same stage of the disease who do not use drugs or alcohol; a higher 
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chance of reinfection (due to ongoing injection risk); and lack of data on 
the outcomes of DAA treatment in this population (Grebely et al, 2015). 
 
Data available on interferon therapy demonstrated that these exclusions 
were unfounded (Grebely et al, 2015) and although data on the use of DAAs 
for PWID was initially limited, a number of studies have now been 
conducted with this population (Dore et al, 2016; Grebely et al, 2017b; 
Mazhnaya et al, 2017; Morris et al, 2017; Norton et al, 2017; Read et al, 
2017). The first study was the C-EDGE CO-STAR study, which considered the 
use of DAAs in people receiving OST and included people with ongoing drug 
use. Over 50% of the study population were using at least one substance: 
amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, 
opiates, or phencyclidine throughout the study period (numbers of 
participants injecting was not ascertained). Results showed adherence of 
over 95% by 96% of participants and SVR12 (SVR at 12 weeks after treatment 
completion) by 91% of study population (Dore et al, 2016). Other studies 
(Mazhnaya et al, 2017; Morris et al, 2017; Norton et al, 2017; Read et al, 
2017) conducted with PWID (recent and historic injecting) showed 
treatment completion by 96-100% of the study population and an SVR12 of 
80 - 96%. However it is important to note that whilst these studies included 
people who have injected drugs, the definitions of ‘recent’ use 
variedbetween studies (1 month to 1 year). One study which defines 
‘recent’ as having injected in the last month, with 48% of the study 
population injecting at least once a week, was the SIMPLIFY study, where 
96% of the study population completed the treatment and SVR12 was 
achieved by 94% (Grebely et al, 2017b). The most important finding from 
these studies was evidence showing little difference in treatment 
completion and SVR rates between drug users and non-drug users receiving 
DAA treatments, giving force to the argument that ‘recent’ injecting / drug 
use should not be an exclusion for DAA treatment. 
 
Regarding alcohol consumption and DAAs, Tsui et al’s (2016) study 
considered alcohol consumption in 15,151 patients who were initiating DAAs 
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for hepatitis C. Using the AUDIT-C tool (Babor, 2001), 68.5% of the study 
population were abstinent, 22.6% were classified as low-level drinking and 
8.9% as ‘unhealthy’ drinking. The study found no significant differences in 
SVR12 between the groups (SVR 91%, 93% and 91% respectively), concluding 
that alcohol use should not exclude people from receiving DAAs. And as 
Grebely et al (2015) argue;  
 
Even if it could be shown that treatment is less effective for 
people who use drugs and alcohol, it does not follow that it is 
equitable or just to exclude them. Potential life-saving therapies 
for the treatment of lung cancer or asthma are not withheld from 
current smokers. Similarly therapies for type 2 diabetes are not 
withheld from those who are overweight and do not adhere to 
dietary recommendations.  
 
(Grebely et al, 2015, p. 781).  
 
It is unclear if the UK was included in Grebely et al’s (2015) ‘other 
countries’ who were excluding people from DAAs based on their alcohol and 
drug use. However, as previously discussed, DAAs ‘are now being rolled out, 
in accordance with national recommendations in all UK countries (PHE, 
2017d, p.17) and UK recommendations do not exclude people from 
treatment based on alcohol and drug use (NICE, 2015a; NICE,2015b; NICE, 
2015c; NICE, 2015d; NICE, 2016a; NICE, 2017; Scottish Government, 2017), 
with the 2015 NICE guidelines stating: ‘..the recommendations do not 
differentiate between any groups of patients.’ (NICE, 2015d), and the 2017 
guidelines agreeing that: ‘The committee noted that its recommendations 
on sofosbuvir–velpatasvir were irrespective of whether or not the person 
uses injectable drugs.’ (NICE, 2017). Instead the guidelines highlight the 
benefits of treating PWID.  
 
It [DAAs] would also allow access to treatment for people who 
have found it difficult to access treatment before, such as people 
in prison, people who use injectable drugs and migrant 
populations. The Committee [advisory committee of NICE] 
recognised the effect of chronic hepatitis C on the lives of people 
with the virus. It concluded that treatments that give very high 
levels of sustained virological response (which is considered 
28 
equivalent to a cure), and so help reduce the rate of hepatitis C 
virus (HCV) transmission and the stigma associated with having 
chronic hepatitis C, are of major importance.  
 
(NICE, 2015a, section 4.1) 
 
However the NICE guidelines on hepatitis C treatment are not enforceable 
but allow flexibility in implementation, thus allowing for individual 
healthcare professional’s reasoning and decision making. 
 
The application of the recommendations in this guidance is at the 
discretion of health professionals and their individual patients and 
do not override the responsibility of healthcare professionals to 
make decisions appropriate to the circumstances of the individual 
patient, in consultation with the patient and/or their carer or 
guardian.  
 
(NICE, 2017) 
 
This is explored further in Chapter 6, of this thesis, where healthcare 
professionals were given vignettes of hypothetical service users and asked 
to explain what care/treatment they would provide for the service user and 
their reasoning for these decisions. 
 
To conclude, the new DAA treatments have brought hope to the hepatitis C 
community, eliminating the barriers associated with interferon based 
treatments. PHE suggests that since the DAAs have been introduced, the 
number of people treated has increased (approximately 40% increase in 
2015) and there have been fewer hepatitis C related deaths (8% fall in 
mortality from hepatitis C related heaptocarcinoma and end stage liver 
disease in 2016) (PHE, 2017d). However the problem still remains that 
around 50% of people with hepatitis C do not know they have the virus, 
therefore efforts to increase testing, along with linking those testing 
positive into specialist hepatitis C services (discussed below) are required 
to increase the number of people receiving treatment (Grebely et al, 
2017c). Without such measures the WHO targets of a reduction in hepatitis 
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related mortality of 10% by 2020 and 65% reduction by 2030 (WHO, 2016) 
will not be met (Grebely et al, 2017a). 
 
2.2.3 Linkage to specialist hepatitis C services 
 
The cascade of hepatitis C care (continuum of care) originates from a model 
used in HIV care (Gardener et al, 2011). In its application for hepatitis C, 
the cascade includes testing and diagnosis, linkage to hepatitis C specialist 
care, accessing treatment and achieving a successful treatment outcome 
(SVR) (Yehia et al, 2014). Not only is consideration required in diagnosis and 
treatment but also linking the two, keeping those who test positive for 
hepatitis C in contact with hepatitis C specialists in order to go on to access 
treatment. The cascade’s purpose is a framework to enable monitoring of 
population level public health and clinical outcomes as well as to identify 
gaps along the cascade (Bajis et al, 2017).  
 
An example of a cascade of care for hepatitis C in England is demonstrated 
by PHE (2016c) using data collected on people who use drugs attending 
specialist services between 2005 and 2014 (i.e. pre DAA era). 
 
1. Of those who tested positive on hepatitis C antibody test, 75% had 
received the RNA test within 6 months of the antibody test. 
2. Of the RNA tests taken, 75% had a positive result (showing they had 
a current infection). 
3. 3.7% of those with a current infection received hepatitis C treatment 
within a year of being diagnosed. 
4. Of those receiving treatment 43.5% achieved SVR. 
 
Whilst this data does not solely include people who inject drugs into veins 
(as per thesis focus), it does provide an insight into gaps in the pathway of 
care for people with hepatitis C. There is a large gap between testing 
positive for a current infection and receiving treatment. Some barriers to 
treatment are discussed in the previous treatment section of this thesis 
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(Section 2.2.2), however there are further issues to consider. This cascade 
does not have data on how many of those testing positive with current 
infections (chronic hepatitis C) were referred onto hepatitis C specialists 
(as would be the norm for other illness, such as a referral to a cardiologist 
for a heart condition). 
 
Specialists are generally understood to be the medical experts in that 
particular disease. Thus whilst the ultimate goal may be to treat hepatitis 
C, specialists (as in any other health condition) provide advice, conduct 
further investigations and monitor and manage the disease. Therefore 
linkage to care is important for disease assessment and management as well 
as treatment. 
 
Along with finding the undiagnosed, linkage to specialist hepatitis C care is 
seen to be an important challenge in reaching WHO GHSS targets on 
reducing hepatitis C related mortality (WHO, 2016; PHE 2017d). To this end, 
linkage to care has been suggested as a ‘research priority’ by experts in the 
field of hepatitis C (Grebely et al, 2017c) with one priority being to identify 
‘barriers and facilitators associated with linkage to HCV [hepatitis C] care 
and treatment at the levels of the patient, provider and system’ (Grebely 
et al, 2017c, p. 55). 
 
In addition, PHE (2017d) recommend; 
 
Those responsible for commissioning hepatitis C treatment and 
care services should continue to work with public health agencies, 
clinicians and other stakeholders to simplify referral pathways; 
improve the availability, access and uptake of approved hepatitis 
C treatments in primary and secondary care, drug treatment 
services, prisons and other settings; and to drive innovative 
approaches to outreach and patient support. It will be important 
to consider those individuals who have been diagnosed but 
subsequently lost to follow-up, as well as those who are newly 
diagnosed or already engaged with treatment services. 
 
(PHE, 2017d, p. 11) 
 
31 
Numerous interventions to increase linkage to care have been reported in 
the literature. Use of FibroScan (non-invasive technique used instead of 
liver biopsy to assess stage of liver fibrosis), is one such intervention 
(Foucher et al, 2009; Marshall et al, 2015), as PWID have previously 
identified having to undergo a liver biopsy as a barrier to hepatitis C 
assessment and treatment (Doab et al, 2005; Swan et al, 2010). Foucher et 
al’s (2009) study used FibroScan on street based outreach with facilitated 
(guided) referral onto hepatitis C care, resulting in 10% of those who were 
hepatitis C positive going onto have hepatitis C treatment. Other 
interventions include patient navigation programmes in the USA, where 
‘patient navigators’ acting as dedicated linkage to care coordinators, 
helped people with hepatitis C to navigate the pathways to hepatitis 
specialist services (Trooskin et al, 2015; Falade-Nwulia et al, 2016; Seña et 
al, 2016), and telemedicine, used by nurses working in prisons in Australia 
(Lloyd et al, 2013) and clinicians in rural primary care clinics in USA (Arora 
et al, 2011; Tahan et al, 2016) to get advice in order to treat their patients. 
Nurse-led educational interventions (Zhou et al, 2016) were also evaluated, 
along with integrated hepatitis C care (Cullen et al, 2006; Tait et al, 2010; 
Ho et al, 2015; Zhou et al, 2016).In these studies, hepatitis C services were 
integrated with mental health services, substance misuse services, prisons 
and GP practices, examples of the interventions are explained in more 
detail below.  
 
In the study by Cullen et al, (2006), 26 GP practices in Ireland had nurse 
facilitated referral to hepatitis C specialists. The intervention consisted of 
a liaison nurse whose role was to providing training and support around 
hepatitis C to GP practices who had patients on methadone, and to liaise 
with hepatology and addiction treatment services. The nurse also held 
consultations with patients, provided testing for hepatitis C and facilitated 
further investigations as required. An increase in hepatitis C testing was 
seen, as was referrals to hepatitis C specialists, although increase in 
referrals were not statistically significant. 
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A 2010 study conducted in Scotland by Tait et al focused on referrals into 
hepatitis C specialist care from prisons, drug and alcohol services and 
general practice. The intervention consisted of introducing a new referral 
pathway with non-medical and outreach nurse-led facilitated referrals 
compared to usual practice of medical led referral. Findings showed 
increased referrals and increased numbers completing hepatitis C 
treatment. 
 
Ho et al’s (2015) integration of care, placed a mental health practitioner 
at clinics providing hepatitis C treatment, resulting in higher rates of 
hepatitis C treatment uptake and SVR rates than in those who did not have 
contact with the mental health practitioners. 
 
Another study by Hagedorn et al (2007) introduced a hepatitis service into 
a substance abuse clinic for veterans in USA. The intervention was hepatitis 
screening, group education and individual nursing appointment where 
screening results were given with referral onto hepatitis clinics, as 
required. Findings showed all patients with chronic hepatitis C were 
referred to hepatitis C clinics, compared to only 50% referral for those not 
taking part in the intervention. 
 
Wade et al, (2015) evaluated the introduction of community based hepatitis 
nurses into clinics for PWID in Australia. The nurses’ role was to provide 
hepatitis C assessment and treatment (interferon based) to PWID, in the 
community. Findings showed SVR rates comparable to rates of those treated 
in hospital settings, showing potential benefits of community based models 
of hepatitis C care. 
 
Unusually, Ahmed et al’s (2013) study was based in an hospital hepatology 
service, at a local district general hospital UK. Thus rather than a 
intervention for linkage to specialist care, this study’s focus was on 
maintaining patients that had already been linked in with the service. The 
study’s intervention was for patients attending the hepatitis C clinic to 
receive input from a multi-disciplinary team (hepatologist, a specialist 
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nurse, psychological support worker and community support team) whilst 
they received their hepatitis C treatment (n=26 patients). The control group 
received the routine care, which did not include support from community 
or psychological teams (n=56 patients). Whilst only having a small sample 
size, the study did find 95% compliance with hepatitis C treatment in the 
intervention group compared to 46% in the routine care group, and SVR at 
69% in the intervention group compared to 20% in the routine care group. 
 
This section has shown there are many different interventions to increase 
linkage to hepatitis C care and treatment for PWID. As recommended by 
NICE guidelines: 
 
Ensure people diagnosed with hepatitis B and C are referred for 
specialist care; for hepatitis C this may involve offering hepatitis 
C treatment in the community for people who are unwilling or 
unlikely to attend hospital appointments, and whose hepatitis C 
treatment could be integrated with ongoing drug treatment (such 
as opiate substitution treatment) 
 
(NICE, 2012c) 
 
This is also noted by Bruggmann and Litwin (2013), who commented that 
‘one size does not fit all’ and many models of care incorporating hepatitis 
C treatment into a variety of settings is required. Moreover it is important 
to provide hepatitis C care at services where PWID are already attending 
(Bruggmann and Litwin, 2013).  
 
2.3 Peer-based support 
 
Another initiative to increase engagement and reduce barriers to hepatitis 
C care for PWID is peer based support (Crawford and Bath, 2013). Peer 
workers can work in a variety of roles and provide a range of support (Keats 
et al, 2015). Peer-based support has been successful in assisting the 
management of other diseases such as HIV, cancer, heart disease, diabetes 
(Crawford and Bath, 2013) and mental health (MacLellan et al 2015). 
However Harris, Rhodes, and Martin (2013), suggest that peer workers may 
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be particularly important in drug and alcohol services where service users 
may mistrust staff, largely due to the strict procedures around providing 
OST (Rance et al, 2012).  
 
As hepatitis C services are sometimes integrated within drug and alcohol 
services, peer workers need to be considered in this context. Studies have 
shown that for hepatitis C, peer workers can provide education about 
hepatitis, its testing and treatment, accompany service users to hospital 
appointments, act as advocates and mediators for service users, facilitate 
referrals to hepatitis C specialists and provide staff with a peer perspective 
(Norman et al, 2008; Charlebois et al, 2012; Alavi et al, 2013; Treloar et al, 
2015; Batchelder et al, 2017). Indeed Bonnington and Harris (2017) note 
that peer support can potentially be helpful at any point along the cascade 
of hepatitis C care. For service users, peer support could be realised in 
terms of increased knowledge on hepatitis C, improved confidence in 
accessing and negotiating healthcare services and pathways, reducing 
perceived stigma, reducing isolation, as well as accessing testing and 
treatment (Galindo et al, 2007; Crawford and Bath, 2013; Treloar et al, 
2015; Batchelder et al, 2017). 
 
There are different models of peer support, which generally comprise one 
on one support, or support provided in group settings (Crawford and Bath, 
2013). Crawford and Bath (2013) categorise peer support into ‘community 
controlled’ and ‘service generated’. The ‘community controlled’ peer 
support model historically was implemented as grass root community 
responses, controlled by drug user (peer) led organisations, and largely 
provided one on one support for people having hepatitis C treatment. 
‘Service generated’ refers to a model of peer support that is conceived and 
led by services, supported by peers and usually takes the form of group 
based sessions, often based around self-help group structures. The OASIS 
(Organization to Achieve Solutions in Substance Abuse) model was an early 
example of a service generated peer model (doctor and peer led support 
groups), often referenced in the literature as successful in engaging and 
educating PWID about hepatitis C, as well as facilitating hepatitis C 
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treatment (Galindo et al, 2007; Sylvestre and Zweben, 2007; Grebely et al, 
2010). A review of the literature has found a small number of articles on 
other (non-OASIS model) support groups for PWID with a focus on hepatitis 
C, which are also led by service providers (Charlebois et al, 2012; Stein et 
al, 2012). These studies also concluded that the groups were important in 
facilitating access and continued engagement in treatment. However these 
articles (except the case study by Galindo et al, 2007) do not provide data 
on the perceptions of those involved in the peer models. Indeed generally 
evaluations of experiences of hepatitis C peer support are limited. A 
systematic review conducted by McLellan et al (2015) on peer support 
across all diseases, found 1 study (Norman et al, 2008) regarding hepatitis 
C in Australia. Further perspectives on peer support in Australia, UK and 
USA have since been provided in work by Treloar et al (2015) Bonnington 
and Harris (2017) and Batchelder et al (2017) respectively. Models of peer 
support vary throughout the studies, making comparison difficult, but there 
were some commonalities in findings. 
 
Norman et al’s (2008) study used a paid peer worker as part of a larger 
multidisciplinary team implementing hepatitis C care and treatment into a 
community drug and alcohol service. Interviews were conducted with 
service users and the peer worker. The peer worker explained her role as 
giving advice and information to service users on clinical and logistical 
aspects of hepatitis C treatment, as well as providing practical support like 
acting as an advocate and providing transport. She felt the role was integral 
in helping people through hepatitis C treatment ‘because the drugs 
[hepatitis C treatment] are savage’ and ‘it’s a terrifying process’ without 
support. This was echoed by the service users "...I think she [peer worker] 
has made the difference between sticking to this [hepatitis C treatment] 
or not..."; a finding also found by in other studies (Batchelder et al, 2017). 
Service users felt the peer worker gave good advice, listened, empathised, 
was non-judgemental, was easier to talk to than doctors and helped 
communication with doctors.  
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The peer worker felt that one of the most important parts of the role was 
that service users were able to openly discuss their drug use:  
 
"Strengths of peer-based services is that there is no us and them, 
that I identify with the clients which is essentially different to 
even a very supportive non-peer worker.... A client who makes a 
bid to stop using and lapses, feels like a failure, they worry that 
they've let [medical staff] down. All of that makes it very difficult 
for them to be honest... Whether the judging is real or perceived, 
it's still very real to clients and it's a huge divide to engage across. 
Having a peer worker in the role means that I know this territory 
because it's my reality too. A lot of what I talk to clients about is 
drug use. I'm very pragmatic, shit happens, people lapse. Lots of 
clients on treatment have profound fears that drug use will 
impact on treatment and they can't talk to clinicians about this, I 
clarify that this isn't going to undermine the treatment, it's about 
being stable." 
 
(Norman et al, 2008, p. 4) 
 
The peer worker having similar experiences (drug use and hepatitis C) was 
also seen as important by some service users. One service user explained 
how, in comparison to medical staff, there was no need to hide things from 
a peer. 
 
There were however some concerns raised about the peer worker model 
during the interviews. Some of the service users raised concerns over the 
level of professionalism for a peer worker. One client suggested peer 
workers would not have the same professional consequences as other 
medical/ health staff with one service user expressing the need for peer 
workers to be both a peer and professional. 
 
The peer workers also raise a couple of concerns, firstly the level of distrust 
that peer workers faced from other medical/health professionals was 
noted, stating that “they [medical professionals] don't welcome peers as 
professionals”. Secondly, issues around the need for supervision, ongoing 
training and a professional framework for the peer role was expressed, with 
the peer worker admitting: "Sometimes I feel like I'm making it up as I go 
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along and the stakes are high, sometimes I feel out of my depth" (Norman 
et al, 2008). 
 
In Treloar et al’s (2015) study, peer workers were introduced into two 
community OST clinics. The aim of the study was to engage service users, 
build trusting relationships and support people through hepatitis C 
treatment. Interviews were conducted with staff, peers and service users. 
Like Norman et al’s (2008) study, this study found that the peer’s own life 
experience was valued by service users, and the success of the scheme was 
put down to the non-judgemental attitude of the peer workers and the trust 
built between peers and service users. Findings from the study met the 
original aims, with one clear benefit noted by staff being the change in how 
service users presented for their hepatitis C assessment and care. Other 
unintentional positive results included peer workers being mediators 
between service users and staff, enabling service users to access other 
clinical and support services (such as a dentist) and changing the 
atmosphere of the services to a more service user friendly space. Benefits 
were also noted by the peer workers personally, as the work was 
‘rewarding’ and they were able to ‘give back’, a sentiment found in other 
studies (Galindo et al, 2007; Whiteley et al, 2016; Batchelder et al, 2017), 
with Batchelder et al (2017) also finding that this improved self-confidence 
of the peer workers. This finding was not found by Bonnington and Harris 
(2017) as discussed below. 
 
As well as building good relationships with service users, it was found that 
positive working relationships were made with staff. However peer workers 
were not necessarily viewed as equal, with one service disallowing peers 
into ‘staff only areas’, and the second service allowing peer workers into 
staff areas but implementing tightened security measure, such as placing a 
camera in the room where the safe was located. Services justified this 
behaviour, saying it was to protect the peer workers as ‘if anything went 
down or if any, any drugs went missing, it would be someone like [the peer 
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worker], you know, where the finger would be pointed’ (Treloar et al. 
2015, p. 995). 
 
Other study findings were that not all service users were aware of the peer 
workers, staff had initial (unfounded) concerns over confidentiality and 
boundaries between peer workers and service users and some service users 
were concerned information discussed with peer workers would be relayed 
to staff. Treloar notes this concern has been found before (Treloar et al, 
2011 cited in Treloar et al, 2015) therefore peer worker’s first task should 
be to establish their autonomy and credibility amongst service users. 
 
In this study it was noted that, unlike in Norman et al’s (2008) study, the 
peer workers received training and regular supervision to ensure their 
hepatitis C knowledge was up-to-date and to help the peer workers manage 
any difficult issues. 
 
In comparison to these studies, Bonnington and Harris’s (2017) study was 
conducted in the UK, with the implementation of unpaid peer workers in 
the form of peer educators and ‘buddies’ into community drug and alcohol 
services. Peer workers were defined as those who had personal experience 
of hepatitis C and buddies did not have experience of hepatitis C but were 
able to empathise with the service user and share experiences. The peer 
educator’s role was to provide training to service users and other 
stakeholders (such as homeless hostel staff) about their experience of drug 
use and hepatitis C, including testing and treatment. They were given 
training by the Hepatitis C Trust and were instructed to give key messages 
when they gave their training. The buddy’s role was more informal in 
nature, meeting service users for ‘a coffee and a chat’ either at the drug 
service or outside, as well as accompanying service users to hepatitis C 
testing and treatment if the service user desired. Regular training was 
provided to all peer workers. Interviews and focus groups were held with 
service users, drug workers and prospective peer educators and buddies.  
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As in other studies (Norman et al, 2008 and Treloar et al, 2015) qualities 
needed for peer worker were to be trustworthy, honest, accepting 
empathetic, informative, but also motivated, proactive, reliable. Service 
users wanted peers and buddies to share their own experiences (hepatitis 
C and/or drug use), to have good knowledge of hepatitis C and, as shown in 
Norman et al (2008), to generally ‘just be there’. People wanted to take on 
the role of buddies and peers so that others would not have the same 
negative experiences that they themselves had, such as being marginalised 
by family and friends following disclosure of a hepatitis C positive status, 
hoping that the peer role would support and therefore lessen isolation for 
service users. 
 
Having access to reliable information after diagnosis also prompted people 
to become peers. “If it helps one person to get to the hospital . . . I always 
used to be terrified. I went on my own, which was daunting, to say the 
least, and I didn’t know anything. I just knew nothing. Everything just went 
straight over my head. And if I’d have had a buddy then, I’d have learnt a 
bit more’” (p.224). Both peers and service users commented upon previous 
hospital appointments where “although the doctor goes through things, at 
the time your head's not straight because you're still taking drugs or 
whatever… there was loads of stuff he said to me, absolutely loads. It just 
flew past my head” (p.224). 
 
However despite these good intentions pre intervention, post intervention 
interviews showed a number of difficulties with the implementation of 
peers and buddies into the service. Firstly there was conflict and a 
hierarchy amongst the peer roles within the service. Services favoured 
‘recovery champions’ (those who were not on any OST) to be peers, due to 
the UK focus on ‘recovery’ in drug treatment (Bonnnngton and Harris, 
2017). Furthermore peers were not integrated and poorly supported within 
the service, which consequently affected their ability to work with service 
users, limiting their impact on facilitating hepatitis C testing and 
treatment. The study concludes by noting that peer involvement can be 
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affected by organisational boundaries and structures, especially regarding 
who is considered a ‘peer’. Thus integrating peer workers into an 
organisations and the wider recovery movement takes time and needs 
careful consideration. 
 
This section has shown that whilst peer involvement is generally accepted 
as important in facilitating hepatitis C services into drug and alcohol 
services with an aim to increase knowledge, testing and treatment, in 
practice there are many different models and a number of pitfalls that need 
to be considered. 
 
2.4 Stigma and hepatitis C 
 
During previous sections of this literature review, fear of discrimination and 
stigma has been recognised as a barrier for PWID to access hepatitis C 
testing and treatment. Furthermore stigma can affect the everyday lives of 
those who live with hepatitis C (Zickmund et al, 2003). The peer support 
section of this literature review gave an example of how hepatitis C 
discrimination can affect people with hepatitis C in everyday life. Peer 
workers in one study (Bonnington and Harris, 2017) explained their own 
experiences of being isolated when marginalised by family and friends 
following the disclosure of their hepatitis C diagnosis, drawing on this as a 
motivation for volunteering to provide support to others in a similar 
situation. Stigmatising attitudes are encountered from family, friends, 
colleagues and within healthcare settings (Butt et al, 2008; Hill et al, 2014), 
and researchers have identified the experience of stigmatisation as one of 
the most significant issues facing people who have hepatitis C (Hopwood 
and Southgate, 2003; Zacks et al, 2006). It is clear from this that stigma 
warrants further consideration in this literature review. 
 
Stigma is defined as ‘a mark of disgrace associated with a particular 
circumstance, quality, or person’ (Oxford Dictionary, 2018) and ‘the 
situation of the individual who is disqualified from full social acceptance’ 
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(Goffman, 1990, p.9). The later gives context to how stigma affects 
individuals, as the peer example above demonstrates. Goffman (1990) 
explains that stigma is a relationship between attribute and stereotype and 
those who have the particular attribute are ‘discredited’ by the ‘normals’ 
(those who do not have the attributes). Furthermore; 
 
‘the standards he [person with the stigmatised attribute] has 
incorporated from the wider society equip him to be intimately 
alive to what others see as his failing, inevitably causing him, if 
only for moments, to agree that he does indeed fall short of what 
he really ought to be. Shame becomes a central possibility….’ 
 
(Goffman, 1990, p. 18) 
 
Where an individual’s stigmatised attribute is known, Goffman describes 
the person as ‘discredited’, and where the attribute is not known, as 
‘discreditable’. He notes the ‘discreditable’ try to avoid revealing their 
attribute that may be subject to stigmatisation, to pass as ‘normal’. Indeed 
research has shown that decisions to not disclose hepatitis C positive status 
is often borne from fear of stigmatisation (Faye and Irurita, 2003; Butt et 
al, 2008; Hill et al, 2014), and non-disclosure limits opportunity for support 
(Faye and Irurita, 2003; Hill et al, 2014). Goffman also explains how support 
can come from others who share the stigmatised position, which for 
hepatitis C could perhaps be related to peer support. 
 
This brief explanation of Goffman’s work on stigma provides theoretical 
understanding that can be related to issues already touched on in this 
literature review, such as people with hepatitis C having difficulties around 
disclosure of their positive status, interactions with health professionals 
(‘normals’) being more difficult than with peers, and stigma posing barriers 
to accessing services and the daily lives of people with hepatitis C. 
Furthermore research has shown that people with hepatitis C can also 
demonstrate internalised stigma by expressing widely held societal beliefs, 
such as feeling ‘like a leper’, dirty or contaminated (Zickmund et al, 2003; 
Hill et al, 2014) which is demonstrated by Goffman’s quote above. 
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Stigma has historically been associated with infectious diseases, such as 
leprosy, tuberculosis and more recently HIV (Butt, 2008). Stigma increases 
if the disease is seen to pose a threat of being transmitted to other people 
but also if the disease is viewed to be acquired by the bearer’s own 
inappropriate or irresponsible behaviour (Butt, 2008; Joffe, 2011). Thus for 
hepatitis C, stigma could be due to the virus being infectious, but also that 
the main route of transmission is sharing injecting drug equipment. 
However in considering Goffman’s work on ‘attributes’, if hepatitis C is the 
‘attribute’ leading to stigmatisation of those with the disease, it stands to 
reason that people who have hepatitis C transmitted from routes other than 
sharing injecting equipment, such as blood transfusions, or needlestick 
injuries in healthcare staff, would also experience the related 
discrimination. Whilst research has shown that people with hepatitis C 
acquired from routes other than sharing injecting equipment do also 
experience stigma, this stigma was due to the association between hepatitis 
C and injecting drug use, ‘they automatically think you’re an addict-an 
addict who shares needles’ (Butt et al, 2008, p.213). 
 
The UK Drug Policy Commission (UKDPC) conducted research on stigma 
towards problem drug users (defined as injecting drug use or long-
duration/regular use of opioids, cocaine and/or amphetamines) without 
consideration of hepatitis C status. (UK Drug Policy Commission, 2010). 
UKDPC note that problem drug users are perceived by the general public to 
be deceitful, dangerous, unpredictable, unreliable, hard to talk with and 
to blame for their predicament. Additionally, health professionals can be 
judgmental and mistrust problem drug users. Consequently, drug users 
report the stigmatising views of others to affect their lives, resulting in 
feelings of low self-worth and avoiding contact with people who do not use 
drugs. In addition, stigma may be a barrier to people accessing support for 
their drug use (UK Drug Policy Commission, 2010). 
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It was also noted that problem drug users reported suffering multiple 
stigmas such as being female, being black, having a mental health problem, 
HIV or hepatitis C, but the drug user status was found to be the most 
stigmatising of all (UK Drug Policy Commission, 2010). Stigma is a complex 
issue, and for PWID with hepatitis C, stigma maybe multifaceted (Paterson 
et al, 2007). 
 
Whilst stigma can be encountered by PWID with hepatitis C, from friends, 
family and colleagues (Butt et al, 2008), there is a wealth of research 
illustrating stigma as a barrier to accessing healthcare. (Paterson et al, 
2007; Swan et al, 2010; Harris, Rhodes and Martin, 2013; Hill et al, 2014; 
Brener et al, 2015). In the literature, stigma is reported to come from 
individual healthcare staff (Swan et al, 2010) as well as healthcare systems 
and its structures (Paterson et al, 2007; Harris, Rhodes and Martin, 2013). 
 
Throughout the literature, services users reported experiences of stigma 
from healthcare staff where they felt judged based on the fact that they 
had hepatitis C (Butt et al, 2008; Swan et al, 2010). They felt that usually 
the response towards them was due to ignorance or misconceptions about 
hepatitis C or because the person associated hepatitis C with injecting drug 
use (Butt, 2008; Swan et al, 2010). A study by Butt et al (2008) asked PWID 
if the stigma of hepatitis C was the same or different from that of drug use. 
The PWID emphasized that the stigma of those with hepatitis C is different 
‘because not only are you a druggie and all that this implies, but [it is 
assumed because you have hepatitis C] you don’t care about other people 
because you shared needles’ (p.211). One participant stated that he 
“wasn’t well liked” by healthcare practitioners when they thought he was 
“just a user,” but when he became hepatitis C positive, they treated him 
“like I was a lower lowlife than before.” (p.211). 
 
Whilst people who have acquired hepatitis C from routes other than 
injecting feel they are treated with the same stigma as PWID (discussed 
above)(Butt et al, 2008; Hill et al, 2014), PWID do not feel that they are 
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treated the same as those who have got hepatitis C from other means (Butt 
et al 2008; Swan et al, 2010). 
 
People who got it through blood transfusions, people have 
sympathy for them but because when you’re using drugs it’s self-
inflicted, people aren’t going to have sympathy for ya and they 
basically don’t care 
 
(Swan et al, 2010, p. 756) 
 
The results of stigma/perceived stigma throughout the literature was that 
the care provided to PWID with hepatitis C was affected (Treloar et al, 
2002; Butt, 2008; Swan et al, 2010). This resulted in care being inequitable 
to that received by people who do not inject drugs (Treloar et al, 2002; 
Butt, 2008; Swan et al, 2010) and even withdrawal of care, support or 
services (Butt, 2008). Reports of staff leaving the room or refusing to care 
for people with hepatitis C were found in Butt et al’s (2008) study. One 
participant reported that following disclosure of injecting drugs and having 
hepatitis C, the doctor made judgemental comments and then asked him 
not to return, and another participant recounted a situation where they 
had attended for a blood test and the nurse recoiled, ‘took a step back’ 
(p.211) when she was informed of the positive hepatitis C status. In terms 
of inequitable care, one participant noted that when he broke his leg, he 
received less analgesia, support and attention than others in the emergency 
department did. He concluded this was due to having hepatitis C and 
injecting drugs. ‘You’re not important. You’re just, you know, in the back 
of the bus’ (p.212). 
 
Past experiences of stigma can lead to mistrust of healthcare staff and 
expectations of future stigma when having contact with services, 
discouraging some from accessing services (Swan et al, 2010; Harris, Rhodes 
and Martin, 2013) ‘I was really badly treated and I know loads of people 
that have been treated abysmally down there, really blatant 
discrimination. Just looking with disgust, clear disgust in the nurses’ faces, 
‘You’re drug addicts, oh, so you got it through injecting, well you should 
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know better’ (Dillon) (Harris, Rhodes and Martin , 2013, p.21). This 
experience led Dillon to vow that he would never undertake hospital-based 
HCV treatment (Harris, Rhodes and Martin, 2013). 
 
However, Paterson et al (2007) found that even if healthcare practitioners 
have positive attitudes towards people with hepatitis C, there are 
institutional and structural forces within healthcare systems that can result 
in discriminatory practices. Reidpath et al (2005) note that stigmatisation 
occurs when people with certain diseases are viewed as being unworthy of 
social investment, and Paterson et al (2007) suggest there are many forces 
within healthcare that contribute to practitioners defining PWID with 
hepatitis C as meriting less investment than others. An example of 
deservedness of social investment being that a person is willing to engage 
in reciprocal exchange (Reidpath et al, 2005) viewed as the basis for trust 
in a patient-doctor (healthcare staff) relationship (Paterson et al, 2007), 
with patients providing relevant information about their health and 
cooperating with treatment and management of care (Paterson et al, 2007). 
Therefore those who do not follow these ‘rules’ are seen as less deserving 
of social investment than others that follow these social norms (Paterson 
et al, 2007). 
 
Furthermore institutional and departmental policies on who is eligible for 
treatment, who receives treatment and the types of support available can 
be a source of hepatitis C related stigmatisation (Stephenson, 2001). Astone 
et al (2004) showed that willingness to fund care and treatment for PWID 
was a significant determinant in what services healthcare staff were able 
to provide to this population. Whilst this study was based in USA, the 
similarities can be drawn with the introduction of DAA treatments in the 
UK. 
 
Thus whilst it is important to address perceptions which are stigmatising 
from healthcare professionals, there is also a need to address how 
governmental and institutional policies and structures impede access and 
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provision of equitable and non-judgemental care for PWID with hepatitis C 
(Paterson et al, 2007). 
 
2.5 Alcohol use in the context of hepatitis C 
 
2.5.1 Alcohol risk and advice for those with hepatitis C 
 
Since the introduction of DAAs the number of people accessing hepatitis C 
treatment is increasing (PHE, 2017d), yet there are still many who do not 
access it. Therefore there is a need to understand more about the 
experiences of those living with hepatitis C in order to reduce hepatitis C 
related morbidity and mortality. 
 
The course of a chronic hepatitis C infection is unpredictable and varies 
between people, with some people being unwell from the start but others 
having the virus for years before symptoms occur (Hepatitis C Trust, 2018c). 
There are however certain risk factors that increase the likelihood of 
accelerated disease progression to complications such as cirrhosis and 
hepatocarcinoma. These risk factors are: being male, being over 40 years 
old at the time of becoming infected, being co-infected with HIV and/or 
hepatitis B and alcohol consumption (Lim, 2001; Chen and Morgan, 2006; 
Drumright et al, 2011; McDonald et al, 2011b; Innes et al, 2013). NICE 
(2016b) state that alcohol is the most important predictor of disease 
progression in hepatitis C, with some evidence indicating that a history of 
previous heavy alcohol use (>50 units a week for a sustained period) (i.e. 
at any point in a person’s life) can fuel progression (Innes et al, 2013) to 
further complications of the liver. 
 
In the UK the Chief Medical Officers’ alcohol advice for the general 
population is to not consume more than 14 units of alcohol a week 
(Department of Health, 2016). Furthermore it is recommended that the 
total amount is not consumed in one or two days, but is spread out over 
three or more days of the week (Department of Health, 2016). However 
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from the literature it appears that although researchers agree alcohol use 
speeds up the disease progression of hepatitis C (Hutchinson et al 2005; 
McDonald et al, 2011a) there is currently no stipulated ‘safe limits’ of 
alcohol for people who have the virus (Bhattacharya and Shuhart, 2003, 
Hutchinson et al 2005). It is thought that even levels below the government 
recommendations may be harmful for people who have hepatitis C 
(Pessione et al, 1998; NICE, 2016b; SIGN, 2013) and clinical guidelines in 
the UK are currently for those with hepatitis C to abstain from alcohol 
(Royal College of General Practitioners (RCGP), 2007; O’Leary et al, 2012; 
SIGN, 2013; NICE, 2016b), although NICE acknowledges that people with 
hepatitis C should stop drinking wherever possible, or reduce alcohol 
consumption if this is not possible (NICE, 2016b). 
 
2.5.2 Alcohol use in PWID: prevalence 
 
Much of the literature on alcohol use in PWID focuses on those who drink 
above government recommendations for the general population (Gossop et 
al, 2000; Hillebrand et al, 2001; Costenbader et al, 2007). Various research 
studies conducted in the USA suggest a prevalence of heavy alcohol 
consumption (where ‘heavy’ is defined as exceeding various thresholds for 
the number of drinks per week) within the PWID population ranging from 
11% to 68% (Arasteh and Des Jarlais, Arasteh et al, Hahn et al, Howe et al, 
cited in Le Marchand et al, 2013). 
 
Closer to home, the DTORS (The Drug Treatment Outcomes Research Study) 
study, conducted in England over a three year period, considered the 
effectiveness of drug treatment. This research did not provide prevalence 
data on alcohol use in PWID specifically but did find that 76% of opiate users 
used multiple opiates or opiates in combination with benzodiazepines or 
alcohol at the baseline point and 43 % and 48% at consequent time points 
in the research (Jones et al, 2009). 
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An earlier research study, the National Treatment Outcome Research Study 
(NTORS), researched people attending drug treatment (of which 87% were 
using opiates) in England between 1995 to 2000, finding a prevalence of 
heavy drinking (over recommended limits) in approximately 25% of 
participants throughout the 5 years of the study (Gossop et al, 2000; Gossop 
et al 2002; Gossop, 2013). However the NTORS study found ‘a wide variation 
in drinking patterns among drug misusers’ (Gossop et al, 2002, p. 174), 
noting an abstinence rate of over a third of the sample, from 3 months prior 
to the study commencing to study completion 5 years later. Gossop (2013) 
suggests alcohol abstinence in drug users is a ‘little discussed’ (p. 1194) 
point, and indeed there is a paucity of research on PWID who may be 
abstinent or drinking low levels. 
 
This thesis did not set out to specifically target either those drinking above 
government recommendations, or those that were drinking lower-risk 
levels/abstinent but aimed to generally explore drinking amongst PWID who 
had hepatitis C who were attending drug and alcohol services. 
 
2.5.3 Relationship between alcohol, heroin and opioid substitution 
treatment 
 
Gossop (2013) notes that ‘few drug takers confine themselves to using a 
single substance’ (Gossop, 2013), but multiple substance use seldom gets 
the attention it deserves. Furthermore, Staiger et al (2012) suggests that 
alcohol use has the potential to interfere with recovery from drug 
dependence, but this has not been addressed comprehensively in the 
research, suggesting that this could be due to research being framed 
according to the primary drug rather than interactions between different 
combinations of drugs and /or drugs and alcohol. Gossop (2013) notes that 
also in treatment, staff may focus on what is perceived to be the main 
substance whilst ignoring other substances. 
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Attention is however, given in the literature to whether people ‘switch one 
addiction for another’, thus substitute heroin with alcohol, largely in the 
context of receiving opioid substitution treatment (OST) such as methadone 
or buprenorphine (Stastny and Potter, 1991; Staiger et al, 2012; Henriquez-
Gonzalez and Patton, 2013). A study in Ireland interviewed 25 people at a 
general practice who had ‘used heroin in the past’. 23 people were 
currently prescribed methadone. The study found that a common reason 
given for drinking was to substitute heroin. The financial aspects of not 
using heroin was also a factor: “I’m not spending as much [money] on drugs, 
and I’m not thinking in the morning about how much money I have to score, 
so I drink more!” (Cullen, 2005, p. 73). 
 
Another study, conducted in the USA, used a qualitative focus group of 41 
clients from a methadone clinic. This study also found that many people 
wanting to discontinue heroin used alcohol as a substitute. The participants 
also explained that people on methadone use alcohol (and ‘pills’) to 
heighten the euphoria of methadone. 
 
‘I found that people that are on methadone are also on 
alcohol…But it’s not enough of a euphoric for us. So we end up 
taking …pills….We combine ‘em, because we wanna intensify the 
euphoria of taking the methadone and …so when we’re combining 
all those drugs together, the hardest one I feel is alcohol to drop, 
because…you know, it’s cooling...you’re high on it...[it] gives you 
the highest euphoria...’ 
 
(Nyamathi et al, 2008, p. 30) 
 
This shows that some people who have been on heroin are still wanting to 
‘get high’ even though they are wishing to stop using heroin. Interestingly 
the comment says that out of all the substances alcohol is the most difficult 
to stop using. These two studies show examples of people switching heroin 
for alcohol whilst on methadone, however the findings in the literature 
present a mixed picture. Indeed Staiger et al’s (2012) systematic review 
found inconclusive evidence on alcohol substituting heroin. 
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The earliest study identified on literature searching this topic, was from 
1978, where Green et al (1978) interviewed 96 people, receiving 
methadone treatment, about their lifetime alcohol use. Results showed 
that of those who drank ‘excessively (in alcoholic, problem, or heavy 
patterns)’ (Green et al, 1978) (presumably dependent or higher-risk higher-
risk drinkers) did so during two main periods: before becoming addicted to 
heroin and during periods of abstinence from heroin. Furthermore, most of 
the participants who were drinking ‘excessively’ whilst on methadone, had 
pre-treatment histories of ‘excessive’ alcohol use. 
 
For some of Green et al’s (1978) participants, the switching of one 
substance to another was not switching to alcohol once on methadone but 
a more complex picture, where alcohol was actually prior to heroin, with 
an ongoing pattern of swapping between the two substances. Stastny and 
Potter (1991) also found that alcohol problems may predate heroin. 
 
The ROSIE (Research outcome study in Ireland evaluating drug treatment 
effectiveness) study (Stapleton and Comiskey, 2010), which considers 404 
opiate users on methadone treatment over a 3 year period, found that those 
who abstained from alcohol were more likely to have abstained from heroin 
than those who had not abstained from alcohol. People were abstinent from 
alcohol and heroin, or using alcohol and heroin, so were not switching from 
heroin to alcohol. The study also found those who abstained from alcohol 
were less likely to be on methadone than those who did not abstain from 
alcohol (Stapleton and Comiskey, 2010). Thus those on methadone were 
more likely to be drinking than those not on methadone. Backmund et al 
(2003) also noted this, finding that people on methadone drink significantly 
more than heroin users not receiving methadone. This finding on alcohol 
use whilst on methadone is also inconsistent throughout the literature. 
 
Srivastava et al (2008) conducted a systematic review on whether being on 
methadone treatment affected alcohol consumption levels. 15 studies were 
identified, 3 studies found alcohol use increased when on methadone, 3 
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studies found a decrease in alcohol whilst on methadone and 9 studies found 
no change in amounts of alcohol drank prior to and whilst on methadone. 
 
In considering alcohol use on methadone, a study conducted in the rural 
England (Kent) (Henriquez-Gonzalez and Patton, 2013) provided a 
questionnaire to 170 people receiving methadone (OST), finding 42% 
consumed alcohol, however ‘hazardous drinking’ (defined as AUDIT score 
of 5 or above) was found in 14.2 % of the study population and alcohol 
dependence was found in 6.5%. Henriquez-Gonzalez and Patton (2013) 
compare results to alcohol prevalence within the general population in UK, 
noting an overall prevalence of alcohol at 85% in the UK (Robinson and 
Harris, cited in Henriquez-Gonzalez and Patton, 2013), hazardous drinking 
(AUDIT identified) at 24% and alcohol dependence at 5.9% in England 
(McManus et al, cited in Henriquez-Gonzalez and Patton, 2013). Therefore 
in comparison with the general population, participants on methadone in 
this study generally drank less. 
 
This section has shown that the research presents a very mixed picture on 
alcohol consumption in PWID. For those who are alcohol dependent or drink 
at higher-risk levels, research shows there are barriers (and facilitators) to 
accessing support for alcohol consumption. 
 
Nyamathi et al (2008) conducted focus groups with people on methadone 
to explore strategies they considered helpful in reducing alcohol use. The 
study found a combination of healthcare provider and personal factors such 
as being motivated to change and taking small steps. Attitudes and 
behaviours of healthcare providers were critical, with the participants 
noting that providers need to show compassion, respect and not ‘look down 
upon’ (p. 30) service users. The perception of being stigmatised because of 
drug use was noted as a major deterrent for service users seeking help. The 
participants also commented on guilt, ‘guilt is what keeps us down,....the 
guilt keeps us on alcohol….on drugs.. to escape…..so we don’t need guilt 
thrown at us……we wanna know how we can be helped today’ (p.30), 
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suggesting that providers needed to be positive and help promote self-
esteem and self-value, in order to aid service users to make changes. Lastly 
the participants noted that providers needed to be committed to helping 
service users progress. 
 
Further research based in primary care in Ireland (Field et al, 2013) 
considered barriers and facilitators to screening and treatment for 
‘problem alcohol use among problem drug users’. Like Nyamathi et al 
(2008), healthcare providers were considered an important factor. The 
patient-professional relationship was noted as important, and participants 
who did not have a positive patient–professional relationship mentioned 
distrust or dishonesty and concealment of problem alcohol use. Again the 
personal factor of motivation was found, as were social factors such as 
support from family and friends. Structural issues such as how services were 
organised and delivered were also a factor. Participants noted services to 
be inflexible, making it difficult to attend due to other commitments. 
Participants suggested that alcohol specific services were required and 
noted a need for outreach services in the community. 
 
2.5.4 Hepatitis C diagnosis and its effect on alcohol use in PWID 
 
As alcohol accelerates the progression of hepatitis C to cirrhosis and 
hepatocaricnoma (NICE, 2016b) and abstinence is recommended (RCGP, 
2007; O’Leary et al, 2012; SIGN, 2013; NICE, 2016b), it is therefore 
important to understand drinking behaviours in people who have the virus. 
 
To note, many of the research studies identified for this section of the 
literature review included a mixed population of people with hepatitis C 
(thus PWID and people who have contracted hepatitis C via other routes) 
therefore studies that do not specify whether participants have injected, 
and studies presenting mixed routes of transmission are included. 
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Some studies in the literature found that having hepatitis C had an 
association with a reduction in alcohol consumption (McCusker et al 2001; 
Scognamiglio et al, 2007; Tsui et al 2007; O’Leary et al, 2012). 
 
McCusker’s (2001) study with PWID in London, considered whether a 
perceived diagnosis of hepatitis C affected their alcohol use. The research 
found that if people thought they had hepatitis C they were more likely to 
reduce or abstain from alcohol. This finding was reiterated in Scotland by 
O’Leary et al (2012), who found those who believed they were hepatitis C 
positive were more likely to stop drinking, however the study also found 
that those who drank continue to do so to excess (over government 
recommendations) (O’Leary et al, 2012). 
 
Research in the USA has also shown that a diagnosis of hepatitis C decreases 
alcohol consumption. Tsui et al (2007) compared people with HIV with 
people co-infected with HIV and hepatitis C and found those with hepatitis 
C were more likely to abstain from alcohol and those who did drink, drank 
less than those with HIV mono-infection. Further work by Tsui et al (2009) 
observed a cohort of young PWID (< 30 years old) over a period of time, and 
found alcohol use (and use of non-injection drugs) decreased immediately 
after diagnosis (and counselling) but this behaviour was not sustained at 6 
months and 12 months after diagnosis. Changes in alcohol consumption over 
time was also found by Stoller et al (2006). Considering ‘non-problematic’ 
drinkers (defined as AUDIT score of 10 or less), the study found that few 
participants ignored advice to stop drinking, with >80% abstinent, changing 
to around 50% over time. Some participants stopped drinking immediately 
after diagnosis, but others needed other incentives such as negative 
reactions to alcohol, perceptions of disease progression, or threats to 
efficacy or eligibility of hepatitis C treatment. Other participants had 
periods of adherence, non-adherence and tailoring of drinking behaviours 
such as cutting back the amount of alcohol consumed, trying counter 
measures to lower the risks of alcohol or monitoring their bodies for signs 
of disease progression. 
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Stephens and Havens (2013) study considered the effects of post-test 
counselling on alcohol consumption following a positive diagnosis of 
hepatitis C compared to those testing negative who received no advice on 
alcohol use. Whilst this study showed that those testing positive (and 
receiving the counselling) reduced alcohol intake, the reduction in alcohol 
was also seen in the group testing negative who did not receive counselling. 
 
Other research studies have shown that PWID do not change their drinking 
after diagnosis of hepatitis C (Ompad et al, 2002; Kwiatkowski et al, 2002; 
Wang et al, 2014; Elliot et al, 2016). Ompad et al’s (2002) study reported 
alcohol dependence in 48% of people with hepatitis C, and half of these did 
not change or even increased their alcohol consumption after being 
diagnosed with hepatitis C, despite counselling. A study based on NDTMS 
(National Drug Treatment Monitoring System) data collected in England 
compared drinking in hepatitis C positive and negative patients, finding that 
patients with hepatitis C were more likely to consume higher amounts of 
alcohol (defined as harmful alcohol use) than those who did not have 
hepatitis C (Wang et al, 2014). 
 
Elliot et al’s (2016) study found whilst 52.8% of PWID abstained from 
alcohol, younger (age not specified) PWIDs with hepatitis C (or HIV) were 
more likely to drink than older (age not specified) PWID with hepatitis C (or 
HIV), however overall having hepatitis C had no association with drinking. 
Elliot et al (2016) concluded that people who had hepatitis C but did not 
inject drugs ‘appeared to understand the need to eliminate drinking as 
they were more likely to abstain than their uninfected peers’ (p. 553), 
suggesting an association between understanding and behaviour. However, 
other studies have found that having knowledge on the effects of alcohol 
on hepatitis C made little difference to alcohol consumption in those with 
hepatitis C (Kwiatkowski et al, 2002; Campbell et al, 2006; Noonan et al, 
2009). 
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A study by Cullen et al (2005) in Ireland found reasons for reduction in 
alcohol by people who had hepatitis C were due to concerns about health 
and as part of overall lifestyle change rather than just knowledge. Other 
studies have also considered lifestyle changes (as well as alcohol) for PWID 
with hepatitis C. 
 
Scognamiglio et al (2007) looked at quality of life in people with hepatitis 
C (12.4% of study population were PWID) and found 74% modified alcohol 
consumption following diagnosis. However the study also found people were 
unnecessarily restricting other aspects of their lives, such as diet and 
exercise, following diagnoses. Unnecessary restrictions on diet and changes 
to sex life following a hepatitis C diagnosis (26% of study population were 
PWID), were also found by Castera et al (2006), as well as many participants 
(71%) discontinuing alcohol. Whilst these studies showed that people with 
hepatitis C modified alcohol consumption, they also showed that people 
may be restricting their lives in ways that are unnecessary. 
 
Harris’s (2010) work provides a qualitative perspective to alcohol use in 
those who have hepatitis C (majority of study population were PWID), 
considering the meanings of alcohol use and dilemmas involved in ceasing 
or reducing alcohol consumption. The study found that for some 
participants the stigma associated with hepatitis C meant they were 
reluctant to disclose they had the virus, causing a dilemma on how to 
decrease alcohol without raising suspicion amongst other people. Some 
participants avoided social events as it was easier than disclosing or lying 
about why they were not drinking. Furthermore participants who continued 
to drink whilst having hepatitis C experienced negative judgments from 
within the medical profession and others with hepatitis C who were not 
drinking, which the author concluded could lead to isolation and negative 
self-esteem. Thus experiences of abstinence (or reduction) and drinking 
alcohol for people with hepatitis C could both be excluding in different 
contexts. 
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2.5.5 Advice/information on hepatitis C and alcohol 
 
Searching the literature to ascertain where PWID get information about 
hepatitis C and alcohol was unsuccessful, finding no articles specific to 
alcohol advice. There were however articles on where PWID get information 
about hepatitis C, although it is important to note that these studies were 
based in Australia, Canada, Italy, Ireland and the USA and not in the UK. 
 
It is well documented throughout the literature (Munoz-Plaza et al, 2008; 
Swan et al, 2010; Treloar et al, 2010; Treloar et al, 2014) that peer to peer 
communication plays an important role in PWID knowledge on hepatitis C. 
Other studies have shown the information is also obtained from healthcare 
staff (Carrier et al, 2005; Cullen et al, 2005) mass media public health 
messages, written materials and posters at clinics, books, television and 
the internet (Carrier et al, 2005). A study in Italy of 162 PWID found the 
source of hepatitis C knowledge was: other patients with hepatitis C (29%), 
healthcare providers (48%) press (36%), internet (10%), television (41%) and 
17% had no knowledge (Zanini et al, 2013). Showing people get their 
knowledge from a number of resources, with healthcare providers being the 
most common method, followed by the television (in the Italian cohort). 
Hepatitis C has not featured regularly on the television in England over the 
years, so this method is an unlikely source of information in England. 
 
Thus on initial searching there appears to be a paucity of research on where 
PWID in England get their information on hepatitis C and especially around 
alcohol consumption. 
 
To note, in an attempt to raise awareness of hepatitis C, increase numbers 
tested and achieve WHO targets (WHO, 2016) in 2017 PHE and partners 
produced a range of resources, namely banners for social media, videos on 
YouTube, online testing quiz and posters to be distributed to GP surgeries 
(PHE, 2018a). These resources were produced after data collection for this 
thesis so are not discussed in the interviews, however where participants 
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found out information was discussed in the observation and interviews with 
service users and is discussed in Chapters 4 and 5. 
 
As noted previously, current clinical guidelines are for those with hepatitis 
C to abstain from alcohol (RCGP, 2007; O’Leary et al, 2012; NICE, 2016b). 
Interestingly studies have explored the alcohol advice healthcare providers 
give to their patients who have hepatitis C. Studies conducted in the USA 
(Blixen et al, 2008; Stoller et al,2009a), found advice given by healthcare 
providers was inconsistent, with advice such as ‘stop completely’, ‘cut 
down’ and the ‘occasional drink was OK’ being provided. Sometimes 
providers gave a mix of messages. 
 
‘I tell them “….become a tee-totaler”, when the patient 
questions this, I tell them that it’s probably unlikely that it would 
cause a great deal of harm if they had the occasional drink’ 
 
‘alcohol was not routinely discussed unless the ‘patient comes in 
with symptoms or abnormal labs [blood results] then it comes up 
as part of the discussion, but on just a routine basis, talking about 
cutting down on alcohol or even the adverse effects of alcohol, 
takes a pretty minimal role’ 
 
(Blixen, 2008, p. 1293) 
 
To my knowledge this study has not been replicated in the UK, however The 
Department of Health itself has produced reports with ambiguous messages 
about alcohol use for people who have hepatitis C (Department of Health, 
2002; Department of Health, 2004). The Hepatitis Strategy for England 
suggested “avoidance of alcohol which may increase the risk of chronic liver 
disease” (Department of Health, 2002, p. 30) and the Hepatitis Action Plan 
stated; “reducing or stopping alcohol could help minimise the liver damage 
from hepatitis infection” (Department of Health, 2004, p. 6). 
 
Harris’s (2010) work with PWID in Australia and New Zealand also found 
mixed messages from medical professionals on alcohol use. Some 
participants were advised that alcohol could speed up the progression of 
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hepatitis C, however others said they received no advice: ‘whenever I 
mention drinking to doctors, they just kind of looked the other way’ 
(Rebecca). The article discusses the impact of ambiguous health messages 
on service users - Luke would have preferred unequivocal advice ‘and I kept 
saying, “are you sure it’s all right to drink?” and whenever anybody says to 
me, like the nurse or the specialist “yeah it’s okay you can have a glass or 
two. But just don’t binge drink or don’t overdo it”. That’s a green light to 
me. Its either you can or you can’t…’ (Harris, 2010, p. 1265). Luke drank 
throughout hepatitis C treatment, the treatment was unsuccessful and Luke 
wondered if his drinking had a played a part in the treatment failure. Harris 
(2010) suggests the apparent lack of definite advice to limit or cease 
drinking by some medical professionals might be due to the dearth of 
clinical evidence that moderate drinking affects hepatitis C progression. 
Furthermore Stoller et al’s (2009a) work with ‘non abusing drinkers’ found 
participants wanted stronger directives from healthcare professionals in 
order to quit drinking. 
This section has shown advice is not consistent with the recommendations 
for people with hepatitis C to be abstinent from alcohol and the dilemmas 
this poses for service users. 
2.6 Conclusion 
This review has considered relevant literature on testing, treatment, 
linkage into specialist hepatitis C support, peer support and alcohol and 
hepatitis C, highlighting barriers and facilitators to accessing support. 
These topics are explored further throughout the research findings. 
From conducting this literature review it is apparent that there is a paucity 
of literature on alcohol use in PWID who have hepatitis C in England, with 
a particular dearth of qualitative research on this topic. Following reading 
the literature on alcohol and hepatitis C, the study aims and objectives 
were formed. These are discussed in the methodology chapter, Chapter 3. 
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Chapter 3 Methodology 
 
3.1 Aims 
 
The aim of this research was to explore alcohol use in the context of 
hepatitis C and to discover PWID experiences and meanings of alcohol use 
and drinking behaviours over their lifetime with a view to informing services 
of PWID needs. 
 
More specifically the objectives of the study were: 
 
1. To identify PWID current and past drinking behaviours 
2. To examine the impact of PWID recovery from illicit drug use on their 
drinking behaviours 
3. To explore the impact a positive hepatitis C diagnosis has on PWID 
alcohol/drug use 
4. To understand where PWID obtain information about alcohol use and 
hepatitis C and what that information is 
5. To explore PWID perceived alcohol and hepatitis C service needs 
6. To explore PWID wider harm reduction and healthcare needs 
 
As explained in Chapter 2 there is a body of quantitative literature on 
alcohol use and hepatitis C however there is a paucity of qualitative 
research on this topic. This thesis intends to bridge that gap, using 
qualitative inquiry to explore the perspectives of people who have hepatitis 
C in the Merseyside region of England. The research aimed to understand 
the experiences, practices and meanings of alcohol for people living with 
hepatitis C to understand their needs and support requirements. The 
research design was inductive in nature, allowing topics and methods to 
emerge as the research progressed. 
 
 
61 
3.2 Methodology – Consideration of approaches 
 
When designing this research, decisions were made on how to ‘tackle’ the 
topic. As I wanted to explore in depth the lived experience, by talking to 
people with experience of the phenomenon of interest, this required a 
qualitative rather than quantitative approach. Quantitative ‘scientific’ 
approaches such as surveys, randomised controlled trials or use of 
secondary data requiring statistical analysis, are hypothesis driven and aim 
to produce ‘objective’, generalizable results (O’Leary, 2017). These 
approaches would not be suitable to provide the in-depth inductive 
exploration of experiences, meanings, interactions and perspectives sought 
in this research. There are however a variety of qualitative approaches 
available which were considered for use in this research and are discussed 
briefly below. 
 
The case study approach uses one (or a few) instances of a particular 
phenomenon with the aim being “to illuminate the general by looking at 
the particular” (Denscombe, 2017, p. 56). Thus by in-depth exploration 
with an individual case insights may be gained that have wider implications. 
Insights that may not have been found with a larger number of cases and 
less in-depth exploration. With this in mind cases are not randomly selected 
but chosen based on known attributes (Denscombe, 2017). For this research 
a case could be a person or an organisation. However how would the case 
be chosen? Firstly, I did not know anyone who matched the inclusion criteria 
(person who injected drugs with hepatitis C). Although it may have been 
possible to find a case from talking with colleagues within the public health 
department or contacting drug services, the nominated person would no 
doubt have been selected based on a criteria important to the 
department/service, such as someone who has previous helped with 
research or someone who is in ‘recovery’. Criteria that were not important 
to this research and participants that may not be ‘representative’ of other 
PWID with hepatitis C. Secondly the research was exploratory in nature. As 
there is so little literature on the lived experiences of alcohol use in those 
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who have hepatitis C, a number of participants were required to understand 
more about the topic. Also with such few historic studies it is difficult to 
know who is ‘representative’ to provide transferable findings (important to 
the approach), such as should the case be a person who drank ‘a lot’ or ‘a 
little’. Thirdly I also did not know the drug and alcohol services well enough 
to be able to say if the service I chose would produce generalizable findings. 
(After conducting the research I am aware that the services considered in 
this research did all run differently, as shown by the period of observation, 
service user interviews, and interviews with professionals). And lastly one 
of the fundamental beliefs of this research is that PWID are not a 
homogeneous group and therefore there is a benefit to observing and 
interviewing a number of people to understand the phenomenon, especially 
as this research relates to access to services, which need to provide access 
for the many and not a few.  
 
Another concern was whether a service user or organisation wanted to be 
researched in-depth. My thoughts from talking to services early in the study 
design phase of this research was that organisations were extremely busy 
and unlikely to give me a lot of time to do in-depth research on site. This 
hunch was indeed correct as when I conducted the interviews at the 
organisations I was often required to wait for a room, and move in and out 
of different rooms, working around the staff who were trying to see their 
service users in the same rooms. So based on these concerns the case study 
method was not chosen for this research.  
 
Action research was also considered but ruled out quickly as it was evident 
from the ‘four defining characteristics of action research’ (Denscombe, 
2017 p. 127) that it was not the best approach for this piece of research. 
The four characteristics are, practical in nature, change, cyclical and 
participation (Denscombe, 2017). Action research requires a practical issue 
to be researched often by a person working in the organisation who 
investigates the issue with a view to making a change. The process is 
cyclical in nature as the issue is identified and once researched, the findings 
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lead to a change which is implemented and then evaluated. The research 
at the very least must involve the practitioners as collaborators rather than 
subjects of the research but more generally it is the practitioners that are 
leading the research to explore their own practice. This approach was not 
suitable for this research as, I am not a practitioner in drug, alcohol or 
hepatitis C services; I did not have an ‘issue’ I wanted to/could change, 
rather the topic was more exploratory with a view to understanding peoples 
experiences and I questioned whether I would be able to receive this much 
collaboration from an organisation and its practitioners.  
 
Phenomenology was also considered as a potential approach to this 
research. At first it appeared suitable as it is concerned with understanding 
descriptions of the lived experience, however on further reading it became 
apparent that this approach was not appropriate for this research. There 
are different version of phenomenology; the two main approaches being 
descriptive as developed by Husserl, followed by Heideggar’s interpretive 
approach (Reiners, 2012; Tuffour, 2017). 
 
The descriptive phenomenological approach is concerned with obtaining 
detailed descriptions of everyday experiences. Concerned with presenting 
the experiences as close as possible to how the participant understands 
them, this approach requires the researcher to put aside ‘bracket off’ their 
preconceived opinions, assumptions and prior knowledge. Heidegger 
rejected the idea of being able to suspend personal opinions, believing 
instead in interpretation of the presented experiences, to explore 
perceptions and meanings (Reiners, 2012; Tuffour, 2017). Although my 
research philosophy is more in line with Heideggers interpretative 
approach, as I do not believe it is possible to ‘bracket off’ my assumptions, 
there are however other criticisms of phenomenological research that 
makes it unsuitable for my study. Phenomenology seeks to understand the 
lived experience but does not seek to explain why they occurred or consider 
past events, histories or social–cultural dimensions (Tuffour, 2017); aspects 
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deemed important for understanding the life histories of PWID who have 
hepatitis C and may or may not be drinking alcohol.  
 
The ethnographic approach was also considered but rejected as a 
methodology due to the ethical complexities associated with access and 
researcher safety. This methodology requires the researcher to spend a 
large amount of time ‘in the field’ (Denscombe, 2017; O’Leary, 2017). As 
one of the main aims was to explore experiences of alcohol consumption 
and drug use, presumably the ‘field’ may often have been out of public 
sight, so I did not feel this was an option for me as the researcher. 
Ethnography also seeks to understand a culture (Denscombe, 2017; O’Leary, 
2017), which was not one of the research aims. 
 
3.3 Methodology – A Generic approach 
 
Rather than allegiance to any one qualitative methodology, this research 
drew on the strengths of a number of different methodologies and used a 
generic qualitative approach to explore the topic. Being highly inductive 
and interpretive in approach, this research fulfils the general purpose of 
qualitative research, yet it ‘is not guided by an explicit or established set 
of philosophic assumptions in the form of one of the known qualitative 
methodologies’ (Caelli et al, 2003, p.4). Instead of working within the 
methodological confines of established methodologies such as 
phenomenology, ethnography or grounded theory, generic qualitative 
research has methodological flexibility (Kahlke, 2014). Thus rather than 
being constricted by theoretical ‘rules’, or ‘claiming a hollow allegiance to 
the accepted methodological positions’ (Thorne et al, 1997, p.172) 
(Sandelowski, 2010) this approach ‘simply seek[s] to discover and 
understand a phenomenon, a process, or the perspectives and world views 
of the people involved’ (Merriam, 1998 cited in Caelli et al, 2003, p.3). 
 
Indeed for this research, the overarching aim was to explore experiences 
and meanings of alcohol for PWID who have hepatitis C. Thus with this main 
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aim established, methods congruent with the research philosophy and 
deemed most useful to explore the research topic were chosen. For 
example, observation of service users was selected to learn the context of 
this topic and to build rapport prior to the interviews, and life history 
interviews using a calendar method were chosen to understand sequences 
of events over time. Regarding analysis, an ongoing constant comparison 
approach (see Figure 2) was used with one stage of the research informing 
the next. This constant comparison approach to analysis originates from 
grounded theory, yet intrinsic to this methodology is the generation of a 
theory (Strauss and Corbin, 1994). Although this research benefitted from 
using the ongoing constant comparison approach to data collection and 
analysis, it was not my intention to generalize the results and generate a 
theory. Likewise whilst using observation, the intention was not to 
understand a culture as ethnography requires (Cresswell, 2007; Denscombe, 
2017). However by selecting these methods/approaches to analysis, and 
using them outside of their traditional philosophy, interesting and 
informative research was produced. Research that would not have been 
possible and questions that would not have been explored, by using the 
more rigid traditional methodologies alone. Rather than finding a 
methodology that provides an ‘awkward fit’ to the research questions, 
‘questions can and should drive methodology rather than the other way 
round’ (Kahlke, 2014, p 47). Furthermore Lim (2011) suggests ‘this tendency 
[to inductive methodological approaches] is natural and even inevitable for 
those conducting their research on a topic or in an area where few theories 
or empirical studies have been available’ (p.53). Indeed as noted previously 
(Section 2.5.4) there has been only one other qualitative research study on 
experiences of alcohol use by people with hepatitis C, opening the way for 
new approaches to this topic, enabling exploration and furthering 
‘knowledge’ in a field that has a scarcity of such empirical studies. 
 
This pragmatic approach to research (Cooper and Endacott, 2007) is 
advocated by many (Cooper and Endacott, 2007; Lim, 2011; Kahlke, 2014 
and Percy et al, 2015, Bellamy et al, 2016) yet the freedom and flexibility 
66 
this approach allows engenders discomfort in those accustomed to working 
with a prescribed framework. Critique centres around ‘how to do it [this 
approach] well’ (Caelli et al, 2003) and issues of rigour (Caelli et al, 2003; 
Cooper and Endacott, 2007; Kahlke, 2014), generating a call for structure 
and ‘criteria for their [generic qualitative approaches] design and 
evaluation’ (Caelli et al, 2003, p.2). Caelli et al (2003) describe four key 
areas which ‘must’ be addressed in generic qualitative research to achieve 
credibility. The four areas are, the theoretical positioning of the 
researcher, congruence between methodology and methods, strategies to 
establish rigour and the researcher’s analytic lens. 
 
Theoretical positioning 
“Theoretical positioning refers to the researcher’s motives, 
presuppositions, and personal history that leads him or her toward, and 
subsequently shapes a particular inquiry” (Caelli, 2003, p. 5). Thus a 
researcher’s reasons for researching a certain topic are “never a naïve 
choice” (p. 5). Caelli et al (2003) recommend that researchers using generic 
approaches must clarify their theoretical positioning by covering three 
aspects, namely, identifying their disciplinary affiliation, discussing what 
brought them to the research questions and any assumptions they make 
about the topics being researched. Indeed it was not a ‘naïve choice’ that 
I am researching this topic, in this manner. 
 
I applied for an advertised PhD on topics that I was interested in, namely 
addictions and infectious diseases. Although I do not work in the field of 
hepatitis C or addictions, I do work as a nurse, so it is not a coincidence 
that I am conducting research on a health condition. Furthermore the way 
in which the research is conducted, qualitative as opposed to quantitative, 
is also not a coincidence, as my job requires me to work within ‘The Code’ 
of professional standards for nurses, which stipulates nurses must ‘listen to 
people and respond to their preferences and concerns’ (Nursing and 
Midwifery Council, 2015, p.4), an endeavour not too far removed from 
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conducting inductive qualitative interviews in order to understand people’s 
experiences with view to informing services.  
Approaching this topic from a different discipline such as the probation 
service or employment services, or from the position of a peer, would 
clearly produce different research questions and findings than research 
considering health and health services by a healthcare professional.  
 
Also for my PhD I have been based within a university public health institute 
where the majority of research conducted is applied, and not just an 
entirely philosophical endeavour. This again will also have influenced my 
style of researching and my desire to use the pragmatic generic qualitative 
approach. 
 
As a nurse, the ‘lens’ in which I view disease is from a medicalised 
viewpoint. Lupton (2012) notes that in Western society ‘medical views of 
the health, illness, disease and the body dominate public and private 
discussions’ (Lupton, 2012, vii), with little thought to the social and cultural 
meanings of disease. This research aimed to understand the meanings and 
experiences of alcohol and hepatitis C, the ‘lived experience’, for those 
who have the virus, requiring me to be aware of how my medicalised 
background leads me to make assumptions about health, disease, health 
seeking behaviours and so on. Some researchers (see phenomenology 
above) believe it is possible to put aside (bracket off) their assumptions, 
however it is my belief that this is not possible. My assumptions based on 
my experiences of working within health, along with identifying gaps in the 
literature, informed the research questions, as well as method, 
methodology and interpretive approach. 
 
Methods, methodology and the analytic lens. 
Caelli et al (2003) require researchers conducting generic qualitative 
research to distinguish methodology from methods and explain the analytic 
lens with which they engage with their data. “Methodology reflects the 
beliefs about knowledge and existence that arise from the values on the 
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philosophical framework that is to be employed” (van Manen, 1998, cited 
in Caelli et al, 2003, p. 6). 
 
This research uses an interpretive theoretical perspective, which ‘seeks to 
understand values, beliefs and meanings of social phenomena.’ (Hussain et 
al, 2013, p. 2375). Inherent to interpretive research is the belief that 
understanding and interpretation cannot be separated (Bhattacharya, 2008; 
Hussain et al, 2013). Bhattacharya (2008) argues that, ‘at some level, then, 
all social research [whether qualitative or quantitative] is interpretive 
because all such research is guided by the researcher’s desire to understand 
(and therefore interpret) social reality’ (p. 464). Clarity of the 
‘understanding being sought’ (Bhattacharya, 2008, p. 464) is given by 
considering the interpretive theoretical perspective in light of the 
ontological and epistemological underpinnings (Crotty, 1998). 
 
Ontology concerns the nature of the social world we aspire to understand 
and what we believe is reality. ‘What is the form and nature of reality and 
therefore what is there that can be known about it’ (Guba and Lincoln, 
1994, p. 108). Epistemology is the theory of knowledge (Crotty, 1998) or 
more specifically explaining ‘how we know what we know’ (Crotty, 1998, 
p.3). The epistemological question is ‘what is the nature of the relationship 
between knower or would be knower [researcher] and what can be known 
[or knowable]?’ (Guba and Lincoln, 1994, p.108). Thus the epistemological 
position cannot be considered without prior thought to the ontological 
position. 
 
Understanding of the interpretive ontological/epistemological stance, is 
perhaps explained best, by first considering, ‘what it isn’t’, and discussing 
the positivist position. 
 
For those working in a positivist paradigm, reality is out there in the world, 
existing independently of being observed. This reality can be studied 
objectively without the perceptions of the researcher (Hussain, et al, 
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2013). Guba and Lincoln, (1994) explain ‘the investigator and the 
investigated “object” are assumed to be independent entities, and the 
investigator to be capable of studying the object without influencing it or 
being influenced by it’ (p.110). Research conducted in this manner, finds 
the ‘truth’ (Guba and Lincoln, 1994). 
 
From an interpretive perspective, reality is constructed and interpreted. 
Thus ‘objects depend for their existence on the perception of people, the 
viewers’ (Hussein et al, 2013 p.2376). As human’s [researcher and the 
researched] perceptions are dependent on their experiences, cultural 
position and ideologies, and a phenomenon can have multiple meanings or 
interpretations (Guba and Lincoln, 1994; Creswell, 2007; Hussein et al, 
2013), thus there are multiple realities and multiple truths. Findings are 
created between the researcher and the researched (Guba and Lincoln, 
1994) and rather than being objective, the interactive researcher 
influences and interprets in light of their own experiences and background 
(Creswell, 2007; Hussein et al, 2013).  
 
Methods are tools used to collect data. The tools used must be congruent 
with the epistemological and ontological beliefs (Calelli et al, 2003). In this 
research observation and interviews were used. Methods were chosen with 
an understanding of and ongoing analysis of the researchers impact and the 
type of knowledge sought. Thus the interview methods chosen (especially 
with the service users) encouraged conversation, on the understanding that 
data is co-constructed. Also throughout the research especially the 
observation period, reflexivity (see below) occurred to reflect upon the 
researchers impact on the knowledge found. 
 
Strategies to establish rigour  
There are many strategies used in qualitative research to establish and 
verify rigour, such as saturation, crystallization, prolonged engagement, 
persistent observation, broad representation, peer review , triangulation, 
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full explication of method and member checking (O’Leary, 2017). A number 
of these strategies are discussed below in relation to this research.  
 
Triangulation involves “using more than one source of data to confirm the 
authenticity of each source” (O’Leary, 2017, p. 385). In this research, 
triangulation was achieved in a number of ways. Firstly, a variety of 
methods were used. For the service user aspect of the research, observation 
and interviews were conducted, as well as follow up interviews using a 
different interview technique with some service users. A range of research 
sites were also used. Service users for the research were from four different 
organisations. This sought to provide a variety of perspectives and not 
produce findings particular to one organisation. Having a range of 
participants along with a constant comparison approach to analysis, also 
ensured triangulation. Thus findings from the period of observation were 
checked with participants interviewed. Findings from interviews were 
checked on an ongoing basis with the next interview participant and so on, 
and interview findings were checked at follow up interviews. Furthermore, 
findings from the service user interviews and observations, were also 
discussed in the interviews with professionals, providing further 
triangulation (Shenton, 2004). Also as the professional interviewed were 
front line (service user facing) staff and commissioners which provided 
further triangulation on findings about the services provided.  
 
Explication of methods requires researchers to provide enough 
methodological detail so studies are reproducible or auditable (O’Leary, 
2017). A thorough explanation of the methods employed in this study 
(observation, calendar interviewing, interviews with vignettes and semi 
structured interviews) is provided in sections 3.5, 3.6, 3.7. and displayed in 
Figure 2 and interview schedules including interview questions are in 
appendices.  
 
Prolonged engagement is where the researcher spends sufficient time with 
participants or at an organisation in order to gain an understanding of 
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context and to establish a rapport in order to build trust (Shenton, 2004; 
O’Leary, 2017). The service user aspect of this research was designed after 
significant consideration of this point, as I believed participants would be 
more willing to share their opinions, perspectives and experiences with me 
(the researcher) if we had rapport and trust. The research design involved 
firstly a period of observation of support groups for people with hepatitis 
C. After a period of time (and hopefully rapport and trust built) the service 
users could then volunteer to take part in the interviews. One criticism of 
prolonged engagement is that researchers may become too immersed which 
could affect their professional judgement (Lincoln and Guba, cited in 
Shenton, 2004). However working reflexively should bring an awareness of 
this behaviour.  
 
Reflexivity is a continuous process of reflection by researchers on how their 
own values, preconceptions, behaviour or presence and those of the 
respondents, can affect the interpretation of responses. This involves 
researchers recognising that they are part of the social world under study 
(Parahoo, 2006). Thus researchers need to reflect on how their position, 
knowledge and interests affect every stage of the research process. Indeed 
in this research, reflexivity occurred throughout and is written into this 
thesis in numerous places, especially the observation method and findings 
sections (section 3.5 and Chapter 4). Prior to conducting the observations I 
considered how I may impact the support group, group leader, group 
members and ultimately the research findings. How should I act? How much 
should I say? Should I tell them I am a nurse? Where should I sit? This 
reflexivity continued on an ongoing basis as situations arose throughout the 
period of observation and throughout the whole research process, 
scrutinising my impact and ‘how I know’, on ‘what I know’ (Jootun et al, 
2009). 
 
Member checking is “checking the interpretation of events, situations and 
phenomena gels with the interpretation of insiders” (O’Leary, 2017, p. 
144). This occurred to a certain extent in this research however it was more 
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difficult in practice than envisaged. When observing the hepatitis C group, 
field notes were made. I offered to show these notes to the group I was 
observing but they declined. I did however have the opportunity each week 
to ask questions about previous weeks observations to clarify situations and 
check my interpretations. Also the service user interviews included follow 
up interviews, where participants could look over their transcribed 
interviews and timelines (see section 3.6.7). Unfortunately only 4 follow up 
interviews occurred, however these were helpful to clarify information not 
just concerning that participants but also in general and to check my 
interpretation of the interview findings. 
 
Saturation is when the researcher believes data collection can cease as any 
further data would not yield new findings or provide further understanding. 
(O’Leary, 2017). Caelli et al (2003) states that saturation in generic 
qualitative studies frequently lacks clarity and requests that researcher 
using generic approaches provide a clear explanation of the meaning of 
saturation within the context of the study. In this research 36 service user 
interviews were planned but after 21 participants I decided that I had 
reached saturation. Not regarding the individual intricacies but the broader 
pictures. For example, I had not reached saturation and (probably never 
would) on individual drinking practices or the individual stories on the 
circumstances surrounding their hepatitis C test, but rather saturation of 
the themes, such as hearing various stories of stigma, various comments 
about the difficulties with accessing treatment, stories of fear and 
examples of lack of knowledge and the impact of this. For the observation 
saturation was reached when there were no new members coming to the 
group and discussions did not provide any additional information or further 
depth. 
 
Methodolatry 
People wary of generic qualitative research for its nonalignment with an 
established methodology, risk being charged with methodolatry, ‘the 
privileging of methodological concerns over other considerations in 
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qualitative health research.’ (Chamberlain, 2000, p. 285). Chamberlain 
(2000) and Porter (2008) argue that a focus on methods/methodology 
originates from a positivist approach to research, and stops us looking at 
the assumptions behind our research (Chamberlain, 2000). Not only this, ‘a 
preoccupation with selecting and defending methods [is] to the exclusion 
of the actual substance of the story being told’ (Janesick, 1994, p.215). 
Thus this research rather than fixating on adherence to orthodox 
methodologies ‘prefers to capture the lived experience of participants in 
order to understand their meaning perspectives’ (Janesick, 1994, p.215). 
 
3.4 Introduction to the research methods 
 
A qualitative multi methods approach was used in this research. The first 
part of the research was with service users (PWID who have/had hepatitis 
C accessing hepatitis C or drug and alcohol services) and the second part of 
the research was with professionals (working in or commissioning hepatitis 
C, drug and alcohol services). 
 
For the service user research, a period of observation at hepatitis C support 
groups was undertaken followed by life history interviews using a calendar 
method. Follow up interviews with timelines (a form of calendar) were also 
conducted with some interview participants. 
 
For the research with the professionals, interviews were conducted. 
Vignettes of hypothetical service users were used with staff who work face 
to face with service users and more traditional semi structure interviews 
were used with commissioners. 
 
Ethical approval was provided by the Liverpool John Moores Research Ethics 
Committee, reference 14/ENC/050. The documents used to support the 
ethics application are provided in Appendix 1 and ethical issues are 
discussed within the methods sections (3.5, 3.6). 
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The methods employed in this research are discussed in more detail in the 
next sections of this chapter and depicted (along with the analytic process) 
in Figure 2. Data in this research were analysed using a combination of 
approaches. Generally, an ongoing constant comparative approach 
occurred throughout the various stages of the research and interview 
transcripts were analysed using thematic analysis as per the method 
described by Braun and Clarke (2006). For the service user interviews, 
individual calendars were studied to ascertain the sequence of events in a 
participant’s life. 
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Figure 2 Methods and analytical process 
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3.5 Observation – method 
 
3.5.1 Introduction 
 
The first stage of this research was a period of observation. 
 
“Observation involves the systematic viewing of people’s actions 
and the recording, analysis and interpretation of their behaviour.” 
 
(Gray, 2018, p.407) 
 
Whilst providing a basic explanation, this description over simplifies the 
research method which is not simply a question of looking at something and 
writing down ‘the facts’ but is a complex combination of the researcher’s 
senses, perceptions and interpretation of meaning (Gray, 2018). 
Furthermore observation concerns itself not just as a research technique to 
gather data, but involves gaining ‘entrance into and social acceptance by a 
foreign culture or alien group so as better to attain a comprehensive 
understanding of the internal structure of the society’ (Merriam 
Webster Dictionary, 2018). The degree to which the researcher seeks 
entrance into and social acceptability of the group depends on the 
researcher’s level of participation in observation. Spradley (1980) suggests 
five different degrees of participation from non-participation, where the 
researcher has no contact with the group, to complete participation, where 
researcher is completely integrated into the group or may even have been 
a member of the group beforehand. For this research, the level of 
participation changed throughout the period of observation and is discussed 
further in Section 3.5.4. 
 
3.5.2 Reasons for conducting observation 
 
As explained in Section 1.5, prior to conducting this research my knowledge 
of hepatitis C was limited. Although I had nursed people with hepatitis C, 
this had been a medical issue in the background, as my role required 
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prioritisation of the more acute condition, such as a heroin overdose in the 
emergency department, or monitoring the patient after a surgical 
intervention when I worked in theatre recovery. Thus this observation 
period was to explore and build an understanding of ‘context’, learning the 
issues that were important to the service users themselves which could then 
be discussed further in the next stage of the research, the service user 
interviews. 
 
The observation period also aimed to facilitate recruitment of participants 
to the interviews. As the observation was to be for a set period of time, it 
was hoped that the service users would learn about the research and would 
subsequently volunteer for the interviews. This also aspired to a shift in the 
traditional power dynamics between the researcher and participants, 
where service users could make an informed decision, over a period of time, 
regarding participation in the interviews and could then approach the 
researcher, rather than the researcher approaching them. 
 
Finally, I hoped that by spending time with the service users rapport and 
trust would be established, with a view to facilitating openness in the 
interviews and thus providing rich, in-depth data on their experiences of 
alcohol and hepatitis C. 
 
In reality this approach proved to be ineffective in finding participants for 
the interviews. At the first meeting with the group (Group 1), I explained 
that I would like to observe the group for several weeks and then I would 
be conducting interviews that they could take part in if they wanted to. I 
explained that if group members wanted to take part in the interviews they 
could let me know and before they took part they would need to read an 
information sheet and sign a consent form. I also explained that their 
participation and information they provided would be kept confidential. 
The group members seemed keen to participate in the interviews and asked 
a few times in the first couple of weeks if they could participate. 
Unfortunately at this point I felt I had not observed the group for long 
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enough to gather enough context and I did not think trust and rapport would 
be built after just a couple of weeks. However unfortunately during the 
course of the observation the group members dwindle and some of the 
people who initially showed interest in participating in the interviews 
stopped attending the group. In the end only one group member went on to 
be interviewed. Prior to data collection this strategy had been discussed 
with the group leader who noted the group was stable and had been well 
attended for many years, however in hindsight this lengthy recruitment 
strategy was not productive in finding interviewees from this group.  
 
3.5.3 Gaining access to the field - finding service user groups to be 
observed 
 
Preliminary discussions with organisations about this research commenced 
early in the research process. With the intention of conducting research 
with service user involvement as per patient and public involvement (PPI) 
policies, I visited a user forum (group for people who use/d heroin who had 
previously conducted their own research and attended conferences). At this 
meeting the study design was discussed and their views on the proposed 
research were obtained. They were keen to be involved with the research, 
however following ethical approval I contacted the forum and unfortunately 
the group had disbanded (see Group 3 below). Other than testing the 
interview method (see pilot interview section 3.6.5.2) there were 
unfortunately no other opportunities for PPI within this research. Indeed 
finding organisations where I could conduct this research proved to be 
challenging and protracted, requiring numerous emails, telephone calls and 
personal visits, resulting in discussions with seven organisations across 
Merseyside, of which two organisations had groups I observed.  
 
Group 1 was situated in a homeless charity. It ran one afternoon a week 
and lasted 1.5 hours. Observation occurred on nine occasions over a four-
month period (November 2014 and February 2015). 
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Group 2 was a hepatitis C group based in a drug and alcohol service. The 
group took place every other week and ran for 2 hours. Observation 
occurred on three consecutive occasions in February and March 2015. 
 
Observations of Group 1 and Group 2 are discussed below, but first an 
explanation of how I located the groups as this challenge was a point of 
learning, to be considered in any future research with this study population. 
It is important to note that in the interest of time management, 
conversations with these organisations were occurring simultaneously in the 
hope that I would gain access to at least one group, requiring much juggling 
and tenacity from me as a lone researcher. Also this section warrants 
explanation, as comments and events that occurred during the process of 
finding the groups, which seemed unimportant at the time, took on a 
different meaning and became significant as the research progressed. 
 
3.5.3.1 Access to Group 1 
 
I met with another researcher from my department, who had recently 
worked with a service user led organisation in Merseyside that provides peer 
support and drug and alcohol recovery information. This seemed like a 
suitable organisation for my research, and after discussions with the chief 
executive of the organisation, I visited the service. At the meeting, an 
explanation of the research was given and I was told, “We don’t do anything 
about hepatitis C here”. I wondered if I had met with the right people at 
the organisation, as their role was to get members involved in volunteering 
and work opportunities, however the importance of this comment became 
apparent as my research progressed, with findings showing occasions where 
hepatitis C was not discussed between healthcare professionals and service 
users. The organisation did however have an opioid support group and they 
provided details of the group leader, who I had numerous calls and emails 
with, however it became evident that the group had unfortunately 
dissolved. On discussion with the opioid group leader, he mentioned that 
this was largely due to the local drug and alcohol services, who referred 
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service users on to this service, going through a tender process. He 
suggested that service users are affected when services change and there 
are different staff, paperwork and processes being implemented. The result 
of this was that no service users were attending this opioid support group 
so there was no group for me to observe; an unfruitful outcome that had 
taken 5 months to establish. However, the visit was beneficial as they 
informed me about a local hepatitis C group in another organisation. I spoke 
on the telephone to the group leader (John), who was happy for me to go 
and meet the group to discuss the research, consequently this group 
became the first group I observed ‘Group 1’. 
 
I went to meet the group and explained my research; they confirmed they 
were happy for me to observe, which commenced a month later after 
obtaining gatekeeper consent (as required by the ethics committee). 
Gaining gatekeeper consent was not without its own complexities, it 
required much diplomacy to finally obtain. Although John (group leader) 
was happy to sign the form, and I felt an urgency to start data collection, I 
was unsure of his standing within the larger organisation, concerned that 
managers/directors at the organisation may not be aware that I planned to 
conduct research there. After further conversation with John it became 
apparent he was a peer educator (a person with personal experience of 
hepatitis C) and a volunteer at the organisation. I felt conflicted as I did 
not want to undermine John. I also strongly believe in the ethos of peer 
educators as a method which in the main, empowers those involved 
(Norman et al, 2008; Batchelder et al, 2017) and as explained previously , 
PWID are viewed as the experts in this research, but I also felt I needed to 
gain organisational approval for my research to go ahead. I surmise this 
caution’s origins lie in my background of working in clinical research where 
a strict approval process is followed prior to conducting research in any 
research site. After careful discussion with John he suggested that the 
manager should sign the form. Mindful of not getting John ‘in trouble’ for 
agreeing to participate in the research, in combination with a not-so-
altruistic need to find somewhere to conduct the research, I broached this 
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cautiously with the managers, who readily signed the gatekeeper consent. 
Once the form was signed I returned to the group the following week and 
the same people were present as at the initial introductory meeting. I 
explained the study again, provided the written information sheet about 
the research and they gave verbal consent for me to observe, so the 
observation started that day. 
 
It is worth acknowledging that the research focus changed at this point, as 
it is likely that observation of a general support group for PWID (such as the 
opioid support group or a user forum) would have provided different 
research findings than observation at a specific hepatitis C support group. 
 
3.5.3.2 Access to Group 2 
 
Communication with this organisation commenced in May 2014 and the first 
observation was in February 2015, thus taking a period of 9 months to gain 
access to the field. I had previously conducted clinical research at this 
organisation, in my role as a research nurse, and it is my belief that this 
previous collaboration, along with my status of being ‘a nurse’ helped me 
to get access for this PhD research. I met with a senior staff member who I 
had met during my previous research and explained the PhD research. She 
suggested that I observe their hepatitis C group rather than any other group 
at the organisation. This seemed appropriate, as I had already been 
observing another hepatitis C support group (Group 1). Following a formal 
approval process and receiving a letter of approval to conduct the research 
from the organisation, I arranged to attend their hepatitis C support group 
(Group 2). When I attended, I met with the two group leaders (Greg and 
Brian) but unfortunately there were no group members there. Greg and 
Brian demonstrated the hepatitis C test they used. Greg signed the 
gatekeeper consent and I arranged to attend the next support group in a 
fortnight. There were no ethical issues with the gatekeeper consent at this 
organisation, as the research had already been formally approved by the 
organisation and Greg was happy to sign the form. 
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3.5.3.3 Access to Group 3 (when established) 
 
As explained previously, the user forum I had met with at the beginning of 
the research had ended. This was due to changes in commissioning of 
services in that local area. The facilitator of the forum suggested another 
local service that I could contact. This service agreed for me to conduct the 
research there, however they did not have any groups I could observe, but 
mentioned they were in the process of setting up a hepatitis C support group 
which I could attend when it was established. On discussion about this the 
staff commented how difficult it was to set up a group, due to the stigma 
of having hepatitis C, saying they were not sure where to hold the group, 
as if people knew you were going to the group then they'd know that you 
had hepatitis C. This is an interesting point that is discussed further in 
Section 4.2.1. With no groups for me to observe I did eventually go on to 
conduct interviews at this organisation. Contact with this organisation 
continued until December 2015, and up until this date the hepatitis C 
support group was to my knowledge not set up. 
 
3.5.4 Method 
 
Two different hepatitis C support groups (Group 1 and Group 2), in two 
different areas of Merseyside, were observed. 
 
After each session, field notes were made in a note book, as soon as possible 
after leaving the group. These notes were factual in nature, regarding 
events that happened and topics that people spoke about. Rarely were 
direct quotes remembered and written down (depicted by quotation marks 
(“) in the field notes included in Chapter 4). After factual observations 
(things seen and heard) were documented, an early interpretation was 
made. The field notes were typed up at a later date. When returning to the 
notes I found that I thought differently about the documented events and 
gave further interpretation. 
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It is important to note that during the observation everything that was 
discussed was not recalled and that names and other identifiable 
information was not recorded. All entries in the field notes were depicted 
with an initial of a pseudonym only. The group participants were aware 
notes were being made and had verbally consented to this. I offered to 
share these notes with the participants, but they declined to see them. 
 
Service users and staff were able to opt-out of this process at any time by 
informing the gatekeeper or the researcher. No one opted-out during the 
course of the observation but if they had, their decision would have been 
accepted without question. The option to opt-out was explained at the 
initial meeting and on an ongoing basis when meeting new people (staff and 
service users). 
 
Although observation at Group 1 commenced prior to Group 2, Group 2 is 
discussed first, due to minimal observation and therefore findings. 
 
3.5.4.1 Observation of Group 2 
 
I attended Group 2 on the first week and met the two group leaders (Brian 
and Greg). There were no group members there. They also explained their 
roles, which comprised of conducting groups for Greg and running the 
needle exchange for Brian. They explained there was previously two 
hepatitis C groups in the organisation, one on the outskirts of town, and 
this one in the town centre. Due to lack of people attending, they decided 
to reduce to one group and kept the town centre group running as it was 
easier for people to get to if using public transport. The next time I 
observed the group (2 weeks later) Brian and Greg were the only people at 
the group again. They had arranged for a service user to attend to meet me 
and take part in the interviews for this research. The interview took 
approximately 1.5 hours and during this time no other person attended the 
hepatitis C support group. The third time I went to the group, once again, 
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no one attended. I decided not to go to the group again as there was not a 
‘group’. 
 
A few months later, when I was at the service conducting an interview, I 
saw Brian. He offered to arrange for me to meet with a person he had 
recently conducted a hepatitis C test on at the group, which had shown a 
positive result. I declined, feeling that it may not be in person’s best 
interests to be interviewed for research so soon after being diagnosed. 
However the discussion with Brian, hinted at the function of the group 
again, as an opportunity for testing and not accessing group/peer support. 
 
From this observation, it was apparent there was no ‘group’ despite two 
staff being on hand to take the group. There were also numerous posters 
and fliers advertising the group in waiting rooms and communal areas 
around the organisation. The reasons for nonattendance at the group were 
unclear at this point in the research, but were illuminated later in the 
observation of Group 1 and the service user interviews (see Sections 4.2 
and Chapter 5). 
 
3.5.4.2 Observation of Group 1 
 
3.5.4.2.1 Researcher’s role 
 
As observation requires the researcher to be the ‘primary tool’ for data 
collection (Schensul et al, 1999) it was important for me to consider my 
role. 
 
Considerations before entering the field 
 
Prior to the first time I met a group, I considered how I might come across 
to the group. I considered how I was going to introduce myself, how I was 
going to explain my research and what I should wear. I felt there was a lot 
riding on people’s impressions of me, and did not want to deter people from 
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helping me. According to Walsh (1998), ”once access to a setting has been 
achieved, the success of observational work depends on the quality of the 
relations with the people under study. Firstly, the researcher needs to 
consider the initial responses of people in the field and how to gain their 
trust.” (p. 225). This ‘impression management’ was to facilitate 
observation and avoid generating obstacles (Walsh, 1998). In terms of dress, 
I opted for jeans and trainers, as felt the group would probably be wearing 
casual clothes and I wanted to fit in, although this was not a vast difference 
from my usual attire on the days I was ‘a student’, this was definitely 
different to the attire I wear on the days I am ‘a nurse’. However there 
were certain personal characteristics that were non-negotiable, such as my 
age, gender, ethnicity, physique and voice, giving an expectation of how I 
act and interact in society and understanding that a person with different 
personal characteristics would build different relationships and therefore 
produce different research results (Denzin and Lincoln, 1994). 
 
At the introductory meeting, everyone sat around a table and talked. The 
room was not much bigger than the table itself. I presumed that every week 
they would sit around the table and talk, so between the introductory 
meeting and the first observation, I considered how I would conduct myself 
within the group and where I would sit. I decided I would sit beside them 
at the table as I thought sitting away from the group, which would 
effectively in this small room be sitting right behind them, would make 
people feel uncomfortable and emphasise their position as research 
‘subjects’ being ‘watched’. Deciding I would need to sit with them at the 
table and converse with them, the decision on how much to talk was, 
however, more difficult. As a naturally sociable individual, whose career as 
a nurse requires regular communication with people, trying to get the right 
balance between joining in with the conversation and observing others was 
something I needed to consider prior to the observation. I was aware of a 
conflict between ensuring data was obtained and a need to maintain 
ordinary social behaviours in order to fit in, create rapport and ensure 
continued acceptance to remain in the group. 
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Self-disclosure 
 
As one of the main aims of the observation was to build rapport with the 
group members in an attempt to build trust in the interviews, I felt I needed 
to ‘be myself’ to forge these trusting relationships, yet this brought up an 
ethical dilemma for me - should I disclose I am a nurse? My concerns were 
that I may sway the discussion towards more medical themes or they may 
start asking me questions about their own health, for example, or that the 
opposite may happen and that people would not talk about certain things 
as there was a nurse present, such as illegal activities (injecting or crime) 
or they may decide not to discuss staff in case I know them. I was also aware 
of the power dynamics of a nurse/patient relationship, which went against 
my research ethos of the participants being the experts in this topic. 
Although feeling duplicitous, I decided I would not tell them I was a nurse 
unless I was asked directly. However I was confronted with this dilemma 
the first time I went to meet Group 1. 
 
A lady asked me directly a few times, in a few ways, my 
background. I skirted around nursing a bit, but in the end felt like 
I was coming across a bit vague and probably like I was hiding 
something. I ended up saying I’d done a degree in health studies 
and a nursing degree. She just replied ‘you’ll have loads of 
degrees’, no one else appeared to pick up on my nursing. 
 
[Field notes: Introductory meeting] 
 
It is impossible to know if the group discovering my vocation impacted on 
the group’s discussions. However when my nursing job came up in 
conversation I was keen to explain I worked in a completely different 
speciality and not the hepatitis C or drug/alcohol services, but I was 
interested in hepatitis C and wanted to learn from them. 
 
Conflict of roles 
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One person said “you get hep C from drinking”, I corrected him, 
should I have? 
 
[Field notes: Introductory meeting] 
 
This situation occurred during the first time I met the group. My response 
had been immediate, as if on autopilot, without thought to the 
consequences of my actions. After, I questioned my response, concerned I 
had acted as a nurse rather than a researcher and wondering how this might 
affect my research. The aim of the observation was to learn from the group, 
not impart knowledge. I speculated, after this ‘correcting’, that group 
members may view me as someone with knowledge, which may encourage 
them to ask me questions about hepatitis C (rather than telling me their 
experiences of it) or perhaps cause hesitancy to speak, in fear of getting 
facts wrong. My concern was of introducing bias by altering how group 
members acted/spoke (Ashton, 2014). This situation prompted me to revisit 
my reflexivity, to acknowledge my influence on the research (Colbourne 
and Squire, 2004). 
 
Although the impact of this situation on the ongoing observation is 
unknown, in its immediacy however, I had potentially curbed a conversation 
about alcohol and hepatitis C, the exact topic I was researching. 
 
Also as it was John’s (group leader) role (and not mine) to educate the 
group, I was retrospectively aware of the potential effects my comment 
may have on my relationship with John; not wanting to ‘step on his toes’ 
by taking over his role, or ‘showing off’ making him feel inadequate, if he 
did not know the information I was giving. Although not meaning to offend 
John, I realised if I had caused offense I could be disallowed to continue 
observing; a catastrophic result for my research, but should I have let the 
comment go, without correcting it? 
 
As hepatitis C is predominately transmitted by contact with blood that 
contains the virus and not through drinking alcohol, this comment gave an 
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interesting but worrying insight into their level of knowledge on the 
transmission of hepatitis C. Not knowing how the virus is transmitted 
increases the risk of transmitting hepatitis C to others but also puts the 
person with hepatitis C at risk of contracting a second hepatitis C virus with 
a different genotype. 
 
Thus I had acted as a nurse would, educating those with an illness about 
the disease to reduce harm. Although in this environment I was a researcher 
and these people were not patients I was looking after, I still felt a duty of 
care towards them. I felt conflicted by my actions but also contemplating 
which of my roles should take precedence in such situations. 
 
This conflict of roles between researcher and nurse is documented by many 
nurse researchers (Beale and Wilkes, 2001; Colbourne and Sque, 2004; 
Wilkes and Beale, 2005; McGarry, 2007; McConnell-Henry et al, 2009-10; 
Ashton, 2014). The majority of literature is based on those who are 
conducting research in a clinical environment (Gerrish, 1997; Beale and 
Wilkes, 2001; Wilkes and Beale, 2005) or where a life threatening situation 
occurs. In my opinion, this is a less ambiguous situation, as nurses in the UK 
follow a code of conduct that requires us to ‘always offer help if an 
emergency arises in your practice setting or anywhere else’ (Nursing and 
Midwifery Council, 2015). Thus we are required at all times to offer help in 
an emergency, which would include whilst conducting research. However 
the roles are more blurred when there is not an emergency situation, but 
one where nursing skills or knowledge could be provided, such as talking to 
bereaved relatives (Ashton, 2014) or as in my situation, offering education 
to reduce harm. The literature reaches no overall conclusions on when 
nurse researchers should act as nurses or researchers (Beale and Wilkes, 
2001; Wilkes and Beale, 2005). During the ongoing observation, I considered 
dilemmas on a case by case basis, striking a balance of acting ‘within the 
boundaries of [my nursing] knowledge base‘ (Eide and Khan, 2008, p. 205) 
and signposting to other sources, such as their own care team. The latter 
of these was the approach used in the majority of cases. 
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Ethical dilemma: “Do you want a lift” 
 
Usually when the group finishes, Kath [group member] gives John 
[group leader] and Seb [group member] a lift home in her car. 
However, tonight Kath didn’t attend the group. When the group 
had finished, we all left the building at the same time and my car 
was parked right outside the door. Should I ask if they want a lift 
home? A spur of the moment decision was required. I offered, 
they accepted. 
 
[Fieldwork Notes Week 4] 
 
This dilemma was a situation I had not considered prior to commencing the 
observation. According to Schensul et al (1999), 
 
“In ethnographic research, researchers lack the kind of control 
over the conditions of research that characterizes clinical, 
experimental, or even cross-sectional survey or epidemiological 
research. Ethnographers must always be open to surprises…”. 
 
(Schensul et al, 1999, p. 274) 
 
My usual behaviour after attending a group in my own social life, such as 
my yoga group for example, would be to offer a lift. I did not really see this 
as anything different, as I had spent time with these people talking over 
tea and cake and now I was driving in the direction of their home. It was a 
cold, dark, winter’s night, so it seemed like the decent and habitual thing 
to do, but what would the ethics committee say if they knew? On the ethics 
application I stated the risk to the researcher was ‘low’, as I would be 
meeting with service users in an organisation, yet I had a service user in my 
car. Although I felt safe, I had invited two men into my car, one of which 
was potentially using illegal substances; I am not sure the ethics committee 
would agree with this action. 
 
When reading on ethnography, at a later date, I found the following point: 
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“Reciprocity also is important. Often, research participants will 
ask researchers for personal favours. Failing to respond not only 
harms relationships but may even jeopardize the project. Thus, 
ethnographers should be individuals who enjoy helping people out 
in difficult situations, rather than viewing such requests as an 
instrumental obligation encountered primarily as a means to 
facilitate getting data.” 
 
(LeCompte and Schensul, 1999, p. 162) 
 
Whilst wanting to help, my reasons for offering a lift were however not out 
of kindness alone but also a conscious decision, due to a continuing 
awareness of how my actions would appear to the group and feeling that 
my continued acceptance within the group may depend on this decision. 
Initially when observing I was continuously working at building relationships 
and trying to gain rapport, in order to maintain permission to observe and 
in anticipation for the future interviews. 
 
The researcher’s changing role 
My position as an observer was difficult to define, lying somewhere between 
participant as observer and observer as participant, fluctuating between 
the two and changing throughout the period of observation. For participant 
as observer: 
 
“the observer and the people being studied are aware that theirs 
is a field relationship which minimizes the problems of pretence. 
It involves an emphasis on participation and social interaction over 
observing in order to produce a relationship of rapport and trust”. 
 
(Walsh, 1998, p. 222) 
 
This description fits with my overt method of observation, where the ‘field 
relationship’ was established when I met the group to explain about the 
research and my role in it. This description also corresponds with my 
endeavour of building rapport and trust with people during the period of 
observation, to increase trust and depth of information provided in the 
interviews. I was also able to achieve a level of ‘social interaction’; we 
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were a small group, in a small room, sitting, talking and drinking tea. 
However, I question how much I was able to ‘participate’. Although I was 
able to sit at the table and have conversations, as the group members were, 
each group member discussed their hepatitis C, which, I was unable to talk 
about as I do not have hepatitis C, therefore my complete participation in 
this activity was not possible. I also consciously did not want to participate 
(talk) too much, as I wanted to observe what the group were saying, to 
learn from them, rather than talking myself. The placing of observation 
above participant is key in observation where the researcher’s role is 
observer as participant. Although it is suggested that this 
 
“restricts understanding because limited participation in social 
activities heightens the possibilities of superficiality, so that 
important lines of inquiry may be missed or not pursued. Things 
go unobserved and the activities of participants are not properly 
understood” 
 
(Walsh, 1998, p. 222) 
 
This point seems somewhat irrelevant here as I largely participated in the 
social activities, which were sitting around a table, drinking tea and talking 
(which was not always about a personal experience of hepatitis C). 
However, I did miss one social activity which was going outside for a 
cigarette break. As a non smoker, it did not occur to me to go outside with 
the smokers. This may have produced interesting information and therefore 
be an omission in this research. However overall my role was as a 
participant observer rather than observer participant, participating 
progressively as time went on. 
 
Early in the period of observation, I noted the following: 
 
One man said ‘fuck’, looked at me and then apologised – was he 
and perhaps they, altering their behaviour/ vocabulary for me? 
 
[Field notes: Introductory meeting] 
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As someone that ‘required’ an apology for a word being used, there was 
some judgement being made on me; I was definitely an outsider, a visitor 
to their group. As the weeks went by I fell into a balanced role of ‘chatting’ 
with the group when they spoke about non hepatitis C related topics and 
listening when they spoke of hepatitis C. My relationship with John was 
different from the rest of the group, as I assisted him in his role of making 
tea at the start of the session or washing the cups at the end. Although not 
a deliberate strategy, but rather trying to make myself useful, I believe this 
‘helpful assistant’ position helped me to be accepted within the group, and 
like Purdy (Purdy and Jones, 2013) in her research, “I was certainly aware 
that I wanted to and was moving in from the periphery of the research 
context in the search for more personal access” (Purdy and Jones, 2013, p. 
300). 
 
Over time, my role within the group evolved further, as my relationship 
with Kath was changing and we were becoming ‘friends’. 
 
Week 7 of the group only Kath, John and I were there. Kath had 
already offered to take part in the interviews and John suggested, 
I should interview Kath in the group time as there were no other 
group members there. I interviewed Kath and when we were 
leaving to go home: 
 
Kath hugged me when I left tonight- she hasn’t done this before 
 
[Field notes: Week 7] 
 
At the time I wondered if she felt closer to me after the interview, as she 
had shared aspects of her personal life with me, not only about her hepatitis 
C and drug use, but other information about her life such as broken 
relationships and family deaths (see Section 3.6 for explanation of the life 
history calendar method). However I observed the group for a further 2 
weeks and she continued to hug me when saying “bye” at the end. 
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I had hoped to build rapport during the observation period and interviews, 
and now I had built this relationship with Kath, I felt uncomfortable. Kath 
was not imagining this ‘friendship’ as we did really ‘get on’ and I could see 
myself being friends with Kath if we’d met under different circumstances, 
however, we had met when I was a researcher, who had to a certain extent 
portrayed a version of myself, reacting to some conversations as my role as 
a researcher and not providing my own opinion. 
 
Discussions in the literature have focused on the blurring of boundaries 
between researcher and participant, and rapport and friendship (Eide and 
Khan, 2008; McConnell-Henry et al, 2010; Miller, 2016). With Duncombe and 
Jessop (2012) suggesting ‘doing rapport’ and ‘fake friendships’ encourages 
participants to disclose information they would not otherwise have done. I 
definitely did not want this for Kath, and I prefer to take my lead from 
Oakley (2016) who suggests distinctions between friendship and rapport in 
research are unhelpfully blurred (Glesne, cited Oakley 2016), concluding 
that friendships are not uniform and in any context can take many forms. 
Indeed Coffey (1999) suggests such ‘ethnographic friendships’ are actually 
important as they remind researchers that they are part of what they study. 
I certainly was not having a ‘fake friendship’ with Kath yet I continued to 
grapple to maintain a degree of the methodologically required 
‘marginality’, “a poise between strangeness which avoids over-rapport and 
a familiarity which grasps the perspectives of people in the situation” 
(Walsh, 1998, p. 227). A position that causes the researcher ‘considerable 
strain’ and will affect the researcher “physically and emotionally” (Walsh, 
1998, p. 227). Indeed our ‘friendship’ was to cause me emotional upset as 
I navigated leaving the field. 
 
As the weeks went by, the group became less well attended, with Kath 
being the only person to attend for the last 3 weeks I observed (weeks 7, 8, 
9). During week 8, my observation was: 
 
John watching TV, kept saying he felt tired 
Kath sitting quietly 
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They chat every now and again 
John didn’t even ask Kath how she was this week 
Group finished early – 5pm 
Kath had only got there 4.30 
 
[Field notes: Week 8] 
 
Although I initially could not understand why John had not led the group in 
the usual way and had not even asked Kath how she was, it became clear 
that they had met earlier in the week when John accompanied Kath to a 
hospital appointment, so this prior meeting may have explained the lack of 
conversation between them. Therefore they were in touch and Kath was 
getting support, outside of the group time, which led me to question why 
Kath was still attending the group when there was in effect no ‘group’. I 
decided that the following week would be my last week of observation, as 
there was no ‘group’ for me to observe and I had reached saturation in my 
observation. 
 
I felt uncomfortable on the last week of observation, realising that my role 
within the group had changed again and I was at risk of over-empathising 
as I had in effect become a group member. I was ‘propping up’ the group, 
keeping the group running, suspecting that as I was leaving the group, it 
would cease to exist. This caused a feeling of guilt which magnified when I 
said bye, and Kath said: 
 
“it’s been nice having some female company” – hugged me 
 
[Field notes: Week 9] 
 
Confirmation that although not my intention, I had played an important role 
in ‘the group’ and a realisation of what Kath was perhaps receiving from 
the group – company.  
 
Walsh (1998) notes, ‘Leaving the field will have to be negotiated, as it 
entails closing relations with participants that may have been firmly 
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established and which they may not wish to relinquish’ (p. 227). However 
as well as the group’s feelings around this, I also found disengaging with 
the group (especially Kath) difficult emotionally, knowing that I may not 
see them again and feeling extremely grateful for their contribution to my 
research and PhD. A realisation that leaving the field had been more 
difficult for me than entering and recognising that I had given minimal 
advanced consideration to disengagement, a situation noted to be common 
amongst qualitative researchers (Allum, cited in Labaree, 2002). 
 
3.6 Service user interviews – method 
 
3.6.1 Introduction 
 
Interviews using a life history calendar (LHC) were conducted with PWID 
who have hepatitis C, to explore their experiences of substance use, alcohol 
use and hepatitis C. Follow up interviews were then conducted using a 
timeline (a form of calendar). As the method employed for these interviews 
is innovative in nature, the initial section of this chapter is dedicated to 
discussing the method and its application. More specifically, this chapter 
commences with an explanation of what calendar interviewing is, with 
examples of how others have used calendars in their research. My 
motivations for using calendar interviewing are then explained, followed by 
my experience of conducting interviews using a calendar, starting from 
designing the calendar to the practicalities of using it and the experiential 
learning that took place. The methodological findings are then discussed, 
explaining the benefits and limitations I found when using calendar 
interviewing. 
 
3.6.2 Background to calendar interviewing 
 
Calendar interviewing is “a data collection method for obtaining 
retrospective data about life events and activities” (Caspi et al, 1996, p. 
101). A chart is used to plot the participant’s life events enabling the 
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“construction of a visual temporal framework” (Wilson et al, 2007 p. 136), 
which allows the timing, sequence and interrelation of events to be seen 
(Axinn et al, 1999). 
 
Calendar based interviewing was developed and first used in 1969 by Balán 
and colleagues, who sought a technique that could gather rich retrospective 
life histories from a large sample size. Prior to this innovation, detailed life 
histories were collected from small numbers of people or quantitative 
approaches were used to gather specific and partial life course data from 
large numbers. Balán et al’s (1969) calendar approach combined these 
aspects, enabling multiple events and their sequences to be explored on a 
large scale. Balán et al (1969) interviewed 1640 Mexican men and gathered 
histories on their education, work, partners, children and health. 
 
Since Balán et al’s (1969) innovation, the method has been developed and 
adapted and numerous studies using calendars of varying names and designs 
have been used in a variety of ways, to gather data on a wide variety of 
subjects, with differing study population sizes. Calendars have been 
adapted for use in many specialities including criminology, psychology, 
nursing, economics, education, marketing, social work, psychiatry, and 
sociology (Belli et al, 2009). A few examples of using calendar interviewing 
in research include: using a ‘self-discovery tapestry’ (Meltzer, 2001), an 
‘occupational events calendar’ or an ‘occupational history calendar’ 
(Hoppin et al, 1998, Engel et al 2001, Zahm et al 2001, Porcellato et al, 
2010; Lilley et al 2011) to explore people’s occupations over their lifetime; 
using a ‘life events calendar’ to understand women’s roles in violent crimes 
(Kruttschnitt and Carbone-Lopez, 2006), socioeconomic behaviours over a 
2 year period (Belli et al, 2001) and drinking, smoking or marijuana use by 
men and women during pregnancy (Bailey et al, 2008); ‘life grids’ to 
investigate health inequalities over a lifetime (Holland et al, 1999), ‘life 
history calendars’ to understand the impact a physical disability (Scott Ricks 
et al, 2011) or domestic violence (Yoshihama et al, 2002) has over a lifetime 
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and ‘life chart interview’ to track the course of psychopathology over time 
(Lyketsos et al, 1994). 
 
From the literature, there does not appear to be an explanation for the 
variation in terminology (Glasner and van der Vaart, 2009). Belli and 
Callegaro (2009) have circumnavigated this issue by coining the term 
‘calendar interviewing’ to be inclusive of all methods using a time based 
chart to gather retrospective data. 
 
In the research conducted for this thesis, the calendar was initially called 
the life ‘events’ calendar, however during the process of conducting the 
research this was changed to a life ‘history’ calendar; although the calendar 
itself did not alter and the change was in name alone, the change was made 
to reflect the research philosophy; aiming for in-depth descriptions of 
participants lives. Martyn and Belli (2002) stated “Life history calendar 
(LHC) may be used interchangeably with event history calendar (EHC) 
however the LHC label is used when long-term life course data is collected 
and EHC is used when specific event data is collected over shorter periods 
of time” (Martyn and Belli, 2002, p. 270). During the course of conducting 
the interviews it became apparent that for the participants, drug use, 
alcohol use and hepatitis C were not ‘specific events over short periods of 
time’ but were intertwined situations with a history, a future and a present, 
infiltrating many aspects of everyday life, lingering, sometimes in the 
background sometimes in the fore, but whose impact was long term; thus a 
‘LHC’ was used to gather rich life histories from the participants. 
 
Since Balán et al (1969) pioneered the technique, calendar interviewing has 
gained momentum, predominantly due to its accuracy on recalling self-
reported data (Sayles et al, 2010; Sutton, 2010). By visualising events on 
the calendar, participants can cross reference these events and consider 
the sequence of events, which can trigger further memories (Freedman et 
al, 1988; Axinn et al, 1999). Many studies have since tested the calendar 
method to assess its reliability for recalling retrospective data (Freedman 
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et al, 1988). For example, Belli et al (2001) compared the quality of data 
obtained from a ‘question list’ interview and a calendar interview when 
recalling retrospective reports from 1 to 2 years before. The study found 
“higher quality retrospective reports” (Belli et al, 2001, p. 63) with the 
calendar method. Considering a longer recall period, Berney and Blane 
(1997) conducted calendar interviews with people aged 64-83 years to ask 
them about their social circumstances during their childhood and youth. 
This data was then compared to archived material from the same people 
that was recorded 50 years earlier. The study found a “useful degree of 
accuracy” (Berney and Blane, 1997, p. 1519) when comparing the two data. 
More specifically, Caspi et al (1996), found a 90% agreement between 
retrospective data collected on a LHC compared to reports from 3 years 
before. 
 
Concern regarding the reliability and validity of retrospective data, is 
largely a quantitative endeavour, thus historically calendars have 
predominantly been used quantitatively. More recently, a few researchers 
have used versions of the calendar as part of mixed methods research (Scott 
Ricks and Harrison, 2011; Porcellato et al, 2016) or for qualitative studies 
(Parry et al, 1999; Martyn and Belli, 2002; Martyn and Martin, 2003;  Harris 
and Parisi, 2007; Nelson (2010); Porcellato et al, 2016). To my knowledge, 
the first example of calendars being used qualitatively was in 1999 in Parry 
et al’s research exploring long term patterns of smoking behaviour amongst 
adults with a smoking related illness. Martyn furthered the qualitative use 
of calendars in her work researching adolescents’ patterns of sexual activity 
within the broader context of their lives (Martyn and Martin, 2003, Martyn, 
2009). Other examples of research using calendars qualitatively include: 
Harris and Parisi’s (2007) work exploring welfare transitions in females; 
Wilson et al’s (2007) study with young people (aged between 16 and 23 
years) to explore their experiences of parental substance use (illicit drugs, 
alcohol or poly drug use) and resilience in this context; Feldman and 
Howie’s (2009) research to understand life after work and the effects of 
health on leisure time activities with older people and Nelson (2010) who 
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explored educational trajectories with Latino young adults. These studies 
vary in design but their commonality lies in their main focus, which was not 
quality of recall, but, as with the philosophy of qualitative studies in 
general, wa to explore individual’s stories and to hear their views and 
experiences. 
 
In regards to the topics (hepatitis C, alcohol and substance use) and study 
population (PWID with hepatitis C currently or in the past, who may or may 
not be on opioid substitution therapy) of this thesis, there have been a 
number of studies across the quantitative (majority of studies) and 
qualitative paradigms that have used calendar interviewing. 
 
In terms of substance use, pioneering examples are: the study of drug use 
careers (trajectories of drug use over time) by Adams and Henley (1977) 
and a calendar technique named the ‘natural history interview/instrument’ 
in 1975 by Nurco et al, (cited by Hser et al, 1992) and adapted in 1977 by 
McGlothin et al (cited by Hser et al, 1992) and more recently advocated by 
Hser, Anglin, Chou and colleagues to study drug careers and drug treatment 
careers (trajectories of drug treatment over time) (Hser et al, 1992; Anglin 
et al 1993). An eminent example in alcohol use research and clinical 
practice is the ‘Timeline Follow-Back’ technique developed by Sobell and 
Sobell (Sobell et al, 1988), which asks people to recall their daily drinking 
over short periods of time (up to 12 months). 
 
More recent examples of calendar research on substance/alcohol use are: 
Skinner et al (2011), Copeland et al (2012) and Fikowski et al (2014). Skinner 
et al (2011) used a calendar quantitatively as part of a larger study design 
following the lives of opiate addicted parents. The parents were originally 
recruited in 1991 and then followed up 2005/2006. In the 2005/2006 
interviews a LHC was used to gather information on drug use, health service 
utilisation, drug treatment, marital status, employment and incarceration 
over the 10 years between 1995 and 2005. At the time of the interview 
using the LHC, approximately half of participants were using illegal drugs 
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(opiates, marijuana, cocaine, crack cocaine, amphetamines or 
benzodiazepines) and others were on opioid substitution therapy (OST), so 
although this study did not consider hepatitis C it showed that a LHC could 
be used with a similar population to this PhD. Fikowski et al (2014) used a 
LHC to explore patterns of drug use and access to drug treatment in chronic 
opioid users in reference to a life time period. Although this research was 
published after I had commenced my interviews so had no bearing on my 
decision to use calendar interviewing with this population, it is another 
example of calendars being used successfully with the study population. It 
also demonstrates that calendars can be used to gather data on a long-term 
‘life time’ basis. Copeland et al (2012) used a life grid to collect life 
histories and explore premature deaths amongst PWID in Scotland. 
 
In relation to hepatitis C, a life grid (McGowan et al, 2013) and timeline 
have been used qualitatively to understand protective practices employed 
to avoid transmission of hepatitis C (Harris and Rhodes, 2011; Harris et al, 
2012) and hepatitis C/HIV (Friedman et al, 2008) in PWID. Harris and Rhodes 
(2013b) have also used a timeline to explore injecting practices within 
sexual partnerships. Although these articles focused on injecting and 
prevention of hepatitis C (and HIV in one article), as opposed to drinking in 
people with hepatitis C, they demonstrate that calendar methods can be 
used qualitatively with PWID to discuss hepatitis C. The timeline method 
used by Friedman et al (2008) and Harris and colleagues (2011, 2012 and 
2013b) was employed in the follow up interviews in this thesis. 
 
Russel et al (2012, 2014) have published two papers that used a ‘lifetime 
event calendar’ to discuss hepatitis C, alcohol and drug use. One paper 
assessed the impact of drug use on outcomes of hepatitis C treatment 
(Russell et al, 2014) and the other explored if alcohol use impacts on the 
outcome of hepatitis C treatment (Russell et al, 2012). Although this study 
considers alcohol and hepatitis C it is different to this thesis in two ways. 
Firstly, it specifically considers the outcome of treatment when drinking 
with hepatitis C, which this thesis does not set out to explore. Secondly, it 
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is with a different study population to those interviewed for this thesis, as 
it focuses on privately insured members of an integrated healthcare plan in 
the USA, where there were high rates of employment. According to the 
authors, the majority of the participants had a history of injecting drug use, 
but ‘they differ from patients recruited from drug treatment programs in 
that few, if any, were withdrawing from recent heavy drug use’ (Russell et 
al, 2014, p. 226). 
 
Calendar interviewing has been used with PWID (who may or may not be on 
OST); to consider alcohol use; to consider substance use; to explore 
different aspects of hepatitis C; and has been used qualitatively, but to my 
knowledge the research explained in this thesis is novel as it combines all 
of these aspects. 
 
3.6.3 Reasons for using LHC 
 
There are three main reasons why the LHC was the chosen method for the 
service user interviews, namely, it enables sequences, triggers and patterns 
of behaviours to be seen over the long term; it places events at a time 
point, giving context to the event; and it is a method that challenges the 
traditional power dynamics of interviews. These points are explained in 
more detail below. 
 
3.6.3.1 Sequences, patterns, triggers and interrelationships of 
behaviours and events. 
 
“…human lives are uniquely shaped by the timing and sequence of 
life events and experiences across rather lengthy periods of time. 
It is now a commonplace assumption that events occurring in the 
past can have powerful influences on present and future well-
being” 
 
(Belli et al, 2009, p. 2) 
 
103 
In keeping with this assumption and in line with the aims and objectives of 
this research (see Section 3.1), I wanted a method that would allow 
participants to describe their past as well as present situations; to explore 
patterns, sequences and connections of events and behaviours, along with 
the ‘triggers’ for behaviours. Calendar interviewing is a method that has 
been shown to enable this (Freedman et al, 1988; Sutton, 2010) by allowing 
sequences of events to be plotted on the calendar and more than one topic 
to be considered. By plotting all domains on the calendar, observation of 
how they relate is possible. As explained by Freedman et al (1988, p. 38) 
“the life course is not a unidimensional series of events unfolding and 
evolving over time but a simultaneous unfolding of many dimensions all 
interwoven temporally and causally in complex ways.” In this research, I 
hoped the method would allow the connections and interrelations of 
hepatitis C, alcohol and drug use over the participants lifetime to be seen, 
illuminating experiences such as: how stopping heroin affected alcohol 
consumption; how a hepatitis C diagnosis affected drinking or heroin use 
not just immediately after diagnosis but over the lifetime; if life events 
affected substance use/alcohol use/the person’s hepatitis C journey; if 
there were any patterns, behaviours or events that affected drinking and 
drug use; if contact with services had any effect on alcohol use, substance 
use or hepatitis C. 
 
3.6.3.2 Situated in time 
 
In addition to the sequence and interrelation of past events being important 
for this work, being able to situate events in time is also crucial to 
understand the context of the event. I believe that illnesses and the threat 
they pose differ depending on when an illness is diagnosed. Consider being 
diagnosed with an illness prior to effective treatment, compared to being 
diagnosed at a time when effective treatments are available. Hepatitis C 
was untreatable when it was first discovered in 1989, since then there has 
been considerable scientific, medical and public health advances, 
improving knowledge, prevention, testing and treatment. Although there 
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are still barriers to diagnosis and treatment, I believe that experiences now 
compared to 1989 may be different. Thus I felt it was important to hear 
peoples’ stories and understand them within a context, with a belief that 
peoples’ experiences of hepatitis C would be different depending on when 
they were diagnosed and what treatments were available at that time. 
 
According to Sandelowski (1999) time should always be considered by 
qualitative researchers, as “…..the people and events they [qualitative 
researchers] study are always situated in time” (Sandelowski, 1999, p. 79) 
and she urges qualitative researchers to consider “the overall temporal 
structure of their study design” (Sandelowski, 1999, p.80) differentiating 
between synchronic (cross sectional) and diachronic (longitudinal) work. 
Because of this, the service user interviews in this research were 
longitudinal in nature as they sought to capture participants’ lifetime 
histories of hepatitis C, alcohol and drug use and included a follow up 
interview a few months after the first interview. 
 
3.6.3.3 Power dynamics 
 
In keeping with my beliefs that those with hepatitis C were the experts in 
this research, I wanted the interview to be non-intimidating, aiming for as 
much rapport as possible and a relationship in which the usual interviewer 
and participant power balance was challenged. The method needed to 
reflect this philosophy, working inductively and enabling participants to 
discuss issues that were pertinent to themselves. The calendar method has 
previously been shown to enable this. 
 
Many authors have discussed how calendar interviewing provides more 
social interaction, trust and rapport between interviewers and respondents 
compared to ‘traditional’ interviews (Parry et al, 1999: Nelson, 2010; 
Sutton, 2010; Harris et al, 2012). Calendar interviewing uses a flexible 
conversational approach (Belli and Callegaro, 2009), where participants and 
researchers work in collaboration to co-construct the calendar (Freedman 
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et al, 1988; Parry et al 1999). Many researchers feel it is this conversational 
approach that encourages the rapport (Belli and Callegaro, 2009; Nelson, 
2010). Furthermore, Harris et al (2012) found “within this format there was 
space for new topics to emerge and for participants to take the lead, 
bringing up issues of importance to him or her” (Harris et al, 2012, p. 34). 
This was also found by Parry et al (1999) who felt respondents were able to 
take control of the direction of the interview and the construction of their 
biographies. She suggested that this method required researchers to 
“relinquishing some control over data collection” (Parry et al, 1999, p. 11) 
and “one of the main attractions for qualitative researchers is its potential 
to alter traditional interview dynamics” (Parry et al, 1999, p. 11). Thus the 
main purpose of using the calendar for this research was not to collect 
‘accurate’ data on recall, but was used primarily as a visual aid to engage 
with the participants, encouraging them to tell their stories and to hear 
their ‘voice’. 
 
3.6.3.4 Consideration of other methods 
 
There are many other methods that can be employed to explore 
participants’ lived experiences. These alternative methods were excluded 
when considering their ‘fit’ to the research topic, research aims and 
objectives and their suitability for use with the research participants. Two 
of the considered methods are discussed here; the biographical narrative 
interpretive method (BNIM) and Murray’s narrative framework. Like the 
LHC, these methods are used to encourage participants to tell their stories, 
are interpretative in nature and have previously been used in health 
research. Murray’s framework has been used to explore the lived 
experience of conditions such as fibromyalgia (McMahon et al, 2012) and 
HIV (Proudfoot, 2014) and the BNIM has previously been used in studies 
considering end of life care decisions (O’Neill, 2011) and men’s experiences 
of domestic violence (Corbally, 2011). 
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The BNIM interview requires an uninterrupted story from participants, and 
commences with the researcher asking an initial unstructured single 
question, a ‘SQUIN’ (single question aimed at inducing narrative) such as: 
“I would like you to tell me your life story, all the events and experiences 
which were important to you. Start wherever you like. Please take the time 
you need. I’ll listen first, I won’t interrupt” (Wengraf, 2001 p. 119). This 
initial interview can then be followed by 2 or 3 further interviews ‘sub 
sessions’ where the researcher asks questions about the information 
provided by the participant in response to the SQUIN (Corbally and O’Neill, 
2014).  
 
As a novice researcher I was unsure if I would be able to use this technique 
to ascertain information on the topics of this research. Although I 
understood that “in qualitative interviewing, ’rambling’ or going off at 
tangents is often encouraged [as] it gives insight into what the interviewee 
sees as relevant and unimportant” (Bryman, 2012, p. 470), I was also aware 
that I had aims and objectives about particular topics to explore. As 
hepatitis C is a stigmatised health condition, I thought there was a 
possibility that participants may completely avoid talking about their 
experiences of hepatitis C in the first interview. However the LHC method 
used in this research encouraged participants to talk freely but the 
researcher could also ask questions as the interview progressed, using the 
conversational style typical of the method.  
 
Although in the BNIM, hepatitis C could be broached at the sub sessions, I 
was aware, from my experience of working as a clinical research nurse, of 
the difficulties involved in getting people to participate in follow up 
interviews. I was concerned that some participants might not talk about 
hepatitis C in the first interview and then not attend the sub sessions. 
Although follow up interviews were planned for the service user interviews 
in this thesis, they were not expected to occur with every participant and 
were not vital.  
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As well as the BNIM being unsuitable as a method for this research, the 
analytical process was also inappropriate. The BNIM has a structured ten 
stage analysis strategy, with four of the stages concerned with analysing 
how the participant tells their story, focusing on the textual structure, 
changes in speaker, tone and topic (Casey et al, 2016). The “lived life” and 
“told story” are analysed separately and then merged into a case account 
which are compared with other cases. Panel analysis also occurs. Panels are 
presented with ‘chunks’ of the participant’s story to interpret. Challenges 
of this method are noted to be; excessive or overly complex data and 
needing skilled and trained researchers (Casey et al, 2016).  
 
Although understanding the value of analysing how stories are constructed 
and language is used, this level of discourse analysis was not required in 
this research as the content of the story, not how it was told, was the main 
focus. During the LHC interviews, participants’ tone was noticed during the 
interviews and whilst transcribing, giving ‘a feel’ for the sentiment behind 
comments, but the main focus was not to use a structured approach to 
formally interpret how people used language. Considering people’s 
narratives in ‘chunks’ rather considering the person’s story as a whole also 
did not seem to be appropriate. The ethos of this research was to build 
relationships with the service users who participated to gain their trust, 
and also to value service users as the experts and as individuals who had 
stories and lives other than drink, drugs and hepatitis C. The possibility of 
breaking their stories down into chunks to discuss with a panel, felt 
impersonal with perhaps the risk of focusing on the lifestyle behaviours out 
of context of the person. As topics of discussion were likely to be about 
sensitive, highly stigmatised topics, I was also unsure as to how participants 
would respond to this method of analysis, knowing that their stories 
(although anonymous) were being discussed by a panel of people they did 
not know. I wondered if this could ‘stunt’ the information they provided. 
As I have never used the BNIM my thoughts are not based on experience of 
using the method but rather an educated ‘hunch’, and perhaps with the 
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appropriate training (as recommended by Casey et al, 2016) this method 
could have been suitable for PWID with hepatitis C. 
 
 Like the BNIM, Murray’s narrative framework is also a narrative approach 
and is therefore concerned with how a participant describes their 
experiences. However Murray’s framework is classed as an experience 
centred narrative approach where the main concern is the content and 
meanings of the presented lived experience, thus understanding the ‘what’ 
(Casey et al, 2016). This involves semi structured interviews and a 
hermeneutic approach to analysis, where the researcher goes back and 
forth between stories rather than a structured linear analytic process. The 
framework does however require participants stories to be explored 
through four lenses, namely personal, interpersonal, positional and 
ideological (Murray, 2000). Like the BNIM the personal lens considers how 
the story is constructed. The interpersonal lens examines how the accounts 
are co-constructed between the participant and researcher, such as 
examining the flow of the conversation. The positional lens is concerned 
with the relationship between the participant and researcher, considering 
where the power lies and the impact this may have on the story told. The 
ideological lens considers the persons story in relation to sociocultural 
norms, such as stigma and hepatitis C. As this approach requires 
consideration of all four lenses, it was not a suitable ‘fit’ for the research 
conducted in this thesis. As explained previously in the analysis of BNIM, 
how the participant’s story is constructed is not a main concern for this 
research, nor is an analysis of how the conversation between researcher 
and participant is formed or an analysis of the power between researcher 
and participant. As previously explained the methods employed in the 
service user aspect of this research (observation and LHC interviews) were 
chosen after consideration of power dynamics and data collection occurred 
with this in mind, however analysis of how the power dynamics affected 
the stories told was not a focus of this research. Rather than analysing the 
data by looking for the topics stipulated by these four lenses, analysis 
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focusing on finding themes within the data was chosen as the main analytic 
technique. 
 
After consideration of other research methods available, the LHC was 
chosen as the best ‘fit’ for the study population and topics researched. The 
next consideration was the design of the calendar.  
 
 
3.6.4 Development of the LHC 
 
As discussed before, calendars can be used qualitatively or quantitatively, 
which dictates the design of the calendar, however there are many other 
aspects of calendar design that need to be considered, such as the 
information required and how they are to be applied. 
 
Calendar interviewing is, in the main, conducted face to face where the 
calendar is completed as part of the interview. However, some researchers 
have completed calendars over the telephone (Freedman et al, 1988), 
asked participants to complete the calendar on a computer (Kruttschnitt 
and Carbone-Lopez, 2006), or the calendar is self-administered by 
participants prior to the interview (Martyn and Martin, 2003; Martyn, 2009). 
Many studies have used calendars in conjunction with other research 
methods or activities, such as Wang et al (2014) who used calendars as part 
of a clinical examination or Skinner et al (2011) who used a LHC for 
interviews conducted 12 years after the initial interviews as part of a 
longitudinal study. 
 
To reflect the level of detail required, some calendars are highly structured 
in their design with a prescribed list of questions and set format of 
completion (Meltzer, 2001; Martyn and Martin, 2003; Harris and Parisi, 
2007). However, Feldman and Howie (2009) used a structured life history 
tool with older people and found that the tool constrained engagement and 
in a pilot test of a structured format Nelson (2010) found participants did 
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not give detailed answers as were restricted by the structure. Instead 
Nelson (2010) opted for blank pieces of paper where histories were drawn 
as the interview progressed. 
 
For the purpose of this research, face to face administration of a paper 
based calendar was chosen as computer access was not guaranteed at the 
research sites and the level of computer literacy amongst the study 
population was unknown. A blank page method (Nelson, 2010, Harris et al 
2012 and 2015) was also eliminated, due to its complete lack of structure 
(Nelson, 2010), which I feared would be difficult to administer as a novice 
researcher. Therefore, a pre-printed semi structured chart was used and 
completed during the interview. The decision to complete the calendar 
with participants rather than over the telephone or self-administered prior 
to the interview was to assist participants with the calendar, enabling them 
to ask any questions they may have about the calendar, to make the 
calendar as non-intimidating as possible for participants and to enable the 
rapport building co-constructed calendar approach as discussed previously. 
I decided to use a calendar based on Porcellato et al’s (2016) occupational 
calendar for its simple, clear design and also because it could be used 
qualitatively. According to Nelson (2010, p. 416), “like any methodology, 
the LHC demands thoughtful implementation and often modification”. 
There were five further things I took into consideration before finalising the 
calendar design, namely: domains, time units, historical events, personal 
events and recording techniques. 
 
3.6.4.1 Domains 
 
Domains are events or situations of special interest, selected to reflect the 
research aims of the study (Caspi et al, 1996; Freedman et al, 1988). For 
example in Freedman et al’s (1988) research with mothers and children, 
there were eight domains (geographical residence, cohabitation and 
marital statuses and transitions, living arrangements, fertility, 
employment, school enrolment, military service and monetary exchanges 
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between respondents and their parents), however in Porcellato et al’s 
(2016) research considering occupations over time, unusually only one 
domain (occupation) was discussed. For my research the chosen domains 
were hepatitis C, alcohol and drug use. I decided not to use any other 
domains, such as service provision despite this also meeting the objectives, 
as I felt that more domains would mean more direction from me as the 
researcher rather than participants being able to talk freely about these 
three domains. 
 
Many of the studies in the literature write the domains on the calendar 
(Caspi et al, 1996; Axinn et al, 1999; Martyn and Martin, 2003), listing them 
down the left hand side and giving them a row each for data recording 
linked to that domain. However, I decided this made the calendar cluttered 
and more complicated to look at, and again this would also be prescriptive 
in terms of the discussion. Instead I chose to explain to the participant that 
I would like to hear about their alcohol use, drug use and hepatitis C over 
their lifetime. Thus these domains were the broad themes of discussion 
allowing for participants to bring up topics that were important to 
themselves. 
 
3.6.4.2 Time units 
 
The time units (day, week, month, year etc.) used on the calendar again 
depend on the data required for the research (Freedman, 1988), along with 
the time period the calendar is to cover (Axinn et al, 1999). For example, 
if the calendar was to cover a two-week period, days would be appropriate. 
However, in this research lifetime information was required and as PWID 
are noted to be an aging population (Beynon et al, 2009), the calendar 
needed to cover decades, therefore recalling events on a daily or even 
weekly basis was unrealistic. It is also important to consider the amount of 
space required on a calendar for the time units involved (Freedman et al, 
1988) and the size of calendar this would produce. I opted for quarterly 
(January to March, April to June, July to September, October to December) 
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time units, as I did not need to know exact dates of when substances were 
commenced, stopped or switched, or the exact date a hepatitis C test was 
performed for example, it was the general patterns that were of interest, 
not the exact day that something happened. For this research, getting 
people engaged and talking and to see the general pattern of events was 
the purpose of the calendar. Each column represented a three-month 
period and each row represented a year. Each sheet of paper covered a 
decade (see Figure 6 in Appendix 5 for a part-completed LHC), so for each 
participant many sheets were used, five sheets if they were aged 50 years 
for example. 
 
3.6.4.3 Historical events 
 
Whilst conducting interviews with older adults, Hoppin et al (1998) noticed 
respondents used world (historical) events and personal events to aid recall. 
“The practice of including landmark [historical] events has since become 
commonplace in LHC research” (Nelson, 2010, p. 416). The purpose of the 
historical events, along with personal events (as will be explained in Section 
3.6.4.4) is to trigger memories and enable an event to be placed at a time 
point. Although my main focus is not on gaining ‘accurate’ data, I felt using 
a tool to aid participants was a worthwhile endeavour. Basing the calendar 
for this research on Porcellato et al’s (2016) I decided to change the 
historical events from their calendar to events that I felt may be more 
meaningful to my participants, such as more local Merseyside events. 
Unintentionally many of my events were those that were more traditionally 
gendered towards males, (such as football specific events). 
 
3.6.4.4 Personal events 
 
Similar to Hoppin et al (1998) and Porcellato et al (2016), computer 
generated stickers of personal events, such as weddings, births, 
hospitalisation, education and incarceration were made, to place on the 
calendar at the corresponding time points during the interviews. I decided 
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to use stickers as felt they would be quick and easy to use and therefore 
would not interrupt the flow of conversation as could just be stuck on 
quickly as the person was talking. I also thought it would reduce the amount 
of writing on the calendar, enabling an event to be noted at a glance rather 
than reading it every time. 
 
3.6.4.5 Recording techniques 
 
There are various techniques to record information on a LHC, but generally 
these strategies feature a combination of symbols with lines connecting the 
symbols, to depict when a situation occurred, how long that situation 
continued, and when that situation ended (Freedman et al, 1988). For 
example, Freedman et al (1988) used an ‘X’ to depict the start and end of 
a situation and a horizontal line between the two X’s to show how long that 
situation occurred (Freedman, 1988). Axinn et al (1999) used letters at the 
start and end of the situation with a horizontal line between, for example 
an ‘M’ indicating marriage at the start of the horizontal line with an ‘S’ 
indicating separated at the end of the line. In Porcellato et al’s (2016) 
occupational history calendar a vertical line was used at the start and end 
of the situation, with a horizontal line between. They also used different 
coloured pens to indicated different employment status such as pink for 
part time and black for unemployed. As the calendar used in this research 
was based on Porcellato et al’s (2016), their recording technique was also 
used, but in this research each colour was used to depict a different 
substance, such as heroin, alcohol, marijuana, or for an event related to 
hepatitis C, such as length of time on hepatitis C treatment. A broken line 
indicated non-continuous use of a substance during that time, such as going 
out for a drink every few months. 
 
How to proceed through the calendar is generally omitted in the literature. 
Bradburn et al,(1987) (cited in Porcellato et al, 2016) suggest recall is 
improved when moving from the present to the past however Nelson (2010) 
encouraged her participants to begin with any topic or time period. She 
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believed by “allowing the respondents to dictate its [the LHC] own 
progression, respondents became engaged and assumed ownership of their 
own narratives” (Nelson, 2010, p. 418). As the focus of this research was to 
engage with participants and encourage them to discuss issues pertinent to 
themselves, rather than on accurate recall of data, Nelson’s (2010) 
approach was followed. 
 
3.6.5 Application of the LHC 
 
This section explains the interview process, which took much thought and 
careful planning and deliberation on whether this method would produce 
the envisaged conversation and rich data that others have claimed (Parry 
et al, 1999; Belli et al, 2001; Harris and Parisi, 2007; Wilson et al, 2007; 
Bell and Callegaro, 2009; Nelson, 2010). The section starts with an 
explanation of the interview method, continues with the thoughts and 
findings from the pilot interview and concludes with sampling, recruitment 
and inclusion/exclusion criteria for the study interviews. 
 
 
3.6.5.1 The interview process 
 
Stage 1: The interview – participants’ history 
 
The LHC was introduced at the beginning of the interview. The calendar 
was placed between the participant and myself (the researcher) and a 
verbal explanation of the calendar and how it was to be used in the 
interview was given. The calendar was used as a tool to assist the 
participant to consider their alcohol, substance use and hepatitis C history. 
Completion of the calendar was a collaborative effort between the 
participant and researcher, and the method was conversational in 
approach. 
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The first step was to record participants’ demographics on the calendar. As 
the calendar is to remain anonymous, names were not included, but instead 
the calendar was labelled with the participant’s code. (A separate record 
of which code matches which participant was stored in a locked filing 
cabinet and viewed by the researcher only). Gender and age were also 
recorded. Age was recorded for each year on the calendar, so therefore 
their current age was by default also recorded. Ethnicity was not included 
on the calendar due to the small numbers of ethnic minorities assessing 
drug services in Merseyside (Whitfield et al, 2017) and the risk of a person 
becoming identifiable. 
 
Participants were asked to plot important personal ‘life events’, such as 
births, jobs, relationships, periods of illnesses and so on, on the calendar. 
The pre-prepared stickers of these events were used sticking them on the 
calendar in the relevant quarter (January-March, April-June, July-
September, October-December) of the relevant year (see Figure 6 in 
Appendix 5). 
 
Participants were then asked to explain their alcohol and substance use 
over their lifetime. As explained previously, each substance (including 
alcohol) was allocated a different coloured pen and a horizontal line was 
drawn on the calendar marking the time they used that particular 
substance. A short vertical line was drawn at the start and end of using a 
substance (see Figure 7 in Appendix 5). Participants were free to decide the 
order of how they discuss their substance use history /move through the 
calendar. 
 
Once the participant felt they had completed their substance/alcohol 
history, if they had not already mentioned when they had their hepatitis C 
test/s, this was asked by the researcher and then plotted on the calendar. 
It is important to note that participants were aware events around their 
hepatitis C diagnosis would be discussed, as this was explained during the 
informed consent process prior to commencing the interview. 
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Following this, I then asked questions and cross referenced information 
given by the participant facilitating further discussion and understanding of 
certain events; for example on Figure 7 (Appendix 5), “Can you tell me a 
bit more about this time in 1984 when you started on alcohol as well as the 
heroin?”. These questions/conversations were different for each 
participant, as they were dependent on the issues raised in their individual 
histories. 
It is important to note that the main focus of the interview was on the 
participant’s history not the calendar itself. The calendar was used to 
‘trigger’ memories, but if the participant was talking freely they were not 
interrupted to complete the calendar. 
Stage 2: The interview – semi structured questions 
Once the participant’s history had been discussed, follow on questions were 
asked. Questions around services and where information about health is 
obtained (as per objectives) were prepared prior to the interviews. Again, 
the questions asked were different for each participant as depended on 
what had already been discussed in stage 1 of the interview. 
All interviews were audio recorded and transcribed. Participants were 
aware of this as it was written on the study participant information sheet 
and was discussed during the informed consent process prior to the 
interview. 
3.6.5.2 The pilot study – testing the LHC 
Although I understood the purpose and benefits of using a LHC as 
documented in the literature, I was concerned regarding the practicalities 
of using it, as I had not used a LHC before and to my knowledge a LHC had 
not been used qualitatively with this target population to discuss their 
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experiences of hepatitis C, alcohol and substance use. Therefore, a pilot 
interview was conducted with a member of a local service users’ forum who 
I had previously made links with. The purpose of the pilot was to trial the 
chosen method to see how it fared when applied. 
 
The interview was conducted in a secluded corner of a public library. The 
purpose of the study and the pilot interview were explained to the pilot 
interview participant (Frank) and written informed consent was obtained. 
I then ran through the interview as if it was a real interview, to see if the 
method worked when applied, to practice using the method, to see how 
long the interview took and to receive Frank’s feedback on the method. 
Prior to the interview I felt apprehensive about using the calendar. My 
concerns were twofold; could I as researcher use this method and will the 
participants like and be able to use the method. There seemed to be 
aspects that could ‘go wrong’ such as getting confused with the numerous 
sheets, pens and stickers, or not being able to ‘think on my feet’ and 
employ the flexible, conversational approach required in this method. 
However, these concerns were largely unfounded and from the researcher’s 
point of view, the method was reasonably easy to apply and the interview 
flowed. Although consideration would need to be given to interviewer 
training if there were multiple interviewers working on a study (Glasner and 
van der Vaart, 2009; Porcellato et al, 2016), for this research I was the lone 
researcher therefore consistency in technique was maintained. 
 
Another concern was whether the method could have a negative effect on 
the participants. As a researcher I am aware of my ethical responsibilities 
to avoid harm to my participants and although I believed that drug users 
who attend services are frequently required to talk about their substance 
use and medical history, I was mindful that going back over history could 
potentially raise difficult events and therefore emotions in some people. 
The information sheet explained that participants did not need to talk 
about any topic they did not want to talk about, and this was also explained 
verbally at the start of the interview. Frank seemingly happily chatted 
118 
about his history, however at the end of the interview he looked at the 
pages (decades) of coloured lines indicating the substances he had used and 
said: 
 
“Shit look at all those years I’ve wasted where I didn’t do anything 
coz I was on drugs” 
 
(Frank) 
 
Obviously he knew he had taken drugs for that period of time but I believe 
this comment was due to seeing his life drawn out in front of him. We are 
often reminded of the power of images in the media, where a picture of an 
event causes a stronger reaction than the written or verbal account of the 
event and I believe the visual aspect of this method has a similar effect. 
 
Frank’s comment then led to two points of learning. Firstly, we discussed 
my initial concern of whether this method would be too upsetting for 
participants; Frank thought it would be fine as people would be used to 
doing similar with the drug services and secondly, after Frank made this 
comment I said “but you’re doing well now”. On reflection after, I realised 
I had been acting not as a researcher but as I would in my role as a nurse. 
 
In practice the calendar technique had worked well, but the completed 
calendar was much more complex and disorderly than envisaged, requiring 
notes to be made on the calendar during the course of the interview. Frank 
gave positive feedback on the method but suggested changing the size of 
the calendar from A4 to A3 enabling it to be seen more easily. This change 
was implemented to the calendar for the study interviews. 
 
Another learning point was the location of the interview. Although I was 
advised that I could conduct the interviews in a public place, such as a cafe, 
in practice, I felt uncomfortable with this, realising that this advice is 
content specific. I felt it was inappropriate to be talking about people’s 
lived experiences of sensitive topics (illegal drug use and communicable 
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diseases) in a public place, and felt this may potentially affect the depth 
of information participants were willing to divulge. 
 
Conducting this pilot was a worthwhile exercise, because not only did it 
enable learning from trialling the method, it also raised some ethical 
dilemmas which required thought prior to conducting the study interviews. 
Following the success of the calendar method in the pilot, this method was 
then used for the study interviews. 
 
3.6.5.3 The interviews 
 
3.6.5.3.1 Participant selection 
 
As this research set out to explore the views and experiences of PWID who 
have hepatitis C, it was therefore important to interview people who met 
this criteria. Purposive sampling was undertaken at drug and alcohol 
services and hepatitis C support groups in Merseyside to locate people who 
met the inclusion /exclusion criteria ( See section 3.6.5.3.2 and section 
3.6.5.3.3). Once a service user expressed an interest to be in the study 
(either by speaking to their key worker/group leader or speaking directly 
to the researcher) the inclusion/exclusion criteria was discussed with the 
potential participant. Participants were recruited based on a self-report of 
meeting the inclusion criteria (including criteria related to hepatitis C), as 
the researcher did not have access to participants’ records within the 
centres.  
 
Purposive sampling is a form of non-random sampling. Although random 
sampling is considered superior to non-random sampling by quantitative 
researchers there is a “growing recognition that there is no longer a need 
to ‘apologize’ for these types of samples” (O’Leary, 2017, p 208). Indeed 
in qualitative research non random sampling is useful to understand 
extreme, unique, deviant, misunderstood, misrepresented, marginalised, 
or unheard aspects of a population (O’Leary, 2017), situations that may be 
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missed with random sampling. Furthermore O’Leary (2017) suggests that 
“when working with populations that are hard to define and/or access non-
random strategies may be the best option” (p. 210). As PWID are generally 
seen to be marginalised and a hard to reach population and hepatitis C is a 
stigmatised disease that is often not spoken about, a non-random sampling 
strategy was chosen. It is however important to note the limitations the 
sampling technique brought to this research. As the research was conducted 
at drug and alcohol services and hepatitis C support groups, this means that 
all the participants were attending these services. So this research does not 
capture the wider range of experiences of people who do not attend 
services perhaps because of ongoing drug use or unknown hepatitis C status, 
or people who do not inject now and do not require OST and feel they do 
not need support from a group for their hepatitis C.  
 
This research has also only captured the experiences of those who wanted 
to talk about their hepatitis C. Due to the stigmatised nature of hepatitis C 
it can be difficult for people to talk about their experiences of having the 
virus so there may be other people at the services who met the inclusion 
criteria but did not want to be interviewed. 
 
3.6.5.3.2 Inclusion criteria 
 
• Current or previous injecting drug use 
• Current or previous diagnosis of hepatitis C (‘previous’ such as those 
who have cleared the virus naturally or have been cured by 
treatment) 
• Ever drank alcohol 
• 18 years of age or above 
• Able to give informed consent 
• Willing to take part and be contacted for follow up interviews 
• Attending a drug and alcohol service and/or hepatitis C support 
group in Merseyside 
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3.6.5.3.3 Exclusion criteria 
 
• Never injected drugs 
• Injectors of performance enhancement drugs 
• Never been diagnosed with hepatitis C 
• Never drank any alcohol 
• Under 18 years of age 
• Unable to give informed consent 
• Not attending a drug and alcohol service and/or hepatitis C support 
group in Merseyside 
 
 
3.6.5.3.4 Participant recruitment 
 
If a service user felt they were suitable for the research, the researcher 
discussed the study with the potential participant and provided a 
participant information leaflet advising them to take the leaflet away, read 
the leaflet (or have the leaflet read to them) and discuss with friends, 
family or their support worker if they would like to. However, all 
participants preferred to be interviewed at the time of the discussion. 
Informed written consent was obtained, with 1 copy of the consent form 
being kept by the researcher and 1 copy by the participant. Interviews were 
conducted in a private room within the drug service/ hepatitis C support 
group building. 
 
3.6.5.3.5 Sample size 
 
The study originally set out to conduct interviews with 36 participants. This 
number was decided by considering Kuzel’s (1999) work, which advises that 
5-8 participants are usually sufficient for a homogeneous sample and 12-20 
for a heterogeneous sample, where it is important to maximise variation 
across the sample. It was proposed at the start of the study, that 
participants would be recruited from services in three different areas of 
122 
Merseyside, therefore 12 participants from each centre were to be sought. 
However, saturation was reached earlier and 21 participants were 
interviewed (16 using the LHC and 5 without the LHC, as explained below 
and in Section 3.6.6.2.1). These points are explained further below.  
 
In reality finding service users to be interviewed for this research was 
difficult resulting in one further site (four in total) being used for 
recruitment. This benefitted the research by providing further variation 
amongst the sample. Not only was there variation in sites as the research 
was conducted at different areas of Merseyside and at organisations 
providing different types of support (hepatitis C support group, drug and 
alcohol service, service focusing on long term recovery) but this also 
provided heterogeneity of the sample of participants. For example some 
participants were still injecting whilst others had stopped injecting but 
were smoking heroin, others had stopped using all drugs and were taking 
OST, some were not drinking alcohol, others were dependent on alcohol, 
some had failed hepatitis C treatment and were waiting for the DAA 
treatment, others had never received treatment and then at the fourth site 
most of the participants were no longer taking drugs, alcohol or on OST and 
were free of hepatitis C.  
 
Even though the sample was not homogeneous, saturation was reached. I 
felt saturation was reached when the same topics were emerging in various 
peoples stories. As explained previously there were of course differences in 
people’s individual life histories but broader topics such as situations 
demonstrating discrimination and stigma, accounts of fear around hepatitis 
C, difficulties accessing services and so on were evident in many 
participants account. I was satisfied I had reached saturation when I went 
to the fourth research site where the majority of people were further down 
the ‘road to recovery’ as were not taking drugs, not on OST and were cured 
of hepatitis C, yet their stories revealed the same broad topics of stigma, 
fear etc., as the participants who currently had hepatitis C and were in the 
midst of active drug use. 
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Rather than using a large sample size to create generalizable results as 
required in quantitative data, qualitative research seeks in depth 
information from small sample sizes. However the broader applicability of 
the findings can still be considered, by asking how transferrable the findings 
are to other instances (Denscombe, 2017; O’Leary, 2017). This is known as 
‘transferability’, “whether findings and/or conclusions from a sample, 
setting or group lead to lessons learned that may be germane to a larger 
population, a different setting or another group.” (O’Leary, 2017, p. 68). 
The heterogeneity of the sample (sites and population) in this research 
increases the transferability, the ‘lessons learned’ (O’Leary, 2017), that 
may be applicable to other services and inform practice and policy. 
Denscombe (2017) and O’Leary (2017) both explain the key to 
transferability of findings, is providing enough information on the research, 
methods, participants, organisations and processes and so on for the reader 
to decide how applicable, ‘transferable’ findings are.  
 
As mentioned above 21 initial interviews were conducted, 16 with a LHC 
and 5 (carried out within the service focusing on long term recovery) 
without. Table 1 shows the distribution of interviews, including the 4 follow 
up interviews using a timeline. 
 
Table 1 Site of interviews 
 
Organisation Interviews 
Conducted 
Follow-up 
interviews 
conducted 
Hepatitis C support group 1 LHC 0 
Drug and alcohol service 6 LHC 0 
Drug and alcohol service 9 LHC  4 
Service focusing on long 
term recovery 
5 without LHC 0 
Total 21 4 
 
To maintain anonymity participants and sites were given codes. Each site 
was given a different letter and each person in that site was given a 
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different number. Samples were analysed on an ongoing basis using the 
constant comparison method, comparing participant to participant 
regardless of site but also noting nuances amongst sites, thus an ongoing 
inter and intra site analysis occurred. The codes assisted me as the 
researcher to understand which interview transcript was from which site, 
and therefore the context when reading back through, analysing and 
interpreting the transcripts. So for example, if a participant said they did 
not know about the hepatitis C support group at their organisation, I could 
look at the code and know which organisation it was and then relate that 
information to that organisation, such as whether that organisation had a 
hepatitis C support group and how that group was advertised within the 
organisation. However at the end of data collection samples were analysed 
as a whole and not split into sites as the broad themes that emerged from 
the data were relevant to all sites. 
 
3.6.6 Methodological findings - benefits and limitations of the LHC 
 
3.6.6.1 Benefits of the LHC 
 
This research is, to my knowledge, the first use of the LHC for PWID to 
explore their experiences of alcohol use and hepatitis C. Furthermore, the 
LHC was found to be an effective method when used qualitatively to explore 
these topics with PWID. Used inductively the LHC produced a large volume 
of data on the views, beliefs, meanings and experiences about hepatitis C, 
substance/alcohol use and health services along with a rich contextual 
understanding of how these and other issues affect the lives of the 
participants. 
 
In Section 3.6.3 I explained reasons why I chose to use the LHC, based on 
the methodological findings of other researchers who had used this method. 
These reasons were: the LHC enables sequences, triggers and patterns of 
behaviours to be seen over the long term; the LHC places events at a time 
point, giving context to the event and the LHC is a method that challenges 
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the traditional power dynamics of interviews. These points are now 
discussed in relation to this research, together with other benefits I found 
from using the LHC method. 
 
3.6.6.1.1 Sequences, patterns, triggers and interrelationships of 
behaviours and events. 
 
One of the main benefits of using the LHC is that it has enabled the 
collection of sequential data, providing a ‘fuller picture’ of alcohol 
consumption following a positive hepatitis C result, as it provides an insight 
over a longer period of time rather than a snapshot of a certain time point. 
This is different from other studies on alcohol use after hepatitis C 
diagnosis, which focus on short periods of time after the hepatitis C test 
result, such as 6 months post diagnosis (Ompad et al, 2002) or 6 and 12 
months post diagnosis (Tsui et al, 2009). Other studies have considered a 
one off cross sectional approach of current alcohol use regardless of time 
since the hepatitis C diagnosis (McCusker et al, 2001; O’Leary et al, 2012). 
My study considers the time from diagnosis to the current day, which is a 
varied time period for each participant. 
 
The method has also enabled observation of how a personal event 
triggered/changed use of a substance/alcohol. This is demonstrated below 
by Ed who plotted family deaths and a leg abscess (caused by injecting 
heroin into his groin) on the calendar as important personal events. 
 
So he [Dr] said “that’s it or lose your leg”, you know what I mean 
 
(Ed) 
 
And did that change your injecting? 
 
(Researcher) 
 
Oh yeah that was it, kicked that to [makes a noise], never again 
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(Ed) 
 
Straight away? 
 
(Researcher) 
 
Yeah straight away yeah you know coz you get a fright, you know, 
like I had the doctors and the surgeons telling ya you know, you 
gonna have to start making preparations here, you know you start 
saying ta ra to your family [voice wavers] and things like that you 
know, yeah but er gives you a kick up the wall then, never again 
and I never will 
 
(Ed) 
 
And when you came out of hospital did you start smoking it again 
then 
 
(Researcher) 
 
Oh god it was about nearly a year, yeah I done well 
 
(Ed) 
 
And what, why did you start again what happened? 
 
(Researcher) 
 
Well me mum died and then, no sorry me niece died first 
 
(Ed) 
Ed explains how the leg abscess stopped him injecting heroin, but the 
deaths of family members led to him commencing heroin use again, albeit 
smoking rather than injecting. This demonstrates the effect these personal 
life events had on his substance use. From this it can be seen that this tool 
could potentially be used therapeutically, to help identify triggers to 
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behaviours and enable service users and staff to see areas where service 
users may require help; in Ed’s case it may be that he needs some support 
around death to help him cope differently if and when the next family death 
occurs. 
 
Another benefit of the calendar is that it allows visualisation of patterns of 
behaviours and events, which enables some questions to be answered 
without having to ask the direct question. For example, information such 
as how long they had been living with hepatitis C or how much they drank 
following a diagnosis of hepatitis C could just be seen on the calendar after 
the personal and hepatitis C related events and lines indicating 
substance/alcohol use were plotted on. It is my belief that this method 
provides more information than if a direct question was asked, such as, for 
the latter example above, ‘what did you drink after your hepatitis C 
result?’. This question may have produced a shorter response, with the 
participant not explaining differences over time. Also as people who have 
hepatitis C are generally discouraged from drinking (RCGP, 2007; SIGN, 
2013), this question has the potential to sound like a judgment, with the 
possibility of participants editing their responses to provide answers they 
think the researcher wants to hear.  
 
Regarding how participants moved through the calendar, the majority of 
participants commenced with the first substance they used and moved 
forward to the present day, although this was not always the case and 
substance use was not always explained sequentially but given in 
combination with stories about other issues. In reality drug users’ lives do 
not always move forward in straight lines. The road to coming off 
substances is often a process as explained by Phil, 
 
 ..and then you’d get off it and then you get back on, you know 
what I mean, you know, you get that battle then of going back 
and forth from methadone then back on it and then erm, you 
know I got off it for a few years and then went back on it again. 
 
(Phil) 
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For those with hepatitis C, the pathway to clearing the virus is also not a 
straight path, with people falling off (and sometimes re-joining) the 
pathway at various points, such as the testing or treatment phase. This 
method has allowed data capture of these nonlinear processes and also 
allows for an understanding of the numerous events that can be co-
occurring for a person at any given time. 
 
3.6.6.1.2 Situated in time 
 
Prior to commencing the interviews, I believed that peoples’ experiences 
of hepatitis C would be different depending on when they were diagnosed 
and what treatments were available at that time. This was shown to be the 
case as demonstrated by extracts from Jack and Steve’s interviews. Jack 
was diagnosed prior to treatments being developed and Steve was 
diagnosed within the last few years and had interferon therapy. 
 
…they found out I had hepatitis C but they didn’t even understand 
it then, you know what I mean, they just said you’ve got liver 
damage right, but then, treatment wasn’t out like the way you 
get now interferon an stuff like that you know, there was no 
treatment for it, it was just basically, me I was shittin meself 
cause I thought it’s a death sentence me, so I sort of did it on 
myself and thought look just go and get fucking bladdered every 
day 
 
(Jack) 
 
Doing what every day? 
 
(Researcher) 
 
Just go and get bladdered every day, just get wasted and 
whatever 
 
(Jack) 
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Drunk? 
 
(Researcher) 
 
Yeah and I felt well ur I thought it was I mean, I’d done something 
there and for a bit [inaudible] about it. I didn’t see anything 
changing I just thought there’s nothing I can do 
 
(Jack) 
 
That’s it? 
 
(Researcher) 
 
Yeah, you know that’s how I see things coz there was no help, 
there was no treatment there was nothing so, you had it that’s 
the way it was 
 
(Jack) 
 
I was gutted at first when I got the result yeah um because I mean 
I had, planned, I was going to, I wanted to go to university you 
know and I thought if I’m on interferon I don’t know how it’ll 
affect me. Um also I was seeing a girl at the time and I’d waited 
for my results before you know, before doing anything and I 
hadn’t told her why we hadn’t done anything, oh fuckin hell you 
know I actually have got it. So yeah put things back and I felt like 
if I started interferon then it was gonna run into any course that 
I was doing so I’ll have to wait til the next year to do even an 
access course, you know felt like I’d put my life off by a year or 
two just, and that’s you know if the treatment does end up 
working I thought, get to feel rough for 6 months a year, just a 
lot of er yeah it was a bit of a, bit of a setback you know I was 
quite gutted at the time 
 
(Steve) 
 
And what happened then and what did the GP do after they told 
you the results? 
 
(Researcher) 
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Yeah they referred me straight to the um, it was quite good 
actually, they referred me straight to the specialist clinic in XXX 
[hepatitis C clinic] and I had an appointment there within, I can’t 
remember, I think it was within like 6 weeks but, yeah I ended up 
starting treatment. 
 
(Steve) 
 
This shows Jack felt his life was over whereas Steve saw his hepatitis C 
diagnosis as more of a ‘setback’. Although this is a simplistic analysis of the 
two data, and there will of course be other factors at play, it does show 
that time provides a context that needs to be considered when analysing 
the data. 
 
3.6.6.1.3 Power dynamics 
 
Many of the participants expressed that they had enjoyed the interviews, 
however it is my belief that it was the conversational aspect of the method 
and not necessarily the calendar itself that people had enjoyed. 
 
No, no I’ve just been enjoying talking to ya, really nice, nice 
speaking to someone. 
 
(Neil) 
 
Mm have you got any questions for me, I think I’ve kind of finished 
really 
 
(Researcher) 
 
Ur no just I think it’s good like, I’m made up I’ve got a little bit 
off me chest 
 
(Pete) 
 
131 
The conversational approach enabled participants to direct the 
conversation, which I believe encouraged rapport between the participant 
and researcher. The technique allowed new topics to emerge, as 
participants talked about issues that were important to themselves. This 
provided information on many aspects that were not included in my initial 
objectives and thus provided the data that is of real importance to PWID. 
This method allowed participants to bring up issues at their own pace and 
at times these were issues of a sensitive nature, (also found by Parry et al, 
1999 and Wilson et al, 2007) such as rape and mental illness. With 
participants talking freely, as opposed to a set of structured questions, I 
felt I gained a holistic view of their lives, with a greater understanding of 
the complexities and the role that drugs, alcohol and hepatitis C have. The 
collaborative working, which allowed me to clarify points that were 
unclear, also allowed participants to ask questions, which provided an 
unexpected insight into their understanding and opinions of hepatitis C, 
alcohol and services, as demonstrated below. 
 
And do they know that you injected and it might be linked to that 
or? 
 
(Researcher) 
 
Urm I didn’t really know that it was linked to that 
 
(Brenda) 
 
OK, OK 
 
(Researcher) 
 
Is that how I would have got it yeah? 
 
(Brenda) 
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Although in this example I had made an error in assuming that the 
participant would know routes of transmission for hepatitis C, this error 
provided an insight into Brenda’s level of understanding about hepatitis C 
despite being diagnosed for approximately 10 years. Interestingly, this is 
harm reduction information that should be given on receiving a positive 
hepatitis C test result, to reduce sharing of injecting paraphernalia and the 
risk of further transmission to others, as well as continued education 
throughout contact with drug services/other health services. Below, Pete 
demonstrates his understanding of the disease and testing process. 
 
As I was waiting yesterday, a lad come in Jane [researcher], he 
had took it [injected heroin] up his groin and he went “yeah I’ve 
come in to find out me results on me hep”. He went “I have got 
it” and he come back out plus he went “me bodies cleared it up 
itself”. Can that happen? 
 
(Pete) 
 
Showing that Pete did not know that some people can spontaneously clear 
hepatitis C. This is information that should be given with the antibody test 
results prior to going for the next stage of testing (PCR test) which looks to 
see if the virus is still present in the body or if it has spontaneously cleared. 
 
Both of these examples show a lack of knowledge on some of the basic facts 
about hepatitis C, which should be frequently discussed by drug and other 
health services and is information that is readily available in hepatitis C 
leaflets. Although the reasons behind the participants not knowing this 
information is not addressed here, the point I am making is that the 
conversational style of the method enabled participants to feel comfortable 
enough to ask questions to me as the researcher, which in-turn gave an 
insight into their level of understanding, which I believe I would not have 
found from ‘traditional’ interviews. 
 
3.6.6.1.4 Other benefits 
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The main advantage of the calendar method is the combination of seeing 
the data on the calendar and hearing the verbal account from the 
participant about these events. Pragmatically this dual approach enabled 
the story to develop throughout the interview and provided benefits for 
both the participant and researcher. 
 
During the interviews participants would sometimes realise the relationship 
between different events, leading to a discussion of these connections as 
they emerged. Parry et al (1999, no pagination) also found this and noted, 
“This is quite different from the ‘traditional’ interviews where the majority 
of associations are discovered subsequently during analysis”.  
 
Finally, an unexpected methodological finding from this study is how 
beneficial I found the calendar method in helping me as the researcher. I 
found the calendar helped me to clarify and contextualise what the 
participants were saying. It helped me to place what they were saying at a 
point in time but also to think about further questions, as shown in this 
extract from Sadie’s interview. 
 
So when you were pregnant with your, just thinking right 
 
(Researcher) 
 
Yeah 
 
(Sadie) 
 
So when you were pregnant with your son 
 
(Researcher) 
 
Yeah 
 
(Sadie) 
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You’d already been injecting? 
 
(Researcher) 
 
Yeah but I wasn’t [stopped speaking] 
 
(Sadie) 
 
Did they do a hep C test then, when you were pregnant? 
 
(Researcher) 
 
3.6.6.2 Limitations of the LHC 
 
When conducting research with a LHC there are logistical concerns that 
need to be considered. 
 
3.6.6.2.1. Interview length 
 
Interviews using the LHC varied in length depending on how much 
participants talked. The majority of interviews lasted between an hour and 
1.5 hours, which is, in general, longer than ‘traditional’ interviews. When 
conducting this research, the time requirement caused a practical and 
ethical dilemma, as explained further below. 
 
As finding participants to take part in the interviews was proving to be quite 
difficult, I approached another service to inquire if I could recruit some 
participants from there. After hearing about the study and my requirements 
to conduct the research, they were extremely enthusiastic and organised a 
date for me to re-attend to carry out the interviews. I went, expecting it 
to be the same as the other services, with 1 or 2 people to interview after 
they had seen their key worker at the service, but they had booked in 7 
people, 5 of whom attended. I was delighted that I had participants, 
however, they had been given appointments to attend the service just to 
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see me, and had been booked in, in 30 minute slots. This therefore caused 
a dilemma, as I knew the 30 minute slots were inappropriate for the method 
but the potential participants were already arriving with the sole purpose 
to be interviewed for this research. From my previous research experience, 
I was aware how difficult it is to organise people to attend for an interview 
and here there were 5 people waiting to be interviewed. In the ethics 
application I had written; 
 
“However it is important to note that the main focus of the 
interview is on the participants’ history not the calendar itself. 
The calendar will be used to ‘trigger’ memories, but if the 
participant is talking freely they will not be interrupted to 
complete the calendar”. 
 
(Research protocol V2, 23rd July 2014) 
 
I decided to continue with the interviews; I went through the same process 
but without the calendar, asking them to describe their substance and 
alcohol use over their lifetime, then asked about their experience of 
hepatitis C and finally the questions about services. I feel this showed 
initiative and flexibility whilst working within the ethical approval, however 
it is also an interesting insight and valuable learning point into the 
practicalities of conducting research ‘on the ground’. This demonstrated 
how as a researcher you are at the mercy of the organisation to which you 
are visiting and how sometimes other people/services misunderstand what 
is required for the research. I also felt a greater responsibility here, not 
just for my own research, but for other researchers, or health 
professionals/services in general, who work with this population who are 
‘hard to reach’ (Zanini et al, 2013) yet here they were attending an 
‘appointment’, I could not turn them away. Interestingly I felt these 
interviews were more difficult to conduct than those I had done previously 
with the LHC, compounding my thoughts that the calendar itself was helpful 
to me as a researcher in understanding the information the participants 
were giving (see Section 3.6.3). Interestingly, I also felt like the information 
given did not have the same depth of that provided with the participants 
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who used the LHC. I felt like I knew the participants who did not use the 
LHC less well, whether this was due to the method or the fact that I spent 
less time with these participants is unclear, however it is my belief that the 
visual aspect of the LHC, where participants’ lives are drawn out in front 
of them, encourages the rich conversations that occurred during the LHC 
interviews. 
 
3.6.6.2.2 Size, space and facilities 
 
Due to its size (A3 sheets), the number of sheets (each sheet represents a 
decade of the participant’s life), the pens and stickers, the LHC is slightly 
cumbersome to administer. Also as the method requires people to be able 
to see the calendar and to apply stickers and draw on it, a table is required 
to lay the total calendar on. Thus the LHC method requires a bigger space 
than ‘traditional’ interviews. 
 
Many in the litertaure who have used calendars talk of sitting side by side 
(Freedman et al, 1988; Caspi et al, 1996; Martyn and Martin, 2003 and 
Wilson, et al 2007), to assist with the collaborative approach to calendar 
completion, however in this resarch this was not always possible, due to 
the layout of the room or facilities available. The services where 
recruitment took place were extremely busy and I was required to fit in 
with the service, using whichever room was free. Sometimes the layout of 
the small rooms were unchageable, and we sat as close as possible but not 
always side by side. Sometimes we were on high chairs with a low coffee 
table, making it difficult to view and work on the calendar. I also had not 
taken into consideration the physical ability of my participants prior to the 
interviews. Many had medical problems with their legs and one person her 
back, resulting in sitting in a certain position or needing a certain height 
chair, meaning it was not possible to sit next to each other and sometimes 
made seeing the calendar quite difficult. 
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3.6.6.2.3 The LHC 
 
Although most participants expressed that they had enjoyed the interview, 
two participants mentioned they were dyslexic, and others said they had a 
bad memory, expressing that they were not going to ‘do it right’. After 
further explanation they understood that their story was the important part 
and not the calendar itself but it is important to consider peoples’ feelings 
towards the calendar in future research. 
 
Also, I was expecting an interactive collaborative approach with both 
myself and the participant adding information to the calendar. This in 
reality did not happen, with the person telling the story and looking at the 
calendar with myself adding the lines and stickers. 
 
Only one person used the historical events down the side of the calendar to 
reference in time the information they were saying. Although I don’t know 
the reason for this, it is possible that the events were not the correct events 
for my participants, as I chose these events myself (see Section 3.6.4.3). In 
research by Hoppin et al (1998) focus groups and informal interviews were 
used to ascertain historical events that were of importance to the study 
population (farmers). This approach may have been helpful with my specific 
population group. However conversely all participants used the personal 
events as ‘anchors’ for telling stories around. 
 
Yeah I went to school but I finished early and went the market at 
15. That was when the trouble started to be honest because I had 
money kind of thing, got in with the wrong crowd, and the next 
thing is drug use… 
 
(Phil) 
 
My feeling after this experience is that for future research using a calendar 
method, I would pilot a calendar with the historical events removed and 
just have a calendar where personal events could be plotted. 
 
138 
3.6.6.2.4 Analysis 
 
The method produced a large quantity of data as it included data gathered 
on the calendar and transcriptions from the audio recordings of the 
interviews. Whilst it is obviously a benefit that the method has produced 
large quantities of rich data, the quantity does however pose a challenge 
in terms of analysis. Also, unlike a ‘traditional’ interview, questions were 
not asked in any specific order, with the conversational style of 
interviewing meaning that searching for themes and coding (thematic 
analysis) was a lengthy process. Other researchers using various analysis 
techniques have also noted difficulties with the data. Sutton (2010) 
suggested steps in the research process including computer programming, 
data cleaning and data analysis are cumbersome and difficult. Martyn and 
Belli (2002) found data entry to take longer than traditional interviews 
(Martyn and Belli, 2002) and Freedman et al (1988) felt coding was more 
difficult and expensive than a conventional questionnaire. Nelson (2010) 
used a LHC qualitatively with 10 participants and like my study, she 
predominantly analysed the interview transcripts. Nelson (2010, p. 426) 
concluded that this method is “not well suited to large samples because of 
the potential complexity of data entry and coding”, concurring with my 
findings on data analysis for this method. 
 
3.6.7 Follow up interviews using a timeline 
 
After the initial interview was transcribed, the verbal information, along 
with information collected on the calendar, was entered into a timeline 
software (Timeline Maker Professional, 2015) to produce a computer 
generated timeline (Friedman et al, 2008 and Harris et al, 2012), (See 
Figure 8 in Appendix 5). This timeline is another form of calendar (Belli and 
Callegaro, 2009), but differs from the LHC in that it is contained on one 
page. The purpose of the timeline was to represent the jotted data 
collected on a participant’s LHC, so it was easier to see for the second 
interview with that participant. It is important to note that the data was 
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not changed during this process, but presented in a different format. The 
timeline was then taken to the follow up interview. 
 
It was never my intention to conduct a follow up interview with every 
participant, but to conduct ongoing analysis (see Figure 2) of the initial 
interviews, see the emerging topics or if more information was required, I 
would contact certain participants for a follow up interview. Participants 
were aware of this as it was written on the participant information sheet 
and a verbal explanation given. However, contacting people for a second 
interview was very difficult and the success here was mixed, largely due to 
how the drug service was set up. At service 1, I was unable to conduct any 
follow up visits; 1 person said his “life had taken a turn for the worse” since 
we last spoke and he couldn’t meet me, 1 said she’d meet me but did not 
attend and 4 people I was unable to contact on the telephone and were not 
returning to the drug service on set days, but were able to ‘drop in’ to the 
service when they wanted to. At service 2, people attended on a set day to 
collect their methadone prescriptions so I was able to meet people on the 
day they were attending and this was the service where all (n=4) of the 
follow up interviews were conducted. From this service, reasons for no 
second interview were: 1 person said he did not want to see me again; 1 
person I decided not to follow up as they had spontaneously cleared the 
hepatitis C many years ago and I felt I had enough information from the 
first interview; 2 other people had come off methadone and had left the 
service. A total of 4 follow up interviews were conducted. 
 
As I was transcribing an interview, questions would arise. I then read 
through the interview transcript of each person and wrote down questions 
that I had. I also wrote down questions from the emerging data from other 
participants’ interviews that I wanted to ask to this person in the follow up 
interview. 
 
We started the interview with the time line laid out on the table for the 
participant to comment on, and then I asked my pre-prepared list of 
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questions and any other questions that arose during the interview from the 
conversational approach. 
 
Again I was concerned about how seeing aspects of their lives mapped out 
would affect the participants. As the technique has the whole lifetimes 
worth of alcohol and substance use on one chart, as opposed to on a few 
pages with the LHC, the number of years on and off substances were even 
more visible. When Harris et al (2012) used this technique with PWID to 
discuss hepatitis C avoidance they found “reflection of the timeline often 
caused participants to see aspects of their lives in a new light, with some 
expressing surprise at how long they had been on methadone, for example. 
The viewing of a life mapped out in this way could also be challenging for 
some participants, provoking feelings of loss and regret” (Harris et al, 2012, 
p 34). The interviews were commenced very gently and I asked if they were 
okay looking at their chart. I was also working within a service where there 
was support for the participants if they needed it. However I did not find 
the same as Harris et al (2012) and all 4 participants in my study who had a 
follow up interview with the timeline, said they felt comfortable with it, 
(as did all 16 particpants in the LHC interviews) but this is a point of 
consideration for future research using calendar methods. 
 
The follow up interviews provided a further richness to an individual’s data, 
whilst also enabling topics raised by other participants to be discussed. The 
follow up interviews were therefore valuable to this study, however, 
disappointingly only 4 follow up interviews were conducted. From the 
follow up interviews I have learnt the importance of understanding the 
service where participants are to be recruited from for the research. In this 
study, service 1 was a drop in service, where service users did not have to 
attend the service on a set date, which affected my ability to see 
participants for a second interview. Also the time gap between interview 1 
and 2 meant that people’s circumstances had changed over that period, 
making it more difficult to contact them for the follow up interviews. 
However, this did also allow me to see if there had been any changes in 
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their substance use or hepatitis C care/knowledge during this time, which 
proved to be extremely insightful. This is demonstrated by this extract from 
a conversation with Beth at her follow up interview, which was 6 months 
after the first interview. 
 
So I was going to ask you, since I saw you last, which was June, 
what’s happened about your hep C? 
 
(Researcher) 
 
Nothing 
 
(Beth) 
 
Have you made any enquiries or anything 
 
(Researcher) 
 
No 
 
(Beth) 
 
Nothing else, nothing new 
 
(Researcher) 
 
No 
 
(Beth) 
 
Have you spoken to the people here [the drug service]? 
 
(Researcher) 
 
No 
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(Beth) 
 
Have they spoken to you about it? 
 
(Researcher) 
 
No, no. When XX [keyworker] was here before XX [keyworker] she 
was talking about there’s somewhere in town where doin 
something over the hep C and I went ‘oh yeah I’m up for that’ but 
nothing 
 
(Beth) 
 
I remember you telling me that story [at previous interview], 
there was a mix up with phone numbers and stuff wasn’t there 
 
(Researcher) 
 
Yeah so I don’t know but I see all these posters on the walls er 
hep C, get tested but I know I’ve got it because it wouldn’t be on 
me medical history otherwise 
 
(Beth) 
 
So last time you said you might go for another test, have you 
thought about that again? 
 
(Researcher) 
 
I don’t know where to go. I got told there was a nurse in here but 
I don’t know 
 
(Beth) 
 
And have you found out any more information since I spoke to you 
last 
 
(Researcher) 
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No, no 
 
(Beth) 
 
Beth’s comments indicate there has been no change to her hepatitis C care 
or knowledge in the 6 month period, which is an interesting research finding 
enabled by conducting a follow up interview. 
 
3.7 Interviews with professionals – method 
 
3.7.1 Introduction 
 
Following the research with services users, the second part of this research 
was interviews with professionals working in services that the service users 
discussed, thus drug, alcohol and hepatitis C services. The purpose of these 
interviews was to explore professionals’ experiences of drug, alcohol and 
hepatitis C services in order to enable a comparison between the ‘lived 
experience’ and the ‘professional experience’. 
 
3.7.2 Participant characteristics 
 
Twelve professionals were interviewed. Seven were service user facing staff 
working in drug, alcohol and hepatitis C services across hospital and 
community settings and five were public health commissioners of drug and 
alcohol services. All professionals worked in the Merseyside area (See 
Appendix 7, Table 3) 
 
3.7.3 Recruitment  
 
Ethical approval for interviews with professionals was obtained from 
Liverpool John Moores University ethics committee, as an amendment to 
the original service user study (observation and interviews). Approval was 
also sought from research departments and service managers at the drug, 
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alcohol and hepatitis C services and public health departments of local 
councils. Following approval, professionals were informed of the study and 
were then free to volunteer to take part. When a professional expressed an 
interest in participation, a participant information sheet was provided, 
along with a verbal explanation of the study. Interviews were arranged at 
a time that was convenient to the participant, to fit in with their other 
work commitments. Interviews commenced with a further explanation of 
the study and written informed consent was obtained. All information 
collected during the research has been treated confidentially and 
anonymised. Direct quotes have been used in the findings section (Section 
6.2), participants names and workplaces have not been included but are 
replaced with ‘P1’ to ‘P12’ to depict the 12 professionals who were 
interviewed. 
3.7.4 Method 
To gain an overall understanding of current and historical drug, alcohol and 
hepatitis C services, semi structured interviews were conducted with public 
health commissioners. Interviews with service user facing staff used written 
vignettes of hypothetical service users (see Boxes 1 to 4 for the vignettes). 
The content of the vignettes was based on information gained from the 
previously discussed service user observations and interviews. 
Vignettes were chosen as they aim to mirror a ‘real life‘ situation (although 
it is important to note that in general, research tools can only ever cover 
aspects and can never completely mirror real life) (Hughes and Huby, 2002). 
As a method vignettes have been used widely in health and social science 
research. A few related examples include: presenting vignettes about 
sharing needles to people who inject drugs to gain a better understanding 
of injecting practices (McKeganey et al, 1995; Carruthers, 2005); providing 
scenarios of patients with urinary problems to healthcare staff to 
understand the factors affecting decision making and management of this 
condition (Farrington et al, 2015) and using a vignette of a female with 
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breast cancer with staff and cancer survivors to see gaps in breast cancer 
services (Lea et al, 2013). For this research vignettes were used to gain an 
understanding of the services provided to people living with hepatitis C. 
Vignettes were also chosen to elicit information about the service rather 
than the participant’s personal viewpoint on the topic. Participants were 
asked to discuss a number of points in relation to the vignette, such as: 
what the service would do for the hypothetical service users; what 
advice/information the service user would be given; how the service user 
would be referred to their service and what service they would refer on to. 
Participants were asked to discuss 1 or 2 vignettes (depending on time and 
the relevance of the vignette to the service). Interviews lasted between 20 
to 30 minutes. All interviews (vignette and semi structured) took place 
between December 2015 and March 2016. 
As with the service user interviews, all interviews with professionals were 
audio recorded, transcribed verbatim and imported into Nvivo. A constant 
comparison approach was used for interviews that discussed the same 
vignette, thereby enabling analysis of how each service would respond to 
that specific hypothetical service user. Thematic analysis was also used to 
identify themes across all the professionals’ interviews. These findings were 
compared and contrasted to the findings from the service user interviews 
and observations, which is presented in the discussion chapter (Chapter 7). 
Box 1: Rob (Vignette 1) 
Rob is a 45 year old man with a medical history of COPD and hepatitis C 
(diagnosed in 2000). He previously injected heroin and crack cocaine but 
stopped injecting 10 years ago. He has been on a methadone script for 15 
years and is currently on 40mls of methadone a day. He currently smokes 
heroin around twice a month and drinks 5 cans of 9% Skol super strength 
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lager a day. He lives with his partner in stable accommodation (a secured 
tenancy with a registered social landlord). His partner does not know that 
he has hepatitis C. She would like to start trying for a baby. 
Box 2: Kate (Vignette 2) 
Kate is a 35 year old female with a 3 year history of injecting drug use. She 
currently injects and/or smokes heroin daily. She is on a methadone script 
although she only attends the drug service sporadically. Kate has had 
periods of homelessness but is currently living in a hostel. She says she finds 
it hard to get to the drug service as it is not near the hostel. She currently 
does not drink alcohol. 
[After initial discussion] 
Kate had a hepatitis C test 2 years ago at her previous GP practice. The 
blood was sent to the laboratories at the hospital. The test showed that she 
has hepatitis C. Kate does not know this as she didn’t go back for the 
results. 
Box 3: Ben (Vignette 3) 
Ben is a 42 year old man who is currently drinking approximately half (35cls) 
a bottle of vodka a day. He previously injected heroin but is now maintained 
on a methadone script. He started drinking 2 or 3 cans of Fosters/Carlsberg 
(3.8-4%) lager a day when he was stopping heroin 2 years ago, but since 
then has changed from lager to vodka. He lives alone. 
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Box 4: Sarah (Vignette 4) 
 
 
Sarah is a 52 year old woman with a medical history of depression and 
hepatitis C genotype 1a with no cirrhosis. She thinks she got hepatitis C by 
injecting heroin a ‘few times’ in her twenties. She has never been addicted 
to heroin, so has never been on methadone or attended drug services. She 
drinks alcohol socially. Sarah goes out with her friends about once a month 
and has 3 or 4 gins. She has previously received treatment for hepatitis C 
which was unsuccessful. She works full time and is a single mum to 2 
teenage children 
 
 
3.7.5 Methodological findings – vignettes 
 
Whilst the vignettes aimed to engage staff in discussions linked to the 
original topics of this research (alcohol, hepatitis C and hepatitis C support) 
the research showed that for service users such as ‘Kate’ and ’Ben’, and 
the staff trying to support them, there are many conflicting priorities other 
than hepatitis C. Thus the vignettes had posed a rather simplistic picture 
and had not encompassed the complexities of life for service users such as 
‘Kate’ and ‘Ben’. Also staff sometimes appeared to find it difficult to 
discuss the vignette, asking for more details , such as ‘what level of fibrosis 
has he got?’ 
 
3.8 Analysis 
 
There is no singularly appropriate way to conduct qualitative data 
analysis, although there is general agreement that analysis is an 
ongoing, iterative process that begins in the early stages of data 
collection and continues throughout the study. 
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(Bradley et al, 2007, p. 1760). 
 
 
 
Due to the different research methods employed in this thesis different 
analytic processes were required for each method, with analysis occurring 
throughout. 
 
For the observation, field notes were made after each observation and then 
I (the researcher) would read these through and write tentative 
interpretations, questions and thoughts to be considered and asked about 
at the following periods of observations, gaining over the weeks an 
understanding of concepts and emerging themes. At the end of the 
observation period data was not coded, opting instead to read the data in 
its entirety to help the identification of emerging themes without losing the 
connection between concepts and their context (Bradley et al, 2007). The 
themes and sub themes identified through this process are displayed in a 
thematic map in Section 4.1. With a perception of context and tentative 
emerging themes, interviews were then conducted to further understanding 
of the experiences of service users.  
 
The service user interviews produced two forms of data per participant; the 
transcribed interview/s and the calendar/s (pleural if participated in a 
follow up interview). These documents required different approaches to 
analysis. Firstly individual calendars were studied to ascertain the sequence 
of events in a participant’s life, to understand points such as drinking 
practices after the hepatitis C result or the time from hepatitis C test result 
to hepatitis C treatment. Then each calendar and the corresponding 
participant’s interview transcript were considered together to give context 
to the data on the calendar and provide clarity and further understanding 
to the experiences relayed by the participant. The calendar and transcript 
were considered in their entirety (as field notes were in the period of 
observation) to identify emerging patterns and themes whilst maintaining 
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the connection between concepts and context. Then using an ongoing 
constant comparison approach emerging topics, patterns and themes from 
one interview were discussed at the next interview and the follow up 
interviews to get further clarity and more in-depth data.  
 
When data collection was complete the interview transcripts were then 
coded. Coding provides ‘a formal system to organize the data, uncovering 
and documenting additional links within and between concepts and 
experiences described in the data.’ (Bradley et al, 2007, p. 1761). The 
coding process was iterative and lengthy as suggested by Bradley et al 
(2007). 
 
The code structure was mainly inductive in nature, thus rather than 
approaching the data with preconceived codes (deductive coding), codes 
were assigned from the data. Firstly data was considered line by line and 
as a concept arose it was given a code. As further data were considered and 
more concepts emerged further codes were given. I continued this process 
until all lines, paragraphs, segments had been highlighted and coded. By 
comparing and contrasting each section, codes were changed and 
reassigned until segments that reflected the same concepts had the same 
codes. Codes were then collated into themes, themes were then checked 
against the coded segments to ensure the theme related to the data in the 
segment, then themes were named and a map was generated (Braun and 
Clarke, 2006; Bradley et al, 2007). Deductive coding is where researchers 
have a ‘start list’ of codes, that they then apply to the data. One such code 
that was used in this research was participant characteristics; age and 
gender of the participants. 
 
There is debate amongst researchers as to whether coding should be 
completed by a single researcher or by a team of researchers. The 
discussions revolve around philosophical approaches, research traditions, 
paradigms and researcher biases (Bradley et al, 2007). I was the only person 
coding the data in this research. This was justified in this research as I was 
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embedded in the research with ongoing relationships with participants and 
my biases and assumptions were not bracketed but acknowledged. 
 
Coding was difficult. As explained previously, the LHC method produced 
vast quantities of data, with most interviews being over 20 pages long, 
furthermore due to the inductive nature and conversational approach, 
questions (and therefore answers) were not in an order like other types of 
interviews with a predetermined list of questions. However coding was 
completed and the themes and sub themes from the service user interviews 
are displayed in a thematic map in Section 5.1. 
 
The interviews with professionals consisted of semi structured interviews 
with public health commissioners and interviews using vignettes with 
service user facing staff.  
 
A vignette was considered by 1 participant, the interview was recorded and 
then transcribed. I then read this transcript and noted points, questions, 
emerging themes which were then raised with the next participant who 
considered the same vignette. This interview was then transcribed. 
Transcripts were then compared and contrasted to understand the service 
that would be provided (or not provided) for the hypothetical service user. 
This process was completed for all four vignettes. Then I compared and 
contrasted all the vignette transcripts looking for commonalities and 
differences. Initially this was by reading the transcripts through in their 
entireties.  
 
The commissioner interviews were transcribed and then read through. Then 
all transcripts (commissioner and vignette) were coded as per the inductive 
technique explained in the service user section above. Deductive 
interviewing of considering participants characteristics was not used. 
 
This process allowed ‘intra’ and ‘inter’ transcript analysis to identify 
themes. For example, the gaps in services were visible from analysing the 
151 
narratives of the participants who considered the same vignette, as they 
explained which services they would provide to that individual hypothetical 
service user and this theme also emerged from the commissioner 
interviews. The themes and sub themes from the interviews with 
professionals are displayed in a thematic map in Section 6.1. These findings 
were compared and contrasted to the findings from the service user 
interviews and observations, which is presented in the discussion chapter 
(Chapter 7). 
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Chapter 4 Observation findings 
 
4.1 Introduction 
 
This chapter presents the findings of the period of observation. As explained 
in Chapter 3, two hepatitis C groups were observed, however ‘Group 2’ was 
not attended by any service users, so there were limited findings from that 
group. Therefore this chapter discusses findings from observation at ‘Group 
1’ only. Group 1 ran one afternoon a week and lasted 1.5 hours. Observation 
occurred on nine occasions over a four-month period between November 
2014 and February 2015. Themes and sub themes identified from the period 
of observation are displayed in a thematic map (Figure 3). 
 
Figure 3 Thematic map for the observations 
 
 
4.2 Findings 
 
153 
4.2.1 Group location 
 
The group was located in a meeting room at the offices of a homeless 
charity. Finding the group on the first day was a challenge, driving around 
what appeared to be an industrial area outside of town. I did not feel 
particularly safe, despite it being mid-afternoon; it was getting dark, the 
area was poorly lit and there appeared to be no one around. Later, I talked 
to John the group leader about the location of the group: 
 
The group used to be behind the hostel [which is nearer to the 
town centre] 
 
(John) 
 
Was that convenient for people? 
 
(Researcher) 
 
People [not living in the hostel] didn't like going as might be seen. 
Also people in the hostel didn't like going as others in the hostel 
might see them going there. 
 
(John) 
 
Stigma? 
 
(Researcher) 
 
John agrees and said that where we were now was “out the way 
and no one will see us”. 
 
[Field notes: Week 1] 
 
People with hepatitis C having to be “out the way” where “no one will see 
us”, resonated with the comments made by staff at Group 3 (see Sections 
3.5.3.3 and 4.2.1), who were deliberating on the location of their proposed 
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hepatitis C group, aware that if ‘others saw group members attending, they 
would discover those people had hepatitis C’. A stance different from that 
of Group 2 who were not ‘out the way’ but had moved their hepatitis C 
support group to the drug service in the town centre, so it was convenient 
for people to get to. A stark difference in approach between the services, 
which caused me to question what evidence these decisions were based on. 
Presumably services wanted people to attend, yet I wondered if the 
intended people were consulted when deciding the location of their support 
groups (Stigma is discussed in Section 4.2.6). 
 
 
4.2.2 Who attends the group 
 
I was informed that there were eight core group members, however during 
the time period I observed, the group consisted of three people (Kath, 
Simon, Seb) who had been coming to the group for about two years, Andy 
who attended once and the group leader/peer educator (John). All group 
members had hepatitis C (John previously) and all group members 
(including John) had injected drugs (although Kath had never been 
dependent and had not received treatment for her drug use). Although the 
hepatitis C group was linked to the hostel, attendance was not limited to 
people who lived in the hostel. Andy and Seb were currently residing in the 
hostel, Simon had previously stayed there but Kath had not lived there. 
Kath had found out about the hepatitis C support group from someone she 
knew who previously ran their own peer led hepatitis C support group. Kath 
was employed full time, John did voluntary work (including running the 
hepatitis C group) and Seb, Andy and Simon were unemployed however 
Simon also worked ‘cash in hand’. 
 
Although all group members had injected drugs, it was evident that every 
group member’s circumstances were different, thus PWID are not an 
homogeneous group. 
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4.2.3 What happens in the group - what ‘support’ is received? 
 
2 turn up for the group (Seb and Kath). All sit around a table and 
talk. Everyone sat down, there’s tea/coffee and a plate of 
donuts. John (group leader) starts off with “How’s your week 
been?” The atmosphere is calm he talks quietly, people are quiet 
and appear to be listening. People talk one at a time, but are free 
to chip in. He also later asked “what’s your plans for this week?” 
the group get things ‘off their chests’. Seb talked about hepatitis 
C but talked more about the other aspects of his life. He is in a 
hostel trying to get a house. His ex-girlfriend has turned up. He 
doesn't want to see her as she may jeopardise his chances of 
getting a house, as she has kicked doors etc. in past. He says she’s 
an alcoholic and he’ll “end up supporting her” “ I haven’t even 
got a house” He says he doesn’t sleep well and is “anxious” he 
says he “does worry about her but can’t go back.” John advises 
him to think about now and not the future and to talk to his key 
worker and ask them why they think he’s not ready for a house. 
Kath is offering advice too (about the ex-girlfriend). John tells 
Seb to think about himself, healthy eating, wellbeing, all part of 
starting to look after yourself. I ask does that start when you get 
your hep C result. John explains “no it's a journey and getting 
tested is part of the same journey of starting to want to look 
after yourself” 
 
 [Field notes: Week 1] 
 
This extract demonstrates that conversations were not just about hepatitis 
C but also other aspects of their lives. However in the second week of 
observation, hepatitis C was the main topic of discussion. This was largely 
due to a new group member (Andy) attending. 
 
Seb, Kath, Simon and a new person, Andy were at the group today. 
Andy says he’s anxious about the group, hep C, symptoms and side 
effects to treatment. He talks of the big sheet of side effects in 
with the interferon [hepatitis C treatment]. He has many 
questions about hep C and treatment. “Can I get it from sex, 
cigarettes?” “I’ve been washing cups in boiling water”. He was 
diagnosed 2 and a half years ago, and started treatment recently, 
although stopped after 4 weeks and has started again. He thinks 
he probably got it [hepatitis C] from injecting as a teen [Andy 
looks around mid 40’s] says he didn’t share needles. The group 
tell him hep C is also in filters and spoons. The group answer all 
his questions. The group are laughing. (I enjoyed being there, the 
group are fun, perhaps Andy will come back) 
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[Field notes: Week 2] 
 
Despite Andy being diagnosed with hepatitis C over 2 years previously and 
attending the hepatitis C service to commence treatment, he appeared to 
lack basic knowledge on transmission of hepatitis C, questioning if sharing 
cigarettes or cups could transmit the virus and not knowing the risk 
associated with sharing any injecting equipment and not just needles. The 
group answered his questions, seemingly knowledgeable about the routes 
of transmission, and gave him good advice about the treatment and other 
aspects of his life; a good example of peer support in practice. Andy did 
not come to the group again. 
 
The regular group members had been coming to the group for around two 
years and had all been through hepatitis C treatment. This longevity meant 
the support they required from the group differed from that required by 
Andy. Over the following weeks, conversations around hepatitis C were 
mainly about treatment and forthcoming hospital appointments. Sometimes 
aspects of their lives, such as drinking, were talked about in relation to 
hepatitis C and sometimes other aspects of their lives were discussed 
without reference to hepatitis C, such as: accommodation, other illnesses, 
money, family and friends. The group members appeared to be in a position 
of ‘waiting’. Seb had recently finished hepatitis C treatment and was 
waiting for blood tests to see if the virus had cleared and Simon and Kath 
had previously received hepatitis C treatment which failed to cure the 
hepatitis C, so were waiting for further treatment. Thus on a backdrop of 
hepatitis C, the group provided support for other aspects of their lives, 
perhaps keeping people on the ‘journey’ ‘to looking after themselves’ that 
John spoke about in week 1. For Kath the group provided company, for Seb 
it showed engagement with services as a step towards recovery from 
addiction and a move towards leaving the hostel, for Simon a chance to 
discuss his alcohol consumption and, perhaps not to be ignored was the fact 
that the group was enjoyable. 
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Other support group members received was ‘buddying’, where John would 
accompany the group members to their hepatitis C hospital appointments. 
Group members appeared to value this support, informing John when their 
next appointments were and checking if he was free to go with them. John 
would also speak to people over the phone outside of the group time. John’s 
support was sincere, steady and encouraging, without force or nosiness and 
was without doubt appreciated by the group. 
 
On the fourth week of observation John gave out information about 
hepatitis C medications that he had found on the internet and written out 
himself. There were no other written resources such as leaflets about 
hepatitis C available for the group to read/take home. In week one John 
talked about how previously a doctor at the hospital had suggested he speak 
to the finance department to see if the support group could receive 
funding. John had declined this as felt “they would try and have a say in 
your service – take over” [Week 1]. There appeared to be no funds provided 
for the group. The group seemingly ran on good will, with John 
volunteering, and the refreshments and space provided by the hostel 
organisation. 
 
The support group used a poster to advertise itself. The poster mentioned 
that guest speakers came to the group, however during the time I observed 
there were no guest speakers. John said they used to have guest speakers 
but they hadn’t for a while. Therefore talking and buddying were the main 
support observed. 
 
4.2.4 Discussions about alcohol 
 
I observed alcohol to be mentioned in the group on five out of the nine 
weeks of observation. This was sometimes in relation to their own 
consumption and sometimes about other people’s drinking. The context was 
both in relation to hepatitis C and separate from it, at times discussing 
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alcohol as its own entity, but often flitting between the two. The reference 
to alcohol took many forms, from a passing comment, to a person sharing 
about their own consumption and on one occasion a group discussion. The 
discussion, although shedding light on some of the original research 
objectives, also raised further interesting points for consideration. Firstly 
findings connected to the original research objectives are considered, 
progressing onto a discussion of the other topics that emerged during the 
period of observation. 
 
Conversation about drinking on treatment. 
 
You can’t drink on treatment as it makes you feel bad 
 
(Seb) 
 
Simon stopped drinking for treatment. He said others don’t but 
he will stop again when he gets treatment again. 
 
[Field notes: Week 2] 
 
“the only reason I want treatment is so that I can drink later in 
life” 
 
(Simon) 
 
 “have you told your hepatitis nurse that?!” 
 
(Researcher) 
 
[laughing] “of course not. Just to drink I won’t be addicted or 
nothing like before” 
 
(Simon) 
 
I can’t imagine New Year’s Eve without a drink 
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(Andy) 
 
You just have to not have a drink 
 
(John) 
 
I’ve been drinking a lot lately as the football’s on – “can’t go to 
the pub and watch football without drinking. Everyone’s 
drinking” 
 
(Simon) 
 
Seb can go to pub and drink coffee. Starts talking about healthy 
living and jokes about will be going to gym and running soon! 
 
[Field notes: Week 2] 
 
Once you start drinking it’s not like taking drugs 
 
“after a few days you start to look different” 
 
(Andy) 
 
Andy said his brother died of alcohol and his mum had problems 
with drink 
 
Seb said his brother also died of alcohol 
 
[Field notes: Week 2] 
 
Conversations indicated that there was variation in the amount of alcohol 
currently consumed amongst the group. Although the discussion about 
alcohol does not give definitive information about Seb’s drinking, it hints 
that his consumption levels were low. No further information was gained 
during the following weeks of observation as Seb did not speak about his 
own alcohol consumption again, although he spoke openly about other 
difficulties in his life including his drug use and other people’s alcohol use 
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(especially his ex-partner), suggesting alcohol was not a main concern for 
him at that time. In contrast Simon talked about his alcohol consumption 
every time he attended the group. In the conversation he talked openly 
about being addicted to alcohol previously and his current drinking levels. 
On week 4 Simon spoke more about his alcohol consumption. 
 
Simon has not been drinking but on Fridays someone phones and 
asks him out to pub. “I can’t say no” goes to pub but “is just 
drinking beer” Thinking of stopping Sky [television] as people 
come around to watch football and bring beer. 
 
Had 4 pints in pub and 16 cans at home recently but this is less 
then he used to “no spirits” 
 
Feeling anxious and stressed as wants to reduce so that blood 
results are okay when he has next meeting with XXX (hepatitis C 
nurse) about treatment. Has had 4 pack in fridge untouched but 
when someone calls he’s eager to get to the pub. 
 
Previously drank litres of cider and bottles of vodka, so moving to 
beer is much better 
 
[Field notes: Week 4] 
 
Although unable to quantify Simon’s current level of drinking, as the time 
period in which he had 4 pints and 16 cans was not provided, the general 
tone of his narrative suggests a struggle with alcohol, as he demonstrates 
practicing a harm reduction strategy of reducing the strength of alcohol 
drunk (moving from spirits to beer). He also mentions previously being 
“addicted” to alcohol. 
 
John also talked about his own alcohol consumption. 
 
John talked about not having a hangover now and he thought it 
was as his liver was better [after receiving treatment and curing 
hepatitis C]. He talked about how in the past he wasn’t bothered 
about drink- said he’d buy a 4 pack, drink 1 or 2 and give the 
others away. He said he use to drink vodka in the morning when 
he wasn’t on drugs, to help him cope with his partner at the time. 
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[Field notes: Week 6] 
Interestingly John told me on two separate occasions that he “was never a 
drinker” although drinking in the morning is considered in both the CAGE 
(Ewing, 1984) and AUDIT (Babor et al, 2001) alcohol screening tools which 
are used to identify those drinking hazardous or harmful amounts. One of 
the research objectives was to examine the impact of recovery from drug 
use on drinking behaviours. As the group talked generally about their 
alcohol and drug use, it was difficult to chronologically order their use to 
be able to explore this objective. Simon for example, talked of previously 
injecting drugs and previously being “addicted” to alcohol, but the 
relationship between the two was unclear from the discussions. John 
however did talk about alcohol use after heroin, but in a different context 
to the original objective, explaining how he had used alcohol in the acute 
phase of stopping heroin use, rather than a long term use of alcohol. 
Went cold turkey [sudden withdrawal off heroin] and drank Korn 
[spirit] to cope with the cold turkey symptoms 
[Field notes: Week 9] 
Guidelines advise people with hepatitis C to stop drinking (RCGP, 2007; 
SIGN, 2013; NICE, 2016b) yet the research on alcohol consumption following 
a diagnosis of hepatitis C reports a varied picture in consumption levels, 
with some people reducing or stopping alcohol and others not decreasing 
consumption (see Section 2.5.1). 
All group members (excluding John) had hepatitis C at the time of the 
observation. Therefore if they were drinking at the time of the observation, 
they were drinking whilst having hepatitis C. However as already discussed, 
understanding the group members’ current drinking behaviours was 
difficult. Although Andy did say he had been drinking since being diagnosed 
with hepatitis C, Simon was the only person to talk explicitly about his 
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drinking. From Simon’s conversation it was apparent that he previously 
drank more than he did at the time of the observation but the reasons for 
this reduction were unclear, i.e. whether he reduced his drinking due to his 
diagnosis of having hepatitis C or whether he was reducing his alcohol 
consumption for other reasons. However, inadvertently hepatitis C did 
impact on alcohol consumption, as both Seb and Simon talked about not 
drinking whilst on treatment for hepatitis C. 
 
Although Simon had reduced his drinking, his comment, “the only reason I 
want treatment is so that I can drink later in life”, implies a short term 
behaviour change only. The comment shows he was aware of the risks of 
the combination of hepatitis C and drinking and therefore knew he had to 
treat the hepatitis C, but rather than wanting to cure his hepatitis C out of 
concern for his health, it was out of concern for his ability to drink in the 
future. This provides insight into the meaning of alcohol in Simon’s life, and 
as noted by Harris, (2010) the benefits people received from drinking are 
often missed from the discourse on alcohol and hepatitis C. 
Throughout the observation period, no reference was made to where 
information about alcohol was obtained. Regarding what information was 
known about alcohol, discussions demonstrated a mix of recommended 
harm reduction strategies (reduce spirits to beer), misconceptions (you can 
get hepatitis C from alcohol) and knowledge gained from personal 
experiences (John says the ones he knows that have died have died of 
drinking - those with hepatitis C and without, drinking has killed them 
[Week 9]). 
 
Simon says he is feeling anxious and stressed as wants to reduce [his 
drinking]. His discourse implies he is reducing his alcohol himself. He does 
not mention any services that are supporting him with this. Over the weeks 
the group talk about alcohol but never discuss alcohol services. 
 
4.2.4.1 Further alcohol related points of interest 
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As well as discussing issues that covered the original alcohol related 
objectives, the group conversations raised other points about alcohol that 
were interesting for this research, and are therefore included below. 
 
4.2.4.1.1 Social and cultural aspects of drinking 
 
Andy: I can’t imagine New Year’s Eve without a drink 
 
Simon: I’ve been drinking a lot lately as the football’s on “can’t 
go to the pub and watch football without drinking. Everyone’s 
drinking” 
 
[Field notes: Week 2] 
 
Simon: Has not been drinking but on Fridays someone phones and 
asks him out to pub. “I can’t say no” goes to pub but “is just 
drinking beer”. Thinking of stopping Sky [television] as people 
come around to watch football and bring beer. Has had 4 pack in 
fridge untouched but when someone calls he’s eager to get to the 
pub. 
 
[Field notes: Week 4] 
 
Watching football and drinking, drinking on New Year’s eve, “everyone 
drinking” at the pub are all comments that demonstrate the normalisation 
and ubiquity of alcohol within Western society. Indeed drinking alcohol is 
embedded deeply within Western culture, evidently causing conflict for 
those who are advised to reduce or stop drinking. Clearly Simon enjoys 
going to the pub and drinking (“the only reason I want treatment [for 
hepatitis C] is so that I can drink later in life”). Pleasure is frequently 
omitted from the literature and health promotion discourse regarding 
alcohol use for those with hepatitis C (Harris, 2010). The meaning of alcohol 
use for people with hepatitis C is explored further in the interviews. 
 
4.2.4.1.2 Other people’s alcohol use 
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The group were cognizant of the dangers of alcohol and frequently talked 
about other people’s alcohol use. John, Seb and Andy all spoke about 
people they knew who had died from drinking alcohol. For Seb and Andy, 
alcohol use had affected members of their own families, with both having 
brothers who had died from drinking and Andy’s mum having ‘problems with 
drink’. It was unclear if/how this family history of harmful drinking had 
affected Seb and Andy’s alcohol consumption. 
 
Seb spoke openly about his ex-partner’s drinking, saying she was “an 
alcoholic”. Towards the end of the observation period Seb stopped coming 
to the group. The group said he had started using drugs again and was also 
back with his ex-partner. Although the run of events were not known, the 
group felt getting back with his girlfriend who was drinking and starting to 
take drugs again were connected. 
 
[Field notes: Week 6]. 
 
4.2.4.1.3 ‘Alcoholics’ are ‘different’ 
 
During the first week, Seb was discussing his ex-partner, explaining “she’s 
an alcoholic”. John replied “alcoholics think differently”. There was no 
further explanation as to how ‘alcoholics think differently’, however in 
week 2 Andy commented that “once you start drinking it’s not like taking 
drugs – after a few days you start to look different”, again pointing out a 
difference between drug users and alcohol users. I wondered how these 
comments related to people who used drugs and alcohol simultaneously or 
for those people who had changed from drugs to drink, and if these people 
had hepatitis C, what support they might receive from the group. 
 
These comments are also interesting as there is actually a group member, 
Simon, who admits to be struggling with his drinking and being an ‘alcoholic' 
previously. I wondered if they thought Simon looked and thought differently 
to themselves or if he was not included in those that are ‘different’. I also 
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wondered what level of drinking they were talking about as John certainly 
did not class himself as ever being a ‘drinker’ yet had previously drunk 
vodka in the mornings to cope. 
 
At this point in the research the importance of people who drink alcohol 
being ‘different’ was unknown, however, reflecting back to the start of the 
research, when meeting with the users forum, they explained how the 
“drinkers” sat separately to the people who inject/ed drugs. This point is 
discussed further in the service user interviews 
 
4.2.5 Knowledge of hepatitis C 
 
As shown previously Andy’s level of knowledge on hepatitis C was low, 
despite being diagnosed for two years and having contact with hepatitis C 
services (as had commenced treatment). The group’s support towards new 
member Andy showed the group had a good basic knowledge of transmission 
of hepatitis C and an experiential understanding of hepatitis C treatment. 
However over the weeks it became clear that their knowledge, including 
John the group leaders, was limited. 
 
Conversations often turned to hepatitis C treatment, although those 
involved in the conversation seemed to understand what was being said, as 
an onlooker, these conversations seemed vague and confusing. Over the 
weeks I questioned the group, to understand the conversations and realised 
my confusion was a result of having different knowledge of the treatments 
than the group themselves did. For example, they referred to a treatment 
as ‘the new one’ however they were not actually talking about the (then) 
current new to market drug (sofosbuvir) but were actually talking about 
telepravir and bocepravir that were the ‘new drugs’ in 2012. Thus, their 
knowledge was not up to date in a field of medicine that was advancing at 
a fast pace at that current time. 
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When talking personally about their own hepatitis C, they were unsure of 
the genotype, using phrases such as ‘the easy one to treat’ or ‘the one to 
treat that only takes 6 months’. Different treatment is given for the 
different genotypes of hepatitis C, so it is therefore important to know the 
genotype. A basic understanding of this would help the group know their 
treatment options. 
 
On week 2, the group discussed where they could get more information 
about hepatitis C. 
 
We had a discussion about where they could access information. I 
suggested the Hepatitis C Trust website. The group (excluding 
John) said they didn’t know about hepatitis C websites. Seb said 
he is doing computer training at the hostel. He is learning how to 
search on the internet. Andy wants to look into doing this training 
too. 
 
 [Field notes: Week 2] 
 
The group did not use computers to find out information and as discussed 
previously there were no leaflets or guest speakers at the group during the 
time period observed. John did his best to educate the group, such as 
looking on the internet to gather information to give to the group. However 
John’s knowledge was incomplete, which he then passed onto the group. 
An example of this was when he informed them of the new drug sofosbuvir, 
not realising that (at the time) sofosbuvir was not being used in clinical 
practice as it had not been approved for use by NICE. 
 
I asked John about his training. He had been trained on a peer to peer 
scheme, which he thought was in 2010 and had not received any refresher 
training since. 
 
4.2.6 Stigma, ubiquity and fear 
 
In week 1, John showed me pictures drawn by someone living in 
167 
the hostel. One picture was a needle and syringe with a hook on 
the end and a dead person hanging off the hook- the hook was 
through the persons chest. John was considering using it for a 
poster for the hepatitis C group. I commented that hepatitis C 
doesn’t necessarily kill you, John said people who inject will get 
it – ”hooks you in, tears you apart” 
 
[Field notes: Week 1] 
 
A poster of injecting drug use to be used for a hepatitis C group advertises 
this group to be for people who have contracted hepatitis C from injecting 
and not by other routes of transmission. The poster demonstrates an 
inextricable link between injecting and hepatitis C, yet hepatitis C groups 
need to be ‘hidden away’ from other’s who attend a drug service or the 
hostel. This inevitability of injecting leading to hepatitis C was 
demonstrated further in week 2. 
 
Simon talks about a neighbour who says he’s got hep C. Simon says 
he went for a test but never went back for the results. Simon’s 
neighbour says all his friends have it, so he’s got it Seb – 
“everyone’s got it” 
 
[Field notes: Week 2] 
 
Presuming this ‘all’ and ‘everyone’ is PWID, this conversation suggests a 
ubiquitous nature of hepatitis C amongst this population, causing me to 
question further why if all PWIDs have ‘got it’, hepatitis C groups are hidden 
away. Seeking clarification on this, I asked John. 
 
Researcher asked about, ‘everyone’s got hep C’ but there’s 
stigma of having it, can it be both? John said stigma is only outside 
of drug circles for example in the hostel those who don’t inject, 
knowing that you had hep C 
 
[Field notes: Week 9] 
 
An explanation suggesting that amongst PWID hepatitis C is not stigmatised, 
yet this explanation does not explain the consideration for confidentiality 
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when planning the location of the hepatitis C support group ‘Group 3’ which 
was based within a drug service. At this point in the research this finding 
was unclear, however this is clarified in the interviews. 
 
Considering ubiquity of hepatitis C further, below is the second part to the 
conversation with Simon about his neighbour who went for a hepatitis C 
test and did not go back for the results. 
 
Why doesn’t he (the neighbour) want treatment? 
 
(Researcher) 
 
It’s not causing him any trouble, no symptoms, bury head in sand 
 
(Group) 
 
Like why men won’t go for a prostate check 
 
(Kath) 
 
[Field notes: Week 2] 
 
Demonstrating that despite suspecting hepatitis C as “everyone’s got it”, 
people avoid confirming their hepatitis C status, for a variety of reasons 
including fear. Fear related to hepatitis C came up in the conversation a 
few times over the weeks. 
 
John says it’s all about fear. The biggest fear is admitting to 
yourself you might have hep C. Fear of telling people, didn't tell 
people for a long time, not family no one. Fear of first injection 
for treatment “Why? Fear of the needle?” 
 
(Researcher) 
 
 No going back. As once you’ve started treatment you have to 
continue with it. 
169 
 
(John) 
 
Fear of side effects to treatment. Fear now of going for last blood 
test (since completing treatment). Fear of finding out if I still 
have it 
 
(Seb) 
 
[Field notes: Week 1] 
 
Yet in the last week of observation John explained that the fear of hepatitis 
C isn’t as bad anymore as people know hep C doesn’t kill you [Week 9]. 
Hepatitis C can however lead onto diseases such as hepatocarcinoma or end 
stage liver disease that people do die of, therefore people do need to access 
treatment and not ‘bury their heads in the sand’. 
 
4.2.7 Hepatitis C services 
 
The hepatitis C services and staff were frequently discussed. The group on 
the whole seemed disgruntled, as they ‘didn’t know what was happening’ 
with their care and the doctors they saw kept changing. Doctors were 
named and described as good or not good, although reasons for these 
descriptions were not given. The location of the services were also 
discussed. 
 
Kath: Has appointment at hospital ‘A’, but wants to go back to 
hospital ‘B’ 
 
[Field notes: Week 1] 
 
Kath has got an appointment at hospital ‘C’ and doesn’t know 
why. John talks about Kath asking for appointments to be moved 
from hospital ‘A’ to hospital ‘B’ and how now Kath’s been given 
an appointment at hospital ‘C’. John says it’s further and she’ll 
have to take more time off work. 
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[Field notes: Week 8] 
 
Later it became clear that the reason for Kath attending hospital ‘C’ was 
medically in her best interest, as she received a fibroscan (scan of the 
liver). This equipment was not available at the other hospitals, however 
the group were not aware of this fact. This prompts questions on the 
reasons behind this and perhaps suggests improved communication is 
required between services and service users. 
 
Although mainly dissatisfied with the hepatitis C service, the group did 
however have a high opinion of the hepatitis C specialist nurse. Indeed they 
seemingly trusted and went along with their plan of care, unquestioning 
aspects that concerned them, which were then discussed at the group. One 
such concern was that they were being given different treatment to X 
(another area of Merseyside). Such concerns over treatment could be 
discussed with their nurse, but they did not talk to her about this during 
the period of observation. 
 
4.3 Discussion 
 
As seen from the findings there are difficulties associated with running a 
hepatitis C support group. Whilst organisations differed on location of a 
hepatitis C group (‘out the way’ or convenient), who led the group (staff or 
peer) and the content of the group (testing or group discussion and 
buddying), a commonality of people not attending the groups, was found. 
The reasons behind non-attendance for Group 2 was not uncovered during 
the observation period but a discussion about this with Group 1 (John and 
Kath) illuminated some of the reasons for this in Group 1. Andy only 
attended the group once and Simon and Seb had stopped coming, John said 
they’ve got their own things going on, Seb was taking drugs again, John 
was working and Andy was trying to get a house [Week 8], showing that at 
that current time, they had priorities other than their hepatitis C. When 
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discussing the declining numbers John mentioned that the local services 
were changing from one organisation to another causing disruption so he 
would need to go around the services again and put posters up to try and 
get new members [Week 8]. The changing of services and the difficulties 
this caused to service users was highlighted throughout the process of 
gaining access to the field, as well as during the period of observation. 
 
By the end of the observation period, Kath was the only group member who 
was attending. Qualitative research invites us to explore the ‘exceptions’ 
as well as patterns of commonality (McPherson and Thorne, 2006; Phoenix 
and Orr, 2017). Indeed Kath was an exception in numerous ways. Not only 
was Kath the only support group member who was observed and then 
interviewed (as per original study design), she also was the only person who 
was not dependent on or previously dependent on substances (heroin or 
alcohol) and therefore was not accessing a drug and alcohol service. Thus 
Group 1 itself was unusual as it was not connected to a drug and alcohol 
service, meaning it was open to people who did not attend these services. 
All other groups and organisations visited for the service user observation 
and interviews for this research were drug and alcohol services, therefore 
Kath was an exception to all other participants on this research. Throughout 
conducting this research I discovered that there were no local hepatitis C 
support groups other than those in drug and alcohol services, showing the 
lack of support available for people who do not attend these services, and 
perhaps an explanation as to why Kath kept attending this group. 
 
This period of observation has illuminated many interesting points, some 
which are linked to the original research objectives and others which have 
emerged during the process. Although the meaning and importance of these 
findings was not clear at this point in the research, the interviews provided 
further information and clarification. 
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Chapter 5 Service user interviews - 
findings 
 
5.1 Introduction 
 
Chapter 5 presents the findings of the service user interviews. In this 
context ‘service users’ were people who have injected drugs (either current 
or previous injecting of psychoactive drugs such as heroin or crack cocaine) 
and who have had hepatitis C at some point in their lives (either current or 
previous). 
 
Interviews were conducted at a variety of drug and alcohol services from 
January to December 2015. Life history interviews were conducted with 21 
service users, of which 4 participants had a follow up interview (see 
Appendix 4 for interview schedule and Appendix 7 for participant 
characteristics). 
 
The analysis discusses three main findings namely; alcohol consumption, 
living with hepatitis C and services, advice and information. Figure 4 
demonstrates these themes and the corresponding sub themes. 
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Figure 4 Thematic map for the service user interviews 
 
 
5.2 Findings 
 
5.2.1 Alcohol consumption 
 
At the time of the interviews, five participants were dependent or high risk 
drinkers, five were abstinent from alcohol and eleven were drinking 
amounts classed as lower-risk levels for the general population (i.e. people 
who do not have hepatitis C), albeit some participants were having the 
weekly amount on one day rather than spreading the amount across the 
week as recommended. However as the calendar method enabled lifetime 
alcohol use to be explored, it found some participants who were currently 
abstinent or lower-risk drinkers had a previous history of higher-risk or 
dependent alcohol consumption. Three participants had been dependent 
drinkers and four participants had been higher-risk drinkers for a period of 
time during their lives. For some participants this period of higher-risk or 
dependent drinking occurred prior to injecting drug use (ranging from 8 
years prior to briefly overlapping), other participants used heroin and drank 
at the same time and for other participants drinking came after drug use, 
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with some of these drinking higher-risk amounts for a short period of time 
only and others becoming dependent on alcohol. 
 
5.2.1.1 Factors influencing alcohol use 
 
All participants (N=21) were aware that drinking alcohol with hepatitis C 
increased the risk of liver damage, yet most had consumed alcohol since 
diagnosis. Only two participants had not consumed alcohol since being 
diagnosed with hepatitis C, however these participants were abstinent prior 
to the hepatitis C test and therefore remained abstinent after, so their 
abstinence was not linked to the hepatitis C diagnosis. Two participants 
found on testing they had spontaneously cleared the virus. As they had 
previously had hepatitis C but no longer had the virus, it is not possible to 
discuss how having hepatitis C affected their drinking, other than to note 
that this event did not alter their drinking (although one person did stop 
injecting after this result, however it is not possible to say if this behaviour 
change was due to the hepatitis C or the groin abscess that had brought this 
person in contact with health services). Sadie had also spontaneously 
cleared the virus when she was tested, however she explained how she did 
not understand the result at the time and thought she had hepatitis C, 
therefore Sadie is included, in the 17 participants who drank knowing they 
had hepatitis C. The participants’ narratives showed a mixed response in 
terms of the recommendation to stop drinking (or reduce if unable to stop) 
(NICE, 2016b) following a hepatitis C diagnosis. Some participants did 
reduce/stop drinking, other participants’ drinking stayed the same as 
before the diagnosis and some participants’ drinking actually increased 
during the time they had hepatitis C. This later finding was only possible 
due to the method employed in this study. As many participants had been 
living with hepatitis C for several years (ranging from 1 to 19 years) and the 
calendar method enabled exploration of drinking over their lifetime, it was 
possible to see that drinking patterns changed over the time participants 
had hepatitis C. Thus the question of whether being diagnosed with 
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hepatitis C affects drinking is a more complex one than is previously 
described in the literature (Chapter 2). 
 
Sadie and Jack did not reduce their alcohol consumption following the 
hepatitis C result. Whilst it is not clear if their consumption increased or 
remained the same, they explained how they had used alcohol to cope after 
receiving the test result: 
 
..so I sort of did it on myself and thought look just go and get 
fucking bladdered everyday…Just go and get bladdered every day, 
just get wasted and whatever. 
 
(Jack) 
 
Drunk? 
 
(Researcher) 
 
Yeah. 
 
(Jack) 
 
I thought to myself yeah well, I’ll just go on right and just do 
what I’ve, I thought one little, get permission sort of thing, yeah, 
drink as much as I can, take as much vodka as I can. 
 
(Sadie) 
 
Both of these participants were consuming amounts of alcohol that would 
class them as higher-risk drinkers and had received treatment for alcohol 
use on a few occasions over the years. Therefore these participants would 
fit O’Leary et al’s (2012) findings that those who drank to excess continued 
to do so following the hepatitis C result. However the research for this 
thesis found five other participants who did not alter their alcohol 
consumption after being diagnosed with hepatitis C, which seemed 
irrespective of the amount drunk. Neil for example would go out every 
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couple of months and binge drink (‘well I went to a barbecue on bank 
holiday Monday and had 9 cans or 10’) and Brenda just drank at Christmas 
and continued with that after diagnosis. 
 
Two participants in the study rarely drank alcohol but had a period of 
higher-risk drinking during the time they had hepatitis C. Thus alcohol 
consumption increased when they had hepatitis C, however this change in 
drinking was not linked to the hepatitis C, but to other factors in their life. 
For Sharon this was because she got a new partner who was drinking and 
for Ed this was to cope with numerous family bereavements. Ed had been 
hepatitis C positive for 8 years and Sharon for 10 years when they started 
to drink higher-risk amounts. 
 
Only Susan did actually stop drinking, however this was not immediately 
after receiving the test result but approximately 6 month later, in order to 
be eligible to receive hepatitis C treatment. Eight participants had reduced 
their alcohol intake since being diagnosed with hepatitis C, yet the in-depth 
conversations during the interviews showed this reduction was not wholly 
attributed to hepatitis C but was actually a decision based on a variety of 
factors that were of importance to the individual. 
 
I’ve never really been a drinker Jane [researcher], but especially 
when I found out I had it [hepatitis C], that’s even made me cut 
down with me dad now, you know what I mean, obviously he’s cut 
down too now that age where he can’t drink, he’s starting 
radiotherapy or chemo. 
 
(Pete) 
 
She [girlfriend] was in XXX [rehab unit] for ‘er alcohol as well as 
drugs so it’s very, it’s not good for me to have cans in the fridge. 
 
(Pete) 
 
[cut down] after I got diagnosed [with hepatitis C]. 
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(Dan) 
 
I might as well move somewhere, where I can just, I don’t know 
any dealers. 
 
(Dan) 
 
I wanna have one night’s sleep Jane [researcher] with nothing in 
me system. 
 
(Dan) 
 
The quotes by Pete (who was a lower-risk drinker) explain that the factors 
affecting his decrease in alcohol consumption were: that alcohol was not 
his drug of choice; other peoples’ (Father and partner) drinking influenced 
his own drinking; and his positive hepatitis C result. In contrast, Dan’s (who 
experienced alcohol dependency) reasons were linked to trying to change 
his life by stopping all substances as well as the hepatitis C result. Hepatitis 
C is therefore not a distinct factor in alcohol consumption but intermingled 
with many other factors occurring in people’s lives. 
 
Other participants said they had decreased their drinking for reasons 
unconnected to their hepatitis C. Gav had reduced because he had 
generally been ‘drinking too much’ and had been told to ‘cut down’ and 
Beth did not drink very much as even a shandy made her feel ‘weird’, which 
she put down to her other illnesses and medications she was taking. 
 
Thus for the majority of participants, hepatitis C was not the determining 
factor in drinking practices. For some participants hepatitis C played a 
partial role in decisions on alcohol consumption but for other participants 
hepatitis C made no impact on their drinking, regardless of the quantity 
drank. 
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This research found that rather than hepatitis C, the main influences on 
alcohol consumption were: partners drinking, drinking to cope and where 
participants were in their recovery process from substance use. 
 
The influence of partners on alcohol (and substance use) was mentioned by 
the majority of participants. Some participants spoke about how their 
partner’s drinking (or drug use) had started their own use. 
 
I’d only have the odd drink now and again, once maybe twice a 
week, sometimes it’d only be once a week…and then it was when 
I met this girl, you know, she was drinking, she’d come out of 
rehab, but then she started drinking again then and we’d go the 
pub have a drink and then it starts ‘oh go the off licence then’, 
and then it got to the stage where I’d wake up in the morning 
going ‘I wanna drink, I wanna drink’. 
 
(Gav) 
 
I was married to a big drinker, but I didn’t know and he’s an 
alcoholic, so I drank nothing, then I ended, ended up worse then 
what he did. 
 
(Susan) 
 
So you’ve not drank at all and then you started in 2010.Why did 
you start? 
 
(Researcher) 
 
Urm, I was with a partner who was drinking. 
 
(Sharon) 
 
For Pete his partner not drinking influenced his own drinking. 
 
..me girlfriend doesn’t drink, so I don’t drink. 
 
(Pete) 
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However others talked about only being able to reduce or stop alcohol (or 
drugs) when they were not with their partner anymore. 
 
He went to prison, and I just slowly stopped drinking. 
 
(Sharon) 
 
Yeah, well ur, it was only moderate, I wasn’t drinking as much as 
when me girlfriend was alive, coz we like sort of complemented 
by each other. 
 
(Kev) 
 
He didn’t wanna stop, you know we’d gone through all that where 
you stop, no I don’t wanna stop, I wanna stop, no I’m not, you 
know, we’d gone through all that and we’d tried like small 
decreases, but that was the end of it for me, you know, I just 
thought to myself, I can’t, I can’t do it. So I ended up throwing 
him out and he was not best pleased, he said well can’t, can’t we 
just carry, I said I can’t I can’t do it, I can’t do it no more. 
 
(Jenny) 
 
These accounts demonstrate the influence partners have on each other’s 
alcohol and/or substance use, showing the complexities of managing their 
own addiction alongside their partner’s. In this research some partners 
were using the same substances and other partners were using different 
substances, for example one participant’s preference was smoking heroin 
but his partner was a higher-risk drinker. It is interesting to note that all 
participants in the study had tried a variety of substances, as had their 
partners, however their current substance (or last substance in those no 
longer using) of choice was not always the same substance as their partner. 
 
Studies conducted in other countries (France, Italy, Ireland, USA) have 
shown alcohol reduction was part of an overall lifestyle change following 
diagnosis of hepatitis C (Cullen, 2005; Castera et al, 2006; Scognamiglio et 
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al, 2007, Stoller et al 2009b). In this research some participants changed 
their lifestyle following the hepatitis C diagnosis. 
 
Started to drink more water, was like one of the things I started 
doing when I got hep C, drink plenty of water eat fruit and veg 
and keep away from red meat, isn’t it? Yeah keep away from red 
meat, eat chicken an all that…and I started to walk a lot you 
know, you know get a bit more exercise. 
 
(Susan) 
 
…my sister’s a nurse and she said ‘you know the best thing you 
can do is go on a low protein diet really’ yeah and um I know, I 
sort of did that 
 
(Tom) 
 
changed your lifestyle? 
 
(Researcher) 
 
Yeah yeah tried to keep me fit you know a little bit yeah, walkin 
to the buses and that yeah, 
 
(Tom) 
 
The topic of living healthily was discussed on three occasions at Group 1, 
with the group leader advising people to drink lots of water on treatment 
(week 6) and also advising the consumption of fish oils and healthy food to 
“help you live longer”. However he explained that the healthy eating and 
wellbeing was all part of a “journey of starting to look after yourself, when 
coming off the drugs” (week 1), indicating that in this research lifestyle 
advice is not given specifically when diagnosed with hepatitis C but as part 
of recovery from substance use. This was echoed throughout the interviews. 
Jenny explained how she started to make changes to her lifestyle as she 
stopped using heroin but also how the treatment to clear the hepatitis C 
was the final part of this recovery process from her heroin addiction. 
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[Talking about stopping heroin] …because then, I was on a journey 
there.  
(Jenny) 
 
I was with the XXX [drug service] and I was doin healthy stuff 
then, you know we were going for walks, there was cooking, you 
know things like that. 
 
(Jenny) 
 
..it [hepatitis C treatment] was getting rid of the, like that was 
me drug use completely gone then….if that [hepatitis C] was still 
there, you know if, if that was still there I’d still have that, with 
me. 
 
(Jenny) 
 
Carrying a bit of your past with you? 
 
(Researcher) 
 
Yeah yeah, it’s took, it’s all completely gone. 
 
(Jenny) 
 
For the participants in this research the run of events in regards to lifestyle 
changes and hepatitis C diagnosis is more complex than explained in 
previous research. Most participants had made changes to their lifestyle 
before receiving a hepatitis C diagnosis; for example those who attended 
drug services for Opiate Substitution Therapy (OST) received a hepatitis C 
test at the drug service, indicating lifestyle changes in terms of heroin 
reduction took place prior to the test. However the recovery process is not 
linear and most of the participants had tried to stop using heroin on a 
number of occasions, some of these attempts prior to the hepatitis C test 
and others after. It appears for this research that for some participants 
where they are in their recovery process from substance use affected how 
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they were able to manage the other lifestyle factors, such as alcohol and 
diet that are advised in living with hepatitis C. 
 
This finding has shown various factors influence participants’ alcohol 
consumption. Furthermore it has shown that different factors influence 
drinking at different points in a participant’s life, often with multiple 
aspects having an impact on alcohol consumption at any one time. Hepatitis 
C is one of the influencing factors of alcohol consumption for some 
participants, however this was not the case for all participants (although as 
influences are changing throughout participant’s lives, it therefore stands 
to reason that hepatitis C may become an influence in the future). This 
finding has also highlighted the complex nature of participants’ lives and 
the difficulties of managing a chronic illness amongst an addiction/s. 
 
5.2.1.2 Alcohol and hepatitis C - medical advice and interpretation. 
 
Throughout the interviews participants discussed the advice they had 
received around alcohol consumption whilst having hepatitis C. Out of the 
18 participants who have/had chronic hepatitis C (3 who spontaneously 
cleared are not included), 6 said they had received no advice about alcohol 
from services (hepatitis C service, drug service or GP). However 2 of these 
6 people had received information about alcohol and hepatitis C by 
attending a peer group or a course linked to the drug service. Of those who 
had not received any advice about alcohol, 2 people (Rich and Steve) were 
abstinent from alcohol at the time they were diagnosed with hepatitis C. 
Steve explains: 
 
Did they give you any advice about alcohol? 
 
(Researcher) 
 
Um well I, obviously I was still in treatment [drug rehabilitation] 
when I went in there [hepatitis C clinic]. My liver functions were 
out but not majorly so and not so they could have sclerosis or 
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anything that would, they were just slightly out on the levels and 
I was, I declared as being abstinent and intending to remain 
abstinent so I don’t know what they might have said if like I’d 
said I’m still having a drink.……But I mean like they didn’t sort of 
say ‘you have to remain abstinent’ or anything. But I mean the 
fact that I’ve said I don’t drink and I’m not intending to drink I 
think that just sort of covered it straight away so they didn’t you 
know. 
 
(Steve) 
 
However this is not a universal approach as others who were abstinent were 
given advice: 
 
Did you get any advice about drinking alcohol and hepatitis? 
 
(Researcher) 
 
Yeah don’t drink alcohol, it’s bad for your liver isn’t it. 
 
(Joe) 
 
Conversely, some participants who drank alcohol felt they had not received 
advice about drinking with hepatitis C. Ed for example received a positive 
hepatitis C test result 19 years ago and had a period of heavy drinking (63 
units of alcohol a week for 7-8 months) yet he was unsure if he had ever 
been given advice about alcohol and hepatitis C. 
 
Have you been told anything about alcohol and hep C? 
 
(Researcher) 
 
Alcohol and hep C, no, no I don’t think so. No I don’t think so. 
 
(Ed) 
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Although it is not known if Ed has been given advice that he does not recall 
or whether he has not received advice, an interesting point is made by 
Susan. Susan, who was extremely upset when she received her hepatitis C 
diagnosis, was not sure if she was given information at that time, including 
if she was given advice about drinking, however she knew she was given 
information about alcohol and hepatitis C at the hepatitis C clinic which 
was at least 6 months after the test result, indicating the benefits of 
ongoing advice. 
 
The majority of participants in the study commented that they had received 
advice about alcohol and hepatitis C. This advice was however not, ‘stop 
drinking’, as recommended in clinical guidelines. 
 
So at the time of your hep C test what advise were you given? 
 
(Researcher) 
 
Oh, uh, not to drink, obviously. 
 
(Kath) 
 
Just to completely stop? 
 
(Researcher) 
 
Um, It’s not advisable. 
 
(Kath) 
 
It’s not advisable to drink? 
 
(Researcher) 
 
Yeah, yeah. 
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(Kath) 
 
How did you interpret that? 
 
(Researcher) 
 
Oh just stop, if you don’t have to don’t. I wasn’t an alcoholic I 
wasn’t much of a drinker so it wasn’t really a major problem for 
me. 
 
(Kath) 
 
It looks from what we said before, that you reduced, not stopped. 
 
(Researcher) 
 
Yeah, yeah but still if I went out and did sumfin I went to a party 
or sumfin I still did. 
 
(Kath) 
 
And did you drink less than you did before you got the result? 
 
(Researcher) 
 
Same probably. 
 
(Kath) 
 
Interestingly Kath’s comments suggest she thought only higher levels of 
alcohol were an issue with hepatitis C, indicating that the advice she had 
received was not to completely abstain from alcohol, as clinical guidelines 
recommend. This is further demonstrated by Kath, when she talked about 
her current hepatitis C appointments. 
 
When you go for your appointments now what are they saying to 
you? Are they giving you any advice about alcohol now when 
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you’re going? 
 
(Researcher) 
 
They just ask me “what you drinking”? 
 
(Kath) 
 
They ask you yeah? 
 
(Researcher) 
 
Yeah and that I don’t drink much. They don’t pass any comments 
really, don’t pass any comments. 
 
(Kath) 
 
Demonstrating that although Kath is not abstinent, the hepatitis C clinic 
are aware of this but do not advise her to stop. Although Kath only drinks 
socially (3 or 4 gins once a month – lower-risk drinker for general 
population) other participants who drink larger amounts of alcohol were 
also not told to stop drinking. Jack was currently alcohol dependent and 
Kev had previously (over 10 years ago) drunk amounts that would class him 
as a higher-risk drinker but currently drank amounts that would align him 
to the lower-risk category. 
 
Did they tell you anything about alcohol? 
 
(Researcher) 
 
Yeah don’t drink, well, drink but not, excessively. 
 
(Kev) 
 
And what kind of advice do they give you about your hep C? 
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(Researcher) 
 
 Nothing’ just ways of like healthy livin’, you know sort of, go to 
the gym, keep yourself healthy, eat, whatever, basically not drink 
but I drink, that’s the problem. 
 
(Jack) 
 
You were told, not drink, none at all? 
 
(Researcher) 
 
No, not basically ‘not drink’, but you know obviously it’s more a 
problem for ya coz that will damage your liver more if you’ve 
already got hepatitis your liver’s damaged anyway. 
 
(Jack) 
 
These quotes indicate that across the range of quantities of alcohol 
consumed, participants were not being told to stop drinking. The only 
participant that was told to stop was Susan, who like Simon from Group 1, 
had to completely stop drinking to receive hepatitis C treatment. However 
Kath had not received the same advice. 
 
Well I was naughty really on the treatment. I don’t remember, I 
just,.. I don’t remember them saying it will, it could, I remember 
thinking don’t drink because it’s your liver that’s damaged, or it, 
you know, because of hepatitis C, I don’t remember them saying 
don’t drink because it [hepatitis C treatment] might not work. 
D’ya know what I mean? If they said, I’m sure if I’d had a been 
told, I mean that may not be the reason it didn’t work, at all, but 
um if they’d told me that ur, you know you can take this for 6 
months and because you’ve had a few drinks however, it will have 
failed and you’ll still have it and then have to have treatment 
again or whatever but um I just remember in my mind it was just 
don’t drink, don’t drink if you can help it, because it’s your, you 
now know you’ve got a condition that affects your liver. Yeah 
because um, coz I have thought, it has played on my mind 
afterwards, is that why it didn’t work, but um, I didn’t drink that 
much. Oh I don’t know, the answer, like I don’t know when I got 
it, I don’t know if it didn’t work because I had a few drinks. 
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(Kath) 
 
And have they said when you might have the treatment again? 
 
(Researcher) 
 
Um they said, actually said January this year that they were 
deciding whether they were going, go ahead with the new 
treatment. who they’re going to give it to probably by the end of 
this year I can either, if I don’t get offered the new treatment, 
the brand new one, then I can have the old treatment again but 
for longer. 
 
(Kath) 
 
Try again, and would you drink again do you think or would you…? 
 
(Researcher) 
 
[interrupting] I probably wouldn’t, no. 
 
(Kath) 
 
Yeah because in your head you think that’s had some impact on 
it? 
 
(Researcher) 
 
Well yeah it’s one of those things that you don’t know. If I was 
say a heavy drinker I’d would say yes definitely, but I mean I know 
other people that, saying other people, I know a couple of people 
that I’ve known from here that have drank during treatment. My 
ex drank on his treatment, he’d a worse strain than me and he 
got rid of it. 
 
(Kath) 
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The lack of clear advice around alcohol consumption led Kath to suspect 
she was in some way responsible for the negative treatment outcome, 
leading her to make future decisions about alcohol based on her own and 
peers’ experiences rather than clinical advice. Kev also demonstrated how 
he had (mis)interpreted advice he was given. 
 
....but they didn’t say stop completely? 
 
(Researcher) 
 
No, no coz you can’t stop can ya, when you’re drinking all the 
time, it’s um thingio, dangerous to stop but I’ve slowed right the 
way down and then stopped. 
 
(Kev) 
 
You have stopped? 
 
(Researcher) 
 
Mm [nodding] 
 
(Kev) 
 
Yeah, you don’t drink now? 
 
(Researcher) 
 
No. As I said every now and again. 
 
(Kev) 
 
Yeah I was gonna say, you said before you drank, every couple of 
weeks, didn’t you? 
 
(Researcher) 
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Its only like 1 or 2 beers. I won’t go out and spend a hundred 
pound on ale, through drink. I’ll have like a couple [of super 
strength cans] or I’ll buy meself a 2 little bottle of cider and go 
and sit in the middle of nowhere. 
 
(Kev) 
 
For Kev his understanding of the message ‘stop alcohol’ was linked to those 
who are alcohol dependent, who are at risk of withdrawal symptoms if they 
stop or reduce suddenly the amount of alcohol they are drinking (NICE, 
2010a). There appears to be some confusion here, as his narrative indicated 
he was not alcohol dependent so therefore could have stopped drinking 
without experiencing withdrawal symptoms. Also Kev’s interpretation of 
‘stopped’ did not actually mean abstinence from alcohol, which was also 
shown by Kath and was a common finding from the narratives. Indeed eight 
participants said they had stopped drinking but were still consuming 
alcohol. I surmise the origins of this discrepancy lie in the interpretation of 
the word ‘drink’. When I spoke about drinking alcohol, I meant any amount 
of alcohol, however participants interpreted this as drinking excessively, 
with many participants explaining ‘I’m not a drinker’. 
 
What about alcohol? Do you drink alcohol? 
 
(Researcher) 
 
No I’m not a drinker. 
 
(Beth) 
 
Have you ever drank any alcohol? 
 
(Researcher) 
 
Oh yeah, yeah 
 
(Beth) 
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A conversation with Joe also highlights this: 
 
I’ve never drunk Jane [researcher] 
 
(Joe) 
 
Never? 
 
(Researcher) 
 
Never drunk no, not a drinker. 
 
(Joe) 
 
You’ve tried alcohol though? 
 
(Researcher) 
 
Tried alcohol yeah, yeah. 
 
(Joe) 
As does one with Phil: 
 
…because I don’t drink you see. Don’t get me wrong if I go out to 
dinner I’ll have the odd pint of lager that’s it, a couple of pints 
and even that’s too much. 
 
(Phil) 
 
How often do you have a drink then? 
 
(Researcher) 
 
No it’s not a drink drink, it’s a drink with a meal. 
 
(Phil) 
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All three of these examples demonstrate that participants drank, despite 
saying they had not/did not drink, showing the term was interpreted 
differently from its original intention. This may be informative for those 
conducting future research on this topic but also for those discussing alcohol 
use with service users. 
 
This research has also shown that participants understand the advice on 
alcohol and hepatitis C to be for those who are drinking ‘excessively’ and 
not for those who do not drink ‘much’. Although, interestingly when 
discussing the advice on alcohol consumption for the general population 
(i.e. for people who do not have hepatitis C), participants did not know the 
recommended weekly limit of alcohol (drinks per week, units per week, or 
what constitutes a unit). Therefore when participants said they do not drink 
‘much’ they were actually unaware of what safe(r) guidelines are to 
benchmark their own drinking against. Participants were therefore using 
other benchmarks (such as other people’s drinking) to judge their own 
consumption levels. 
 
Although participants were aware that drinking with hepatitis C increased 
the risk of liver damage, misinterpretations of the effects of alcohol on the 
hepatitis C virus were evident throughout the narratives. As in Group 1, 
Mark and Jack thought alcohol could cause hepatitis C. 
 
You’re tempting it [hepatitis C] to come back, you know with the 
alcohol  
 
(Mark) 
 
… it [hepatitis C] can either be there by drink or be there through 
drugs so, you know that’s what most people don’t understand you 
know, you can actually get it through drinking without being 
involved in drugs. 
 
(Jack) 
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This was surprising as Jack had demonstrated a high level of knowledge 
about hepatitis C throughout his interview and had previously provided 
training and support around hepatitis C to others. Another misconception 
was that by reducing alcohol consumption hepatitis C could be cured. 
 
you know you can get rid of it [hepatitis C] yourself if you’re not 
chaotic, um drinking as much, an doin what I’m doin [injecting]. 
 
(Kev) 
 
Kev’s narrative indicates confusion not only on alcohol use and hepatitis C 
but also spontaneous clearance of the virus and the role of injecting in 
hepatitis C. 
 
This research has shown that participants were aware drinking with 
hepatitis C increases the risk of liver damage, however it appears that 
healthcare professionals seemingly have not advised the participants to 
abstain from alcohol. Although the reasons for this are not known, this may 
be reflective of the inconclusive evidence on the amount of alcohol that 
expedites hepatitis C. This is discussed in the literature review (Section 
2.5.1) and is explored further in the interviews with professionals in Section 
6.2. The research has also found that participants interpreted information 
differently from how it was intended, pointing to the need for clear 
explanations, checking understanding and revisiting advice on an regular 
basis. 
 
5.2.1.3 Alcohol reduction 
 
Twelve participants in the study had a history of harmful alcohol 
consumption (alcohol dependence or higher-risk drinking) at some point in 
their lives. Five of these participants had received support through a service 
(either residential or home detox) to reduce the amount of alcohol they 
consumed, whilst others said they had not accessed a service, but had 
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reduced their alcohol intake on their own. Some participants did this by 
simply reducing their alcohol whereas others used substances to help them 
lower their alcohol consumption. For Sharon this was by using a 
benzodiazepine which she had obtained without attending a service. 
 
How did you stop drinking? 
 
(Researcher) 
 
Um, I just weaned myself down. 
 
(Sharon) 
 
Did you? 
 
(Researcher) 
 
Yeah and took tablets and they helped me. 
 
(Sharon) 
 
What tablets? 
 
(Researcher) 
 
Urm benzos. 
 
(Sharon) 
 
So was it like through a service, that you got the tablets? 
 
(Researcher) 
 
No, no, no. 
 
(Sharon) 
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 You were just using benzos? 
 
(Researcher) 
 
Yeah. 
 
(Sharon) 
 
Other participants had reduced their alcohol intake by using heroin. 
 
So you know you go through withdraw off it, you know 
withdrawals and that 
 
(Ed) 
 
Off the heroin or drink? 
 
(Researcher) 
 
Off the drink. Still have the heroin or else you go down there as 
well you know and that experience of withdrawing off the ale, 
which is horrible you know. I was lucky, I just made a decision, 
I’m not gonna be like that again, I’m not gonna let it, you know 
start having cans a day, every day, get like that 
 
(Ed) 
How did you stop [drinking] then? 
 
(Researcher) 
 
I just stopped it. 
 
(Ed) 
 
Did ya, just like that? 
 
(Researcher) 
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Yeah, just like that. 
 
(Ed) 
 
No help from any services? 
 
(Researcher) 
 
No, no like I said I still had me gear [heroin]. 
 
(Ed) 
 
Put it this way, I just stopped it, to be honest, I think to be honest 
the heroin, I know it sounds stupid but the heroin made me stop. 
 
(Phil) 
 
Although both Ed and Phil had used heroin to help them change their 
drinking, they had used the two substances in different ways. Ed had started 
on heroin first then had a period of higher-risk drinking (63 units of alcohol 
a week for 7-8 months) whilst still using heroin and then continued on just 
the heroin. Phil felt he ‘was getting close to becoming an alcoholic’ but 
then started using heroin instead. 
 
Phil and Ed were not under a drug service at the time they were drinking 
excessively but were aware of alcohol services and decided not to seek 
help. Sharon was under a drug service at the time of her higher-risk drinking 
(over 100 units a week) but did not want help for her alcohol consumption. 
Sharon also commented in her interview that she was not aware her 
drinking levels were harmful until she received unequivocal information. 
 
I came here one day and they went mad at me, they said “Sharon 
you know, you shouldn’t be drinking end of” but I was absolutely 
bladdered and they said “you know, you’ve got cirrhosis you’ll 
end up killin yourself” and it did frighten me. So, I mean I could 
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have had help here with the drinking but I just done it, yeah, 
yeah. 
 
(Sharon) 
 
Gav, however did want help for his alcohol dependency but was faced with 
barriers to accessing treatment. 
 
So when they [GP] said, ‘you need to reduce your drinking’, did 
they give you help any, refer you to anybody? 
 
(Researcher) 
 
No, they tried to refer me to somebody, and then they said ‘well 
what we can try is a home detox and give you librium’, so I said 
‘OK that’s fine, I’m happy with that, the librium’ so he phoned 
up he said ‘oh we’ve got a new nurse starting a young nurse, she’s 
new but she mightn't let you do a home detox’, so I said ‘why’ he 
said ‘well because you’re on valium, he said the librium’s got 
valium in’, he said ‘only a bit, but not much’, I said ‘well it’s not 
gonna affect me, you know, I’m not gonna go take all the librium 
tablets’ you know, I said ‘I will take them properly’, you know, 
but he just that the girl turned around and said ‘no I’m not givin 
him them’, so they wouldn’t help me with it. 
 
(Gav) 
 
You know when you were saying they were going to do a home 
detox and then they couldn’t, did they suggest you do like a 
residential detox then? 
 
(Researcher) 
 
No they were saying one time try and get me in XX house [name 
of alcohol detox unit]. Then they said ‘oh there’s no places there’ 
so I couldn’t go. 
 
(Gav) 
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Whilst there may be medical reasons for Gav not having a home detox, and 
waiting lists for a residential detox unit, Gav felt ‘they wouldn’t help’ him 
with his alcohol consumption and consequently did not ask for support 
again, (although he did managed to reduce his alcohol consumption 
himself). Although participants may have received support in the form of 
brief interventions, it is clear from the narratives that participants felt they 
had not received help and had done it alone. 
 
This research has found that some participants did not receive help to 
reduce their alcohol consumption, with barriers to accessing support 
including: the negative impact of previous encounters with services; not 
realising drinking levels were harmful; and not wanting help for drinking. 
 
5.2.1.4 Views on alcohol 
 
Throughout the narratives, participants talked about people they knew who 
were alcohol dependent, many of whom had died ‘from the alcohol’. 
Participants often expressed that alcohol was more hazardous to health 
than heroin. 
 
I think drink’s the worst to be honest, I’ve seen actually more of 
my mates die in the last year over drink than heroin, crack 
anything I’ll be honest with ya. I’ve been to about 7 funerals, 2 
of them have been me cousins you know what I mean, over drink, 
I think it’s terrible, I think it’s the worst like, it’s ruined my 
family. 
 
(Pete) 
 
..but you know, once you’ve seen what alcohol does to people, 
alcohol’s worse than heroin, it is, and er, no doubt about it, I’ve 
lost more mates to alcohol then I have with heroin, you know 
what I mean. 
 
(Phil) 
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This perception that alcohol is worse than heroin may explain people’s 
defensive comments, such as ‘I’m not a drinker’ when I asked about alcohol 
consumption. It may also partially provide an explanation for the findings 
from the period of observation (Chapter 4) where support group members 
suggested people who are alcohol dependent are ‘different’ from drug 
users. Whilst people becoming dependent and dying from alcohol use 
prompted various emotions such as sadness and fear of their own alcohol 
consumption, there also appeared to be a level of stigmatisation towards 
people who were drinking excessively from within their own PWID 
community. For people who are already stigmatised due to their hepatitis 
C and history of injecting drug use , a further layer of stigma, could 
potentially isolate people further. Gav explains how his addictions have 
affected his relationship with friends. 
 
Well sometimes I’m with other people [drinking] but I might just 
like, coz I don’t want no one seeing me doin it, sometimes I might 
just get a can and just drink [demonstrates hiding the can as he 
drinks], you know, just put it in the entry [alley] or something. 
 
(Gav) 
 
Why don’t you want people to see you drinking? 
 
(Researcher) 
 
I just, don’t know, just the way I was, with other things, I don’t 
want people thinking ‘oh look at the state of him again’ you know, 
all that, that’s what it is you know. There’s some people who do, 
when you get back to them ways, people look down on ya, you 
know, well some people do, you know, take yer own friends once 
I was on heroin no one wanted to know me, you know, no one 
tried to help me, you know what I mean, but all of a sudden when 
I starting to getting meself together and looking clean and smart 
an, oh they were all OK then, but I used to just talk to me 
[inaudible], coz I thought it doesn’t work with me like that, you 
know, I have this thing he didn’t wanna know when I was bad [ill], 
you know, an all of a sudden when I’m OK and that, you know, 
they wanna be all matey again. 
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(Gav) 
 
So if they saw you now, with a can? 
 
(Researcher) 
 
You know now if they see me with a can, I don’t care, I’d just say 
to them ‘so what’ if I’ll have a drink, I’ll have drink’ what are 
they gonna do? But they don’t say nothing now, they just talk to 
me coz they know I am not lying, I’ll only have 1 every now and 
again so they’re not funny with me then, it’s strange. 
 
(Gav) 
 
Gav explains how he lost friends when he was addicted to heroin and would 
lose them again if he became addicted to alcohol. Many other participants 
talked about how they had reduced their social circle, by leaving their 
partners or moving to a different area, to reduce their own heroin use, and 
‘heavy’ alcohol consumption could isolate people further. 
 
5.2.1.5 Discussion 
 
The findings on alcohol consumption have shown that patterns of alcohol 
use and reasons for drinking are varied amongst PWID. Whilst hepatitis C 
may play a role in decisions on alcohol consumption for some PWID, many 
other factors also influence drinking, especially over time. Advice from 
healthcare professionals on alcohol use and hepatitis C appears to be 
confusing for some service users, suggesting a need for consideration of 
language and terminology used. Furthermore service users experience 
barriers to accessing alcohol support. Dependent or higher-risk drinking, 
also appear to be discriminated against by other PWID who may not be 
drinking at the same levels, resulting in decreased support from peers and 
an increased risk of isolation.  
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5.2.2 Living with hepatitis C 
 
Participants expressed the impact hepatitis C had on many aspects of their 
lives, not only in terms of physical health, but also emotionally, and in their 
relationships with other people. Stigma, fear and knowledge of hepatitis C 
appeared to be interrelated, impacting on people living with hepatitis C 
and affecting the support they received. 
 
5.2.2.1 Fear and knowledge 
 
As in the support group I observed (Group 1), participants talked about 
feeling scared by many aspects of having hepatitis C, however narratives 
predominately focused on testing and diagnosis. Generally, participants 
feared being diagnosed with hepatitis C, however some participants feared 
the test itself. 
 
And how did you feel going for your test? 
 
(Researcher) 
 
Scared. Had palpitations, I thought they were gonna take loads of 
blood off me and XX [staff member] just went ‘dink’ on me finger. 
 
(Dan) 
 
And pricked your finger. 
 
(Researcher) 
 
Yeah. I was made up she done that, I always thought a needle to 
take blood off me. 
 
(Dan) 
 
So you were worried about the needle? 
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(Researcher) 
 
Because you know just one needle and it might just set me off 
[injecting drugs again]. She said “no it’s just a prick on your 
finger”. I was made up then. 
 
(Dan) 
 
Dan shows here that he was not knowledgeable about the testing procedure 
prior to going for the test, causing him to have an incorrect understanding 
of the sampling procedure which led to him feel scared. Potentially with a 
better understanding of the test, Dan’s fear could have been reduced. 
 
Steve who proactively sought a test, still ‘bottled it’ (to not do something 
because you do not feel brave enough, (Macmillan dictionary, 2017)) on his 
first attempt to go for a test. 
 
I think they used to do it in detox, they used to do a test, they 
use to screen you and I asked about it when I was in there and 
they said they don’t do that anymore, so when I come out I had 
to get registered with a doctor and it took quite a while and I 
think I did have an appointment and I ended up, I bottled it a bit 
and I went and sat in a bookies all afternoon, didn’t go for the 
appointment to get the test you know. 
 
(Steve) 
 
Showing that despite wanting a test, fear stopped him from attending for 
the test. Others attended for the test but were then too scared to return 
for the results. Pete explained how he only received his test results because 
the nurse followed him up with phone calls. 
 
So I went “OK” and done it [hepatitis C test] an….I didn’t go back 
for the results. I don’t know why, an they started phoning me and 
I thought “why are they phoning me like”, you know what I mean, 
I thought like, you know I thought “am I unlucky enough to have 
it” 
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(Pete) 
 
…..then you had to get me in there, I wouldn’t go back for me 
results, I had an inkling you know what I mean 
 
 (Pete) 
 
That’s really interesting to me, you actually came for the test 
and then you didn’t want the result? 
 
(Researcher) 
 
Yeah. 
 
(Pete) 
 
If I’ve had a blood test done, I want those results. 
 
(Researcher) 
 
[laughing] Yeah, ahhh, no I was the other way round, only when 
the nurse said “Pete, we need to meet”, an I thought, “bloody 
hell I better get over there”, and as I said it was positive. 
 
(Pete) 
 
Like Simon’s neighbour in Group 1, Pete had not gone for his test result as 
he was scared of receiving a positive result. For the majority of participants 
the fear of receiving a positive hepatitis C result was linked to a fear of 
dying. 
 
..me I was shittin meself [scared] coz I thought it’s a death 
sentence me. 
 
(Jack) 
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..mine come back inconclusive, right, so I went along thinking, oh 
I’ve got hep C, I’m gonna die. 
 
(Sadie) 
 
..I, thought you could, well you couldn’t live with it basically. 
 
(Kev) 
 
Yeah, I thought I was dying. I was in tears, yeah had to get um, 
had to get escorted home, from here coz I was in that much of a 
state, when I got told. …hearing what I thought was a death 
sentence. 
 
(Susan) 
 
Jack explained that his reaction was because he’d been tested many years 
ago, when there was little information and no treatment for hepatitis C. 
However the other participants who also thought they were going to die 
from the hepatitis C, were tested more recently, when knowledge of 
hepatitis C had increased and treatments exist. Neil explains how he was 
scared due to lack of knowledge about hepatitis C, and was not given 
information at the time of testing or when he received his positive result. 
 
Well I, I was very scared coz I didn’t know anything about it 
[hepatitis C] at the time. I didn’t know what it was about or I just 
thought it was like, that it was HIV. 
 
(Neil) 
 
So what information did they give you when they gave you the 
test? 
 
(Researcher) 
 
Nothing. 
 
(Neil) 
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Nothing…OK and then then you got the results... 
 
(Researcher) 
 
I even remember the day, like I didn’t exist, basically I got told I 
had hepatitis “get out”, I thought I was gonna die, they didn’t 
give us a lot of information, didn’t tell me it was gonna be alright, 
didn’t tell both of us [Neil and his partner] about the treatment, 
no and it.....[paused] weren’t very nice. 
 
(Neil) 
 
For many participants the reaction to the test result was linked to fear from 
misunderstandings and myths of hepatitis C transmission, disease 
progression and treatment. Sadie explained about the information she 
received following her test. 
 
Um, I had the test right and then it come back inconclusive right, 
do you know what I felt terrible because, erm, I thought well I 
didn’t really speak anything, and I thought they didn’t explain 
when they said it’s come back inconclusive right so it means ..you 
might have hep C, now nobody said to me come back and get 
another test done, go for counselling and I just thought to myself, 
I’ve got hep C. 
 
(Sadie) 
 
Consequently she thought she had hepatitis C and it was not until 4 years 
later when she was retested that she understood she had self-cleared the 
virus, (which happens around the first 6 months after transmission only). 
Both Susan and Neil misunderstood the course of the disease progression of 
hepatitis C, thinking that they were going to die imminently: 
 
I thought I was gonna ‘ck’ [makes noise] conk out and that was it. 
 
(Susan) 
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Oh god, it was like.. the floor opened up and I went with it, I fell 
back [when he received the positive hepatitis C result]. 
 
(Neil) 
 
Why was that? 
 
(Researcher) 
 
Well because I was scared an, no one told me nothing so I thought 
immediately I was gonna die [laughs]. 
(Neil) 
 
So did you think you were going to die quickly? 
 
(Researcher) 
 
Yeah I thought I was just gonna drop. 
 
(Neil) 
 
When asked about how he felt receiving the positive hepatitis C result, Pete 
did not mention death (perhaps because he knew there was treatment-see 
below), but still reacted badly to the result. 
 
And I was devastated coz I just thought na not me no, I’ve got to 
be seriously unlucky to have this an, she said you’re negative for 
AIDS er HIV, and then she saved the last one hepatitis C and I just 
looked at her and I just expected her to say neg and it was pos 
know what I mean and I, I cried in front of her, I did, I was 
devastated. 
 
(Pete) 
 
This account implies there was an element of surprise on receiving the 
positive result, again leading to questions about pre-test information and 
his understanding of the risk factors for transmission, as he had previously 
shared injecting paraphernalia. 
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The above quotes raise questions about the information given at the pre 
and post-test consultations and how this information is received and 
understood by service users. Only one participant reacted differently from 
all the other participants when receiving her hepatitis C result. Kath 
explained her reaction was linked to her prior knowledge of hepatitis C. 
 
..oh well I’ve got it, it’s not killed me, type of thing, actually it 
was a bit of a confirmation as to why I get tired so easily. It was 
a little bit of it, not relief, it was a little bit that way. 
 
(Kath) 
 
Well I already knew about it. I think if, cause my brother’d been 
diagnosed with it. And he’d had a years’ treatment yeah, so I 
knew what, that was the first I’d even heard about hepatitis C 
and he told me, so I didn’t feel, I knew about it then. 
 
(Kath) 
 
The effect of having knowledge of hepatitis C was also demonstrated by 
some of the other participants. Participants who initially thought they were 
dying when they received their hepatitis C result, talked about how they 
felt about their hepatitis C once they had improved knowledge. 
 
I’m not bothered, now that I know a bit more about it, it doesn’t, 
you know, I’ve made a mountain out of a molehill basically. 
 
(Kev) 
 
..you don’t, well you can die from it like but, it’s not as serious 
as what I thought it was. 
 
(Susan) 
 
It didn’t really bother me, once I knew about it, it didn’t bother 
me. I knew that nobody could catch it off of me like, using a cup 
or glass. 
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(Susan) 
 
Largely this fear of being diagnosed with hepatitis C was linked to lack of 
knowledge about the disease and therefore fear of dying but others who 
knew there was a treatment, feared the treatment itself (interferon/ 
ribavarin). 
 
I‘m still terrified of having the needles for this interferon, I’ll be 
honest with ya I am terrified of them. 
 
(Pete) 
 
I heard people were telling me ghost stories “oh that interferon, 
the needles like that [showing size of needle with hands- about 
30 cms long] they put it in your belly” and that it’s like you’re 
havin chemotherapy, you’re being sick for a week. 
 
(Pete) 
 
I always ask doctors about it [hepatitis C treatment], if things 
were available, so I started learning over it. The treatment scared 
me coz it goes like a cancer drug, where it can make you lose that 
much weight you can look worse than when you’re on smack and 
crack anyway. 
 
(Jack) 
 
As well as being scared for their own health, participants also frequently 
discussed their fears about transmitting hepatitis C to other people, (as 
shown by Susan’s quote above), mainly this fear was for partners or 
children. 
 
I’ve got a lot of nieces and nephews, they’d be coming round and 
I’d be knocking about with them, scared. I’m not gonna do 
something wrong in the slightest but I am dead scared, you know 
in case one of them has a fall and I was to pick him up, an you 
know what I mean, anything like that. I had to go tell me sisters 
about it and they were shocked and, you know they were really 
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really upset, that I had that, coz you know I got that hep C, and 
the way they are, I think they’re just being cautious, now that I 
told them about the hep C, ‘listen I’ll have to take care about the 
kids, and if the kids do anything like that, you know it can’, you 
know you’re always like that, ’take care about letting the kids 
play, you know letting your kids’, the boys come running and want 
to jump around me. Me sister’s telling them ‘ok lads, stop it, 
leave it alone now’ you know and they always used to like 
[demonstrating play fighting] you know and I couldn’t do it with 
them anymore. 
 
(Ed) 
 
How did that feel? 
 
(Researcher) 
 
That’s horrible, you know coz you are attracted to it, they’re like, 
even though me nieces and nephews but they’re like your own 
sons and daughters. Yeah so urm yeah that was a bit of er you 
know a bit of a punch in the face, you know that I couldn’t 
interact like that with the kids no more. 
 
(Ed) 
 
I was just conscious that I had it, knew that I couldn’t get a 
girlfriend, or I wouldn’t you know pass meself off onto a girl if I 
had hepatitis C nothing like that. Obviously you know come clean 
about it if you did have it but from the point I knew I had it, I just 
knew that I couldn’t have a relationship I just didn’t wanna pass 
it on myself to a female, an unsuspecting female you know. It’s 
not the kind of, you know, it’s not the easiest things to say ‘oh 
by the way I’ve got hep, do ya still wanna see me?’ Do ya know 
what I mean? So I thought ‘well that’s me relationship snookered’. 
 
(Joe) 
 
Um also I was seeing a girl at the time and I’d waited for my 
results before you know, before doing anything and I hadn’t told 
her why we hadn’t done anything, oh fucking hell you know I 
actually have got it. 
 
(Steve) 
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This fear led participants to restrict behaviours in order to minimise the 
risk of others contracting hepatitis C. Although there is a small risk of 
contracting hepatitis C through sexual contact (Athwal and Prince, 2017), 
this risk seemed disproportionally important, with many participants 
voicing this as a concern and applying unnecessary restrictions. Also as 
there is no risk of contracting hepatitis C from social contact, there is no 
reason to avoid play with children. Participants in this research appeared 
to be going to extreme lengths to avoid others contracting the virus from 
them. Indeed the extent of Kev’s fear about his family contracting hepatitis 
C from him is demonstrated below: 
 
You know I would, I’d kill myself if me daughter got it [hepatitis 
C], or me mum or even family. 
 
(Kev) 
 
This reaction seems extreme but perhaps representative of the depth of 
feelings around having hepatitis C. 
 
5.2.2.2 Effects of stigma 
 
Although most participants expressed a fear of dying when they received 
their hepatitis C diagnosis, some participants did not fear dying but 
expressed how they considered suicide. Sharon talked about her suicidal 
feelings leading up to receiving her results and Dan spoke about considering 
suicide, once he found out his result. 
 
Worried sick yeah, felt suicidal. I was just terrified to tell you the 
truth. 
 
(Sharon) 
 
When I did get it [the positive hepatitis C result], I was walking 
home on Friday an I felt like killing myself. I was in 2 minds just 
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to throw meself into the docks. 
 
(Dan) 
 
Both explained their reasons for their feelings. 
 
Yeah. What were you scared of with the hep C? 
 
(Researcher) 
 
My family, friends, everythin, me. 
 
(Sharon) 
 
Yeah, what were you worried about with your family? 
 
(Researcher) 
 
Er how they’d treat me. 
 
(Sharon) 
 
Right, yeah and why did you think they wouldn’t treat ya? 
 
(Researcher) 
 
Well hep C you know, it was bad when I got it, you were treated 
like a leper. There wasn’t much heard about it, so, you know, it 
was bad. People stayed away from ya sort of thing, if they heard 
you had it. 
 
(Sharon) 
 
Felt like killing meself, after me result Jane [researcher], I’ll, I’ll 
be honest I felt like just doing meself in, I thought who’s gonna 
like, no one’s goin to like me or talk to me and things like that. 
Well people look at you anyway, weird, you know, I haven’t had 
the hit [injected heroin] for…last year. 
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(Dan) 
 
And why were you feeling like that? 
 
(Researcher) 
 
Um…I just felt, I’d let meself down, let the family down. I thought 
do I tell them, do I have a cup at the side or a plastic cup, do I 
have to wear gloves or mask, when I go into me mums. 
 
(Dan) 
 
Both felt suicidal in connection to fearing being shunned by others when 
they found out they had hepatitis C, demonstrating the impact of having a 
disease that is highly stigmatised. Porter (2014) suggests two reasons for 
the stigma linked to hepatitis C that are demonstrated in the narratives 
here. Firstly, as hepatitis C is an infectious disease, people are fearful of 
contracting hepatitis C themselves and secondly because hepatitis C is 
associated with injecting drug use which is a stigmatised activity. Both 
Sharon and Dan’s narratives describe fear around the infectious nature of 
the disease, with Sharon drawing parallels to leprosy and Dan describing 
(incorrect) methods to reduce the risk of transmission to his family. Dan 
also expressed the double stigma he faced, by having hepatitis C and 
previously injecting drugs. This double stigma was also expressed by Pete, 
who explained how others ridiculed and how this affected him. 
 
I don’t know it’s embarrassing as well 
 
(Pete) 
 
What are you embarrassed about? 
 
(Researcher) 
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Just like about stigma, you know what I mean, “You dirty little 
junkie” you know all of that, an I can’t, how can I say well I’ve 
only ever had 3 injections, I was unlucky, you know what I mean. 
 
(Pete) 
 
 
Interestingly Sharon (and Rach below) thought her feelings around diagnosis 
were due to when she was diagnosed, suggesting that stigma, although still 
present, had reduced over the years. 
 
Er, no, not many people talk about it 
 
(Sharon) 
 
No. Why’s that? 
 
(Researcher) 
 
I think again they feel like, “oh if I say I’ve got hep C people won’t 
treat me the same” that’s what I feel anyway. 
 
(Sharon) 
 
Right. You still feel that? 
 
(Researcher) 
 
No not so much now, I’m saying I feel that’s what people think. 
Coz that’s how I used to think. 
 
(Sharon) 
 
Guess that was a while ago though when you had it first but do 
you still feel a little bit like that now? 
 
(Researcher) 
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Erm well if I’m in a group I’m the first to say I’ve got it now, I can 
talk about It now easy. I might get a bit upset but I’m the first to 
say I’ve got hepatitis C and then people will start saying “oh I’ve 
got it, I’ve got it” you know. 
 
(Sharon) 
 
Yeah, yeah, so do you think there’s less of a stigma now or not? 
 
(Researcher) 
 
There’s not as much stigma but there’s still stigma, definitely 
yeah. 
 
(Sharon) 
 
Yeah, and all of that, that you were saying before about like 
people not wanting to touch you and all of that, does that still 
happen? 
 
(Researcher) 
 
Erm yeah I’ve had people come me house and they won’t have a 
drink and I feel like it’s because, we’ll I know it’s because of me 
hepatitis C, you know what I mean, people have told me, that 
they’ve said that too them, they didn’t have a drink coz I’ve got 
hep C. D’ya know what I mean they must think they can catch it 
off the cups, some people are very naïve. 
 
(Sharon) 
 
However when Dan discovered he had hepatitis C, he reacted similarly to 
Sharon despite being diagnosed 14 years later (Sharon was diagnosed in 
2000 and Dan in Dec 2014). Showing the effects that stigma still has on 
people who have hepatitis C. Rather than opposing these stigmatised views 
of hepatitis C, participants appeared to uphold the views, repeating the 
stigmatised ideas. 
 
215 
How did you feel when they told you you had hep C? 
 
(Researcher) 
 
I was devastated because I’m a mother of 4, urm and me mum and 
dad have never used drugs. They don’t even know why I ended up 
on it, coz I’d never been around it or nothing like that. Urm I 
don’t know it was like it was like urgghh sort of thing. You know 
it was like uuuurrgghh [visibly cringing - screwing up face and 
recoiling body]. It was like urgh you know one of them. It was 
discriminated and it was then back then, maybe people are more 
aware of it now, there’s more awareness about it but years ago 
there was none of that, so, it wasn’t somethin like you’d tell 
people about, it was somethin you kept to yourself ….well it’s 
caught, caught through dirty needles and dirty spoons isn’t it so 
it is a dirty disease. When you think of it like that, it is. That’s 
the way it is. 
 
(Rach) 
 
once I was on heroin no wanted to know me, you know, no one 
tried to help me, you know what I mean, but all of a sudden when 
I starting to getting meself together and looking clean and smart 
an, oh they were all OK then. 
 
(Gav) 
 
Thus instead of challenging the stigma, participants appeared to concur 
with the stigmatising views of hepatitis C and injecting drug use, further 
perpetuating the stigma and feelings linked to the stigma. In the quotations 
above Rach talks about hepatitis C being ‘dirty’ and Gav describes being off 
heroin and looking ‘clean’, suggesting a connection between heroin and 
looking dirty. Perhaps explaining why participants frequently mentioned 
being clean throughout the narratives, (‘erm I’m always clean looking’ 
(Dan)), as if in defence of not being ‘dirty’. For Beth the stigma of having 
a ‘dirty disease’ stopped her from disclosing her hepatitis C status to anyone 
in her personal life except her sister (who had also injected drugs and 
tested positive for hepatitis C). 
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Well yeah. It’s only me and me sister that know I’ve got hep C. 
I’m too scared to tell the family. 
 
(Beth) 
 
Why what you scared of? 
 
(Researcher) 
 
I don’t know I don’t know. To me hep C is like HIV or AIDS, do you 
know what I mean, it’s got that... yeah, yeah, yeah. 
 
(Beth) 
 
Right. Why haven’t you told anyone else? 
 
(Researcher) 
 
Oh no I’m too scared, too scared. 
 
(Beth) 
 
What are you actually scared of? You don’t have to answer me if 
you don’t want to. 
 
(Researcher) 
 
It’s, as I say its, hep C to me it’s one of them “Oh disease, urgh 
don’t touch nothing” Do ya know what I mean? And I’m, the 
cleanest person on the planet, everyone in our house says I’ve got 
that OCD, you could eat off the floor, I’m that clean, but yeah 
it’s just a dirty disease and I’m you know that I’m saying oh I don’t 
want to tell anybody who’ll go “oh dirty disease” that’s the way 
I think and I don’t want them looking at me “oooh”. 
 
(Beth) 
 
Right and do they know you injected? 
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(Researcher) 
 
Yeah, yeah, yeah. 
 
(Beth) 
 
And are they OK with that? 
 
(Researcher) 
 
And they’re ok with that, yeah, yeah [laughing]. 
 
(Beth) 
 
Hep C’s just a different level? 
 
(Researcher) 
 
Yeah…. Oh, but no it’ll stay with me to me grave. 
 
(Beth) 
 
Disclosure of hepatitis C and fear of others finding out was a common theme 
throughout the narratives, with participants expressing how stigma 
affected access to support. Rich felt unable to talk about his hepatitis C 
even to healthcare professionals, affecting the amount of professional 
support he could receive and Phil’s narrative explained how stigma of 
hepatitis C affected informal support, increasing the risk of becoming 
isolated. 
 
Many years I didn’t care about that. I really didn’t care. I tried 
really forget about I’ve got something. I tried to not think about 
that, you know, that was madness. 
 
(Rich) 
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Why didn’t you wanna think about it? 
 
(Researcher) 
 
I was full of shame, guilty to even say something about, you know, 
to my doctor, to whoever, ‘I’ve got hep C ….’ 
 
(Rich) 
 
How does it feel knowing there’s a new treatment? 
 
(Researcher) 
 
Oh it’s very good, specially when, you know, you’re fed up, you 
see one thing about having hepatitis you feel kind of like a 
zombie. That you’re infected and you can infect other people. 
You feel it, that’s the only thing, you know, put a bell round your 
neck ding ding, ding ding, like a leper. And you can’t help feeling 
it and you know when you tell people, people that are clued up 
are ok but some people that haven’t got a clue are kind of “Oh 
OK” you know what I mean, kind of sitting back as if you’re gonna 
pass it on, which you know its hepatitis B, is the one that you can 
catch through paper cups or from you know, it’s very easy to 
catch, which anyone can get, any walk of life, hepatitis B in water 
and anything but hepatitis C is definitely blood to blood, you 
know what I mean an people don’t understand that. It’s like when 
AIDS came on people didn’t understand about that either did 
they, they thought you just look at someone and you can catch it, 
you know what I mean, an you know it’s just a bad thing all round, 
but you feel like a leper an erm you know you’re scared of people. 
With the hep C for you’re worried about them finding out about 
you know, you just feel really kind of erm, what’s the word er cut 
off by it. You’re worried in case people find out kind of thing. 
You just don’t want people to know, you know you tell your close 
people but you don’t want everyone to know do ya? There’s no 
need for everyone to know, you know what I mean, like Joe Blogs 
down the shop, you know you won’t be going in with a syringe full 
of blood, so you know what I mean, the thing is you’re goin in 
there and you just wanna do your everyday jobs just get on with 
it, but the thing is, it’s like a disability in a way, you can’t do 
things coz of it. 
 
(Phil) 
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Kath was the only participant who did not feel stigmatised. 
 
You’ve not mentioned stigma at all out of everything we’ve 
talked about. 
 
(Researcher) 
 
No I know a lot of people talk about it, it’s weird in the drug 
world, it’s like hepatitis C blah blah blah I think well they’re 
already addicts so why’s hepatitis C such a big thing? I mean I 
don’t go around telling people cause most of the people I know or 
work with they wouldn’t have a clue what it was anyway, they 
just wouldn’t. I mean have told a couple in work, that I’m close 
to, they just didn’t have a clue. And um.. so I haven’t felt 
labelled. 
 
(Kath) 
 
Although the reasons for Kath not feeling stigmatised are unknown, it is 
worth noting that she was the only participant who had never been 
dependent on heroin. Although Kath did inject heroin she did not identify 
with PWID. 
 
Because there must be people like me that haven’t, yeah that 
have caught it in other ways or don’t know how they’ve caught it, 
non-drug users that have got it. 
 
(Kath) 
 
This suggests that stigma associated with injecting drug use, may be related 
to those who become dependent. Moreover like the alcohol stigma from 
PWID who drink lower-risk levels towards PWID who drink at higher-risk 
levels/are dependent, this indicates that there may be stigma between 
non-dependent and dependent drug users. 
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5.2.2.3 Physical symptoms 
 
Throughout the interviews, participants talked about the symptoms of 
hepatitis C. Whilst some participants experienced no symptoms, others had 
aching, tiredness or a ‘fuzzy head’ (forgetfulness and decreased 
concentration – which was also mentioned in Group 1). 
 
Jaundice (‘going yellow’) was however the most frequently mentioned 
symptom, either in relation to their own or other people’s hepatitis C. 
Whilst this was the most commonly discussed symptom, participants 
seemed unsure of its significance, asking questions such as ‘do you 
definitely go yellow when you’ve got hepatitis C?’, or saying ‘I didn’t go 
yellow’, showing a lack of knowledge on symptoms of hepatitis C and 
seemingly questioning their own diagnosis. Despite the uncertainty, 
jaundice was however used to identify other people as having hepatitis C. 
 
I got it off me bird didn’t I. When she got it off a fella….She was 
using needles, I didn’t know. I just got it being with her know 
what I mean. I don’t blame her because you don’t know you’ve 
got it. I have seen people go yella, I’ve seen, but I never went 
yella and me bird never went yella. The lad that she got it off he 
went yella. He died in the end know what I mean. But like he went 
yella, but the one he passed it onto was my girl she passed it on 
to me and but she never went yella and I never went yella….you 
don’t automatically go yella do ya? 
 
(Mark) 
 
but um I remember going quite yellow over some periods, an I 
remember the attacks of the hep C, I’d be aching an all that but 
just get through it  
 
(Tom) 
 
I was hearing all the lads in the hostel at the time “oh he’s got 
it, he’s got hepatitis”. So I was thinking,“ I’ve shared needles, 
I’ve shared spoons, with these”, you know what I mean. 
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(Pete) 
 
What were they saying about these people, you know the lads in 
the hostel? 
 
(Researcher) 
 
Just er .. “see there such and such, dead yellow his eyes, he’s 
yellow” un you get that off [hepatitis C], it’s one of the symptoms 
in it. 
 
(Pete) 
 
Whilst there are numerous causes for jaundice, narratives showed jaundice 
as an indicator of hepatitis C, highlighting those who (potentially) had the 
virus and causing service users to consider their own risk. 
 
This situation is reminiscent of other infectious disease such as leprosy, 
where visible symptoms identify people as having the disease, which 
historically (and currently in some countries) causes others to fear for their 
own health, and in turn marginalises those who experience the disease, 
making it harder to seek medical attention and receive treatment which 
can cure the disease (Seddon and Seely, 2006). Whilst this research did not 
seek to explore the experiences of those with jaundice, the labelling of 
those who are ‘infectious’ is evident, with the narrative from Pete showing 
an element of gossip rather than sympathy towards the person who 
(potentially) has hepatitis C. Within our culture sympathy would be the 
normative response towards people suffering from a disease, yet this is not 
evident here, perhaps due to hepatitis C being a stigmatised disease.  
 
Except for jaundice, participants were generally unsure of the symptoms of 
hepatitis C, questioning if how they were feeling was a symptom or 
identifying unlikely symptoms. 
 
I haven’t got a clue. I’ve got that many things wrong with me. I 
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feel, I don’t know what’s the matter with me, so I don’t know 
whether it’s that [hepatitis C ]….Haven’t got a clue. 
 
(Brenda) 
 
Do you feel ill with it [hepatitis C]? Do you get symptoms? 
 
(Researcher) 
 
Well, I don’t know what it is, no one’s actually told me how you 
feel when you’ve got it, coz there’s times, specially in the last 2 
months, where I’ve actually like, it’s been when I’ve had an 
argument with me girlfriend as well, and she’s gone home and 
I’ve been there on me own and I don’t know whether it’s me head 
working but it’s like me blood’s boiling inside and urgh it’s hard 
to explain, not like pins and needles going round and I’m thinking 
“is that the hepatitis C starting to, have a kickin in me”, do you 
know what I mean, am I just worrying about nothing coz I’ve had 
a fight with me girlfriend, am I just paranoid coz there’s, no like 
I don’t know. You know I, all’s I heard was, you go all like, oh you 
look yellow [jaundiced] you know. Did you hear that about going 
yellow? Your eyes are yellow and all that like, I’ve never gone 
yellow, but as I said, just twice in the last couple of months where 
I, I’ve just felt “argh I don’t feel right here like". 
 
(Pete) 
 
I know I’ve got hepatitis C but I don’t know what all the symptoms 
are…I don’t know nothing, nothing. I know one symptom I’ve been 
told that your stomach swells. That’s all. That’s it. 
 
(Beth) 
 
Do you think you’ve got any symptoms? 
 
(Researcher) 
 
I don’t know but me stomach has swelled here [indicating 
umbilical area of abdomen] 
 
(Beth) 
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Both Pete and Beth described and worried about symptoms that were 
unlikely to be linked to the virus (‘blood boiling’ after an argument and 
swollen umbilical area of abdomen). Beth had learnt about the stomach 
swelling (presumably ascites) by another patient in a hospital waiting room 
and Pete gained his knowledge of symptoms from other people he lived with 
in a hostel. Thus they (and other participants including Brenda above) had 
not discussed symptoms with staff involved in their care, but interestingly 
asked me as the researcher about symptoms. 
 
Kath experienced tiredness which affected her both mentally (forgetful and 
reduced concentration) and physically. For Kath this tiredness was the 
worst aspect of having hepatitis C, due to its impact on her quality of life. 
 
Tiredness and fuzzy head, I get a lot of that 
 
(Kath) 
 
Fuzzy head as in headache or? 
 
(Researcher) 
 
No just get forgetfulness it’s connected. It’s like forgetfulness, 
tiredness, lack of concentration, general unawareness of what I’m 
doing half the time, you know like leaving things, forgetting 
things and just tired, like, they’ll be something I’ll just get these 
zonk feelings, really tired. 
 
(Kath) 
 
Sometimes I felt like you know work was dead hard, and I thought, 
should I have to work with this bloody thing [hepatitis C] it gets 
me so tired, you know, should I be able to work part time or take 
it easier but financially it just can’t be done really. 
 
(Kath) 
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Yeah I think working full time is not the best idea, but you have 
to, cause it means your energy is used in work and then I’m really 
tired when I go home then and then my mood just drops and I 
can’t be bothered with this and can’t be bothered with that, 
always feel like I have to push myself to do the most mundane 
things, you know pushing myself whereas I remember on the 
treatment [hepatitis C treatment] I got like a burst of energy. 
Still had side effects [to hepatitis C treatment] but I started 
feeling really good at one point and I was thinking bloody hell if 
I feel like this all the time that would be great. 
 
(Kath) 
 
Unfortunately the hepatitis C treatment did not work for Kath so she still 
had hepatitis C at the time of the interview. Despite Kath struggling with 
fatigue which affected her both at home and at work, Kath had only told a 
few close friends at work that she had the virus. Whilst Kath denied 
experiencing stigma related to the hepatitis C, her lack of disclosure to 
managers at work, leads to questions on whether another less stigmatised 
chronic disease would have been divulged and more support provided.  
 
5.2.2.4 Discussion 
 
This section has highlighted some of the challenges of living with hepatitis 
C. There appears to be a correlation between lack of knowledge and fear. 
Participants’ narratives demonstrated how not knowing about many aspects 
of hepatitis C, such as testing, treatment, prognosis, disease progress and 
symptoms, caused fear and worry. Stigma was also omnipresent. This 
affected participants self-esteem but also impacted on disclosure of a 
hepatitis C positive status. Ultimately fear, lack of knowledge and stigma 
were factors that impacted on the support sought and provided, to those 
living with hepatitis C. 
 
5.2.3 Services, advice and information 
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5.2.3.1 Information and advice on hepatitis C  
 
One of the objectives of this research was to establish where PWID obtain 
information on hepatitis C and what that information was. Findings on this 
topic showed that the service users accessed information and advice from 
a variety of sources. Television was mentioned by some service users, either 
from watching medical documentaries, or programmes about celebrities 
who had hepatitis C. 
 
So what do you know about hep C? 
 
(Researcher) 
 
That it makes your liver bad. It goes worse after um a time. It 
was on the telly 
 
(Brenda) 
 
Right OK. Why was it on the telly? 
 
(Researcher) 
 
It was something to do with that Baywatch woman 
 
(Brenda) 
 
Oh Pamela Anderson 
 
(Researcher) 
 
Yeah something to do with her 
 
(Brenda) 
 
Leaflets, books and the internet were also mentioned, however the 
majority of participants had learnt about hepatitis C from verbal sources. 
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For some participants this was from others with hepatitis C, either 
informally from friends and acquaintances, or in more formal peer support 
groups. The majority of participants mentioned attending courses at drug 
services or in prison and some participants had received training to be peer 
workers. Verbal information was also received from healthcare 
professionals. 
 
There were however barriers noted with many of these sources of 
information. For the internet, there were varied levels of computer literacy 
amongst participant. Some participants searched the internet, others were 
receiving training, but many others mentioned that they could not use 
computers. There was also a level of scepticism of the information available 
on the internet. 
 
when you read the internet you’ve gotta think what’s the pros 
and cons, something that’s said is gospel one minute can become 
different the next.  
 
(Phil) 
 
I think those places like the internet you know you can get a lot 
of information about that, but somebody said to me ‘Rich don’t 
read you know nothing what you can find on the website because 
a lot of bullshit you know so go to a doctor and speak with him 
about if you’ve got any questions what’s going on or how it is’ 
 
(Rich) 
 
and do you feel comfortable doing that? 
 
(Researcher) 
 
Yeah, especially if this doctor person is, you know, a [hepatitis C] 
specialist 
 
(Rich) 
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Kev feared using a computer in public due to the risk of stigma and 
discrimination of having hepatitis C 
 
 
but I haven’t had a look at hep C because I can’t get a computer 
free enough. I don’t wanna go in the library and have a look at it 
 
(Kev) 
 
yeah. Why’s that?  
 
(Researcher) 
 
because, well, coz people will be saying “oh look at him having a 
look at that”, you’re studying, so it’s not like, between you and 
me you could tell I’m doin what I’m doin and you’re just on the 
computer and studying 
 
(Kev) 
 
What do you mean? 
 
(Researcher) 
 
You can tell I use by the vital signs like, I don’t know, but yeah 
 
(Kev) 
 
Learning about hepatitis C ‘in public’ and stigma was also mentioned by 
Pete. 
 
Well you know, to be honest Jane, I’d take the leaflets and you 
know, when you’re in the waiting room and all that I was too 
terrified to read them and I didn’t want people to see me reading 
hepatitis you know leaflets, you know the stigma and all that and 
when you got home then the leaflets went in a cupboard. 
 
(Pete) 
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Pete also did not read the leaflets in private at home. Later in his interview 
he explained his partner did not know he had hepatitis C therefore he hid 
all information about hepatitis C from her.  
 
The efficacy of leaflets is questionable, as Pete did not read them and Kev 
had misinterpreted the information. 
 
I didn’t know anything about it [hepatitis C] and then I 
researched, I done some studying into it, well not studying, but 
me own leaflets and that and then I realised you, you can get rid 
of it yourself if you’re not chaotic. 
 
(Kev) 
 
Tom felt attending groups was the best way to learn about hepatitis C. 
 
Coz there’s leaflets and there’s posters around isn’t there when 
you go to the services  
 
(Researcher) 
 
Um I think it’s only when you do the groups that you learn about 
it really  
 
(Tom) 
 
A number of participants mentioned receiving information from healthcare 
professionals, however sometimes service users did not understand what 
health professionals were saying. This meant that participants left 
consultations without understanding the information that they had be given 
about their illness/care. The use of medical terminology rather than ‘lay’ 
terms was one such barrier. 
 
So what information did they give you at the hospital? 
 
(Researcher) 
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I remember this conversation with that woman and she showed 
me everything on the computer but I have to be honest with you, 
she spoke with me that language you know, with that crazy 
amazing words so I just ‘ok’, ‘ok’ but I ask ‘everything alright 
with my liver? I don’t have to worry for now about that?’ she said 
‘yeah you don’t have to worry about that’ so that was for me 
enough you know to calm down 
 
(Rich) 
 
So you didn’t understand some of what she was saying? 
 
(Researcher) 
 
Yeah exactly 
 
(Rich) 
 
Didn’t you feel you could ask her? 
 
(Researcher) 
 
Yeah I feel because, I feel bad, but really that language what this 
woman spoke to me was little bit you know, I need to read some 
medical books to understand them 
 
(Rich) 
 
Participants also mentioned that they were not always provided with 
information that they needed. Steve had not received enough advice on 
transmission, Pete had questions about treatment and Kath wanted more 
information on living with hepatitis C. Kath also noted the manner in which 
advice was provided was clinical in nature, lacking a supportive quality.  
 
thought they might mention more about, coz I was living in a 
shared house and like if I cut myself shaving to me I’d really panic. 
I didn’t really know what to do, I didn’t know whether you just 
wipe the blood up and then you have to sort of like, I thought 
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they might give you more advice about how, about that sort of 
thing about blood you know, how to be careful with, with that 
but I don’t think I’ve ever really had any advice on that, that 
would be the one thing that really concerned me that I didn’t 
really know how to approach you know 
(Steve) 
I wouldn’t mind just hearing what is this interferon ur, how big is 
the needle, is it like chemotherapy, alright I know you don’t lose 
your hair but your sposed to feel like crap, for the week after it, 
sick and vomiting an run down and it lasts you know the course 
lasts for 6 months 
(Pete) 
There wasn’t much um, basically all I’ve ever done is just seen X 
[nurse] at the clinic. Her telling me, I’m gonna be on the 
treatment for so long, side effects, no I think she’s busy, she’s 
clinical in what she has to tell you. I think there should be like, 
how to manage and what the future could be like and stuff like 
that. There’s not much sort of, I’d say there’s no nurturing around 
it. D’ya know what I mean, it’s a bit empty really. 
(Kath) 
The participants also gave examples of incorrect information they had 
received from healthcare professionals. These were mainly linked to 
spontaneous clearance of hepatitis C. Brenda was diagnosed with hepatitis 
C in 2005, so was in the chronic phase of the virus where spontaneous 
clearance is not possible. 
Have you found out any more information about hep C since we 
last spoke? 
(Researcher) 
I went to urm XX [hospital] and they said to get tested again coz 
it can just go away on its own or something. I think that’s what 
they said but I didn’t know where to come 
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(Brenda) 
 
Was it a clinic for your liver? 
 
(Researcher) 
 
No it was for something else, it was to see a specialist for 
something, think it was me bones or something, they said to get 
retested 
 
(Brenda) 
 
However, as found in the Section on alcohol advice (medical advice and 
interpretation; section 5.2.1.2.) participants noted that the timing of 
information was important. Jenny noted that she was only able to focus on 
hepatitis C when her ‘mind was clearing from the drugs’ and ‘you take 
little, little bits each time that you go there [services].’ This indicates that 
healthcare professionals may need to give ongoing advice to service users. 
 
5.2.3.2 Barriers to accessing and staying on the cascade of care 
 
As discussed previously (Section 2.2 in the literature review) the cascade of 
hepatitis C care is, testing and diagnosis, being linked in to hepatitis C 
specialist care, accessing treatment and achieving the desired outcome 
(achieving SVR). This section considers the first three steps from testing to 
accessing specialist hepatitis C services and treatment, which was discussed 
by many participants during the interviews. Many participants gave 
examples of situations where they had encountered barriers to accessing 
support for their hepatitis C. Commonalities in experiences were described 
and are highlighted in this section through discussion of the experiences of 
two participants (Steve and Beth). 
 
For some participants the difficulties started at the beginning of the 
cascade of care, when trying to access a hepatitis C test. Steve took the 
initiative and actually asked for a test whilst in residential rehabilitation 
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for his drug use, but the service was not provided. Instead he had to register 
with a GP and attend the GP practice in order to be tested. This could have 
been a different outcome if Steve had not attended the GPs. Steve was 
determined to get tested and the impetus was on him to push for a test, 
rather than the service being easily accessed and healthcare professionals 
being proactive in this process. 
 
Other participants wanted to be retested as had been diagnosed many years 
ago but had not progressed along the cascade of care to receive treatment.  
 
Beth was diagnosed in 2002, and at that time saw hepatitis C specialists in 
secondary care but did not receive treatment. 
 
And then …I was going on appointments and I used to go there 
regularly, go and get me bloods checked and used to send me to 
scans but when they assessed me she went “you’re not fit to start 
the treatment” [interferon based treatment] and then I just, 
faded then 
 
(Beth) 
 
And did you stop going to the appointments or did they stop the 
appointments? 
 
(Researcher) 
 
Well there was nothing they could do because mentally and 
physically my health was in a, bit of, through drug use and me 
dad dying and that, I wasn’t strong enough to start the treatment 
so I just never went back 
 
(Beth) 
 
Beth wanted a retest yet despite regularly attending the drug and alcohol 
service and talking to healthcare professionals about testing, she did not 
know how to get retested. She also did not want to visit her GP for a test.  
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when I was talking to the doctor [at drug and alcohol service] 
before Christmas, I was telling him that I have hep C but it’s been 
years since I’ve been looked at again and he said that he’d get me 
tested again in the New Year and we’ll go from there but he left. 
He’s gone and there’s not a doctor here no more so, I don’t know. 
And 2 weeks ago I was here [at the drug and alcohol service], I 
was telling them and XX (staff) said “there’s a thing [testing] 
going on tomorrow in a place in town, do you want to call in?” 
and gets in me car and I didn’t have me phone, so when I got home 
there was a phone call with an unknown number and I didn’t have 
no one’s number so I missed that. 
 
(Beth) 
 
Ahh. Yeah. Would you think about going to your GP? 
 
(Researcher) 
 
No, no. Oh I don’t like him. I don’t like him [Laughing] 
 
(Beth) 
 
Why? 
 
(Researcher) 
 
[Laughing] I don’t know, I don’t like him. No. No. I’ll ask XX 
[keyworker] and she did say there’s a nurse in here who does the 
bloods and that. I’ve never seen her, but on me next appointment 
I’ll just say XX [keyworker] make me an appointment to see XX 
[nurse] then. You know give me any numbers so I can phone. 
 
(Beth) 
 
In the second interview with Beth 6 months later, there had been no 
progress in receiving a retest. Beth attended the drug service monthly to 
meet with her keyworker and receive her methadone script, yet she had 
not mentioned her hepatitis C and neither had the healthcare professionals, 
and she still did not know ‘where to go’ for a test. 
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So I was going to ask you, since I saw you last, which was June, 
what’s happened about your hep C? 
 
(Researcher) 
 
Nothing 
 
(Beth) 
 
Have you made any enquiries or anything? 
 
(Researcher) 
 
No 
 
(Beth) 
 
Have you spoken to the people here [at drug service]? 
 
(Researcher) 
 
No 
 
(Beth) 
 
Have they spoken to you about it? 
 
(Researcher) 
 
No, no. 
 
(Beth) 
 
So last time you said you might go for another test, have you 
thought about that again? 
 
(Researcher) 
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I don’t know where to go. I got told there was a nurse in here but 
I don’t know 
 
(Beth) 
 
If the drug and alcohol service were able to provide testing, Beth could 
have been tested at the service when she asked about receiving a retest, 
but again like Steve’s example, the service was not available and the 
healthcare professionals were not proactive.  
 
Beth had previously been under the hepatitis C service at the hospital in 
2002. Routine practice is for hospital doctors to write letters to patients’ 
GPs on discharge from hospital, or after an out-patient appointment, 
therefore Beth’s GP should know her positive hepatitis C status, but 
hepatitis C is not mentioned by the GP when Beth attends for other issues 
such as a ‘water infection’ and Beth does not mention hepatitis C to her 
GP. Also during the interviews Beth talked about discussing hepatitis C with 
hospital doctors, who, although they were from a different speciality 
(respiratory as opposed to gastroenterology/hepatology), did not sign post 
Beth regarding her hepatitis C. 
 
So what happened then [after she stopped attending the hepatitis 
C specialists at the hospital], did they keep in touch with you? Or 
did your GP keep in touch with you? 
 
(Researcher) 
 
No nothing 
 
(Beth) 
 
Or did you keep in touch with them? 
 
(Researcher) 
 
236 
No 
 
(Beth) 
 
You didn’t receive letters from the hospital or from your GP? 
 
(Researcher) 
 
Nothing, no and it just never bothered me and I never thought 
about it and back in 2012 when I was in [hospital], when I had a 
bad flare up [of COPD] and they’d sent me for an x-ray and that 
and the doctor come back and he went ‘have you got problems 
with your liver?’ and I went ‘oh god yeah I was diagnosed with 
hepatitis C’ so I don’t know if it’s got bad or but they’ve never 
like questioned me on it or delved into anything since they’ve told 
me I wasn’t fit enough for the treatment that was it, that was it, 
no more clinic nothing. 
 
(Beth) 
 
Right and in hospital in 2012 when he said ‘oh you’ve got hep C’ 
and you said ‘yeah I know’ are they following that up now 
 
(Researcher) 
 
No, no 
 
(Beth) 
 
No appointments or anything? 
 
(Researcher) 
 
No. 
 
(Beth) 
 
Have you asked them, ‘what are you doin about my hep C?’ 
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(Researcher) 
 
No, no. I’m too sacred 
 
(Beth) 
 
What are you scared of? 
 
(Researcher) 
 
it’s the way the system is an. We were only talking the other day, 
not about hepatitis C, about all these you know cancer an all that, 
the way that I see the system now is unless you’ve got money no 
one will investigate nothing, who do you go to, to investigate, if 
I wanted to look further to see how much more damaged me liver 
is, how long it’s got left, where do I go, what do I do. I don’t 
know. 
 
(Beth) 
 
Well I guess I’d probably go to my GP, but last time you said to 
me that you don’t like your GP, you wouldn’t go, can you tell me 
a bit more about that? 
 
(Researcher) 
 
I don’t know, I just, I don’t like goin to him. 
 
(Beth) 
 
Is that just about your hep C or you don’t like goin to him in 
general? 
 
(Researcher) 
 
I don’t like goin in general. If I, I just don’t feel comfortable with 
him. I’ve got to be on deaths door before I’ll go and it’s just I’m 
in there with what I’m goin for, like if I’ve got a water infection 
or what have ya, I’m in and I’m out. If I was to go to a clinic where 
it specialises for the hepatitis C then I’d feel comfortable 
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(Beth) 
Right that’s really interesting thank you for that information. 
Does your GP know that you’ve got hep C? 
(Researcher) 
Well it’s on me medical files in XX [hospital] and every time 
you’re in hospital they get a copy of..., so I haven’t got a clue 
(Beth) 
So they might know, but they don’t ask you when you ago about 
your water infection 
(Researcher) 
No, no, no. 
(Beth) 
Both participants narratives demonstrate asking for a test and it not being 
convenient to obtain. It may be that Beth does not need retesting , however 
Beth wants to speak to a specialist about her hepatitis C, yet healthcare 
professionals are not facilitating this linking-in with specialist care. 
These examples show moments of lost opportunities, where service users 
ask for a particular service but are not able to receive it easily or quickly. 
This barrier was evident throughout the wider interviews. 
Despite there being over 10 years between Steve and Beth being diagnosed 
with hepatitis C, both had an unsatisfactory experience when receiving 
their test results (as had many other interview participants). 
Yeah I knew I was being tested but while I was in the hospital they 
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didn’t come round and say “oh your test has come back and you’ve 
got hep C”. It was just another appointment months later under 
a different Dr and just going through my history and “oh you’ve 
got hep C” and I said “what?” 
(Beth) 
And what did the GP do after they told you the [positive hepatitis 
C] results?
(Researcher) 
Yeah they referred me straight to the em, it was quite good 
actually, they referred me straight to the specialist clinic in the 
hospital and I had an appointment there within…, I can’t 
remember, I think it was within like 6 weeks, it was that soon and 
then I went for the appointment there and because I’d only had 
the one [antibody test], I’d only been clean at that stage for 4 
months and I’d had 1 positive test, so it can be acute hepatitis 
can’t it where it can come and go within the 6 months so it was 
theoretically possible I picked it up in the last month of using. So 
they wanted to wait 3 months, have 2 positive tests, so I had to 
go away and come back 3 months later. Went back 3 months later, 
did the test, went back another month for the results and they’d 
lost the tests 
(Steve) 
At the hospital? 
(Researcher) 
Yeah and they hadn’t rang me in between, you know, the months 
that I’d waited, so I had to do another test and wait another 
month before I started treatment but, yeah I ended up starting 
treatment [interferon based treatment] 
(Steve) 
It appears in Steve’s case that staff were taking bloods but not checking for 
the results, meaning the situation of the lost tests was only established 
when Steve attended an appointment a month later. Steve had already 
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waited a few months for his results and then had to repeat the test and 
wait for results again. Barriers to receiving hepatitis C treatment for people 
who use drugs or drink alcohol, include professionals’ concerns over service 
users levels of engagement. However in this case, the service user (Steve) 
could have concerns over the healthcare professionals’ ‘level of 
engagement’, whilst Steve himself demonstrated high levels of engagement 
to stay in the process and eventually receive treatment. 
Despite Steve’s experience with testing, he praised the pathway from his 
GP to the hepatitis C specialists at the hospital, along with the nurse who 
provided his hepatitis C treatment, as she would wait for him. 
waiting ‘til the end of her shift when the appointments were 
actually finished to deal with me like, they were really good 
there, they sort of accommodated around my schedule as well 
yeah 
(Steve) 
Two other participants also experienced a ‘good system’ from GP to the 
hepatitis C specialists in secondary care. However it is interesting to note 
that all three participants had attended the GP actively requesting a 
hepatitis C test, rather than the GP suggesting testing. 
For Beth the pathway from primary care to secondary care had not run as 
smoothly. Whilst she did not attend her GP for a test/referral to secondary 
care, healthcare professionals (GP and staff at the drug service) had also 
not facilitated this process. Unfortunately Beth was not the only participant 
who appeared ‘stuck’, without progressing through the cascade of care. 
Many other participants talked about not knowing what was happening 
about their hepatitis C, or what steps to take to start the pathway to 
receiving treatment, despite attending their GP and regularly meeting with 
keyworkers and other healthcare professionals (doctors, pharmacists, 
nurses) at drug services. This lack of linkage to specialist hepatitis C care 
poses a major barrier for participants to fulfil the later stages of the care 
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cascade, thus accessing treatment and the opportunity to be cured of 
hepatitis C. 
One participant (Phil) had been through treatment (interferon based) 
before, but the treatment had been unsuccessful and he had not achieved 
SVR. However he praised the hepatitis C clinic at the hospital: 
they were great, they phone you up on your phone and everything 
(Phil) 
What for? 
(Researcher) 
To make sure I turn up 
(Phil) 
Oh to say ‘come for your appointment’ 
(Researcher) 
Yeah ‘you coming?’ Are you definitely gonna come to this 
appointment? but they were great in the hospital they really were 
(Phil) 
At the time of the interview he was waiting for treatment with the new 
interferon free regime (DAA). ‘..they reckon about a year or so, I will get 
the go ahead, [for DAA treatment]’. Whilst waiting for the treatment he 
attended the hepatitis C clinic at the hospital ‘every 6 months, go down 
and just talk to them’. This example shows whilst Phil was also not 
currently moving along the care cascade as he was waiting for treatment, 
he was well informed and knew what was happening with his care. He was 
242 
having regular contact with the specialists and communication from the 
clinic/hospital was proactive in keeping him in the system. 
The quotes above demonstrate difficulties participants faced in navigating 
the healthcare systems in order to access and be maintained in hepatitis C 
services. However participants were not assertive in expressing their needs. 
Seemingly Beth‘s GP and support workers do not regularly ask her about her 
hepatitis C, she also does not ask them. One reason for this was fear of 
discrimination, which is discussed in the following section. 
5.2.3.3 Stigma and its effects on accessing and continuing in services 
Discrimination from professionals working in services was expressed 
throughout the interviews. Some participants felt they were discriminated 
against because of their drug use, others felt the discrimination was due to 
having hepatitis C, and for others the issues were more intertwined, 
experiencing discrimination against both opioid use (as well as opioid 
substitution therapy – methadone) and hepatitis C as professionals made 
connections between the two. 
Beth had experienced discrimination from a health professional whilst 
staying in hospital. The impact of this was that she was wary of talking to 
other health professional about her hepatitis C. 
So last time [previous interview] when you were leaving you said 
‘oh its really nice to be able to talk to somebody’ I think you said 
you felt a bit relieved that you’d spoken to somebody about it 
[hepatitis C] 
(Researcher) 
Yeah, yeah 
(Beth) 
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So can you tell me a little but more about that? 
(Researcher) 
I don’t know because you’re someone that’s doing research and 
you know about it, I feel comfortable talking about it to you, 
where I don’t know, I’m scared of people looking at me as if I’m 
dirty and you know ‘oh she’s got a disease’ 
(Beth) 
Even the health professionals though and the drug professionals? 
(Researcher) 
Yeah, yeah, some of them yeah, yeah, yeah…Because when you 
go into hospital, I mean don’t get me wrong they’re brilliant some 
of them but others they’re like, I don’t know, they just when they 
hear of methadone knowing you’re a drug addict they look at you 
differently and treat you differently I’ve found 
(Beth) 
Right and hep C? 
(Researcher) 
Yeah yeah because years ago I was in XX [hospital] me toe had 
swelled up and there was this male nurse there and like 12 months 
beforehand me sister was in hospital and this male nurse got close 
to me young sister and I knew him and when he found out I had 
hepatitis C he run to tell other nurses ’oh she’s got hepatitis C’ 
and I thought, d’ya know what I mean, so that’s what puts me off 
telling….you know, other people, because the way he reacted I 
thought ‘oh my god’……. 
(Beth) 
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Sharon felt discriminated against because she used drugs. She had 
previously attempted to receive hepatitis C treatment but had been 
unsuccessful. She felt this was because she used drug at that time. 
 
I went to the hospital a couple of years ago and I had an 
appointment there and they said they only gave it [hepatitis C 
treatment] to certain people and I felt…………erm how can I put 
it, victimised and I thought why not me, alright I was using [drugs] 
but I wasn’t a bad user and I was fobbed off definitely, I could 
have been treated years ago and they didn’t do it 
 
(Sharon) 
 
You know when you said certain people got it, who was getting it, 
who was getting the treatment? 
 
(Researcher) 
 
Er people that didn’t use [drugs] 
 
(Sharon) 
 
During the interview Sharon explained how she had recently come out of 
prison. Whilst in prison she had spoken to staff about her hepatitis C and 
the prison had referred her to the hospital for hepatitis C treatment. She 
was due to start treatment the following week, ‘I’ve been passed and I’m 
going for it, finally’. Being ‘passed’ for treatment suggests those seeking 
hepatitis C treatment need to be accepted and achieve a certain 
standard/criteria order to receive treatment, a situation not experienced 
by people requiring medication for other illnesses, such as inhalers for 
COPD, lipid lowering medications such as statins for hypercholesterolemia 
or medication to regulate blood sugar levels in diabetes. Whilst these 
illnesses may require patients to meet certain clinical indicators that 
treatment is required, such as cholesterol levels for the statins, or blood 
sugar level for diabetes medications, in Sharon’s circumstance the criteria 
was not that of clinical indicators such as liver function but rather due to 
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her drug use. As these other diseases can also be caused by lifestyle factors, 
such as smoking, poor diet and obesity, this raises questions on why 
hepatitis C treatment is not given to those who take drugs yet these other 
medications are not withheld from people who smoke or eat unhealthy 
foods. 
 
Neil felt discrimination during receiving hepatitis C treatment because of 
the infectious nature of the hepatitis C virus. 
 
Yeah started treatment about 2 years ago. I done 3 months [of 12 
month course] and the side effects, it weren’t just because of the 
side effects, some of the nurses in there. I was seeing a different 
nurse every single time I went in, and they were 2 specific nurses 
I couldn’t tell you who they was, they were like, let’s just say I 
was speaking to you they’d move away [demonstrating moving 
away from researcher], put on 2 sets of gloves 
 
(Neil) 
 
Why do you think they were doing that? 
 
(Researcher) 
 
I don’t know. I think they were, to me I think they were 
discriminating. I think they were doing because I had hepatitis. 
Coz all the other nurses they didn’t even put gloves on. They want 
to bloody wear masks. 
 
(Neil) 
 
[conversation about side effects] ………..Do you think if you’d not 
had side effects, you would have carried on [with the treatment]? 
 
(Researcher) 
 
I think.. the staff put me off a little bit. 50 50 
 
(Neil) 
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All three narratives show the detrimental effects that discrimination has 
had on the participants. For Neil the discrimination was a contributing 
factor on why he did not complete treatment, and for Sharon and Beth their 
narratives demonstrate how past experiences with professionals where they 
felt stigmatised and discriminated against, affected how they viewed their 
current situations. 
 
5.2.3.4 Services not meeting service users’ needs 
 
Participants mentioned difficulties they experienced in attending services. 
For many participants the number of appointments they needed to attend, 
the distance to services and the cost of travel was a concern. 
 
You know when you think I go from home to there [hospital], 
that’s 3,4,5 quid in a day. I haven’t got 4 or 5 quid a day, it’s a 
long way and it, you know, it can be a few times a week. I have 
that, then I have doctors appointments, then I have peer 
appointments and it’s a lot of money, so yeah I’ve got a bike but 
then I can only go so far. 
 
(Jack) 
 
For Kath, the barrier to accessing support for her hepatitis C was twofold. 
Firstly this research found that the all hepatitis C support except Group 1, 
was through drug and alcohol services, which Kath did not attend. Secondly 
Kath worked through the day when services she would like to attend ran. 
 
There’s knowledge and there’s advice but um,.. it’d be nice to 
have more like therapeutic things on offer, relaxation or Indian 
head massage or like stuff that probably makes you feel good, you 
know. I mean there is, there is things like that but they’re always 
during the day. If you work you can’t go to anything. There’s 
nothing really much for people with a condition in the evening 
time when you work. 
 
(Kath) 
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Do you think there’s any services that other people with hep C 
might require?  
 
(Researcher) 
 
I don’t know, ‘coz I mean, the only people I know is like my ex-
husband and then Simon and Seb [support group members] from 
here and they’ve got a very different lifestyle than me, you know, 
I’ve got a family, a job stuff like that. They’ve got very different 
lifestyles. Um, so I don’t really know, I think, I mean, I think Seb 
[from support group] accessed all the services and stuff. I feel 
like, I’m a bit of an outsider in a sense because, I haven’t been an 
addict or an alcoholic. I’ve been a sporadic user, sort of carried 
on my life you know working and having kids and doing all the sort 
of normal things. You know, my ex has had a lot of access to 
services and done courses and all that and probably Seb [from 
support group] has and stuff like that whereas that’s not really, 
it’s never been part of my life. I’ve never been on methadone, 
I’ve never been to the drug service. 
 
(Kath) 
 
As Group 1, was not run through a drug and alcohol service (and was in the 
evening), Kath was able to access the group. Many participants (including 
Kath) who had attended a hepatitis C support group over the years, 
commented on how the group had helped them. As explained by Phil 
hepatitis C can make people feel ‘cut off’, and the hepatitis C support group 
reduced feelings of isolation. 
 
What support did you get from the support group? 
 
(Researcher) 
 
Um I got um a lot of support because I thought I was the only one 
with hep C and then I went there and there’s loads what have got 
it, so I’m not the only one 
 
(Susan) 
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How does it feel thinking you were the only one? 
 
(Researcher) 
 
It was horrible. Terrible. 
 
(Susan) 
 
first time I spoke probably with other addicts about you know, 
about that [hepatitis C] because when I came to this country I felt 
I’ve got only hep C, no one else, no one else, you know, so that I 
felt different 
 
(Rich 
 
Why did you come here [to hepatitis C support group]? 
 
(Researcher) 
 
it just came into my head that I felt a bit isolated and I wanted 
to have somebody to identify with, you know because nobody 
really knows at work, only a couple of choice friends know, and I 
just thought, I just wanted the support really. 
 
(Kath) 
 
However, despite service users noting the benefits of hepatitis C support 
groups, the period of observation (Chapter 4) found that they were poorly 
attended but also that the number of groups were declining. Some 
participants felt that financial considerations affected peer support.  
 
I used to take people to the hospital, you know, for their first 3 
appointments, just to go like a buddy 
 
(Susan) 
 
Yeah does that still happen now? 
 
249 
(Researcher) 
 
No, no It’s all stopped. It’s all these cut backs in it, that’s the 
trouble, everythings being cut 
 
(Susan) 
 
Reasons for not attending a hepatitis C group were discussed in the 
interviews. Having other priorities such as unwell family members and 
stigma relating to hepatitis C were suggested.  
 
Why don’t people come to that hep C support group? 
 
(Researcher) 
 
I think it’s the word, you know because of the stigma in it, erm a 
hep C group … coz you come in, if you come in and say [to 
reception] well I’m going to the hep C support group. 
 
(Jenny) 
 
Participants talked about the ‘embarrassment‘ of having hepatitis C, 
appearing to uphold wider societal stigmatising views of the virus, and 
being ‘scared’ of acknowledging their own positive status. However 
participants in one drug and alcohol service, also said they were unaware 
of the group, despite posters for the group being around the service.  
 
Did you know there’s a hep C support group at this organisation? 
 
(Researcher) 
 
No, no, didn’t know about it, I didn’t know about it [Note – there’s 
a poster advertising the support group on the wall to her left]. I 
didn’t know, I don’t really ask any questions and that..no. 
 
(Brenda) 
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Do you think you would go to a support group? 
 
(Researcher) 
 
Yeah  
 
(Brenda) 
 
It should be noted that the room where these interviews were conducted 
was a small interview/counselling room with a poster on each wall. Each 
poster advertised a different support service. One of the posters was for 
the hepatitis C support group. In addition, the small waiting room where 
people sat to wait for their keyworker appointment had numerous posters 
up (and leaflets). In this room there were three of the same hepatitis C 
support group poster.  
 
The reasons for not knowing about the group were not established. It may 
be that posters are not the most effective method to convey information, 
however Brenda commented that she does not ‘really ask questions’ and 
Beth who also did not know about the group stated ‘I’ve been given no 
information on that’. These comments suggest that keyworkers and service 
users may not discuss the hepatitis C support group at their appointments. 
 
However having knowledge of the group did not appear to correlate with 
attendance at the group, as at follow up interviews participants had still 
not attended.  
 
5.2.3.5. Discussion 
 
This theme has shown the service users’ views and experiences of accessing 
healthcare services and advice/information on hepatitis C . Barriers and 
facilitators were highlighted. Communication between healthcare 
professionals and service users on hepatitis C appeared to be a barrier. 
Examples were given where hepatitis C was not broached by either 
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healthcare professionals or service user during appointments. In addition 
when hepatitis C was discussed, professionals used terminology that service 
users did not understand or healthcare professionals were providing 
incorrect advice. The timing of verbal advice and the need for ongoing 
advice was also highlighted by service users.  
 
There appeared to be occasions of ‘missed opportunities’ where service 
users asked for a service, such as a test, and the service was not available. 
Moreover healthcare professionals did not appear to be proactive at these 
time points and did not take the opportunity to discuss hepatitis C with the 
service users. 
 
Examples were given where healthcare professionals and pathways 
between services were praised by the service users, however there were 
also examples of historical stigma and discrimination which impacted on 
access to support.  
 
Hepatitis C support groups were valued by many service users, yet many 
groups were poorly attended. More research is required into the barriers 
that prevent those with hepatitis C attending. 
 
5.3 Chapter summary 
 
This chapter has explored service users’ lived experience and perceptions 
of hepatitis C and alcohol. Participants’ described the complexities of living 
with hepatitis C alongside using substances, showing how fear, lack of 
knowledge and stigma affected their access to support, in terms of 
healthcare services but also wider support networks. Peer support was 
viewed as beneficial; further work is required to understand why 
attendance at hepatitis C support groups is poor. 
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Chapter 6 presents the findings from interviews with professionals working 
in drug, alcohol and hepatitis C services, exploring working practices and 
service provision. 
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Chapter 6 Interviews with professionals 
– findings
6.1 Introduction 
This chapter presents the findings of the interviews conducted with 
professionals. As explained in Chapter 1, the term ‘professional’ in this 
context is used to mean: people who work in the field of hepatitis C, and/or 
drugs and alcohol; providing their professional experience, as opposed to 
lived experience of hepatitis, alcohol and drugs, during the interviews. 
Semi structured interviews (see Appendix 4 for interview questions and 
vignettes) were conducted between December 2015 and March 2016, with 
12 professionals. 7 were service user facing staff working in drug, alcohol 
or hepatitis C services, and 5 were public health commissioners of hepatitis 
C, drug and alcohol services (See Appendix 7 for participant 
characteristics). 
The analysis discusses four main findings, namely: lack of national focus for 
hepatitis C, conflicting priorities, ‘chaotic’ services and stigma. The themes 
and sub themes are displayed in the thematic map (Figure 5) below. Within 
the findings facilitators were identified, but generally findings constitute 
barriers to providing services/support for PWID with hepatitis C. 
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Figure 5 Thematic map for the interviews with professionals 
6.2 Findings 
6.2.1 Lack of national focus. 
During the interviews, the participants who commission services, explained 
about their role and the services under their remit. This showed the 
participants had different considerations depending on the geographical 
area and population they covered. Whilst this was not unexpected, as the 
purpose of commissioning is to provide services for the local population, 
the level of freedom in the system and lack of national direction for 
hepatitis C was evident. Each participant had their own focus around 
hepatitis C, with no overall national strategy to work towards. One 
participant (P2) explained how he was going to use questions from ‘a paper’ 
to audit the hepatitis C service within the drug service he commissioned 
and as a focus for the organisation’s hepatitis C ‘strategy’. 
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In fact I was looking at a paper, what it’s got here after each 
section it’s got these prompt questions, so I think what I’m gonna 
suggest, is we take all these prompt questions and put them in 
like a little basic audit format and then go through it with the 
service and say ‘go away and have a look at these’, ‘how do you 
answer these ‘yes’ or ‘no’’ and then it gives us a work plan to get 
things back up to where we want them to be [after retendering]. 
 
(P2) 
 
I was wondering what the short and long term strategies are for 
hep C? 
 
(Researcher) 
 
In what sense?  
 
(P2) 
 
Just like where it’s going, where the services are going, what the 
aims are, what the objectives are?  
 
(Researcher) 
 
Well our aim is to start off with, get the screening up to the 
highest level that we can, so raise, as this paper asks the question 
‘Have you asked the question of all the people you need to ask it 
of.’ ‘Are you promoting the availability of treatment to the ones 
that you need to promote it to’ and then are we getting those 
people able to access, so that’s what the strategy is. For me it’s 
quite a nice project because its finite pretty much isn’t it, there 
are people that are infected, but relatively speaking they’re not 
a massive number probably, and we’ve got a treatment. So if 
we’ve got a system that is, that can work to prevent people 
getting infected, if we make sure we’ve got that still working in 
the way we need it to work, and that we also then start to work 
on the people who’ve already got the infection and clear the 
virus, so it’s a sort of, it’s something we’re not going to get rid 
of it altogether obviously, but we can certainly reduce the 
prevalence, that’s got to be the aim, ambition. We did have a hep 
C strategy but the trouble with strategy documents too often is 
lots of work gets put into putting them together and, that 
becomes the exercise but whereas I think what this will give us is 
a work plan.  
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(P2) 
 
This suggests a previous local (and not national) strategy for hepatitis C. 
(The Hepatitis C Strategy for England (Department of Health, 2002) and 
Hepatitis C Action Plan for England (Department of Health, 2004), were not 
mentioned, presumably as they are obsolete, there was also no EU strategy 
for hepatitis C at the time of the interviews and interviews were prior to 
the WHO Global Health Sector Strategy for hepatitis C). Furthermore local 
variation in strategic approach was evident when comparing participants 
from two different areas of Merseyside. Participant P2’s strategic approach 
appears to be very focused on hepatitis C. In comparison participant P3 took 
a much wider view of hepatitis C as ‘one tiny component’ of the ‘whole 
BBV agenda’, as well as considering aspects of the broader health and social 
care agenda (which are discussed in ‘the endeavour for integrated care’ 
section below). This expansive approach caused difficulties for participant 
P3; expressing during the interview, ‘everything just feels a little bit 
overwhelming’ and ‘I can’t see a clear strategic approach’. 
 
Participant P2 also commented on the hepatitis C Action (steering group) 
commissioning toolkit. 
 
Have you seen the Hep C Action commissioners’ toolkit for hep C? 
 
 (Researcher) 
 
…we certainly have looked at toolkits in the past, and things like 
that are quite useful because, you know if something comes on 
your desk, ‘oh right, okay then let’s look at this’ then something 
else comes on your desk, but when it comes then it raises the 
profile of that issue again, it’s a bit like this [this research] I 
suppose. I do remember doing that toolkit, that was before we 
did the tendering, but it brings it back to people’s attention and 
its gives us a structure and it gives a set of questions for people 
to reflect on and answer, so yes we did do that and like I say 
that’s I suppose what I’m proposing to use this paper for to create 
something new as a fresh, coz as, you do it and it gets pushed to 
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the top of agenda for a while, but then it gets over taken, so 
you’ve got to specifically keep bringing something else back to 
the front of the agenda and keep it going. 
 
(P2) 
 
Whilst the comments emphasise further the autonomy in local decision 
making, they also suggest a paucity of national formalised monitoring of 
hepatitis C services (as well as competing demands, which is discussed in 
the ‘commissioning in transition’ section below). This lack of national 
monitoring was highlighted further, as the participants described the 
national performance indicator for hepatitis C: the proportion of people 
who were receiving treatment for their drug addiction, who had (ever) 
received a hepatitis C test. Thus there are no national requirements on 
people receiving a recent hepatitis C test or an awareness of treatment 
targets. From the service user’s interviews it was clear that some 
participants had been diagnosed with hepatitis C for many years but had 
not received hepatitis C treatment, and also that some participants 
continued to engage in sharing injecting paraphernalia. The participants 
seemed aware of these issues and had set their own targets, however 
targets were not the same for each authority. 
 
No well basically in terms of, the only indicator that we’ve ever 
been measure against is on NDTMS [National Drug Treatment 
Monitory System] and that was the proportion of your IDU’s that 
have been tested [for hepatitis C] against drug treatment and 
there’s services up and down the country that are working 
towards that particular indicator, but that’s never a measure of 
success in my view because the people haven’t gone on to access 
treatment which is what we’ve asked [nurse] to measure. 
 
(P1) 
 
Okay so within our commissioned drug and alcohol treatment 
service, substance misuse treatment service there are key 
performance indicators that we expect to be met, of an offering 
of screening and I think the standard expectation within the 
national data set is around the proportion of the active treatment 
population tested for hepatitis C, we feel that that does not give 
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a complete picture so locally we have an additional target within 
our key performance indictors which sets a requirement for the 
commissioned service not just to meet that percentage of the 
overall [drug] treatment population who have ever had a test for 
hepatitis C but for those who have had a test for hepatitis C 
within the last twelve months because I think that becomes more 
meaningful. You could have 100% of the treatment population 
who have ever had a test for hepatitis C but 95% of those might 
have had a test 5 or 6 years ago so it’s currently exposed to, we 
wouldn’t pick any problems or treatment needed up through that 
if we didn’t have this more kind of recent, so I think that is 
something that we are mindful of. Now we, it’s probably fair to 
say that in terms of performance around those we don’t see as 
higher rate of performance around the shorter time frame 
expectation as we do on the overall so whilst we exceed the 
national target and expectation for the percentage ever tested 
with in the treatment population that’s not always the case 
within the last twelve months so it’s something we are working 
hard to improve. What we also, both in national and local target 
from the proportion to test positive a target for the number 
offered referral treatment so the treatment pathway so you 
might think well how effective is that as an indicator of success 
because having an offer does not necessarily mean that someone 
will take up that treatment option so I think that is one of the 
things that we’ve struggled with, we have a very high return on 
that target expectation of all people who have a positive test for 
hepatitis C having the offer of treatment, we don’t have as high 
a completion or success in terms of people commencing and 
completion…  
 
(P5) 
 
I was going to ask actually, do you have numbers of people who 
have actually had treatment? 
 
(Researcher) 
 
I don’t think the numbers that we have are particularly reliable 
and that’s one of the areas that we are working on with our 
service at the moment. 
 
(P5) 
 
Offering treatment, but not having ‘reliable’ numbers on how many have 
accessed treatment appears concerning. Also from the vignette interviews, 
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it was evident that service users needed to meet certain criteria (such as 
not injecting and not drinking over certain amounts) to be suitable for 
treatment. This seems at odds with the target to offer treatment to all 
service users with hepatitis C, however this aspect was not discussed by the 
participants who commission services. Despite questioning the usefulness 
of this target, this research does highlight local level intentions over and 
above the national requirements. 
 
More generally, when considering prevention and behaviour change at a 
population level, one participant (P2) explained how a national level focus 
is required. 
 
….general population messages which happen and work, but they 
happen as like national campaigns mostly really, because its only 
in the national level campaigns that have the resource behind 
them to get that you know TV adverts sustained year after year 
of putting a message out, little local campaigns are like pebbles 
in a pond I think, the ripples, if the ripples do reach the side, 
they reach the side not enough.  
 
(P2) 
 
I guess with health interventions like that it’s probably going to 
be decades until you see results.  
 
(Researcher) 
 
Yeah and locally all your plans are short term aren’t they, 
whereas a national campaign, you know smoking has been years, 
decades of targeting smoking and I think we’re just getting to 
that point with alcohol now….  
 
(P2) 
 
Although this participant is not specifically discussing hepatitis C, the 
difficulties of making an impact at a local level without a national drive are 
expressed. 
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6.2.2 Conflicting priorities 
 
Conflicting priorities were seen throughout the interviews, indicating 
conflict at both strategic and organisational levels. 
 
6.2.2.1 Commissioning in transition - changes in agendas, priorities and 
resources. 
 
Throughout the interviews, participants referred to the changes that 
occurred in April 2013 following the Health and Social Care Act (2012), when 
PCTs (Primary Care Trusts) were replaced by CCGs (Clinical Commissioning 
Groups) and public health commissioning transitioned into local 
government. This period of change also saw the move to integrated drug 
and alcohol services. 
 
..there was a significant shift in focus in terms of the drug and 
alcohol service from around about 2013 and it shifted the focus 
of everything really with agencies dissolving, creation of Public 
Health England, we had to pick up some of the functions of that, 
the dissolving of the local primary care trust, creation of CCGs, 
public health coming into local authorities, responsibility for a 
lot of this specialist commissioning with public health coming into 
local authorities and within all of that almost unprecedented 
change there was a change in focus of substance misuse and 
treatment in services and what that change in focus brought 
about was an integrated drug and alcohol service.  
 
(P5) 
 
These changes saw hepatitis C services being commissioned by both the CCG 
and local authorities, with the addition of NHS England (NHSE) who agreed 
to fund the newest (DAA) hepatitis C treatments for some patients in 2014. 
One participant explained the impact of these changes on hepatitis C 
services. 
 
I think what we’ve got to consider right from the onset is, under 
the PCT they had the overarching leadership for the whole of the 
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services now that it’s gone you have got the CCG that has 
responsibility for primary care and hospitals, you’ve got public 
health who are responsible for screening, however we have 
addiction services here with us [public health] as well so we’re 
responsible for making sure those service users get the whole 
package. ...and then you have got NHSE to throw in the mix here 
because they have just took on the prescribing costs haven’t they, 
the prescribing cost for the drug [DAA hepatitis C treatments] and 
that as well so it…NHSE, CCG and local authorities all have a 
responsibility but that pathway isn’t stream lined.  
 
(P3) 
 
The participant explained further the difficulties of trying to get the 
pathway streamlined in the current climate of changing agendas and 
differing priorities amongst the strategic bodies. 
 
[Researcher – explains research has gathered service user 
perspective on the gaps in services] I think the strategic one is 
your absolute key one because sadly it’s a different priority for 
every, whether it be NHSE, councils, CCG, people miss this and 
just go ‘oh the pathway hasn’t changed’ and I say ‘no the strategic 
priorities have changed’, so if strategic priorities have changed, 
it doesn’t have the same push anymore, they might be prioritising 
something else, it’s not that they are not caring, it’s just it’s not, 
for today their agendas have changed and I think that has really 
been missed, is how all our agendas have changed, and someone 
like public health where you’ve put public health back into local 
authorities, it’s taken a massive big sway in another way that I 
never thought would happen and evenly for them, councils never 
thought of clinical services, whereas they’ve got to consider 
clinical services now.  
 
(P3) 
 
As well as there being different priorities between the organisations, the 
changes to the commissioning structure also meant commissioners were 
now responsible for a larger remit, resulting in less resources, different 
working relationships and seemingly less focus on hepatitis C. 
 
The idea is that what I wanna now be able to do is to influence 
how we progress our local hep C strategy locally, and largely that 
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will focus probably just on drug users to begin with to mop up 
that last 250 [who have not been tested]. But unless we kind of 
suddenly have a mass influx of migrants with hep C that presents 
a risk, I can’t see us facilitating a specific strategy group for hep 
C coz everything now is tending to be arm’s length, light strokes 
with a broad brush, in other words it’s all kind of, what we were 
able to do before to drive stuff, we’re just not able to do in the 
same way, because you know, I manage a drug programme of 
which now hep C is a part, the DAAT [Drug and Alcohol Action 
team] used to do that, there were 12 people at peak in the DAAT, 
so I’m looking after the substance misuse treatment system, I’m 
also the lead for suicide prevention, BME engagement, I’ve just 
finished a piece of work on domestic violence, so you’re pulling 
in quite broad range of different stuff really.  
 
(P1) 
 
You know we had a DAAT team, you know at one point there was 
12 of us delivering the drug and alcohol programme, there’s 
probably not 12 of us in the public health team anymore, so we 
haven’t got the resources to do it in the same way and that’s 
interesting too because we were effective when we were that 
team focused on drugs and alcohol very specifically and had a 
good resource to do it, and I look now at how we, how stuff is 
falling, this idea of spinning plates, well plates are falling off 
now, we have to lose some, but there will be a consequence of 
that because there was a value in those things, we won’t reap the 
consequence straight away, we’ll go through a cycle, we’re 
striping stuff out of the system now, you know hep C is not getting 
as much attention as it did, so things like this [research] are good 
to raise profile again. 
 
(P2) 
 
It’s funny coz that’s one of the other things we were quite 
connected, different areas would know what was going on, I know 
[commissioner in another area of Merseyside] well, we’d know 
what was happening in [other areas of Merseyside], we’ve lost 
that as well, we’re disconnected from each other now, we do 
meet up sometimes, PHE still get the commissioners together 
quarterly I think and it’s good to meet up with people and hear 
what’s going on.  
 
(P2) 
 
And I think because it [hepatitis C] has been around for a long 
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time I think there has been a significant assumption made that 
we’re further on than actually what we are and I think it really 
became apparent when, with the demise of the PCT and 
everybody taking a different responsibility but actually it really 
did sort of open basically our eyes to say, this was fragmented 
anyway however it’s worse now, because actually what you’ve 
done is with that fragmentation is really impacted on our service 
users because our services are now commissioned differently and 
we don’t have the same resources that we used to have, and we 
don’t have the same relationships that we used to have for some 
of those pathways so it’s how do we manage that. 
(P3) 
These quotes from the participants indicate hepatitis C is not a priority in 
the ‘grand scheme of things’. Furthermore the commissioning process does 
not permit hepatitis C to be a commissioning priority for the CCG or local 
authority, requiring it to be commissioned indirectly within a pathway. 
So do you meet up with the CCG commissioners about the hep C 
services and pathways? 
(Researcher) 
In some instances yeah, so hepatitis C is an interesting one 
because there isn’t actually, hepatitis C is one of those things 
from a CCG point of view and from a local authority point of view 
is probably not, doesn’t fall into any of the direct priority groups, 
which for those of us close to it, it’s sometimes disappointing but 
we are recognising that you know it is not always….so you know 
from a CCG point of view when they set out their priorities, things 
like cardio vascular disease and respiratory disease they are 
amongst the kind of top priorities, reduction in hospital 
admissions and long stays, so it’s kind of where does hepatitis C 
fit in to that, the kind of long term conditions bit of it, so it is 
very often something that will be commissioned within a pathway 
rather than a direct provision in itself. From a local authority 
point of view, from our point of view for example prevention, 
identification. Prevention of hepatitis C would generally speaking 
come within the realms of the substance misuse services that are 
commissioned, now again that’s, you know, we don’t actually go 
out to directly commission a hepatitis C service, so treatment or 
prevention, but it is a focus, so within our substance misuse 
service – why is that so? I am sure you completely understand that 
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the vast majority of hepatitis C infections annually are either 
directly or indirectly attributed to drug use and some of the 
means by which substances are consumed so it absolutely is an 
integral part of looking at our drug treatment programmes. 
(P5) 
Moreover one participant (P1) explained how commissioning of services is 
complex, especially when working on issues that require joint 
commissioning. Interestingly some of the participants who commission 
services met with their CCG counterparts but other participants did not. 
Those who did not meet with the CCG commissioners seemed less 
knowledgeable on the treatment section of the pathway, as they did not 
mention NHSE funding the new DAA treatments and the current system of 
these treatments being provided by lead sites under the Operational 
Delivery Networks (ODNs). Although this is understandable as hepatitis C 
treatment is not under the remit of public health commissioning, it shows 
gaps in their understanding of the whole hepatitis C pathway. 
Is there a commissioner for CCG in [area of Merseyside]? 
(Researcher) 
No, not, well, they commission acute services, so… 
(P1) 
It’s me not understanding the commissioning process really, you 
know as a nurse on the ground, you don’t really know how it’s all 
(Researcher) 
I don’t think half the commissioners do because some of the 
systems are that complex, it’s really strange for example I’m a 
suicide prevention lead and that’s public health’s responsibility 
but CCG are responsible for commission the mental health service 
as they form that beginning of that continuum, so it’s strange, 
public health work preventively and commission services to test 
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those at risk of hep C and really we should be pulling in some of 
those other communities as well, in terms of the actual medical 
treatment regime presumably CCG’s will be commissioning hep C 
treatment from the hospitals, but who that would be I don’t 
know. But if they commission hospitals then its CCG’s will be 
commissioning the treatment element and no doubt either 
internally within the hospitals whatever consultants will decide 
what drugs they prescribe, there may be some influence from 
with the CCG’s as well I don’t know. 
(P1) 
As a newcomer to commissioning, I just thought maybe you all got 
together, you all talked about what was best for the people in 
your community and then you all made a pathway that linked up 
(Researcher) 
common sense would tell you that that’s what you should be 
doing, but for example, alcohol related admissions are a really, 
really big problem it always has been historically, its improving 
but if I’m a commissioner working preventatively and I know that 
alcohol related admissions are costing 2 million pound a year for 
the hospital I might go to them and say I’ve got a new service and 
it’s going to save you 2 million pound a year but I’m going to put 
a 100K in it for next year and I want you to from the money that 
you’ll save. It’s alright me turning round and say I’ll commission 
this service which will save more money but if it’s not, if those 
savings aren’t being realised within someone’s budget it just 
looks like I’m taking a 100k out the hospital to put it in a 
community based service so people don’t wanna know, there’s all 
this talk around joint commissioning and pooled budgets and it 
never happens, because people end up, this is my view anyway, 
you look after drugs and you look after mental health and you 
look at, and everybody gets a set of performance indicators and 
a budget to manage against, 
(P1) 
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No we don’t link up with them [CCG commissioners for hepatitis 
C], they sort of left us to it, I think because we had quite a strong 
DAAT team, anything drug related was just left to the DAAT team 
to do, and like I say the hep C, the treatment, well the CCG are 
paying for I presume, they must be coz the hospital are providing 
it, but we’ve not had to sit round a table and negotiated that, 
the treatment pathway has been established, and I think the 
hepatology consultant from the hospital has championed it from 
his side and to some extent that has been a bit of a stone that 
I’ve deliberately not wanted to draw people’s attention to 
because my concern is if we draw too much attention to it, people 
might take more control of it and that might make it more 
restrictive, where at the moment anybody who’s wanted 
treatment has been able to access that treatment, so I don’t, so 
the CCG have just let it get on with it, it hasn’t been a 
partnership work in that sense but it hasn’t been obstructive 
either, so that may not be the classical way of doing it, but I have 
tended to think, well it’s not broke so let’s not try and fix it even 
more than it is. If it gets to a point where people are struggling 
to get access to treatment then we’d have to get into that 
negotiation but at this time I’m not aware that it’s happening, 
anybody whose identified and ready for treatment has been able 
to access the treatment 
(P2) 
I found it quite interesting. I think ‘X’ [name of hospital] might 
have different treatment, lots of new drugs [DAAs] isn’t there, 
and I think’ X’ are using some of those, so I wonder how that works 
and whether people from [area of Merseyside] can be referred 
over to ‘X’ 
(Researcher) 
I think last time, to be honest in all the upheaval of [retendering], 
I’m not as in touch with that as I was when we’ve spoken about it 
before. I do recall that there was some suggestion that for certain 
exceptional cases, there was the opportunity, people would get 
referred to ‘X’, but that wasn’t the norm it was for a particular, 
it was a sort of quid pro quo arrangement between the two 
hospitals or the two units, the consultants could refer, I think 
they referred all people from the consultant 
(P2) 
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This section has shown the many challenges facing commissioning of a 
hepatitis C service within the current commissioning structure. Alongside 
the changes in commissioning, the government’s larger agenda of 
integrating services (health and social) to improve the fragmentation of 
care has caused further concern for participant P3 (as discussed below). 
6.2.2.2 The endeavour for integrated care 
The Government’s vision for services to be integrated to meet the 
increasingly complex needs of patients, has been on the agenda since the 
Health and Social Care Act (2012). All participants that were interviewed 
who commission services, talked about the integration of hepatitis C 
services by explaining their pathway from the drug services to receiving 
hepatitis C treatment in hospital (and increasingly in the community). 
However only on participant (P3) mentioned integrating wider services; 
showing another level of complexity for a strategic approach to hepatitis C. 
the whole BBV agenda is really important and that’s [hepatitis C] 
like one tiny component so again it’s where’s our starting point, 
should we be going straight for hep C or should there be other 
things that we’re gonna look at as well alongside that. The most 
important thing is how does that sit with our new alcohol 
strategy, a homeless strategy, if we are going to ask people to 
look at integrated pathways, health and social care agendas 
should these not be priorities in the strategic plans, so that is 
another conversation that is taking place at the moment. 
(P3) 
there is no point in public health writing an BBV strategy when 
actually we know we’re probably not going to get all the 
outcomes of that strategy met and also as well, them being with 
the council now and not sitting with health you have to then 
consider the social side, so it’s the areas of depravation, it’s 
someone’s housing need so there is an awful lot that you need to 
tap into, which actually I hadn’t considered when I was on the 
PCT and now being here [local authority] the first thing you know 
my council colleague says, ‘what about this cohort of people?’ 
‘What about this cohort of people?’ And again they might have 
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been a substance misuser ten fifteen years ago but maybe have 
been left vulnerable, may have mental health issues, may have 
homeless issues, but the service doesn’t come to them so again 
they are like well it should, and if we are going to address health 
and well-being this is where we need to start and it’s about 
looking at everybody’s needs as an individual which is great, but 
it doesn’t actually answer the question of what we say about the 
hep C pathway being fragmented, the services being fragmented 
and I’m trying to sort out that one grey area at the moment, so 
health and social care broader agenda has got a long way to go in 
offering collaborated integrated services. 
(P3) 
As an integral part to integrating health and social care, health and 
wellbeing boards were established and became operational in April 2013 
(Kings Fund, 2016; Humphries and Galea, 2013). The health and wellbeing 
boards ‘are ideally placed within local communities to bring together key 
partners to deliver better outcomes for individuals, including the most 
vulnerable, and there is great potential for further joint working’ (HM 
Government, 2017 p. 29). In ‘Opportunity Knocks: An Audit of hepatitis C 
services during the transition’ (Hepatitis C Trust, 2013a) a recommendation 
was made; ‘Local authorities should have a designated liver health lead on 
their local health and wellbeing board, with hepatitis C designated as a 
clear part of their remit’. (Hepatitis C Trust, 2013a, p. 6). Bearing this in 
mind, this topic was discussed during the interviews giving an interesting 
insight into participants’ knowledge of this. 
What do the health and wellbeing boards do about hep C? 
(Researcher) 
They leave it to, it’s one of those things I suppose that because, 
I think the DAAT’s [Drug and Alcohol Action team] were quite 
effective, certainly our local DAAT was quite effective, think 
people got in to the habit of you know just let them get on with 
it, we don’t have to worry about it that’s being sorted out over 
there, which in some ways is quite good because it means we 
could get on, we were able to just get on and do it, and not have 
to worry so much about satisfying everybody else, I don’t think 
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it’s very big on the health and wellbeing board’s agenda. 
(P2) 
I’ve read somewhere health and wellbeing boards need to have a 
representative about hep C, so I thought ‘oh I’ll interview them’ 
but I don’t know who they are. 
(Researcher) 
I suppose in theory it would be my manger who’s the deputy 
director of public health. They go to the health and wellbeing 
board, so the director of public health is, yeah does she go? I think 
she does yeah, or is it chaired by the director of public health? I 
don’t go so I don’t know the people but I think also within the 
public health team, people, my colleagues think ‘oh [name] will 
deal with that’ coz I’ve been dealing with it for a long time and 
it’s been reasonably well managed, so they think well we don’t 
need to worry about that, that’s all been sorted out over there. 
(P2) 
Do you know much about the health and wellbeing boards and hep 
C on them, is there much…? 
(Researcher) 
I’m guessing, the health and wellbeing board obviously exists as 
this tripartite kind of system each with these 3 different 
strategies which are overlaid to produce a health and wellbeing 
strategy and I’m sure it’ll be mentioned in there, but I’m sure it’s 
not the focus. 
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(P1) 
So you don’t know like the named person who would know more 
about hep C on the health wellbeing board? 
(Researcher) 
No. 
(P1) 
I don’t know if they have anyone, but um.. 
(Researcher) 
I’m not so sure, I think it depends whether it’s a priority or not 
isn’t it you know what I mean, the Impression I get from health 
and wellbeing boards is that where public health will talk an 
awful lot about the preventative stuff, GPs are very interested in 
waiting times, rates of prescribing and so on so, you’ve got kind 
of this trichotomy of three different people pulling in different 
directions and I think that makes it difficult for boards like that 
to function when they are so distinct and separate, you know 
those interests. 
(P1) 
Although the participants suggested hepatitis C may not be a priority for 
the health and wellbeing boards (as was shown in the HCV Action report 
‘Health and Wellbeing Boards & Hepatitis C’) (HCV Action, 2014), this could 
not be substantiated as interviews were not conducted with health and 
wellbeing board members. However, the overall strategic importance of 
hepatitis C within these local councils can be questioned, if they do not 
know, a) who represents public health on the board and b) the board’s 
overall hepatitis C agenda. 
Not only is the integration of care a government agenda and a concern for 
commissioning, the vignette interviews showed how these difficulties are 
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experienced ‘on the ground’. When considering the vignettes, participants 
would attend to the issues posed, but would also exceed this and explain 
other aspects they would consider when seeing service users. Figure 9 
(Appendix 6) shows all the aspects that one participant (P12) would 
consider for ‘Kate’ during her first consultation at the drug and alcohol 
service, and other services she could be referred onto for help. Thus not 
only is ‘Kate’s’ heroin use, methadone use and hepatitis C assessed, the 
wider concerns are evident, including her physical, sexual and mental 
health as well as her living and work arrangements. Regarding her injecting, 
as well as hepatitis C, consideration would be given to other blood borne 
viruses such as hepatitis B and HIV, as well as bacterial infections, such as 
endocarditis and abscesses which would require injection sites to be 
checked. He (P12) would provide harm reduction advice in terms of safer 
injecting, advise on injecting paraphernalia provision and tailor the 
methadone script to reach a level that helped ‘Kate’ to reduce her heroin 
intake. 
 Regarding her social circumstances, as she is currently homeless, staff at 
the hostel would be contacted to discuss ‘Kate’s’ needs. He (P12) would 
also ask if ‘Kate’ was engaged in sex work, with consideration of her sexual 
health including hepatitis A and referral to a charity that supports sex 
workers. Although the vignette said ‘Kate’ did not drink, alcohol was still 
discussed, with participants explaining that if ‘Kate’ did start drinking 
excessively, this would complicate her situation further, adding a layer of 
difficulty to the management of some of her other health issues. Firstly in 
terms of any mental health problems, alcohol was a barrier to accessing 
mental health support, as the mental health ‘crisis team would only see 
her if she turned up there not intoxicated’ (P12), secondly, alcohol (at 
some levels) is an exclusion for hepatitis C treatment and thirdly, alcohol 
would affect the management of her methadone. This was highlighted when 
another participant (P11) discussed vignette ‘Ben’, as rather than talking 
about alcohol and hepatitis C, as per study design, this participant talked 
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at length about the difficulties of managing methadone when service users 
drank alcohol. 
…because of the risk with alcohol on top of methadone, we’d look 
at reviewing the methadone dose, you know, if they’re stable on 
the methadone, do they need that reducing? Depending on what 
dose methadone he’s on, could it be that he could convert to 
subutex - because you’re less likely to overdose on subutex. So, 
that he’s currently maintained on a methadone script doesn’t 
mean that you have to keep that methadone script. So working 
with the client, if he’s used methadone before he might want to 
carry on using it, so we really need to look at whether it’s the 
right option for him - mentally and physically. So we’d look at 
blood testing as well, and we’d see how his liver’s coping, mainly 
we’d focus on if his liver’s compromised, then we do really need 
to look at bringing the dose down, and converting him over to 
buprenorphine perhaps. 
(P11) 
Methadone affects the liver does it? 
(Researcher) 
Well it’s because of the way it works. It can stay in the liver 
longer if the liver’s compromised if they’re drinking. So we don’t 
really like drinkers on methadone here. We prefer to convert 
them over to subutex, because they’re less likely to overdose. 
Because methadone is a sedative - like alcohol. So that’s the focus 
the prescriber would look at – really challenge whether we need 
to carry on with that methadone script the way it is. Look at 
formulating a plan with them, and how we can change it. 
(P11) 
…And big risk for him as well is accidental overdose. He’s at risk 
if he’s previously injected. It’s great that he’s methadone only, 
but a risk is he might return to heroin and accidentally overdose, 
because he’s not as tolerant any more, especially if he goes 
straight back to injecting. So a lot of risk management around 
that. 
(P11) 
273 
So although ‘Kate’ did not drink alcohol, we could surmise if she drank, she 
would be at a similar, if not greater, risk than ‘Ben’ (as she was injecting 
heroin), of overdosing. The risk of overdose would be another, and arguably 
more pressing, concern than her hepatitis C (which does not generally 
damage the liver until many years after being infected) for staff to address. 
These interviews have shown that for professionals working in drug and 
alcohol services, supporting service users such as ‘Kate’ and ’Ben’, there 
are many conflicting priorities to attend to, with some issues requiring more 
urgent consideration than hepatitis C. Furthermore, substance use conflicts 
with hepatitis C treatment, as drinking excessively and injecting are 
exclusions for treatment. One participant explained how she would not 
even refer service users who injected, for hepatitis C treatment. 
If people are still using in the way of smoking a few times I’d still 
refer them for treatment because they can function on that. Just 
because they’re still using a few times a week doesn’t mean they 
can’t function with everyday life, and appointments and stuff, 
but I wouldn’t refer them if they were injecting. 
(P7) 
And if ‘Kate’ was referred to the hepatitis C clinic in secondary care: 
She wouldn’t turn up. They’re our highest DNAs. So we would 
discourage them, even if she’s got a diagnosis of hepatitis C, to 
refer to the hospital at this stage. Because she really needs to 
engage with - the injecting, she’s not going to be treated. But 
that needs to be addressed. The smoking heroin we can deal with. 
She’s clearly on a methadone script but it’s not working, because 
she’s still injecting and smoking. She doesn’t engage with the 
drugs services, so they need to engage with drug services; she’s 
homeless. So the Hep C is absolutely the least of her problems at 
the moment. The only thing that we would do is if this patient 
turned up, we would spend quite a bit of time explaining what 
hepatitis C is, and how it’s transmitted, and that she’s putting 
other people at risk, or she’s caught it from someone because 
she’s still injecting. So we’d talk about paraphernalia, and not 
sharing it, and the risks…. 
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(P8) 
 
Her homelessness needs to be sorted. She needs to engage. She 
doesn’t drink alcohol, which is a good thing. So I would say she 
needs to be told about her hep C, she needs to be told that it 
potentially can cause cirrhosis. Possibly if she did engage with us, 
if she did turn up, I would do all her bloods, and I would do her 
fibro scan. And I wouldn’t discharge her – I would try to encourage 
her to be treated. But whether she would engage with us, I don’t 
know.  
 
(P8) 
 
The narratives suggest that even if ‘Kate’ did engage with the service, she 
would not receive hepatitis C treatment as she was injecting drugs. All 
participants who considered the ‘Kate’ vignette agreed that ‘Kate’ would 
not be given hepatitis C treatment, although it was unclear if it was the 
injecting per se or the lack of engagement with services which was 
attributed to injecting. This shows the barriers for ‘Kate’ to receiving 
hepatitis C treatment and/or advice from the hepatitis C specialists in 
secondary care. Therefore ‘Kate’ would need to have support from 
primary/community services. Participants felt that many service users did 
not visit their GP and were more likely to attend the drug services. However 
as shown in the discussion of ‘Kate’ and ‘Ben’, there are many other, more 
pressing aspects to attend to in consultations at the drug and alcohol 
services as well as the hepatitis C. As ‘Kate’ is not attending the drug 
service regularly, the hostel staff would be instrumental in helping ‘Kate’ 
with any concerns she may have. In regards to her hepatitis C, again there 
may be other issues that would take priority. 
 
We used to try and do an education session [on hepatitis C] for 
the hostel workers and for the hostel dwellers, so we used to try 
our best to do some education sessions, so a lot of the keyworkers 
in the hostels are, you know I’d like to think in each hostel at 
least a few of them are au fait, whether or not it happens I don't 
think it does, I think they’ve got too many other problems going 
on in the hostels, day to day problems for them to worry about 
the hep C, I really don’t.  
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(P9) 
Vignette interviews of the professionals’ perspectives, have shown barriers 
in providing hepatitis C support for service users who have addictions, with 
substance use (injecting heroin or drinking excessively) as well as other 
factors, such as mental health, physical illness and homelessness, posing 
‘conflicting priorities’ to providing hepatitis C related support. 
6.2.3 ‘Chaotic’ services 
PWID and/or have an alcohol dependency are perceived by some as being 
difficult to engage in services and to treat (Zanini et al, 2013; Grebely et 
al, 2015), due to the ‘chaotic’ nature of their lifestyles (Sylvestre, and 
Zweben, 2007). However this research has also found services to be 
somewhat ‘chaotic’, which is discussed in more detail below. 
6.2.3.1 Disparity in knowledge, advice and referral to other services. 
When comparing the participants’ narratives of the vignettes, it was 
evident that they had different knowledge and would give contrasting 
advice to service users. Furthermore the differences in knowledge resulted 
in varied criteria for referral to other services amongst the participants. 
This is demonstrated by considering the ‘Rob’ vignette. 
‘Rob’ was deemed to be currently unsuitable for hepatitis C treatment, by 
all participants who considered the ‘Rob’ vignette. Whilst all the 
participants noted that his alcohol consumption was too high to receive 
treatment, one participant (P10) would also inform ‘Rob’ that his heroin 
use (smoking) would exclude him from treatment. 
..inform about the [hepatitis C] treatments that are available 
now but again informing that although methadone isn’t a problem 
they probably wouldn’t initiate treatment until he was clear of 
the heroin for a period of time. 
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(P10) 
 
However, the participants who provide hepatitis C treatment said smoking 
heroin would not exclude ‘Rob’ from hepatitis C treatment. 
 
So ‘Rob’ for example would he be suitable to be referred onto 
treatment if he is smoking and drinking? 
 
(Researcher) 
 
The smoking of the heroin and the crack if he’s engaging and he’s 
not too chaotic with that, I mean you’ve said he currently smokes 
heroin twice a month, no that’s fine. His drinking, no he’s not 
suitable.  
 
(P9) 
 
This shows that ‘Rob’ would be given conflicting information on his heroin 
use in terms of his suitability for hepatitis C treatment. Although the 
incorrect advice had been given by a participant from the alcohol team, 
(and ‘Rob’ would have been given the correct information by the hepatitis 
C team, if he met with them) incorrect advice could lead to confusion. 
Furthermore being required to abstain from heroin, could potentially 
prevent ‘Rob’ from seeking hepatitis C treatment, and the wrong exclusion 
criteria for treatment could stop service users from being referred on for 
hepatitis C treatment. All participants who considered ’Rob’ did however 
agree that he was consuming too much alcohol to currently receive 
hepatitis C treatment. Indeed, all participants interviewed using the 
vignettes agreed that alcohol consumption was an exclusion for the 
treatment, however when questioned on the amount of alcohol people 
could drink and still receive hepatitis C treatment, there were 
inconsistencies in opinions. 
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One participant working in a community drug and alcohol service explained 
‘Rob’ would not even be referred on for hepatitis C treatment because he 
was drinking. However the participant was not completely sure of the 
criteria for hepatitis C treatment, initially saying no alcohol, but then 
suggesting a limit of approximately 2 -3 units a week (glass of wine or bottle 
of beer). 
 
Yes so if he wanted hep C treatment?  
 
(Researcher) 
 
He’d have to stop drinking.  
 
(P12) 
 
OK and then if he managed to stop drinking?  
 
(Researcher) 
 
If he managed to stop drinking first of all it’s the retest. Maybe 
he hasn’t got hep C anymore, ok, so if we retested him and he’s 
still positive for hep C and he’d stopped drinking we would then 
refer him through. Now we can always get him to see [hepatitis 
C nurse working in the drug and alcohol service], that’s not a 
problem but she would not be able to refer him into treatment 
[for hepatitis C] if he’s carrying on drinking. It’s an exclusion 
criteria at the [hepatitis C clinic].  
 
(P12) 
 
All levels of drinking?  
 
(Researcher) 
 
I think so. Couldn’t swear to that but I think so. I mean if they 
have a glass of wine, a bottle of beer, at weekends, maybe he’d 
be able to get away with that but beyond that I don’t think so.  
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(P12) 
 
However, the participants involved in giving hepatitis C treatment provided 
different answers to the accepted alcohol levels for hepatitis C treatment. 
One participant (P7) explained ‘heavy drinking’ is an exclusion, although 
they did not explain what constituted ‘heavy’ drinking. She also explained 
people needed to ‘reduce or be abstinent’, which appears to be confusing 
advice. Regardless of this, her advice was not 2-3 units a week as expressed 
by participant P12. 
 
And what about drinking? Would they be referred for treatment 
if they were drinking?  
 
(Researcher) 
 
Depends on how much they were drinking. If they were drinking 
heavily I’d refer them to the alcohol team if that was something 
they wanted to do. Obviously I can’t make them do that. I’d say 
“this is what’s available to you” and obviously I’d give them the 
risks of drinking with hep C. And the risk of cirrhosis and things. 
So if they were drinking I’d say “I’ll refer you to the alcohol 
team”. “When you’ve engaged with them, when you’ve cut down 
or become abstinent, we’ll re-review the situation again and then 
I can look at referring you for your hep C treatment”.  
 
(P7) 
 
Another participant who provides hepatitis C treatment, also considered 
‘Rob’, giving a different explanation on alcohol consumption in the context 
of hepatitis C than participant P12 and shedding further light on the 
explanation provided by participant P7. She explained ‘Rob’s’ alcohol 
consumption would need to be ‘reduced’ to receive treatment, although 
she did not express to what level. However her explanation gave further 
insight into the complexities of this situation, explaining how the stage of 
liver disease affects the advice given, so if ‘Rob’ had cirrhosis, then he 
would need to be abstinent, and presumably, if he did not have cirrhosis he 
did not need to be abstinent. Thus, this advice was not given to meet a 
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criteria for treatment per se but as general advice for the health of his 
liver. Also seemingly more important than an actual amount of alcohol 
consumed, was engaging with services. The reason for this was not 
ascertained. 
 
OK, OK, so is the advice really to completely cut out alcohol or to 
reduce it or what’s….?  
 
(Researcher) 
 
Not completely cut it out but we do need it to be, I mean every, 
you know 5 cans of super strength a day it’s far too much, so what 
we’d have to do is give him some support and see him making 
some steps to you know to actually engaging and being positive, 
so I think we’d need to do is, is see him showing willing. If he 
wants the [hepatitis C] treatment then he has to make some 
changes in his life as well, so I think it would be unrealistic to say 
completely come off it, that would be our goal obviously our main 
aim, if he was cirrhotic then we’d, I’d refer him in to the liver 
team, we’d keep an eye on him that way and we’d just work with 
him but at the moment he would not be suitable for [hepatitis C] 
treatment, we’d have to work with him definitely to get his 
alcohol reduced and if he was cirrhotic he really needs to be 
abstinent, so depends on his stage of liver disease you know if he 
has got any.  
 
(P9) 
 
Later in the interview with participant P9, she elaborated further on 
hepatitis C treatment and alcohol, explaining how treatment would be 
given if drinking was within the government recommended units for the 
general population (21 units a week at the time of the interviews for males, 
not 24 units as expressed by this participant). This is a vastly different 
amount of alcohol than the 2-3 units participant P12 suggested. Again 
however the complexities of this decision was illustrated by participant P9, 
explaining that this amount of alcohol was only for people who were not 
dependent on alcohol, with people who were dependent needing to be 
abstinent. Again a decision not based on the hepatitis C treatment itself, 
but on the person’s pattern of alcohol use. 
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What level of drinking would you treat [hepatitis C] on? 
(Researcher) 
So I mean our forms actually just class as heavy, moderate, so 
moderate is I suppose is within your units and under your units, 
so for men its 24 units and under isn’t it, so we’d also discuss that 
you know “your safe units are 24 with 3 alcohol free days and 
that’s what we need to try and get you to”, but if you are 
dependent on alcohol then I think the only safe limit is nothing. 
And then discuss, there are lots and lots of anti-craving drugs out 
there now, so what we could say is, if we can get you off the 
alcohol then hopefully we can give you some medication that will 
stop the craving and help you continue to be abstinent so that’s 
where we wanna be, but if we’ve got people who aren’t 
dependent and are just drinking maybe 50, 60 units a week but 
they’re not drinking every day to that level, then we’d basically 
say we need to get you down to 3 days free and within your 
recommended limits so that’s what we’re trying to get to. 
(P9) 
As participant P9 would advise people with cirrhosis to be abstinent, we 
can surmise that the ‘safe units’ a week would be for people who do not 
have cirrhosis. However when another participant (P8) discussed vignette 
‘Sarah’, who did not have cirrhosis, she advised under 7 units of alcohol a 
week - a lower amount of alcohol than the weekly limit of units 
recommended for the general population (14 units a week for females and 
21 units a week for males at the time of the interviews). 
Just re-iterate alcohol should be really no more than seven units 
per week for a non- cirrhotic. 
(P8) 
Okay so that alcohol’s okay is it, yeah [talking about ‘Sarah’s’ 
alcohol consumption]? 
(Researcher) 
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Yeah, once a month, two to three gins, that’s fine. We’d 
discourage them to drink, I would discourage them to drink as a 
matter of habit. Even though that’s fine, I would stress the 
importance of making sure that don’t drink for the sake of 
drinking, maybe try and keep it for special occasions, but that’s 
up to her. 
(P8) 
So there appear to be discrepancies between participants on the advice 
provided to service users, but also on the alcohol criteria for hepatitis C 
treatment which may affect service users being referred for treatment. As 
shown above, participant P12 would not refer ‘Rob’ for hepatitis C 
treatment as he was not abstinent, yet he may not actually need to be 
abstinent (if he was not dependent on alcohol or have cirrhosis). Thus 
‘Rob’s’ referral for treatment would depend on which member of staff he 
saw. Fortunately for ‘Rob’ a hepatitis C nurse was working in the drug and 
alcohol service where participant P12 worked, so ‘Rob’ would see the 
hepatitis C nurse in the drug and alcohol service, who would then refer him 
for hepatitis C treatment (once he had reduced his drinking). It is however 
important to note that the hepatitis C nurses have not always run clinics in 
the drug and alcohol services, so prior to this current provision, ‘Rob’ would 
seemingly not have been referred for hepatitis C treatment. 
Regarding ‘Rob’s’ alcohol intake, participants talked about the measures 
‘Rob’ himself could employ to reduce the amount consumed, such as using 
a drinks diary and slowly reducing the amount and strength of alcohol he 
drank, but participants also mentioned services he could attend for 
detoxification. Figure 10 (Appendix 6) shows where ‘Rob’ would be referred 
for an alcohol detoxification depending on which drug service he attended. 
As can be seen from the schematic for ‘Rob’, there is variation as to which 
service ‘Rob’ would be referred onto. Interestingly there is a difference in 
referrals between service 1a and 1b which is the same drug service based 
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in 2 different locations. Drug service 1b would refer onto detoxification 
staff within their own service but 1a would not refer to this. Although the 
reasons for this are not known, this shows variation in referral pathways 
within this drug service. Also, interestingly drug service 2 would refer onto 
the alcohol team who explained they would not be able to conduct an 
ambulatory detox (detox via outpatient clinics) for ‘Rob’ due to his heroin 
use and would refer him to the inpatient detoxification unit. Thus this 
referral pathway would require ‘Rob’ to attend an extra appointment to 
reach the same end point as other referral pathways. Therefore ‘Rob’s’ 
care is different depending on which drug service he attended and to a 
certain extent which staff member he saw at the service. 
Although in this section examples so far have focused on alcohol and heroin, 
there are many instances throughout the interviews where different advice 
would be given about a topic. An example here shows the different advice 
provided about household transmission of hepatitis C. The first quote is 
advice that would be given to ‘Rob’s’ partner who he lives with, and the 
second quote was information that would be given to a service user at the 
time of testing. 
…..and explain the risk of transmission so in terms of routine 
household contact it’s nil basically. In terms of the risk factor, 
the only risk factor she’s got is sexual transmission. 
(P12) 
Not sharing personal equipment. Anyone who you live with, in 
your family, could be at risk. They need to get a test. You can’t 
share any toothbrushes or razors, and stuff, with them. 
(P7) 
Hence there is different advice provided about the household transmission 
of hepatitis C by the two participants. 
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Furthermore, throughout the interviews there was evidence that 
participants did not know the purpose/criteria of other staff/services. This 
is demonstrated by the following example. Participant P12 said, ‘she [P9] 
can do HIV screening [at the dug service] but I’m not sure if she does’ but 
participant P9 said ‘I don’t do other bloods I just do a hep screen’, showing 
that a participant from a drug and alcohol service did not know which blood 
tests the hepatitis C nurse (working at the same drug and alcohol service) 
takes from service users. This disparity was also found amongst participants 
working in the alcohol services, with the example below showing that 
participant P10 did not know the criteria for the alcohol detoxification unit, 
which is later clarified by another member of the alcohol service. 
Yes, what about [alcohol detoxification unit]? 
(Researcher) 
Do they take them on methadone? I’m not entirely sure where 
their stance is on methadone. 
(P10) 
..if they meet all the criteria, if they’re alcohol dependent, if 
they’re stable say on a methadone script, if they’re stable on it, 
you know we can take them in [to the alcohol detoxification unit] 
and you’d get the methadone supervised as they would in the 
community, so they can still have the detox and still be 
maintained on the methadone. 
(P6) 
Although using hypothetical service users, it would appear that there are 
inconsistencies in the professionals’ knowledge, affecting the advice given 
to service users, as well as referrals onto other services. This finding was 
‘intra’ and ‘inter’ services. Thus, within a single service professionals could 
have different knowledge from their colleagues, and across the services 
there was varying knowledge. Although the latter is perhaps to be expected 
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to a certain degree, as professionals become specialised in their area of 
practice, they did not seem to be aware of their limitations and continued 
with incorrect advice/referrals for the (albeit hypothetical) service users. 
There was also evidence of incomplete knowledge at a strategic level. Two 
participants (P1 and P3) were both unsure of the hepatitis C testing carried 
out at the drug and alcohol services they commissioned. Participant P3 had 
incorrect knowledge on the current testing and referral procedures at 
‘service A’, suggesting they could not undertake testing so would refer to 
the service user’s GP. Whilst this may have occurred historically at ‘service 
A’, according to the vignette interviews this was not currently the case, as 
a nurse from the hospital would attend ‘service A’, conduct venepuncture, 
send the blood sample to the hospital laboratory, receive the results and 
refer the service user into the hospital for treatment as necessary. Although 
this gap in knowledge is perhaps understandable, as the nurse is employed 
by the hospital and therefore presumably funded by the CCG and not the 
local council, it shows the participant is not aware of the provision at a 
service they commission. 
Another participant (P1) was also unsure of the testing method used at the 
drug and alcohol service he commissioned. 
So at the moment [drug and alcohol service] should be doing 
[hepatitis C] testing. 
(P1) 
Dry blood spot testing? 
(Researcher) 
Well I don’t know whether it’s dry blood spot testing but they’re 
supposed to do 3 way test, like we used to do, we used dry blood 
spot testing it was a 3 way test for hep B, C and HIV. As far as I’m 
concerned that should be continuing in 1 shape or form. 
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(P1) 
Showing a lack of knowledge of the testing his commissioned service 
provides, despite a backdrop of government reports (PHE, 2015; PHE, 
2016b) recommending increases in testing and diagnosis and research into 
interventions (such as introducing DBS testing into drug services) (Hickman 
et al, 2008) to increase uptake of testing. 
6.2.3.2 Disparity in services 
The ‘Rob’ vignette discussions showed the different alcohol detoxification 
options available to ‘Rob’ depending on which services he attended. 
Disparities were also seen amongst the hepatitis C services provided by the 
different drug and alcohol services, which for service users would mean 
receiving different care depending on which service they were attending. 
One participant (P4), who commissioned drug and alcohol services from 
more than one provider, explained how the services under his remit worked 
differently, resulting in inconsistencies in the service provided to service 
users and fragmented care. 
Then the other thing that you have got is the disparity in what 
they deliver as services as well. So some services users really 
don’t get a really good service because, they might have a 
relationship with a key worker because they have come through a 
drugs service, so they will look at them from end to end [DBS test 
to referral for treatment] however you have got some services 
which would send a letter back to the GP [requesting hepatitis C 
testing] then the letter may or may not be read by the GP and 
then also as well you have got the hospital that delivers the 
[hepatitis C] treatment element, but that covers the Mersey 
region footprint so somebody has got to get themselves to the 
hospital themselves, so the system is quite fragmented at the 
moment. 
(P4) 
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Thus there are differences in the hepatitis C pathway (from testing to 
treatment) provided at the two drug and alcohol services he commissions, 
with one service conducting hepatitis C testing and referring on to the 
hepatitis C specialists in secondary care, yet the other service requiring GPs 
to test and refer. The comment about the treatment covering the Mersey 
footprint, refers to how the newest hepatitis C treatments (DAAs) are 
provided, which is from a main site for the region (Operational Delivery 
Networks), requiring some patients who do not live near that specific 
hospital to travel further than others who live nearer. Increasingly in the 
literature there are studies considering different models to increase uptake 
of treatment (Wade et al, 2016). Due to the safety, efficacy and all tablet 
regimens of DAA treatment, one such intervention is to provide DAA 
treatments in community settings (Wade et al, 2016). 
 
All participants involved in commissioning of services mentioned providing 
hepatitis C treatment in the community, however the models of care and 
timescale were different in each area. Two participants (P3 and P5) 
explained the current plans to start treating hepatitis C in the drug services. 
 
I was at the CCG yesterday and they’re very aware that from a 
clinical service as in treating the hepatitis, they’ve got to come 
out of the hospital setting and they have got to come to some 
services which is great again, ….. they’re going to come out 
potentially of hospital and deliver in the community alongside 
ideally, some of the addiction services. 
 
(P3) 
 
we are on the verge of having a collaboration with clinical staff 
from one of our major local hospitals working with the drug and 
alcohol team in providing satellite clinics in the actual drug and 
alcohol service. 
 
(P5) 
 
From the vignette interviews, it is apparent that the service participant P3 
is referring to, is to bring the DAA treatments out to the drug services, 
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however it is unclear from the interview with participant P5 which 
treatments (DAA or interferon based treatments) will be provided in his 
area. 
 
Although both participants discussed the imminent community hepatitis C 
treatment services, there had already been some treatment in the 
community. Participant P3 referred to a previous time when service users 
could receive treatment at one particular GP practice, also the area 
covered by participant P1 had been providing hepatitis C treatment in the 
drug service (and even service users' homes) for many years. 
 
For us we would have all these different drug providers referring 
to harm reduction team, they would do the test, test is positive 
they would go to [nurse] who’s based in the harm reduction team 
but also co-located in X [hospital], so it would be [hospital] that 
would be doing their treatment. What was good about our 
treatment pathway was that, that treatment could be conducted 
anywhere, once people had been initiated onto a programme so 
if they wanted to go up to hospital every week to get their needle, 
great, if they wanted to come into the [drug] service and receive 
their injection there or within the person’s own home, so in that 
way you know it was very flexible in terms of administering the 
meds.  
 
(P1) 
 
This section shows a disparity in hepatitis C treatment provision in the drug 
and alcohol services across the areas of Merseyside covered in these 
interviews. 
 
6.2.3.3 Omissions in support 
 
Narratives explained the gaps and omissions in the hepatitis C service 
provided to service users, both historically and the present day. The main 
issues discussed were: difficulties with increasing testing; the complexities 
of getting service users from diagnosis to treatment; and omissions in advice 
and support provided. Although no exact cause was identified across the 
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interviews, generally these shortfalls were considered to be due to issues 
with staff (training issues, the language staff used, staff’s reluctance to 
discuss hepatitis C). 
…were keyworkers actually raising this [hepatitis C] regularly 
with them [service users] and reviewing it? I thought from my 
time when I was a practitioner, did I initially when I was very 
early on in my career, avoid the question of hep C coz it could 
bring about a technical question from the service user that I 
didn’t feel confident enough, didn’t know enough about, 
pegylated interferon [treatment] or what the genotypes were and 
so if I steer the conversation away, they wouldn’t ask a question 
and that, because I would be fearful of getting it wrong or 
admitting I don’t know, which then I thought might have an 
impact. And these are the kind of questions I was sitting there 
thinking about. So I felt that there was kind of a training issue 
somewhere in there or, you know a service user turned round and 
said to me ‘I’ve been and had a word with XX XX’ [nurse] ‘she 
started talking and then all I heard was oohrarohhhraaoo’ because 
professional people, technical words and it makes no sense to 
them really and this guy [peer] is just telling me how it is. 
(P1) 
Convinced, convinced there’s been training issues in the past with 
individuals because as well another thing that we introduced was 
an opt out arrangement as well you know for testing because 
when I was a practitioner, although, as I was learning my trade, I 
was a drug worker you know way back, and I have got to say I 
think that 70-90 % of my caseload agreed to a test, so I knew that 
it was how you framed the question sometimes. You’d be like 
‘look da da da da, you’ve put yourself at risk, I’m gonna send you 
for a hep C test is that OK’ because that kind of is saying you know 
you’ve gotta tell me ‘no I don’t wanna go’ and then we can have 
that conversation but yeah its rather than asking the question ‘do 
you want a hep C test and not really explaining why or how.’ 
(P1) 
We’ve had I think a degree of success, getting so far down the 
path which has been hampered firstly by the reticence of one 
service to push the issue of hep C with their client group for 
whatever reason that is. 
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(P1) 
 
[Nurse] did a good job of supporting people through the 
treatment, I think what she was less effective at, and I think it’s 
a bit of a perhaps I think a wider criticism of NHS services 
sometimes is, she was a bit of like her expectation is “I’m here, 
I’m doing a good job why don’t you come and use me”. I think 
sometimes it’s got to be a bit more, go out, be more proactive, 
promote what you’re doing more energetically, more proactively 
and recognise that there is a lethargy within other professionals 
but also with service users you know, that you’ve really got to 
sell it and certainly when we set the pathway up the ideas about 
hepatitis treatment were quite ambivalent and how effective was 
it, it’s really uncomfortable, it’s really upsetting, it’s really 
distressing, over the course of time that pathway has been 
running there’s been great improvement in that treatment it’s 
much more effective, and it sounds like its less intrusive and less 
difficult for the people who go through the treatment and we’ve 
got lots of people around the system now who are benefactors of 
that, who’ve cleared the virus and we’ve worked very hard at 
pushing it, with our treatment providers but then when we had 
our organisation system meetings but then I’m not wholly sure 
that it got fully into the mind-set of the work force and I think 
that’s part of why we were recognising that it really was the 
time, the tendering was the shake-up, it’s really shaken people’s 
previous, you can’t stay sitting in the seats like you were before 
doing the same thing over and over again coz we’ve 
fundamentally changed everything.  
 
(P2) 
 
Throughout the interviews it was apparent that funding also affected 
service provision, causing uncertainty and impacting on which services 
could be provided. One participant explained how the change in funding 
stream for public health services from the Department of Health to local 
authority caused concern. 
 
And the nature of the NHS being that basically you don’t know a 
lot of things so “this might happen” and “we’ve done this but we 
don’t know”, so it’s bidding for contracts at the moment.  
 
(P12) 
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Are you out for tender? 
(Researcher) 
Well we’re eternally out for tender, yes. Well our funding stream 
is going from the Department of Health to local authority so there 
might be huge cutbacks, so one thing that might happen for 
example is that we’ll have to reintroduce waiting lists, so if 
somebody drops out of treatment [for their addiction] well the 
next appointment is in 10 months. 
(P12) 
One participant (P9) described how funding affected the hepatitis C testing 
provision in one of the drug and alcohol services, explaining that although 
staff have the skills, there are financial constraints on providing this service 
for service users. 
And do they do [hepatitis C] testing in [drug and alcohol service] 
then? 
(Researcher) 
They don’t, we’re currently trying to get that funded, so the only 
way of testing there at the moment is via X [hepatitis C nurse 
from secondary care]. They do have nurses that actually can take 
bloods but unfortunately are not funded for blood borne viruses, 
so that’s something that we’re in discussion with at the moment 
with the CCG. 
(P9) 
Despite the aforementioned staff related barriers to providing hepatitis C 
services, it was also evident from the interviews that staff were also 
facilitators in trying to provide the best service possible for their service 
users, despite issues with funding. In the example above, funding was not 
available for the nurses at the drug service to take bloods to screen for 
blood borne viruses, so a hepatitis C nurse from secondary care goes to the 
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community drug and alcohol services to run a hepatitis C clinic where 
service users can be tested (although it is to be noted that this service is 
not provided every day, with half the week covered at 1 drug and alcohol 
service and the other drug and alcohol service-which has 2 different 
locations-has the nurse attending each location for a morning every other 
week). The staff were also trying to change the service by discussing it with 
the CCG who commission services. Funding was an ongoing issue, one 
participant (P11) explained that historically they had a testing service 
which was stopped. She explained how she had been instrumental in setting 
up the current testing provision with the hepatitis C nurse from secondary 
care but how she would also like to drive this further by having further 
testing and support groups for service users. 
And what I’m looking at, because I set up that service with 
[hepatitis C nurses], we’ve been doing it for a year and half now, 
but before that we didn’t have a BBV service. We used to have a 
BBV nurse about ten years ago, and before that, but the funding 
stopped. So because it’s something I’m interested in, it took a 
while, that I got [hepatitis C nurse] started here. And now that’s 
started, what I’d like to do now is to focus on a bit more peer 
support. So I’d like to have a support group or something, you 
know. I’m talking with some of the clients about what they’d like. 
So that would be nice to offer people. 
(P11) 
So I’m applying for a grant with [drug company] I think it is, to 
get some dry blood spot tests, to look at screening more people 
when [hepatitis C nurse] is not here. And anyone can do that, not 
just qualified [registered nurses]. 
(P11) 
This effort by staff was also evident when discussing ‘Kate’s’ (vignette) 
hepatitis C treatment, as staff were aiming to bring hepatitis C treatment 
out of the hospital to the community drug and alcohol services. 
Is there any chance that she could be treated out in the 
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community anywhere? 
(Researcher) 
Yeah. So we would like to treat her. We’re in the process of trying 
to set that up. [Hepatitis C nurse] is now employed with us, and 
is going to go back to treating in [GP practice] and we’re just 
putting a business case together for treating in the community, 
of which [drug and alcohol services] are the two drug centres. So 
you’re right, so even if she got all these things sorted [drug use, 
methadone script etc.], she wouldn’t have to be treated in the 
hospital. We’d treat her in the community. 
(P8) 
Yeah. So that would be her coming to the drug services? 
(Researcher) 
Yeah. At the same time as she picks up her methadone, she could 
get her sofosbuvir and daclatasvir or sofosbuvir and ledipasvir 
[hepatitis C medication] or whatever. So even if she had to come 
in once a week to pick up her methadone, or to see the drugs 
team, we could give her the medication at the same time. 
(P8) 
Again, this shows staff trying to provide services that are more service user 
focused. This was also evident in the alcohol services, with staff proposing 
new services to meet service users’ needs, but also working voluntarily 
where there was a gap in services and no funding to fill it. 
..my background was with the alcohol team, so I worked with the 
alcohol team, then I got brought up to the hepatology team to do 
liver cancers and hep C and I was sort of taken to the liver cancer 
side of things more than anything else, but one of the members 
of staff was off for a period of time, so I was doing the hep C 
clinic, the complicated, complex hep C clinic and the number of 
patients there who were, you know, who needed interventions as 
regards their alcohol intake was unbelievable, so I put together a 
proposal for me to actually have my own separate clinic down at 
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that clinic at that time, for anyone alcohol dependent or who was 
significantly drinking that I could deal with them before they 
started their hep C treatment. So that's going through the 
motions at the moment 
(P10) 
And that's your work at [drug and alcohol service]? 
(Researcher) 
Yeah I work for [drug and alcohol service]. I run the group 
voluntary because it’s not funded 
(P6) 
Oh, this is in your own time 
(Researcher) 
Yeah so, unfortunately the [inpatient alcohol detoxification 
unit], see the problem is we take people away from the drink and 
away from the drugs, there’s a big void left there. So you need 
something to fill that with and while people are finding out their 
own identity and what they like doing, that's where the group I 
run can be there to support you. 
 (P6) 
So you’re doing it coz there’s nothing else for that point in 
their…. 
(Researcher) 
[Interrupting] It’s not funded yeah. Once people are taken away 
from the alcohol in the [inpatient alcohol detoxification unit] say, 
there’s nothing for them to do and there’s a big void there, so 
say someone’s been drinking and taking drugs for 20 years, ‘Ben’ 
294 
for instance will be taking drugs and drinking for 27 years, all his 
life basically, so there’s a lot of questions need answering there. 
There’s a lot of soul searching and finding yourself, that needs to 
be done and the best way for that is to have support off other 
people who are doing the same thing. 
 (P6) 
Thus the participants who worked in services with service users provided 
examples of how they were trying to improve services, however at a 
strategic level there was no consensus on how to tackle the issues. 
Participant P3 admitted there was uncertainty on the direction of efforts; 
..and it’s where’s the starting point, we all know what the 
problem is but we don’t actually know how we are going to go 
forward, we all have ideas, we all have suggestions but it is 
around actually we need to take a step back because there’s an 
awful lot of people that weren’t screened, that weren’t asked 
the question or if they were asked the question, they didn’t go 
forward and speak to anyone about being diagnosed or being 
screened or following anything up so, there’s a whole host of 
people that actually five to ten years ago were asked a question, 
but nothing has happened and that’s a real concern for 
me………what they’ve realised was when it come down to it people 
weren’t offered peer support, people didn’t understand what 
they were going for [hepatitis C treatment], people weren’t 
informed about the length of time it [treatment] would take, how 
poorly you may be [on treatment], who you’ve got to see and why, 
and the one thing that was really good when we done that 
[considered service] it was the fact we needed to go back to basics 
and if you are going to do anything and make a success of it we 
need to strip this right down … 
(P3) 
Furthermore whilst acknowledging the previous hard work and initiatives to 
improve hepatitis C outcomes in their areas, the participants explained a 
lack of empirical evidence on the effectiveness of the interventions on 
which to now draw. 
She [nurse] done amazing work and we were quite surprised that 
it wasn’t documented and I am just assuming it was just timing 
or miscommunication, it was never written up and it was never 
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turned in to best practice or, so considering we have strong links 
with the university everything that we are saying today actually 
was a lot of what she has done in the past, but it wasn’t 
documented. 
(P3) 
And in order to deliver that peer mentoring programme with the 
dry blood spot testing which the signs, although I’ve got no 
evidence to evaluate that intervention in the way that I wanted 
to, the signs were that that was very successful in picking people 
up. 
(P1) 
This section has shown that finances affect which services are provided, 
resulting in some services which are required by PWID, such as hepatitis C 
testing, being omitted. Despite there being a need for increased hepatitis 
C testing (PHE, 2018a) and an awareness that PWID are more likely to attend 
their drug and alcohol service than any other service (P7, P8), testing is not 
routinely provided by the drug and alcohol services. This section has also 
shown that staff act as both barriers and facilitators in service provision. 
Regarding facilitation, staff not only work innovatively to deliver services, 
but also propose services to funders, to better serve their service users. 
Despite a paucity of ‘evidence’ of previous effective interventions and a 
level of uncertainty on the best way forward for services, all participants 
who commissioned services did however agree that there was a 
requirement for greater input from primary care. 
6.2.3.4 Barriers in primary care 
As well as the disparity in hepatitis C provision available to service users at 
various drug and alcohol services, there are other people who do not have 
access to these hepatitis C services at all, as they are not in contact with 
the drug and alcohol services. The commissioners interviewed were aware 
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that services were not serving everyone with hepatitis C, requiring more 
involvement from GPs. 
Then you have got the next grey area which is service provision 
then comes from several different areas coz an awful lot of 
people might not be in [drug and alcohol] treatment anymore 
which is a real you know, such a shame, so it’s about how you 
educate and how you get the GPs on-board to look at people’s 
overall health and well-being and that is a real challenge at the 
moment to say could you look at letters [about hepatitis C 
testing], could you, you know check if people have come in, and 
you might have been asked the question five or six years ago 
[about hepatitis C risk] but what about today? 
(P3) 
What sort of services are available for people who aren’t actually 
at a drug service? I have spoken to somebody who injected years 
and years ago and has never really been addicted and has never 
been on methadone or been in like a treatment programme [for 
drug use], is there any services for those people? 
(Researcher) 
I think that is a real gap and I think at the moment, I could tell 
you what would happen but again it’s where that person is kind 
of going to meet, where the touch point is going to be for access. 
Because probably that person in that sort of situation is not likely 
to access a drug or alcohol treatment service where if they have 
a concern, where might they go? So I think what we need maybe 
is to have more doctors and nurses in primary care who have 
sufficient understanding or knowledge so when I say I could tell 
you what would probably happen it is a bit variable. So you might 
if you had concern through any potential historical exposure, you 
were likely never to connect with a drug and alcohol treatment 
service then probably the only place you would connect with 
would be through primary care. Now if you were to mention it 
through your GP or Practice Nurse I think this is where the 
variability may possibly come in because those more in line would 
probably advise that you should actually go along to one of the 
hepatitis C treatment clinics at the hospital and they would be 
able to organise a test if necessary or any advice but it’s not a 
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pathway as such I don’t think it’s an ideal situation. 
(P5) 
The participants agreed it was important for hepatitis C to be considered 
in primary care, however they talked about barriers to this. These barriers 
can broadly be categorised into barriers at the staff level, service level, 
national/population level. ‘Staff level’, refers to the GPs themselves. 
Participant P5 suggested there is variability in practice around hepatitis C 
amongst GPs/practice nurses, with a requirement for increased knowledge 
and understanding. In addition to this, two participants (P3 and P4) 
suggested GPs, as a profession, need guidelines and evidence to encourage 
change in working practices. Other commissioners mentioned GPs 
inclination and skills to identify patients’ issues and refer accordingly was 
also a factor. At a service level, service demand including GPs workload and 
time pressures were mentioned by all participants who commission 
services. Another participant (P1) also touched on the historical culture of 
issues around drug use being dealt with by drug services and not by GPs. 
Considering the wider public health view, participant P5 discussed the 
barriers to providing population based testing as opposed to focused 
hepatitis C testing. 
So does that [meeting] include GPs as well? 
(Researcher) 
Not so much GPs coz we struggle to engage GPs I think in terms 
of, things like the drugs agenda, they’ve kind of traditionally seen 
that our [drug and alcohol service] provider is the expert in 
everything so. 
(P1) 
So does much [hepatitis C] testing go on at GPs? 
(Researcher) 
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I would doubt it, we looked at some of the NICE guidance round 
hep C for some of the other groups, you know we were thinking 
specifically about BME communities and especially with the influx 
of Eastern bloc migrants and basically, we were trying to create 
a public health hep C strategy that would include all those at risk 
groups and this trainee consultant wrote this strategy and a 
doctor said ‘I would never think to ask the question of immigrants 
around certain things’, and he, absolutely uber bright, but it was 
just time pressures, you know you’ve got time pressures to see a 
patient 
(P1) 
Coz the hep C trust have got a big drive haven’t they for GPs at 
the minute, GP training 
(Researcher) 
It’s what you include as your check list but then its, if we 
including everybody’s cross cutting strategies in terms of you and 
me and I’m your patient, you’re then turning round and saying 
I’ve got me checklist but hopefully you’re offering all kinds of 
direction so then it becomes a lot of the skill of the practitioner 
of being able to respond accordingly to the issues that I disclose 
as to where you wanna take me with that. 
(P1) 
this person had been going to the GP for years with tiredness and 
depression, fuzzy head and it [hepatitis C] wasn’t picked up for 
years so hopefully things are better now 
(Researcher) 
I wouldn’t be that confident because again you know I don’t think 
we have resources to do kind of wide, big scale population sort of 
screening outside but I think when we are looking at kind of 
funding streams nationally my suspicion is that we would be 
reminded of the vast majority of hepatitis C infection rests within 
a particular population. We do not want to discriminate any 
population but if we are looking for effective prevention and 
treatment, that is where we have got to focus our efforts and to 
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some extent in a climate of shrinking resources I probably have to 
say I have a degree of sympathy with that because I do know if we 
effectively direct identification and treatment to within our drug 
using population, because we don’t have any kind of vaccination 
for hepatitis C, I think from a health projection point of view 
what we need to do is to shrink that potential pool of infection 
to such a point where the likelihood of anyone acquiring hepatitis 
C through practices becomes remote so again it’s that back drop 
for arguing but I don’t think we would get there to be honest, 
that’s no consolation for those people who find themselves in that 
situation… 
(P5) 
Yeah, yeah, I’m just reading on the hepatitis C Action website, 
there seems to be a focus on GP training. 
(Researcher) 
I am a real fan of locating more services within primary care and 
I think that probably applies to drug and alcohol treatment 
service but the problem is primary care, GPs are really under the 
hammer at the moment aren’t they, they are not in a position to 
be taking on more and more, but from a public health point of 
view where better to deliver population health than within 
primary care. Those are the people that are seeing their 
community and I think perhaps not too far into the future we 
would like to see more involvement than there is now. What have 
traditionally been turned to specialist drug and specialist alcohol 
services in community I think any of those given the capacity, and 
I think that is the problem, that I don’t think there is a capacity 
to do it, but if there were the capacity with primary care, I think 
primary care would quite comfortably pick up a lot of those kind 
of services and I think the nature of specialist service would 
perhaps be up scaled to more sort of kind of hospital treatments 
(P5) 
If you look at it on a weighting, the place where you need to get 
a change, to make something change quite quickly, is in primary 
care and I think that is why one of the significant things that the 
CCG has spoke about is an education package for GPs, so they 
would target first of all GPs, with the special interests and do it 
on the addictions GPs first of all and then see if they could have 
a lead within each neighbourhood so they have got colleagues to 
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talk to because the one thing that I have noticed the more 
clinicians I come across is they are very wary of doing anything 
that isn’t got a policy, procedure and guidelines behind, they like 
everything, identify for them what we want them to do. So there 
is an awful lot of training and an awful lot of time needed, 
questions and answers and that for them really 
(P3) 
So hepatitis C Action have got a GP training package but I kind of 
feel like well you would only know about that if you were 
interested in hep C or you are looking for it…. 
(Researcher) 
We have found that on quite a basic level, if you take alcohol, 
just to get, within GP practice to do the audit score, audit C is 
what three questions, the amount of time we have had to go 
round the houses on that. I suppose to give the GPs some defence 
they have got a whole host of other issues going on and this is just 
one, and it’s like [P3] said it is having the champions within 
specific areas who take an interest in that and using their skills 
and knowledge to try and create something, it’s almost like trying 
to create a model isn’t it, it’s almost like proof of concept, and 
saying yeah we know we can make it work but there is tons of 
practical issues so it’s difficult to get there to say we have got a 
joined up model here. 
(P4) 
Although barriers were acknowledged, the participants did not have 
cohesive ideas on how to address and overcome them. Participant P3 
explained that the CCG spoke of an education package on hepatitis C for 
GPs, but participant P2 felt it was the responsibility of the drug and alcohol 
service to remind GPs about hepatitis C. 
And what about GP practices, do you know much about how GP 
practices test for hep C and refer on? 
(Researcher) 
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Well again the drug service was connected to all the GP practices 
and we promoted the service through the shared care network 
and that was the expectation, and those were the frustrations. 
We have a shared care network that covers all GP practices, the 
hep C nurse is embedded in the drug service, the shared care 
workers should be part of promoting the hep C screening to all 
the GPs, if the GP has somebody on their books, who they think, 
it didn’t have to be a drug user either, you know, if there’s 
somebody that’s at risk, so we’re promoting it through the direct 
contact with GP practices in the shared care scheme, but I don’t 
think it was being promoted as much, or as effectively as it could 
be and equally I’m not convinced that GP, and I do understand the 
situation the GPs in they, you now general practice, they’re jack 
of all trades, they’re looking at so many different things, hep C 
might not be, it might be a priority for us but it might not be a 
priority for them and it’s a relatively small number of people that 
it affects, so that they’re not as focused on hep C, but then that’s 
the task of the service to keep pushing and keep agitating and 
keep raising the profile, so it’s a constant ongoing. 
(P2) 
6.2.4. Stigma 
Although there were many examples throughout the interviews of staff 
working to improve services for service users (as shown above), there were 
also accounts that displayed notions of stigma and prejudice towards PWID. 
Accounts showed evidence of: stigmatising terminology; personal views 
aligned with wider societal prejudice of PWIDs rather than professional 
reasoning; and inequity in service provision. Some actions and opinions 
were rationalised by financial constraints or by notions of clinical 
impression/nurse intuition. 
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6.3 Chapter Summary 
The professionals’ experiences of drug, alcohol and hepatitis C provision 
have provided insight into working in and commissioning these services. 
Participants gave examples of initiatives to improve services, such as 
running groups on a voluntary basis and writing bids for new services, 
however findings largely constituted challenges and barriers to providing 
services. Difficulties were seen at staff, service and strategic levels. Lack 
of strategic direction for hepatitis C services, disparity between services, 
services not providing required provisions, different knowledge, advice and 
referrals between professionals and discriminatory views about service 
users were some of the findings. Ultimately the purpose of services is to 
provide for the people who are using the service, therefore there is value 
in considering how service users experience services. Chapter 7 compares 
the findings from the service user observation and interviews with the 
findings from the interviews with professionals. Thus providing a 
comparison of the professional and the lived experience of hepatitis C, 
alcohol and drug use. 
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Chapter 7 Discussion 
7.1 Introduction 
This chapter discusses the main findings from the research. Findings from 
the service user interviews, interviews with professionals and observation 
of hepatitis C support groups are discussed, considering the lived 
experience and professionals’ experience of alcohol, drugs and hepatitis C. 
The overall research findings were barriers to service users accessing 
support for their hepatitis C. As explained in the introduction to this 
research, ‘support’ relates to a variety of help, including advice, testing, 
treatment and management of hepatitis C. Analysis of the results identified 
four main findings namely, alcohol, knowledge, stigma and services. 
7.2 Alcohol 
This research set out to explore alcohol use in PWID who have hepatitis C. 
Within the service user population of this research, findings showed a mixed 
picture of alcohol consumption. At the time of the research, some 
participants were dependent drinkers, some were abstinent and others 
were drinking lower-risk levels (as recommended for general population). 
Thus like the NTORS study of drug users in drug treatment in England 
(Gossop, 2002) this study also found that there was wide variation in 
drinking patterns amongst PWID, including abstinence in some. However 
the calendar method used in this research enabled lifetime alcohol to be 
considered, showing that alcohol consumption changed over time. Of those 
who were drinking lower-risk levels or abstinent at the time of interview, a 
third had a history of higher-risk or dependent drinking at some point in 
their lives. Higher-risk/dependent alcohol consumption also had a varied 
pattern amongst the participants, with some drinking prior to drug use 
(eight years prior for one participant), others overlapping drink and drugs 
and others started drinking after the drug use, with some drinking for a 
short period of time only and others becoming dependent on alcohol. 
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The majority of participants in this study were receiving treatment with 
OST (buprenorphine or methadone) at the time of the interviews. Therefore 
the question of whether PWID swap drugs for drink when on OST varied 
between participants, showing as per the studies analysed in the literature 
review that there is variation amongst PWID. Some participants in the 
research did increase drinking when on OST and their drug use had 
decreased, others were drinking at dependent/higher-risk levels prior to 
commencing on OST and others were abstinent on OST. However patterns 
of alcohol and drug use were found to be complex, with many factors 
impacting on a person’s alcohol consumption over their lifetime. 
 
One aspect the research aimed to explore was whether being diagnosed 
with hepatitis C affected alcohol consumption. The research found that all 
participants were aware of the dangers of drinking with hepatitis C, 
however all (except 2 participants who were abstinent prior to diagnosis) 
had drunk alcohol since being diagnosed. In response to the advice to stop 
drinking (or reduce if unable to stop) following a hepatitis C diagnosis, some 
participants did stop or reduce drinking, as found by other studies in the 
literature review (McCusker, 2001; Scognamiglio et al, 2007; Tsui et al 2007 
and O’Leary et al 2012). However O’Leary et al’s (2012) study found that 
those who drank to excess continued to do so following diagnosis. Whilst 
this was also a finding in this research, it was not just those drinking higher-
risk levels whose drinking remained the same pre and post diagnosis, but 
also some lower-risk drinkers did not change the amount drunk following 
their positive hepatitis C result. This study (as in Ompad et al’s study, 2002) 
also found that for some participants their drinking increased. Furthermore 
as this study explored lifetime alcohol consumption, rather than drinking a 
short time after diagnosis (Ompad et al, 2002 and Tsui et al, 2009), or a 
one off cross sectional consideration of alcohol regardless of time since 
diagnosis (McCusker et al, 2001 and O’Leary et al, 2012), it found that 
alcohol consumption was not fixed but changed over time.  
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Whilst hepatitis C was a contributing factor for some participants’ drinking, 
for other participants having hepatitis C had no impact on their alcohol 
consumption, with partners drinking, drinking to cope and where 
participants were in their recovery from substance use being the main 
influences on alcohol consumption over their lifetimes. Elliot et al (2016) 
suggested an association between understanding about hepatitis C and 
alcohol and drinking behaviour, however like other studies (Kwiatkowski et 
al, 2002; Campbell et al, 2006; Noon et al, 2009), this study found that 
having knowledge on the effects of alcohol and hepatitis C, made little 
difference to drinking behaviours, especially over time. 
For participants who had drunk at higher-risk or dependent levels, this 
research found that many did not seek help for their alcohol use, instead 
lowering their drinking by themselves, either by just reducing their alcohol 
or using substances (non-prescribed benzodiazepine or heroin) to help them 
reduce. For those who did seek help, narratives suggested that participants 
had received support in terms of brief interventions, however participants 
did not recognise this as support. The majority of participants were taking 
OST for their drug use, therefore it may be that advice and not medication 
for their alcohol use, was not deemed as support. Furthermore it appeared, 
as explained by Gossop (2013) that healthcare professionals were focusing 
on the perceived main substance (heroin) whilst underrating other 
substances (alcohol). 
As per the literature (Nyamathi et al, 2008; Field et al, 2013), this study 
found that relationships with healthcare professionals was an important 
factor to accessing support for alcohol use. One participant noted that 
healthcare staff would not help him to have a home detox and consequently 
he did not ask for support again. As well as the negative impact of previous 
encounters with services, other barriers to seeking support for alcohol 
consumption included not realising drinking levels were harmful and not 
wanting help for drinking. Furthermore the vignette interviews highlighted 
that methadone and/or heroin use impacts on alcohol treatment options. 
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For those who continued to drink, one consequence found in this research 
(as per literature review) was that alcohol consumption is a barrier to 
receiving hepatitis C treatment. Historical accounts from the service users 
showed that they had to stop drinking to receive treatment, and 
observation of Group 1, confirmed that this exclusion still applied. The 
vignette interviews with professionals showed a much cloudier picture. 
Whilst all professionals agreed alcohol consumption was an exclusion for 
treatment, there were inconsistencies on the amount of alcohol people 
could drink and still receive hepatitis C treatment, thus abstinence was not 
suggested for every (hypothetical) service user. However ‘heavy’ (over 
recommended weekly units for general population) alcohol use was deemed 
as an exclusion for treatment, with (hypothetical) service users being 
advised to reduce or stop depending on their drinking behaviour (i.e. 
dependent or nondependent) and level of liver cirrhosis. Thus advice was 
not for treatment per se but rather general advice for the liver. Treating 
hepatitis C would aid the liver and, as noted in the literature review, 
treatment is possible in dependent/higher-risk drinkers and SVR rates are 
not affected by alcohol consumption (Le Lan et al, 2012; Tsui et al’s, 2016). 
Furthermore even if treatment was shown to be less effective in people 
who use alcohol, it is not equitable to exclude them (Grebely et al, 2015), 
yet in this study ‘heavy’ drinkers were found to be excluded. 
Terminology around alcohol use was found to be inconsistent throughout 
the interviews with professional (and the literature). Some professionals 
considering the vignettes used the terms ‘heavy’ and ‘moderate’ alcohol 
use, yet these are not clinical diagnostic terms and other professionals 
discussed ‘drinking’, but on further questioning they meant higher-risk or 
dependent drinking behaviours. This later finding was also found in the 
service user interviews, with participants misunderstanding ‘do you drink 
alcohol?’ to mean problem drinking (higher-risk or dependent). Therefore, 
many service users in the research said they had ‘stopped’ drinking, but 
were actually not abstinent, instead consuming alcohol at increasing-
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risk/lower-risk levels. Service users in this research, like Harris’s (2010) 
study, felt they were given mixed messages about alcohol consumption, 
which in this study, led to decisions on future alcohol use, being based on 
their own and peers’ experiences rather than clinical advice. Harris (2010) 
suggests the lack of definite advice on whether to stop drinking or reduce 
by some healthcare professionals could be due to the lack of evidence on 
which amounts of alcohol actually affects hepatitis C progression 
(Bhattacharya and Shuhart, 2003; Hutchinson et al 2005). This finding calls 
for consistent terminology and clearer messages around alcohol use with 
hepatitis C, in order to enable support for service users. 
7.3 Knowledge 
One of the main findings from this research was the level of knowledge 
services users had about hepatitis C. Some services users had a good 
knowledge base with a few omissions in their understanding, but others 
showed a very poor level of knowledge, not knowing the most basic facts. 
Routes of transmission were commonly misunderstood within the 
narratives. All service users who took part in the research had injected 
drugs at some point in their lives, either currently (at the time of the 
research) or in the past, however not all were aware that hepatitis C could 
be transmitted through sharing injecting equipment. Most participants 
(except one person) were aware that hepatitis C is transmitted through 
sharing needles, however some were not aware that it is also possible to 
get the virus through sharing the rest of the injecting equipment such as 
syringes, filters, spoons, water and tourniquets. This lack of knowledge is 
concerning, as the advice to not share injecting equipment is fundamental 
in preventing the spread of hepatitis C (along with other BBV). 
Hepatitis C is mainly transmitted through blood to blood contact, however 
some participants showed a lack of awareness of this, thinking it could be 
transmitted through saliva, touch or the airborne route. ‘Can I get it 
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[hepatitis C] from sex, cigarettes? I’ve been washing cups in boiling water’ 
(Andy). ‘Do I have to wear gloves or mask?’ (Dan). Whilst it is possible to 
get hepatitis C through sex, the risk is small (2% risk of transmission; Athwal 
and Prince, 2017), with the risk increasing if co-infected with HIV or if 
exposure to blood occurs, however many participants placed 
disproportionate concern over the sexual risk making unnecessary 
restrictions on their lives and increasing the risk of becoming isolated (see 
stigma section below). ‘I just knew that I couldn’t have a relationship I just 
didn’t wanna pass it onto a female, an unsuspecting female you know’ 
(Joe). One participant thought that hepatitis C could be caused by drinking 
alcohol, ‘you can actually get it through drinking without being involved in 
drugs’ (Jack). 
Furthermore many of the service users in this research showed a lack of 
knowledge about the disease and its natural history. Participants 
demonstrated a poor understanding of antibodies, spontaneous clearance, 
genotypes and the generally slow disease progression of chronic hepatitis 
C. There were also many accounts of incorrect comparisons with HIV. This
lack of knowledge impacted on participants’ understanding of hepatitis C
testing, the management and prognosis of their disease and treatment. For
example, misunderstanding that she had antibodies but not chronic
hepatitis C, led Sadie to think she had hepatitis C for 4 years, before she
understood that she had spontaneously cleared the virus many years before;
Kev thought he could clear hepatitis C himself if he was not drinking and
injecting; participants thought there was no cure for hepatitis C (‘like HIV’),
or that they were going to die very quickly after diagnosis; and lack of
understanding about genotypes saw people attending Group 1, discussing
wanting treatments that would not be suitable for the genotype of the
disease they had.
As in the literature, (Craine et al, 2004; Khaw, Stobbart and Murtagh, 2007; 
Grebely et al, 2008; Strauss et al, 2008; Swan et al, 2010; Jordan et al, 
2013; Harris, McDonald and Rhodes, 2014), this research found that lack of 
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knowledge about hepatitis C, disease progression, location of testing sites 
and availability of treatment were barriers to accessing testing and 
treatment. Although service users in the research had already been tested, 
there were numerous historical accounts of their experiences of being 
tested and how their lack of knowledge caused fear of receiving a positive 
result but also fear of the actual testing procedure. Some participants 
delayed a test due to fear of having to undergo venepuncture, finding on 
attending that it was a finger prick test. Most participants explained that 
they were not aware hepatitis C treatment existed when they were tested, 
increasing the fear of being diagnosed with the virus. However, throughout 
the research it was evident that many participants still did not have up to 
date knowledge about current treatment options. One participant had 
delayed treatment for years due to fear of interferon injections (amongst 
other reasons), and had only recently discovered from an old acquaintance 
that tablet (DAA) treatments were available. 
 
Generally participants’ narratives showed low levels of knowledge about 
hepatitis C, despite being diagnosed with the virus for years (ranging from 
1 to 19 years) and attending drug and alcohol services. 
 
Participants got their information about hepatitis C from a variety of 
sources namely; talking to others with hepatitis C; watching medical 
documentaries on television; watching television and reading about 
celebrities with hepatitis C; leaflets; the internet; attending groups and 
doing courses either at the drug services or in prison, attending hepatitis C 
support groups; receiving peer worker training or verbally from 
professionals.  
 
There were however barriers noted with many of these methods. Regarding 
the internet, levels of computer literacy were mixed, some participants 
searched the internet whilst many others mentioned that they could not 
use computers, some participants were sceptical, mistrusting information 
on the internet and others feared using public computers due to the risk of 
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stigma and discrimination, (findings which cast doubt over the benefits of 
PHE’s recent largely internet based hepatitis C campaign, for this 
population). Those who had received peer worker training were 
demoralised, feeling their knowledge was not valued as there was no 
structure in place to use peers or to update their knowledge. Leaflets were 
not read by all participants and there were numerous concerns with verbal 
information provided from professionals. 
 
Vignette interviews with professionals working in drug and alcohol services, 
identified that not all professionals had correct knowledge about hepatitis 
C, providing incorrect advice on transmission and the criteria for hepatitis 
C treatment. Some of the professionals who commissioned services who 
were interviewed, suggested that professionals working at drug and alcohol 
services were reluctant to discuss hepatitis C with service users and 
required further training. Observation of Group 1, found that group leader 
John’s knowledge was not up to date. Unlike the peer workers in the studies 
analysed for the literature review (Treloar et al, 2015; Bonnington and 
Harris, 2017) John had received initial peer worker training but had never 
had further training or supervision. 
 
Concerns about the delivery of verbal information by healthcare 
professionals was also a finding. Some service users felt professionals used 
medicalised language that was difficult to understand, requiring the use of 
lay terminology and descriptions. Also the timing of information appeared 
to be important. For some participants information given at the time of 
diagnosis was not ‘taken in’, and others noted not being able to absorb 
information when they were under the influence of substances. Therefore 
it may be beneficial for professionals working with PWID with hepatitis C to 
regularly discuss hepatitis C with service users to check their understanding 
and to relay any missing information. Findings from this research suggest 
that hepatitis C was not discussed frequently with service users attending 
drug and alcohol services. Follow up interviews (ranging from 2 – 6 months 
after the initial interview) were conducted with 4 service users, finding that 
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there had been no progress between interviews, in terms of knowledge or 
progress along the care cascade. Indeed generally throughout the service 
user interviews, participants seemed to be ‘stuck’, unaware of the 
management plan for their hepatitis C or how to get retested or how to 
access treatment. Other participants said they were ‘waiting’ although 
many did not seem to know why they were waiting or what was delaying 
them from moving along the cascade to either being referred to specialist 
hepatitis C care or to accessing treatment. Whilst the reasons for this are 
not known, it was apparent from the service user interviews, observation 
and discussions of the ‘Kate’ vignette with professionals, that service users 
often had many other priorities, such as other health conditions or family 
commitments and that professionals working with service users also had 
many conflicting priorities such as providing OST and considering housing 
needs, that were more urgent than hepatitis C, so it may be that hepatitis 
C is not a priority. However this research also found that many service users 
who were taking part in the research, wanted to talk about hepatitis C to 
the researcher. Service users would see their keyworker at the drug and 
alcohol service first and then speak to the researcher after, often asking 
questions about hepatitis C. One participant said this was because the 
researcher had knowledge on hepatitis C and she felt ‘comfortable talking 
about it’ (see stigma section below) perhaps suggesting that she questioned 
the keyworker’s level of knowledge and confidentiality. 
 
Whilst knowledge was generally low amongst the participants, the benefit 
of having knowledge about hepatitis C was demonstrated by a few. One 
participant did not express fear regarding her positive test result, 
explaining this was because she was already knowledgeable about hepatitis 
C and treatment through a family member’s experience. Other 
participants’ explained they were ‘not bothered’ about having hepatitis C 
once they were more knowledgeable about the virus, knowing there was 
treatment, they were not going to die imminently and they could not pass 
it on to others through social contact. 
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7.4 Stigma and Discrimination 
 
Stigma was a finding at every stage of this research, during observation at 
the hepatitis C support groups and throughout the service users and 
professionals interviews.  
 
The service users’ lived experiences of stigma in relation to hepatitis C, 
showed that stigma affected many aspects of their lives. Stigma was 
experienced from family, friends and healthcare professionals, but 
perceptions of anticipated stigma pervaded throughout people’s lives. As 
described in the literature (Butt, 2008; Joffe, 2011), stigma was 
experienced in relation to hepatitis C being an infectious disease but also 
due to its association with injecting drug use. Narratives of experienced 
and perceived stigma from family and friends were often connected to the 
infectious nature of hepatitis C, ‘people come me house and they won’t 
have a drink ..people have told me…they didn’t have a drink coz I’ve got 
hep C’ (Sharon).  
 
Many service users talked about the dilemmas they faced around disclosing 
their hepatitis C status to friends and family members. This was often 
connected to the fear of stigma and being discriminated against. For some 
participants this meant they did not tell the majority of their family and 
friends that they had the virus. Narratives showed the difficulties of living 
with this ‘secret’, having to lie or omit information in conversations and 
hide hepatitis C related materials, such as clinic letters, for fear of others 
finding out. Not feeling able to talk openly about having hepatitis C 
impacted on social relationships as well as the amount of support afforded 
to those with the virus, and may explain why a number of the service users 
expressed enjoying the interview or ‘feeling better’ after the interview, 
I’m made up I’ve got a little bit off me chest (Pete). Kath expressed how 
difficult it was to work with the fatigue she felt from her hepatitis C. Whilst 
Kath did not assign her non-disclosure at work to stigma, it leads to 
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questions as to whether another less stigmatised chronic disease such as 
diabetes would have been divulged at work and more support provided.  
 
Rather than service users fighting against stigmatising views, the 
interviews, as in the related literature (Zickmund et al, 2003; Hill et al, 
2014), provided many accounts of internalised stigma, where service users 
upheld wider societal views of people with hepatitis C being ‘dirty’ and 
‘like lepers’. As explained by Goffman (1990) the stigmatised are aware 
‘...to what others see as his failing, inevitably causing him, if only for 
moments, to agree that he does indeed fall short of what he really ought 
to be. Shame becomes a central possibility...’ (p.18). This was evident 
throughout the service user interviews, where the shame of having hepatitis 
C, and its connotation of being a ‘dirty disease’, stopped many from 
disclosing their status, receiving support and increasing the risk of isolation. 
‘you feel like a leper an erm you know you’re scared of people. With the 
hep C you’re worried about them finding out about you know, you just feel 
really kind of erm, what’s the word er cut off by it’ (Phil).  
 
Participants who attended hepatitis C support groups (Group 1, or previous 
groups) felt they benefited as they received support, felt less isolated and 
realised they were not ‘…the only one [with hepatitis C]’ (Susan). However, 
concerns over inadvertently disclosing hepatitis C status and the risk of 
being stigmatised impacted on the support afforded by support groups. 
Group 3 did not ‘get off the ground’, as concerns over hepatitis C related 
stigma led to difficulties in choosing a location that would maintain 
confidentiality and not expose those attending as having hepatitis C. Group 
2 saw minimal attendance which the service users interviewed thought was 
due to a variety of reasons including the stigma associated with hepatitis 
C. Having to report to reception in front of others in the waiting room posed 
a risk of disclosing a hepatitis C positive status. Furthermore some 
participants felt unable to access information themselves, such as not being 
able to read hepatitis C leaflets in a waiting room and not feeling able to 
use public computers to search about hepatitis C, in case others saw and 
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presumed they had hepatitis C. Thus concerns over inadvertent disclosure 
inhibited people from gaining advice and information about the virus, and 
from receiving support from peers.  
 
Many participants talked about past experiences of stigma with healthcare 
professionals. Unlike the experiences with family and friends, narratives 
showed a mix of stigma to both the infectious nature of hepatitis C and 
injecting drug use. ‘…they’d [nurses] move away… put on 2 sets of gloves’ 
(Neil), ‘..when they [hospital staff] hear of methadone, knowing you’re a 
drug addict, they look at you differently and treat you differently I’ve 
found’ (Beth). However, narratives from the interviews with professionals 
did not find any stigmatising views connected to the infectious nature of 
hepatitis C. It is important to note that interviews were only conducted 
with healthcare professionals working in services that should be au fait with 
hepatitis C (drug and liver (alcohol and hepatitis C) services) and different 
results may have been found if interviews had been conducted with people 
working in other areas of healthcare. 
 
As in other research (Butt et al, 2008; Swan et al, 2010), findings showed 
experiences of stigma in healthcare caused service users to feel judged, 
which ultimately posed as a barrier to support. For Neil the experience of 
stigma from nurses partly contributed to him discontinuing his hepatitis C 
treatment (although he was also having side effects) and for other 
participants past experiences of stigma affected how they viewed their 
current situation, impacting negatively on their health seeking behaviours. 
Whilst these are historic accounts of stigma within healthcare, 
unfortunately there was evidence of current discriminatory views amongst 
the healthcare professionals interviewed. Stigmatising perceptions were 
related to addiction, especially injecting drug use and narratives showed 
PWID were indeed judged by some of the professionals. Service users were 
not viewed as individuals but were grouped together based on their lifestyle 
behaviours. This stereotyping saw people with hepatitis C who had a history 
of injecting drug use being discussed as a homogeneous group whose actions 
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and even appearance was attributed to drug use. One professional referred 
to people with hepatitis C who had a history of injecting drug use as a ‘type 
of people’, however from the observation and service users’ interviews, it 
was evident that whilst there were some commonalities, the service users 
were individuals with diverse experiences and needs. 
 
The literature review identified that PWID may mistrust staff working in 
drug and alcohol services largely due to the strict procedures around 
providing OST (Rance et al, 2012; Harris, Rhodes and Martin, 2013), 
however the research conducted for this thesis identified that some of the 
professionals interviewed showed a general mistrust of PWID. Furthermore, 
safety procedures at services were discussed by one professional, as a 
means to validate service users’ accounts on alcohol use, rather than in 
relation to the safe prescribing of OST. ‘Well you breathalyse her obviously. 
Ask if she’s had problems with alcohol in the past. That might be the case 
but the thing is she’s living in a hostel so as I said 90-95% of residents in 
hostels are drinkers or users, or both. So you wouldn’t just say “ok, she 
doesn’t drink alcohol” (P12). 
 
One of the main findings from the literature on peer workers, was that 
service users appreciated the support peer workers provided because they 
did not judge and were empathetic. Whilst some of the professionals 
interviewed, did show empathy, it was also evident that other professionals 
did not have empathy and did judge PWID. In contrast to this, the period of 
observation at Group 1, found ‘John [peer worker] would accompany the 
group members to their hepatitis C hospital appointments. Group members 
appeared to value this support, informing John when their next 
appointments were and checking if he was free to go with them. John 
would also speak to people over the phone outside of the group time. 
John’s support was sincere, steady and encouraging, without force or 
nosiness and was without doubt, appreciated by the group’ (Finding by 
researcher, in Chapter 4, observation findings). 
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The tone of the entry about the peer worker, in comparison to the 
professional’s (P12) quote, shows the difference in approach between some 
healthcare professionals and peer workers towards PWID, supporting 
further the perceived notion that some healthcare professionals judge but 
peers are supportive. 
 
As well as some healthcare professionals holding stigmatising views, 
organisational systems and structures also appeared to discriminate against 
PWID. Testing and treatment are two crucial requirements for people living 
with chronic hepatitis C who would like to clear the virus. However, this 
research found these services were not easily accessible for PWID. 
 
Firstly, testing was not provided routinely by every drug and alcohol 
service. One of the professionals interviewed acknowledged that staff at 
her service had the skills to perform venepuncture and did collect blood 
samples for other purposes but were not funded to obtain blood for BBV 
testing. A recent initiative saw nurses from secondary care visiting the drug 
and alcohol services to test and refer people into secondary care, however 
they did not provide this service every day, or even every week at one drug 
and alcohol service. Testing is provided at GP practices and the genito-
urinary medicine (GUM - sexual health) clinic. It is however generally 
acknowledged that many PWID do not regularly visit their GP, and one of 
the professionals noted that ‘the GUM clinic are a bit sick of addicts turning 
up asking for BBV screens especially if there’s no sexual health risk’ (P12). 
As figures show over 90% of hepatitis C in the UK is transmitted through 
sharing equipment to inject drug (PHE, 2017e) and the risk of sexual 
transmission is around 2% (Athwal and Prince, 2017), this leads to questions 
as to why testing is not readily available where the service is needed most, 
requiring PWID to attend other services that provide testing, but where, 
because of their route of transmission, they are discriminated against. Thus 
the service structure for testing contributes to the marginalisation of PWID 
and presents barriers to accessing this support. 
 
325 
Hepatitis C treatment was also found to be affected by institutional factors. 
Some service users in the research noted that they had completed hepatitis 
C treatment but it had been unsuccessful, so were waiting for treatment 
again. Although some participants did not know why they were waiting 
(presumably for DAA treatment), one participant (Phil) knew he was waiting 
to meet the criteria for the new DAA treatment. None of the participants 
voiced concerns about having to wait for treatment, seemingly content to 
wait for their turn, but having effective treatment rationed is 
discriminatory and as Charles Gore (CEO of the Hepatitis C Trust) noted, “it 
feels like people with hepatitis C are being picked on”. 
 
Interviews with professionals also highlighted injecting and alcohol use (at 
some levels) as barriers to receiving hepatitis C treatment (as found in the 
literature review). Whilst some professionals discussed concerns about 
engagement with treatment, one participant focused on people who 
receive treatment as being ‘good investments’ suggesting that those who 
consume alcohol with hepatitis C would not be good investments and should 
not receive hepatitis C treatment. This finding reflects the literature 
(Reidpath et al 2005; Paterson et al, 2007), noting that institutional 
stigmatisation occurs when people are not viewed to be worthy of social 
investment, and not complying with management of care (such as 
continuing to drink in this example) is deemed undeserving of investment. 
Contrasting hepatitis C with other diseases, people with asthma who 
continue to smoke, or those with high cholesterol who do not follow the 
recommended diet, are not excluded from receiving treatment, so people 
with hepatitis C should also not be excluded from treatment due to lifestyle 
factors. Treatment decisions should be based on clinical need rather than 
judgements on lifestyle behaviours, and as alcohol and hepatitis C in 
combination can lead to cirrhosis and hepatocarcinoma, there is a clinical 
need to reduce the risk of this disease progression by treating hepatitis C 
in those who continue to drink. This section has shown that discriminating 
against people who drink or inject is a barrier to accessing treatment. 
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Whilst alcohol was found to be a barrier to receiving hepatitis C treatment, 
another finding in relation to alcohol was that those who consumed alcohol 
at dependent or higher-risk levels were discriminated against by friends but 
also from the PWID community. 
 
Many PWID in this research noted that ‘alcohol was worse than injecting’ 
drugs and commented strongly that they were “not a drinker”; an evident 
physical divide was noticed at one organisation with PWID and those who 
consumed alcohol (dependent or higher-risk levels) sitting in separate 
groups. 
 
For participants who had injected but were also drinking 
(dependent/higher-risk levels) the stigma associated with substance use 
(drugs and alcohol) had caused friends to stay away, but those drinking also 
saw stigmatisation and lack of support from peers within the PWID 
community. As discussed previously, hepatitis C and injecting are 
stigmatised, so for those who also drink there is potential for a ‘triple 
stigma’ with greater risk of isolation and increased barriers to receiving 
support. 
 
Furthermore, there was evidence that those who were trying to reduce or 
stop drinking may also become more isolated. Drinking is ubiquitous in the 
UK, so those who are trying to stop drinking may curtail social activities 
where drinking is involved, “can’t go to the pub and watch football without 
drinking. Everyone’s drinking” (Simon). Simon was “thinking of stopping 
Sky [television] as people come around to watch football and bring beer”. 
Harris’s (2010) study in New Zealand and Australia noted that due to stigma 
associated with hepatitis C, people found it hard to reduce their alcohol 
intake without raising suspicion amongst others, sometimes choosing to 
avoid social events rather than lying or disclosing their hepatitis C status. 
Whilst this was not found in this research, it was apparent that not 
drinking/drinking less reduced social activities amongst a population that 
327 
are already at risk of social isolation due to stigma associated with their 
hepatitis C and history of injecting drug use.  
 
7.5 Services 
 
The main finding relating to services, was that there did not appear to be 
a clear hepatitis C pathway from the drug and alcohol services to hepatitis 
C specialist support in secondary care. Many of the service users 
interviewed appeared to have been tested years ago, and have not 
progressed along the cascade of care. Some participants had reached 
specialist care but were deemed not suitable for treatment, others were 
treated but they did not clear the virus. Since then some participants had 
maintained contact with the specialists but did not know their plan of care 
and others had lost touch with the specialists and were trying to get back 
on to the pathway again but faced barriers getting a retest or accessing 
treatment. Furthermore, the interviews with professionals gave further 
insight into the issues, with some participants who commission services 
acknowledging that the pathway was fragmented, with no overall strategy 
of how to improve the pathway for service users. Some of the professionals 
who commission public health services were not aware of details on the 
continuum of the hepatitis C pathway into secondary care, which falls under 
the remit of CCG commissioners, despite PHE (2017d) calling for those 
responsible for commissioning to simplify pathways to increase access and 
uptake of hepatitis C treatment. Professionals working face to face with 
service users, also demonstrated a lack of cohesion and unstreamlined 
pathways, with varying referral routes, differing advice and a lack of 
awareness of other services’ provisions. 
 
Finances were also a barrier to service provision, dictating which services 
could and could not be provided, decisions which were not necessarily in 
the best interest of service users. Service users expressed frustrations at 
having to travel for numerous appointments, yet services which could be 
provided locally at drug and alcohol services were not being provided. 
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Although professionals discussed potential future plans to provide DAA 
treatment in the community at the drug and alcohol services, at the time 
of the interviews crucial hepatitis C testing was not even standard at every 
service. Whilst initiatives were in place to test and link into specialist care, 
these services were not every day, requiring service users to return for 
further appointments. 
 
The recent change in commissioning from the Department of Health to local 
authority saw a reduction in funding, with professionals noting there had 
previously been more money, more resources and more healthcare 
professionals providing hepatitis C support. Therefore services were 
reduced and as one participant said ‘this idea of spinning plates, well 
plates are falling off now, we have to lose some’ (P2). In addition, 
professionals acknowledged that ‘hep C is not getting as much attention as 
it did’ (P2), a point that had not eluded service users, with many aware 
that services were providing less than they previously did. This was 
especially noted for peer support, with service users comparing previous 
peer support to the current situation, “it’s all these cut backs in it, that’s 
the trouble, everything’s being cut” (Susan). Furthermore service users and 
professionals noted the ‘eternal’ retendering of services caused upheaval 
and uncertainty on service provision. 
 
7.6 Conclusion 
 
This chapter has discussed the main research findings, highlighting barriers 
to accessing and providing hepatitis C support. Thus not only have service 
users’ barriers been explored but also the challenges that providers face 
are evident. For service users lack of knowledge, alcohol use and stigma 
were the main barriers to accessing hepatitis C testing, treatment and /or 
management of their disease, but also more informal support, such as from 
friends, family and peers. For professionals working in drug, alcohol and 
hepatitis C services, lack of strategy, financial restrictions and lack of 
cohesion amongst services are challenges to providing services and a 
329 
streamlined pathway between services for service users. Whilst it was 
evident through the professional interviews that efforts were being made 
to improve services, such as bidding for grants and implementing initiatives 
to improve testing and pathways into specialist care, there was also 
evidence of stigmatising attitudes as well as organisational and structural 
discriminatory practices towards PWID with hepatitis C. Consideration of 
stigma and discrimination as well as innovative working is required to 
support service users along the cascade of care to treatment. 
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Chapter 8 Conclusion 
8.1 Introduction 
The aim of this research was to explore experiences and meanings of 
alcohol use for PWID who have hepatitis C and to understand their needs 
and support requirements. More specifically the research set out to explore 
lifetime alcohol use, considering the relationship between injecting drug 
use and alcohol use, and also the impact of a hepatitis C diagnosis on 
alcohol and drug use. For support requirements, the research aimed to 
understand where information about hepatitis C and alcohol was obtained 
and what that information was, as well as exploring PWID perceived service 
needs (alcohol, drug, hepatitis C and general healthcare). 
Research was conducted with both service users (PWID with hepatitis C) and 
professionals (people working face to face with service users and public 
health commissioners) enabling exploration of this topic from different 
perspectives, thus providing the lived and professional experience of 
alcohol use and hepatitis C. 
This chapter concludes the thesis, including; a summary of the main 
research findings, the strengths and limitations of the research, the 
contribution to knowledge and recommendations for the future. 
8.2 Summary of the main findings 
Alcohol consumption varied greatly between participants. A mix of, lower-
risk drinking (as recommended for the general population, who do not have 
liver disease), increasing-risk drinking, higher-risk drinking, alcohol 
dependence and abstinence, was evident amongst the participants at the 
time of the research. However it was also evident that alcohol use (and 
drug use) altered over time for each individual with many factors 
influencing consumption. The relationship between drug and alcohol use 
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varied amongst participants. For some participants alcohol use started 
before drug use, for others alcohol use started or increased when heroin 
use decreased such as when they were on OST, others had a period of 
higher-risk alcohol use many years after heroin use had decreased, some 
decreased alcohol as they decreased heroin and were abstinent from all 
substances, and others decreased their alcohol use over time unconnected 
to their heroin use. Thus alcohol use fluctuated over time and for many was 
irrespective of heroin use. 
 
Considering whether a hepatitis C diagnosis affected alcohol use and drug 
use, findings about drug use were difficult to ascertain. Most participants 
had made changes to their lifestyle before receiving a hepatitis C diagnosis; 
for example those who attended drug services for OST received a hepatitis 
C test at the drug service, indicating lifestyle changes in terms of heroin 
reduction was prior to the test. For others hepatitis C testing occurred 
amongst another event, such as being admitted to hospital with a groin 
abscess, making it unclear which factor led to stopping injecting. 
 
Regarding alcohol use, all participants were aware that alcohol expedites 
hepatitis C, however having the virus was not generally the main factor 
affecting long term alcohol use. For some participants having hepatitis C 
was a partial factor for changes to consumption, but generally different 
factors influenced drinking at different points in a participant’s life, often 
with multiple aspects having an impact on alcohol consumption at any one 
time. Rather than hepatitis C, the main influences on alcohol consumption 
were, partners drinking, drinking to cope, where participants were in their 
recovery process from substance use and needing to reduce or stop alcohol 
for hepatitis C treatment. 
 
All participants (except one, who had not been dependent on heroin) had 
sought help to reduce heroin use and had received OST, yet of those who 
had experienced higher-risk or dependent drinking, many did not seek help 
for their alcohol use. Barriers to accessing support for alcohol were; lack of 
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knowledge that their drinking levels were harmful, not wanting help for 
drinking and previous negative encounters with alcohol services. 
Participants felt they reduced alcohol without support. Whilst some had 
used other substances to reduce their alcohol consumption, many of the 
narratives described using harm reduction techniques (such as reducing the 
strength of alcohol they drank). It was not ascertained where participants 
had learnt these harm reduction techniques, although it is possible this was 
from healthcare professionals but participants did not recognise this as 
support. Healthcare professionals working in alcohol services, use intuition 
to decide if service users can have certain alcohol treatments (such as a 
home detox). Professionals felt this subjective assessment rather than 
adhering to a framework was a facilitator to alcohol treatment for some 
service users. 
 
Alcohol was found to be a barrier to receiving hepatitis C treatment, 
however not all levels of alcohol consumption were an exclusion, and 
messages from healthcare professionals were not always to be abstinent 
from alcohol as per recommendations. Despite other research studies 
showing that higher-risk levels of alcohol does not affect SVR rates, and 
that it is possible to treat people who are alcohol dependent/drinking 
higher-risk amounts, this population were excluded from hepatitis C 
treatment in this study (until they changed their drinking). Thus, some 
service users in this study felt they could not access support for their 
alcohol use and would therefore also be currently unable to have hepatitis 
C treatment. 
 
Messages around alcohol use and hepatitis C were mixed. Some participants 
who drank alcohol felt they had not received advice about drinking with 
hepatitis C, whilst others who were not told to stop drinking felt advice was 
unclear. Furthermore this research found inconsistencies and 
misinterpretation of the terminology used around alcohol. Healthcare 
professionals used informal terms that were not clinically recognised (such 
as ‘heavy’) and service users (and some professionals) misinterpreted terms 
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which led to confusion. ‘Drink’ and ‘stop’ were two such terms, with service 
users expressing they did not drink or had stopped, when they were not 
abstinent from alcohol and health professionals said drinking was an 
exclusion for treatment meaning drinking at higher-risk levels/dependency 
was an exclusion. 
 
Service users deemed ‘Do you drink?’ to mean an addiction to alcohol, with 
discussions showing stigmatising views from PWID to those who do consume 
alcohol at higher-risk levels. Discrimination of those who were 
dependent/consumed alcohol at higher-risk levels increased the risk of 
isolation. Furthermore the ubiquitous nature of alcohol within England, also 
presented dilemmas for those with hepatitis C, with participants avoiding 
social activities in order to avoid drinking alcohol. Thus dependent/higher-
risk drinking and trying to reduce or stop alcohol, were both found to be 
exclusionary, increasing the risk of social isolation for PWID with hepatitis 
C. 
 
As well as alcohol, other barriers to accessing hepatitis C support were 
identified in this research. Furthermore barriers to providing hepatitis C 
support were also identified. Barriers were found at service user, service 
and strategic levels. 
 
For service users, as well as alcohol; lack of knowledge, fear, stigma and 
having other priorities were the main barriers to accessing support for their 
hepatitis C, with each of these factors impacting on the other factors and 
having an accumulative effect. For example, stigma and fear of perceived 
stigma, affected service users’ self-worth, impacting on their willingness to 
use computers or read leaflets about hepatitis C in public areas or to ask 
professionals about hepatitis C, which therefore affected their knowledge. 
Other examples were; not having knowledge on hepatitis C increased fear, 
other priorities impacted on the time and effort service users gave to 
getting support to learn, manage or treat their hepatitis C and conversely 
lack of knowledge led to de-prioritisation of hepatitis C. Many service users 
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did not discuss their hepatitis C with health professionals due to a mistrust 
of healthcare professionals based on previous experiences of discrimination 
or conversely service users trusted healthcare professionals were 
overseeing their hepatitis C care, unquestioning as other aspects of their 
life took priority. Ultimately these barriers prevented service users from 
accessing support and progressing along the care cascade. 
 
Whilst there were many examples of professionals working hard to facilitate 
services for PWID with hepatitis C, such as applying for grants to fund new 
services and working in innovative ways to improve services, there were 
also examples of service level barriers to PWID with hepatitis C receiving 
support. 
 
Commissioners suggested some professionals working with service users 
were reluctant to discuss hepatitis C and service users noted poor 
communication from health professionals as a barrier to support. Language 
and terminology used around hepatitis C and alcohol was difficult to 
understand and there were omissions in information provided. Some 
healthcare professionals provided information but lacked knowledge of 
hepatitis C, giving incorrect information about transmission and symptoms. 
Knowledge on services was also incomplete, with professionals not being 
aware of the services provided by other organisations or sometimes within 
their own organisation. Furthermore some professionals were 
unknowledgeable on other services criteria and the pathways between 
services, resulting in service users not being referred and ultimately not 
progressing along the pathways to hepatitis C (and alcohol) support. 
 
Professionals working with service users also demonstrated a need to 
prioritise care, having many aspects to consider which required 
prioritisation above hepatitis C as were more urgent in nature. Thus other 
priorities were barriers to providing hepatitis C support. 
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Finally, although service users talked of historic experiences of 
discrimination from healthcare professionals there was evidence that some 
professionals, despite choosing to work in drug, alcohol and hepatitis C 
services, do currently hold stigmatising views on PWID with hepatitis C. This 
finding supports service users’ perceptions that healthcare professionals 
judge them, and that stigma still exists, which provides an ongoing barrier 
to PWID accessing services. 
 
As well as the professionals working within services, the services themselves 
also posed barriers to PWID accessing support for hepatitis C. One example 
was that drug and alcohol services did not routinely offer hepatitis C 
testing, a key service for PWID. Whilst finances drove service provision, 
decisions could also be deemed as discriminatory, as testing provisions were 
available in sexual health services despite the small risk of sexual 
transmission compared to the high risk of transmission from sharing 
injecting equipment, posing questions as to why services are not directed 
to where the need is highest. 
 
Regarding finances, the restructuring of public health commissioning from 
NHS to local authority, saw a reduction in funding as well as resources for 
drug services and hepatitis C. Professionals who commissioned drug and 
alcohol services noted they were now required to consider a diverse range 
of issues with hepatitis C not getting ‘as much attention as it did’. The lack 
of funding was noted by service users, who were aware that services were 
being cut back, especially peer initiatives. Furthermore hepatitis C 
pathways were fragmented and there was an overall lack of strategic 
direction for hepatitis C services. 
 
8.3 Strengths and limitations of the research 
 
This research has added to the current body of literature on alcohol use in 
PWID who have hepatitis C. However rather than taking a cross sectional 
approach or considering alcohol use for a short period of time post hepatitis 
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C diagnosis as per other studies, this study has explored lifetime alcohol 
use for participants. Thus it is has been possible to explore the long term 
impact a hepatitis C diagnosis has on alcohol use, furthering understanding 
of the support requirements for PWID with hepatitis C. 
 
As this research was inductive in nature and used methods that encouraged 
participants to ‘talk freely’, it not only explored experiences of alcohol and 
hepatitis C, but also found out a vast amount of information about barriers 
(and to a lesser degree facilitators) to accessing services. This is a strength 
of this research as, 1) the findings are topics important to service users. 
Although PPI was not used as much as initially intended the research did 
enable the lived experience of service users to be heard, 2) this information 
should be of interest to those working (in whatever capacity) in the fields 
of substance use and/or hepatitis C, 3) demonstrates the benefits of using 
a generic qualitative research design which allows a pragmatic choice of 
methods to explore topics. 
 
Another strength of this research is that the topic has been explored from 
three different perspectives, that of service users, professionals working 
with service users and professionals who commission services. This has 
enabled a multilayer consideration of the topics, allowing perspectives to 
be compared and contrasted but has also highlighting how the challenges 
faced by each group interrelate and impact on the other groups. 
 
A great deal of consideration was given to where participants were 
recruited from. This decision was made with the research questions, aims 
and objectives in mind. What did I want to find out and where should I go 
to find this information? As around 90% of hepatitis C cases in England are 
transmitted through sharing injecting drug paraphernalia, it was logical to 
recruit participants for the service user interviews at drug and alcohol 
services. These services provide both drug and alcohol support so if PWID 
with hepatitis C were also seeking help for alcohol I would capture this 
population here and I would also capture PWID with hepatitis C who were 
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not seeking help for alcohol. If I had attended an alcohol service there may 
have been some service users who had hepatitis C but the majority would 
not so it would be difficult to find participants meeting the study inclusion 
criteria. Also I would not have found the diversity in drinking patterns that 
I found in this research, as everyone at alcohol services are seeking help for 
drinking. I also considered recruiting participants from hepatitis C clinics in 
a hospital however I decided against this as did not want to solely recruit 
people who were accessing hospital services. I thought more service users 
meeting the inclusion criteria would be found at the drug and alcohol 
service than a hospital and also the sample would be more heterogenous at 
a drug and alcohol service. By recruiting participants from the organisations 
I attended I found barriers to accessing services for hepatitis C and/or 
alcohol that I would not have found by interviewing those already attending 
hospital services.  
 
The professionals recruited to this research were chosen based on the 
speciality and location within which they worked. For the front line staff 
(vignette) interviews, participants were recruited from drug and alcohol 
services, a community alcohol service, a hospital alcohol service and a 
hepatitis C hospital service (which also provided an outreach hepatitis C 
service at the drug and alcohol services). These services were chosen 
deliberately as they provided services that were mentioned in the service 
user interviews and period of observation. By interviewing staff from these 
services further in-depth information on the emerging themes from the 
service user interviews was obtained along with providing services a chance 
to tell ‘their side of the story’. Commissioners were chosen based on their 
geographical locations, which were the areas the research was conducted 
in. This enabled service provision to be considered from a further angle. 
 
In considering the limitations, firstly it is important to note that the PWID 
who participated in this research were attending services. Thus the 
experiences of PWID who do not engage with drug, alcohol and hepatitis C 
services were not captured in this research, which may have produced 
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different results. As WHO targets on reducing hepatitis C mortality draw 
closer, there is an increasing need to diagnose and treat hepatitis C, 
therefore understanding the experiences and needs of those who do not 
engage with services is vital. Arguably this population are the most 
important, albeit the most difficult, to support. 
 
Furthermore certain groups of professionals were not interviewed for this 
research. Keyworkers at drug and alcohol services, GP’s and CCG 
commissioners may have added further insight into the topics explored. 
Keyworkers may have been able to provide further understanding on 
whether hepatitis C is discussed in appointments with service users and why 
service users appear to be ‘stuck’ and not progressing along the care 
cascade. Permission to interview keyworkers was not granted.  This is a 
limitation, however, this was unfortunately out of my control. CCG 
commissioners’ views on the hepatitis C pathway from community services 
to hepatitis C specialists and treatment in secondary care would have been 
of interest for this research. GP’s were discussed by commissioners in this 
research, as needing to increase hepatitis C testing and referral into 
secondary care, but also it was noted by professionals and services users 
that PWID tend to not to visit their GP. Therefore it would have been of 
interest to explore GP’s perspectives on services for PWID who have 
hepatitis C. Preliminary discussions about the research did occur with one 
GP. The GP was keen to help however after consideration of the necessary 
ethics and site approval required to be able to conduct research at this GP 
practice it was deemed too difficult to proceed. As the approval process 
was likely to be protracted and data collection with the service user 
population had taken longer than foreseen it was decided amongst the 
research team working within the time constraints of a PhD, to cease the 
primary care ‘line of inquiry’. 
 
 
To explore general healthcare needs for PWID was one of the research 
objectives, which was not explored in detail during the course of this 
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research, largely due to the amount of other information captured during 
data collection. Interviews with service users and GPs may have been able 
to provide an insight into this objective. 
 
8.4 Contribution to knowledge 
 
This research has explored experiences of alcohol use and hepatitis C in 
PWID and their support needs, as per the research aims and objectives. 
 
The main contribution to knowledge from this research is that it explores 
the lived experience. As discussed in the conceptual framework little is 
known about the lived experience of alcohol and hepatitis C in PWID as 
historically research on this topic is quantitative in nature. The only 
previous study (Harris, 2010) considering the lived experience of alcohol 
and hepatitis C in PWID was conducted in Australia and New Zealand, so to 
my knowledge this research is the first study exploring this in England. As 
PWID are generally considered to be a marginalised hard to reach 
population, and injecting drug use and hepatitis C are stigmatised topics 
which are not freely discussed, the insights this study provides into the lives 
of people with these experiences is valuable for people working in services 
and policy makers. 
 
Alcohol 
This study has found a wide variation in drinking patterns which adds to the 
current body of knowledge on this topic. Whilst the majority of historic 
research focuses on ‘heavy’ alcohol consumption within the PWID 
population (Arasteh and Des Jarlais, Arasteh et al, Hahn et al, Howe et al, 
cited in Le Marchand et al, 2013) this study has like the NTORS study 
(Gossop et al, 2002) found that not all PWID drink large amounts, with some 
people drinking moderate or lower levels (for general population without 
hepatitis C) and actually some PWID are abstinent. As noted in the 
literature review, abstinence is a ‘little discussed’ point with Gossop, 
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(2013) recommending further research on abstinence in drug users. This 
research adds to this body of knowledge.  
 
The variation in drinking was also evident across the population of people 
taking OST, adding to the debate as to whether PWID swap drugs for alcohol 
once on OST (Stastny and Potter, 1991; Staiger et al, 2012; Henriquez-
Gonzalez and Patton, 2013). The findings show PWID who take OST are not 
a homogeneous group and there is variation in lifestyle behaviours and 
therefore support requirements. 
 
In the conceptual framework, Neale’s (1997) work on rethinking theory in 
homelessness was discussed. Drawing parallels between homelessness and 
PWID with hepatitis C as both are marginalised hard to reach populations, 
Neale’s theoretical assumptions were considered. One assumption was ‘the 
differences between homeless individuals are multiple and are not 
adequately explained by theory’, the findings on variation in alcohol 
consumption in PWID supports this theoretical assumption for the study 
population. 
 
The debate from the historic literature considered whether people 
decreased (McCusker et al 2001; Scognamiglio et al, 2007; Tsui et al 2007; 
O’Leary et al, 2012), increased (Ompad et al, 2002) or there was no change 
(Ompad et al, 2002; Kwiatkowski et al, 2002; Wang et al, 2014; Elliot et al, 
2016), to alcohol consumption following being diagnosed with hepatitis C. 
This research also considered this, again finding variation amongst the 
sample, however the most illuminating point about alcohol consumption 
found in this research was that every service user had drank alcohol at some 
point during the time they had hepatitis C (except two participants who 
were abstinent from alcohol prior to their hepatitis C diagnosis) despite 
recommendations being to be abstinent from alcohol (Royal College of 
General Practitioners (RCGP), 2007; O’Leary et al, 2012; SIGN, 2013; NICE, 
2016b). All of the service users were aware that drinking with hepatitis C 
increased the risk of liver damage. Descriptions of their experiences, 
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reasoning and meanings of alcohol demonstrated social, historical and 
cultural influences on drinking behaviours, such as the role alcohol has in 
socialising within this country and the stigma associated with drinking 
amongst PWID (discussed below). Consideration of these influences may 
mean that people with hepatitis C choose to drink. These findings are 
important for health providers working with people who have hepatitis C to 
consider. Furthermore the findings on language around alcohol will be of 
interest to health providers. The research found that ‘do you drink alcohol?’ 
was intended by the researcher to mean any alcohol, but interpreted by 
the participants to mean dependent on alcohol or drinking large amounts. 
This finding is an important contribution to knowledge, requiring staff to 
check patients/service users understanding when discussing alcohol. 
Furthermore this research also found that staff provided varied advice 
about alcohol and hepatitis C. This was previously found in the literature 
review, however these studies were based in USA (Blixen et al, 2008; Stoller 
et al,2009a) and Australia and New Zealand (Harris, 2010), so this finding 
from England adds to this body of knowledge. 
Grebely et al (2015) suggested people who were drinking should receive 
hepatitis C treatment. However this research found that people could be 
excluded from hepatitis C treatment based on certain levels of alcohol use. 
As there appears to be no scientific rational for this practice this point 
requires consideration by those working to provide services for people with 
hepatitis C, to ensure services are equitable for all. 
Knowledge 
This research found that there was generally a low level of knowledge on 
hepatitis C amongst the service users in this research, despite the fact that 
they were attending services at the time of recruitment. Routes of 
transmission, disease progression, natural history of the disease, testing 
procedures, testing sites and treatment were all areas that people required 
further information on. These findings are important local contributions to 
knowledge. Although similar findings were cited in the literature review 
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(Craine et al, 2004; Khaw, Stobbart and Murtagh, 2007; Grebely et al, 2008; 
Strauss et al, 2008; Swan et al, 2010; Jordan et al, 2013; Harris, McDonald 
and Rhodes, 2014), these findings will be of particular interest to local 
providers aiming to increase testing and treatment and to decrease the risk 
of reinfection. On a wider scale these findings are important as show that 
the challenges to increase knowledge amongst PWID about hepatitis C still 
exist.  
 
From conducting the service user interviews it appeared that hepatitis C 
was not discussed frequently with service users at appointments. Due to 
circumstances out of my control I was unable to interview staff at these 
organisations, however the vignette interviews with (more senior) staff 
from other organisations found gaps in the staffs’ knowledge. Provider 
knowledge is an important factor in increasing testing and treatment (Swan 
et al, 2010; NICE, 2012c; Jordon, 2013). Locally this finding should be of 
interest to providers, with a view to increasing hepatitis C testing and 
treatment. 
 
There is also a need to address agency on the part of service users to take 
responsibility for furthering their own knowledge. The benefits of peer 
support in providing information was witnessed at the hepatitis C support 
group and mentioned in the service user interviews, however these support 
mechanisms could be utilised further. Peer support (especially hepatitis C 
support groups) appeared to be diminishing locally, yet the benefits were 
evident in the literature review and from the findings of this research. 
 
Stigma 
Whilst the stigmatisation of injecting drug use and hepatitis C, is well 
documented in the literature, this research has found that those with 
alcohol dependency or consuming alcohol at higher-risk levels, experience 
further discrimination due to their drinking, including stigmatising 
perceptions from other PWID who do not drink such amounts, increasing the 
risk of isolation. Participants who injected drugs, had hepatitis C and drank 
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experienced a ‘triple stigma’. Those experiencing this compound stigma 
appeared to have poorer outcomes in terms of their physical health but also 
described more experiences of loneliness and social exclusion. 
 
Also exploring the meanings of alcohol use for PWID with hepatitis C, found 
that those trying to reduce or stop drinking avoided social situations where 
alcohol would be consumed. Thus both drinking and not drinking was found 
to be exclusionary and reduce contact with others.  
 
Furthermore, although the literature provides examples of stigma from 
healthcare professionals towards PWID with hepatitis C, this research has 
shown that stigma remains a current issue and is still a barrier to PWID with 
hepatitis C accessing support. 
 
Barriers to alcohol support for PWID were also identified (previous research 
analysed, was based in Ireland and USA), with one such barrier being 
previous negative experiences when accessing support. There appears to be 
a need for non-judgemental support from healthcare professionals towards 
those seeking support for substance (including alcohol) use and hepatitis C. 
 
Services 
The main finding relating to services was that there was not a clear pathway 
from drugs and alcohol services to hospital based hepatitis C specialists. 
Again this finding adds to the contribution of knowledge at a local level, 
but may be transferable and provide insight to other geographical areas of 
England. Providers, policy makers, commissioners, are all required to ‘get 
on-board’ to ensure a less fragmented pathway to specialist hepatitis C 
care. Many of the service users on this study were ‘stuck’, having received 
a positive test result many years before but not progressing along the care 
cascade into specialist hepatitis C care with the ultimate aim to receive 
treatment. If we are to eliminate hepatitis C by 2030 the pathways to 
treatment need to be streamlined.  
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Treatment also needs to be provided in settings other than hospitals. The 
professionals in this research discussed future plans of providing hepatitis 
C treatment in community settings and in particular at the drug and alcohol 
services, however at the time of the interviews this was not in place and 
testing was also not available every day at these services. Some of the 
service users in the research wanted to be retested but were unaware of 
where to go for a test and wanted treatment but did not know how to get 
referred for treatment but were attending the drug and alcohol services for 
appointments. Providing testing and treatment from drug services needs to 
be considered. 
 
Methodological innovation 
The application of the LHC in this research has been appraised at length in 
section 3.6.6 indicating the benefits and limitations of the method. The 
main methodological advances are noted here. Firstly LHC’s have previously 
been used with PWID (who may or may not be on OST); to consider alcohol 
use; to consider substance use; to explore different aspects of hepatitis C; 
and have been used qualitatively, but have not previously been used to 
explore these topics in combination. This research has shown that a LHC 
can be used successfully to explore and understand the experiences of 
alcohol use and hepatitis C in PWID. The main advantage of the calendar 
was the dual approach of being able to hear the person’s account whilst 
visualising the data on the calendar. This was helpful for both the 
researcher and participants to explore the topics in depth. 
 
The vignettes were also innovative as were designed by the researcher 
based on the findings from the service user interviews and observations. 
Although vignettes have previously been used with healthcare staff to 
understand the factors affecting decision making and management of 
health conditions and to see gaps in services, they had not previously been 
used to consider hepatitis C and alcohol services for PWID. The vignettes 
produced interesting and valuable findings. Some of the professionals 
interviewed asked for more information such as clinical results to aid their 
345 
clinical decision making. As these were not available (as were not part of 
the vignette), this benefited the research further as the participant would 
then describe the service they would give under a variety of circumstances. 
 
8.5 Future recommendations 
 
A number of barriers to accessing and providing hepatitis C (and alcohol) 
services have been identified in this research. These barriers require 
consideration to improve services for PWID. Future recommendations for 
service users, service providers and policy makers are noted below.  
 
Service users 
Peer support locally appeared to be diminishing. As shown by this research 
and the corresponding literature, peer support can provide information, 
stop those with hepatitis C feeling isolated and forge links between service 
users and services. More work is required locally to explore why attendance 
is poor and to re-establish successful peer networks. 
 
Service providers 
Service users lacked knowledge on hepatitis C and found messages around 
alcohol use to be unclear. There appears to be a need for healthcare 
professionals to discuss hepatitis C and alcohol with service users, providing 
additional and more frequent information and advice, and using language 
and terms that service users understand. Further research is required to 
establish whether keyworkers working in community drug and alcohol 
services, discuss hepatitis C with service users and to understand what 
information is discussed or reasons why hepatitis C is not discussed. The 
research also found that there were gaps in some professionals’ knowledge 
on hepatitis C, as well as a lack of knowledge on criteria for referral to 
other services and hepatitis C and alcohol pathways. Furthermore, some 
service users in this research were not progressing along the care cascade 
despite regularly attending drug and alcohol services. There appears to be 
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a training need for professionals working in services, which again would be 
of interest to explore with further research. 
 
Stigma from healthcare professionals was another barrier for service users 
accessing services. As historic incidents of discrimination affect current 
health seeking behaviours, there is a need for professionals to be non-
judgemental towards PWID with hepatitis C to build trust in 
professional/service user relationships, and increase access to support. 
Professionals may require training on caring for people with addictions 
(alcohol and PWID), however Paterson et al (2007) note that education and 
understanding is not a guarantee that this will be integrated into clinical 
practice. 
 
Locally commissioners need to work with services and service users to 
establish services and non-fragmented hepatitis C pathways, which enable 
service users to progress from testing to specialist care and achieving SVR.  
 
Policy makers 
Substance use (alcohol at certain levels and injecting drug use) was found 
to be a barrier to accessing hepatitis C treatment. Further published 
research is required to provide evidence on treating those drinking and 
injecting. Furthermore providing hepatitis C treatment to people who use 
substances needs to be supported by policy.  
 
8.6 Final personal reflections 
 
This research has been interesting, enjoyable and challenging and I have 
learnt much throughout the process. Although I have worked in clinical 
research for many years, this PhD has given me the opportunity to design 
my own research and undertake research methods for the first time. The 
period of observation was far more challenging than I initially perceived it 
to be, requiring me to think carefully about many aspects, such as how to 
access the field, how to dress, how much to interact and how to leave the 
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field. This experience provided points of learning which I would consider 
prior to conducting observation again in the future. As a method, the period 
of observation worked well in building rapport with service users and 
enabling me to gain an understanding of issues surrounding hepatitis C and 
addiction, but the observation did not provide service users to be 
interviewed as per the initial study design. Although there were service 
users who enquired about taking part in the interviews, they had 
unfortunately stopped attending the support group by the time I started the 
interviews. I had missed an opportunity. The learning point from this being 
to not delay interviewing and seize the moment if people are asking to take 
part as they might not be available another time. In the future I would not 
set up participant recruitment in this way. 
 
I enjoyed designing the calendars and the vignettes used in the interviews, 
as well as reading about how other researchers had developed and used 
these methods. On reflection the calendars and vignettes worked well but 
if I used these methods again I would consider involving participants in the 
design by either doing more pilot interviews or focus groups to aid 
development as there were points that could have been improved. For the 
life history calendar the historical events down the side were not used and 
for the vignettes one professional appeared uncomfortable, changing what 
he was saying on numerous occasions. There is further research to be done 
here on asking participants how they experienced using vignettes.  
 
Ultimately regarding data collection I feel privileged to have been able to 
spend time with participants, especially the service users who spoke openly 
about their experiences and feelings despite the topics of discussion being 
personal, emotional, and highly stigmatised. I am also grateful for the 
services who allowed me to conduct the research in their organisations. 
There were particular members of staff in the organisations who were very 
supportive, assisting with finding participants and finding space for me to 
conduct interviews. This is one aspect of the research that I am proud of as 
348 
I worked very hard to build the collaborations with organisations and the 
relationships with staff.  
 
Initially I planned a PPI approach, working in collaboration with service 
users on every aspect of the research. Unfortunately, this was not possible 
however in hindsight this seems ambitious for a PhD project when the group 
was not already set up and the relationship between the university 
researcher and group was not established, especially considering the short 
timeframe for PhD completion. PPI would have required frequent meetings, 
training, consideration of boundaries and confidentiality between service 
user researchers and service users participating in the research, gaining 
access to organisations and so on. However, I would like to undertake 
further PPI work in the future as believe it is important to have 
patients/public/service users involved in research. 
 
Although organisations were willing to support this research there are 
points of learning that I would consider when choosing organisations for 
future research. In hindsight I should have spent more time finding out 
about the services prior to commencing data collection. An example being 
that I was trying to conduct follow up interviews at a service with a ‘drop 
in’ not appointment system, so I was unable to know when participants 
would be visiting the service again. The other service I attended had 
scheduled appointments so I could see when participants would be 
returning to the service and then see them for the research at the same 
time. Another point for future research is that I would also spend more time 
checking services understood the requirements of the research. For this 
research despite meetings and explanations of the research requirements, 
one service misunderstood how long the interviews would take and booked 
participants in slots that did not give enough time to complete the 
interviews using the correct technique. 
 
As well as data collection this research has given me the opportunity to 
learn other research skills such as transcribing, data management using 
349 
Nvivo and data analysis. Also during the course of this PhD I have had the 
opportunity to get involved in many aspects of academia, including 
attending conferences, presenting at conferences, giving lectures to 
undergraduates, marking assignments and supervising students. I 
particularly benefitted from presenting a poster at the INHSU (The 
International Network on Hepatitis in Substance Users) conference in Oslo 
in 2016, as had the opportunity to meet experts in the field, authors whose 
research I had read and have referenced throughout this thesis.  
 
Lastly, this research has been challenging throughout, requiring personal 
qualities of perseverance and resilience to reach completion. The 
motivation behind completing this research was the desire to understand 
and improve situations for people living with hepatitis C which I intend to 
continue exploring in the future.  
 
8.7 And finally… 
 
Hepatitis C disproportionately affects populations who are marginalised and 
have poorer access to healthcare and health outcomes. Despite hepatitis C 
being preventable and curable, millions of people around the world are 
living with the virus. In the UK thousands of people have chronic hepatitis 
C. Yearly surveys of PWID, suggest that only around half are aware of their 
hepatitis C antibody positive status; a figure which has remained stable over 
the last 6 years. And historically only around 3% of people with chronic 
hepatitis C accessed hepatitis C treatment. Whilst the introduction of DAA 
medications has seen an increase in the numbers treated over the last few 
years, the fact remains that many people are undiagnosed and therefore 
untreated. However even if people are diagnosed, they may not go on to 
access treatment.  
 
The WHO has set targets to eliminate hepatitis C (and B) by 2030. If the 
targets are to be met and hepatitis C eliminated, concerted efforts are 
required to increase diagnosis and treatment. Understanding barriers to 
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accessing and providing, testing and treatment is vital to increase uptake, 
along with understanding the barriers that prevent those already tested 
from linking into hepatitis C specialist care. In the words of Public Health 
England: 
 
 
“much work has been done, but there is still much to do”. 
 
(PHE, 2018a p.5) 
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??????????????????????????????????? ???????????????? ?????????????????????
???????????? ??? ???????? ???? ???? ?????????? ?? ?????? ???????? ???? ???????????
???????????????????????? ???????????? ?????????????????????????????????. 
???????????????????????????????????????????????????????????????????????????????? ???????????
Service users from your organisation are being invited to take part in a research study. You are being 
invited to take the role of a gatekeeper for part of this research. Before you decide, it is important 
that you understand why the research is being done and what it involves. Please take time to read 
the following information. If there is anything that is not clear or if you would like more information, 
please ask. Feel free to talk to other people about the study, such as colleagues, service users and 
friends. 
1. ?????????????????????????????????
We are interested in talking to people in drug treatment/support services who have injected drugs 
and have been diagnosed with hepatitis C at some point in their lives. The overall study aim is to 
increase understanding of injecting drug users’ health care needs with view to improving services. 
We would like to understand more about alcohol consumption in injecting drug users. We would also 
like to understand where information about alcohol is obtained, what this information is and how 
this information is perceived by people who inject drugs or have done in the past.? 
2. ????? ??????????????????????
The research will be in two steps: 
1) Period of familiarisation
2) Interviews
Period of familiarisation 
The researcher who is from John Moores University, will spend time at the drug treatment/support 
centre, where the participants will be recruited from. The purpose of this being for service users to 
spend time with the researcher outside of the interview, with a view to establishing rapport and trust, 
to facilitate openness in the interview.  
At a suitable meeting the researcher will introduce herself and explain the research. The researcher 
will then continue to attend forums that are already in place at the centre, with a view to building 
relationships with service users. This will enable people to ask any questions they may have about 
the research which may crop up over a period of time.  
The researcher will record any topic related observations at the first appropriate opportunity. These 
observations will not include any personal or identifiable information, just general observations; 
building an understanding of context. Throughout this time, service users will be able to approach 
the researcher to volunteer to be involved in the interviews.  
Service users and staff are able to opt-out of this process at any time by informing the gatekeeper or 
the researcher. This decision will be accepted without question. The option to opt-out will be 
explained by the researcher at the initial meeting and on an ongoing basis when meeting new people 
(staff and service users). 
??????????????? ?????????????????
??????????????????????????????
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??????????????????????????????????? ???????????????? ?????????????????????
Interviews 
After the period of familiarisation, there will be one-to-one interviews with service users who meet 
the study’s inclusion criteria. Service users will be required to sign a consent form to take part in the 
interviews.  (Please read the service user participant information sheet for further information). 
3.???????????????????????????????????
The gatekeepers role is to: 
1) be aware the researcher will be undertaking a period of familiarisation and documenting general
observations (not personal or identifiable) 
2) inform the researcher if a service user or staff member wishes to opt-out of the period of
familiarisation 
3) sign a consent form acknowledging the period of familiarisation. (Please note gatekeepers are
signing to acknowledge the researcher is conducting a period of familiarisation within their centre 
and are not signing to consent for service users and staff to participate. Staff and service users are 
able to opt-out if they require.  Also gatekeepers consent is not for the interview stage as service 
users themselves will be required to give consent for participation in the interviews). 
4.??????????????????????????????????????????????
You have been chosen to act as a gatekeeper as you have been identified by the centre/service, to be 
the most suitable person to fulfil this roll.  
5.????? ??????????? ??????????????????????????????
All observations collected during the research will be anonymised (people will not be able to be 
individually identified). Information will be stored securely in The Centre for Public Health at 
Liverpool John Moores University. Audio files will be stored in a password protected computer and 
paper copies will be stored in a locked filing cabinet, in a locked room. Only the researcher and 
supervisor will have access to the information.   
It is expected that results of the study will be published in academic journals, reports and/or results 
presented at conferences but individual details will not be mentioned and organisations will not be 
named without prior consent from the organisation. 
????? ?????? ???? ????????? ???????? ????????? ????? ??????? ????????? ??????? ?????????? ???????? ????
???????????????????????????????????????
????????????????????????????????
If you need further information or are worried about any aspect of the study, please do not hesitate 
to contact Jane Evely, the researcher working on the project. 
???????????????????????????????Jane Evely?
j.e.evely@2014.ljmu.ac.uk 
0151 231 4441 
?????????????????????????????????????????Dr Gordon Hay?
G.Hay@ljmu.ac.uk 
0151 231 4385 
?????????????????????????????????????: Dr Conan Leavey 
C.Leavey@ljmu.ac.uk 
0151 231 4544 
???????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????? 
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??????????????????????????????????? ???????????????? ????????????
???????????? ??? ???????? ???? ???? ?????????? ?? ?????? ???????? ???? ???????????
???????????????????????? ???????????? ?????????????????????????????????. 
???????????????????????????????????????????????????????????????????????????????? ???????????
Please take time to read the following information. Please ask if there is anything that is not clear or 
if you would like more information.  Feel free to talk to other people about this study, such as friends, 
family, colleagues or your support worker. This is a voluntary project, and when we have discussed 
the study, if you would prefer not to take part, your decision will be accepted without question and 
will not affect the support you receive. If you decide to take part you can withdraw from the study at 
any stage. 
?? ?????????????????????????????????
The overall study aim is to increase understanding of injecting drug users’ health care needs with 
view to improving services. We would like to understand more about hepatitis C and alcohol 
consumption in injecting drug users. We would also like to understand where information about 
alcohol is obtained, what this information is and how this information is perceived by people who 
inject drugs or have done in the past. 
?? ???????????????????????????????
The research is in two parts. The first stage is a period of familiarisation and the second stage is an 
interview. This leaflet is about stage one of the study only. A separate information leaflet and a 
consent form to sign, is available for a small number of people (around 10) who take part in the 
interviews.   
Period of familiarisation 
The researcher, who is from Liverpool John Moores University, will spend time at the drug 
treatment/support centres. The purpose being for service users to spend time with the researcher, 
to getting to know each other prior to the interview, with a view to facilitate openness within the 
interview.  The researcher will also be able to learn about the service provided by the centre.  
People will be able to ask any questions they may have about the research which may crop up over a 
period of time.  
After each day the researcher will take notes about the observations she has made. These notes will 
not include any personal or identifiable information. 
Service users and staff can opt-out of this process at any time by informing staff or the researcher. 
This decision will be accepted without question.  
?? ???????????????????????
No. It is up to you to decide whether or not to take part. You are free to opt-out at any time without 
giving a reason. A decision to withdraw will not affect your rights or any future treatment/service you 
receive. 
4. ????? ?????????????? ?????????????????
??????????????? ?????????????????
??????????????????????????????
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??????????????????????????????????? ???????????????? ????????????
If you decide to take part, you do not need to do anything different to usual. The researcher will just 
be in the centre and may attend meetings that you attend and will record events that occur through 
the day.  
?? ????? ????????????????????????????????????????????????
Yes. All information collected during the research will be anonymised (you will not be able to be 
individually identified) and remain confidential (nobody other than researcher and supervisor will see 
your information). Information about you will not be disclosed to anyone, however if you disclose to 
the researcher that you intend to seriously harm yourself (e.g. suicide) or others (e.g. serious assault), 
this information will need to be shared with support staff at the drug and alcohol service you attend.    
Information collected will be stored securely in The Centre for Public Health at Liverpool John 
Moores University. Audio files will be stored in a password protected computer and paper copies will 
be stored in a locked filing cabinet, in a locked room. Only the researcher and supervisor will have 
access to the information.   
It is expected that results of the study will be published in academic journals, reports and/or results 
presented at conferences but your individual details will not be mentioned.  
????? ?????? ???? ????????? ???????? ????????? ????? ??????? ????????? ??????? ?????????? ???????? ????
???????????????????????????????????????
????????????????????????????????
If you need further information or are worried about any aspect of the study, please do not hesitate 
to contact Jane Evely, the researcher working on the project. 
???????????????????????????????Jane Evely?
j.e.evely@2014.ljmu.ac.uk 
0151 231 4441 
?????????????????????????????????????????Dr Gordon Hay?
G.Hay@ljmu.ac.uk 
0151 231 4385 
?????????????????????????????????????: Dr Conan Leavey 
C.Leavey@ljmu.ac.uk 
0151 231 4544 
???????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????? 
402
Participant Information Sheet – Service Users  Version 1.0, 26th June 2014 
LJMU REC No.:   14/EHC/050      
??????????????????????????????????? ???????????????? ????????????
???????????? ??? ???????? ???? ???? ?????????? ?? ?????? ???????? ???? ???????????
???????????????????????? ???????????? ?????????????????????????????????. 
???????????????????????????????????????????????????????????????????????????????? ???????????
You are being invited to take part in a research study. Before you decide, it is important that you 
understand why the research is being done and what it involves. Please take time to read the 
following information. Please ask if there is anything that is not clear or if you would like more 
information.  Feel free to talk to other people about taking part in this study, such as friends, family 
or your support worker. This is a voluntary project, and when we have discussed the study, if you 
would prefer not to take part, your decision will be accepted without question and will not affect the 
support you receive. If you decide to take part you can withdraw from the study at any stage. 
?? ?????????????????????????????????
We are interested in talking to people in drug treatment/support services who have injected drugs 
and have been diagnosed with hepatitis C at some point in their lives. The overall study aim is to 
increase understanding of injecting drug users’ health care needs with view to improving services. 
We would like to understand more about alcohol consumption in injecting drug users. We would also 
like to understand where information about alcohol is obtained, what this information is and how 
this information is perceived by people who inject drugs or have done in the past. 
?? ???????????????????????
We are interested in talking to people in drug treatment/support services who have injected drugs 
and have been diagnosed with hepatitis C at some point in their lives. This could mean that you 
currently have hepatitis C or that you previously had hepatitis C which has now gone (either through 
naturally clearing or treatment). We would like to talk about alcohol consumption, so would 
therefore like to speak to people who drink alcohol now or have drank alcohol in the past. We are 
aiming to speak to around 30 people in total.    
?? ???????????????????????
No. It is up to you to decide whether or not to take part. If you do decide to take part, you will be 
given this information sheet to keep and asked to sign a consent form. You are still free to withdraw 
from the study at any time without giving a reason. A decision to withdraw will not affect your rights 
or any future treatment/service you receive. 
4. ????? ?????????????? ?????????????????
If you decide to take part in this study it will not affect your usual support in any way. The research 
will involve a one-to-one interview with a researcher who is from Liverpool John Moores University. 
The interview will explore your alcohol and substance use over your lifetime. You may have the 
opportunity to take part in follow up interviews to explore your comments further (there will 
probably be no more than 3 interviews in total). 
The interviews will be audio recorded and later transcribed verbatim (typed up, word for word). 
??????????????? ?????????????????
??????????????????????????????
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??????????????????????????????????? ???????????????? ????????????
?? ????????????????????????????????????????
Benefits  
It is unlikely that the study will be of direct benefit to you immediately, however the information will 
be shared with teams responsible for drug and alcohol services and hepatitis C services in Merseyside, 
which may lead to improvements in services in the future.  
All study participants?will be given a £10 voucher for each interview they attend???
Risks 
During the interview, we will discuss your history of alcohol and substance use. You do not have to 
talk about any topic, or answer any question, that you do not want to. After the interview you will 
still have the chance to ask any questions you may have about the research. You can withdraw from 
the study at any point. If you wish to discuss personal issues raised by the research, we recommend 
that you talk to your support worker, for ongoing support. Taking part in the study will not affect 
your current treatment/support. 
?? ????? ????????????????????????????????????????????????
Yes. All personal information collected during the research will be anonymised (you will not be able 
to be individually identified) and remain confidential (nobody other than researcher and supervisor 
will see your information). Information about you will not be disclosed to anyone, however if you 
disclose to the researcher that you intend to seriously harm yourself (e.g. suicide) or others (e.g. 
serious assault), this information will need to be shared with support staff at the drug and alcohol 
service you attend.     
Information will be stored securely in The Centre for Public Health at Liverpool John Moores 
University. Audio files will be stored in a password protected computer and paper copies will be 
stored in a locked filing cabinet, in a locked room. Only the researcher and supervisor will have 
access to your information.   
It is expected that results of the study will be published in academic journals, reports and/or results 
presented at conferences but your individual details will not be mentioned.  
????? ?????? ???? ????????? ???????? ????????? ????? ??????? ????????? ??????? ?????????? (14/EHC/050, 
30/07/2014)?
????????????????????????????????
If you need further information or are worried about any aspect of the study, please do not hesitate 
to contact Jane Evely, the researcher working on the project. 
???????????????????????????????Jane Evely?
j.e.evely@2014.ljmu.ac.uk 
0151 231 4441 
?????????????????????????????????????????Dr Gordon Hay?
G.Hay@ljmu.ac.uk 
0151 231 4385 
?????????????????????????????????????: Dr Conan Leavey 
C.Leavey@ljmu.ac.uk 
0151 231 4544 
???????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????? 
404
Participant Information Sheet – Staff  Version 1.0, 18th October 2015 
LJMU REC No.:   14/EHC/050      
??????????????????????????????????? ???????????????? ?????? ????
???????????? ??? ???????? ???? ???? ?????????? ?? ?????? ???????? ???? ???????????
???????????????????????? ???????????? ?????????????????????????????????. 
???????????????????????????????????????????????????????????????????????????????? ???????????
You are being invited to take part in a research study. Before you decide, it is important that you 
understand why the research is being done and what it involves. Please take time to read the 
following information. Please ask if there is anything that is not clear or if you would like more 
information.  Feel free to talk to other people about taking part in this study, such as friends, family 
or your colleagues. This is a voluntary project, and when we have discussed the study, if you would 
prefer not to take part, your decision will be accepted without question. If you decide to take part 
you can withdraw from the study at any stage. 
?? ?????????????????????????????????
The overall study aim is to increase understanding of injecting drug users’ health care needs with 
view to improving services. More specifically we would like to understand about alcohol 
consumption and hepatitis C in injecting drug users and their health care needs surrounding this.     
?? ???????????????????????
We are interested in talking to people who work in drug, alcohol and liver services, about the 
services provided to injecting drug users with hepatitis C. We have already interviewed around 20 
people attending drug services who have injected drugs and have been diagnosed with hepatitis C at 
some point in their lives. We would now like to talk to staff who work in these services. We are 
aiming to speak to around 12 staff in total. 
?? ???????????????????????
No. It is up to you to decide whether or not to take part. If you do decide to take part, you will be 
given this information sheet to keep and asked to sign a consent form. You are still free to withdraw 
from the study at any time without giving a reason.  
?? ????? ?????????????? ?????????????????
If you decide to take part, the research will involve a one-to-one interview with a researcher who is 
from Liverpool John Moores University. The interview will take approximately 20 minutes, depending 
on your answers.  
The interviews will be audio recorded and later transcribed verbatim (typed up, word for word). 
??????????????? ????????????????
?????????????????????????????
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??????????????????????????????????? ???????????????? ?????? ????
?? ????????????????????????????????????????
Benefits  
On completion of the study, overall results will be shared with teams responsible for drug and 
alcohol services and hepatitis C services in Merseyside, which may lead to improvements in services 
in the future.  
Risks 
During the interview we will discuss the service where you work. (Please see section 6 below 
regarding confidentiality). 
You do not have to talk about any topic, or answer any question, that you do not want to. After the 
interview you will still have the chance to ask any questions you may have about the research and 
you can withdraw from the study at any point.   
?? ????? ????????????????????????????????????????????????
Yes. All information collected during the research will be anonymised (you will not be able to be 
individually identified) and remain confidential (nobody other than researcher and supervisor will see 
your information). Information will be stored securely in The Centre for Public Health at Liverpool 
John Moores University. Audio files will be stored in a password protected computer and paper 
copies will be stored in a locked filing cabinet, in a locked room. Only the researcher and supervisor 
will have access to your information.   
It is expected that results of the study will be published in academic journals, reports and/or results 
presented at conferences but your individual details will not be mentioned and the organisation 
where you work will not be named. It is important to note however, that although your organisation 
will not be named, it may be possible to identify the organisation due to the small number of 
organisations providing drug, alcohol and hepatitis C services in Merseyside.  
????? ?????? ???? ????????? ???????? ????????? ????? ??????? ????????? ??????? ?????????? (14/EHC/050, 
30/07/2014)?
????????????????????????????????
If you need further information or are worried about any aspect of the study, please do not hesitate 
to contact Jane Evely, the researcher working on the project. 
???????????????????????????????Jane Evely?
j.e.evely@2014.ljmu.ac.uk 
0151 231 4441 
?????????????????????????????????????????Dr Gordon Hay?
G.Hay@ljmu.ac.uk 
0151 231 4385 
?????????????????????????????????????: Dr Conan Leavey 
C.Leavey@ljmu.ac.uk 
0151 231 4544 
???????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????? 
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Consent Forms vs 4 May 2012 Page 1 of 1
Experiences of alcohol use and hepatitis C among current and recovering 
injecting drug users in Merseyside: Implications for treatment services. 
Name of Researcher and School/Faculty: Jane Evely, Faculty of Education, Health & Community 
1. I confirm that I have read and understand the gatekeeper information sheet dated 28th
July 2014 (version 1) for the above study.
2. I have had the opportunity to consider the information, ask questions and have had
these answered satisfactorily
3. I understand that the study involves a period of familiarisation where the researcher
will attend forums at the service/centre and will record general observations
4. I understand that service users and staff can opt-out and I agree to inform the
researcher if I know a person wishes to opt-out
5. I agree to act as gatekeeper in the study
………………………………..  .……………………………..     ………………………………………… 
Name of Gatekeeper Date Signature 
………………………………….. …….…………………………  ………………………………………
Name of Researcher Date Signature 
…………………………………….. ………………………………..   ……………………………………….. 
Name of Person taking consent Date Signature 
(if different from researcher) 
Note: When completed 1 copy for participant and 1 copy for researcher 
LIVERPOOL JOHN MOORES UNIVERSITY 
CONSENT FORM 
Appendix 3 Consent Forms
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Consent Forms vs 4 May 2012 Page 1 of 1 
Experiences of alcohol use and hepatitis C among current and recovering 
injecting drug users in Merseyside: Implications for treatment services. 
Name of Researcher and School/Faculty: Jane Evely, Faculty of Education, Health & Community 
1. I confirm that I have read and understand the information sheet dated 26th June 2014
(version 1) for the above study.
2. I have had the opportunity to consider the information, ask questions and have had
these answered satisfactorily
3. I understand that my participation is voluntary and that I am free to withdraw at any
time, without giving a reason and that this will not affect my legal rights
4. I understand that any personal information collected during the study will be
anonymised and remain confidential
5. I understand that the study involves  interview(s) which  will be audio recorded
6. I understand that parts of our conversation may be used verbatim in future reports,
publications or presentations but that such quotes will be anonymised
7. I am happy to be contacted by the researcher for follow up interviews for the study
8. I agree to take part in the study
………………………………..  .……………………………..         ………………………………………… 
Name of Participant Date Signature 
………………………………….. …….…………………………    ……………………………………… 
Name of Researcher Date Signature 
…………………………………….. ………………………………..     ……………………………………….. 
Name of Person taking consent Date Signature 
(if different from researcher) 
Note: When completed 1 copy for participant and 1 copy for researcher 
LIVERPOOL JOHN MOORES UNIVERSITY 
CONSENT FORM 
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Consent Forms vs 4 May 2012 Page 1 of 1 
Experiences of alcohol use and hepatitis C among current and recovering 
injecting drug users in Merseyside: Implications for treatment services. 
Name of Researcher and School/Faculty: Jane Evely, Faculty of Education, Health & Community 
1. I confirm that I have read and understand the information sheet dated 18th October
2015 (version 1) for the above study.
2. I have had the opportunity to consider the information, ask questions and have had
these answered satisfactorily
3. I understand that my participation is voluntary and that I am free to withdraw at any
time, without giving a reason
4. I understand that any personal information collected during the study will be
anonymised and remain confidential
5. I understand that the study involves an interview which will be audio recorded
6. I understand that parts of our conversation may be used verbatim in future reports,
publications or presentations but that such quotes will be anonymised
7. I agree to take part in the study
………………………………..  .……………………………..         ………………………………………… 
Name of Participant Date Signature 
………………………………….. …….…………………………    ……………………………………… 
Name of Researcher Date Signature 
…………………………………….. ………………………………..     ……………………………………….. 
Name of Person taking consent Date Signature 
(if different from researcher) 
Note: When completed 1 copy for participant and 1 copy for researcher 
LIVERPOOL JOHN MOORES UNIVERSITY 
CONSENT FORM 
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Appendix 5 Calendar figures 
Figure 6 The LHC with participant’s age and personal events added 
422
Figure 7 The LHC with lines drawn to depict drug or alcohol use 
423
Figure 8 Example of a participant’s timeline 
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Appendix 6 Professional Interviews figures
Figure 9 Issues identified for 'Kate' and related services
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Figure 10 Referral pathways for alcohol treatment for 'Rob' depending 
on which drug service he attended
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Appendix 7 
Table 2 Respondents’ gender, age group and respondent type 
Pseudonym Gender Age Group Respondent Type 
Andy M - Observed 
Beth F 45 - 54 Interviewee 
Brenda F 45 - 54 Interviewee 
Dan M 45 - 54 Interviewee 
Ed M 45 - 54 Interviewee 
Gav M 35 - 44 Interviewee 
Jack M 45 - 54 Interviewee 
Jenny F > 54 Interviewee 
Joe M 45 - 54 Interviewee 
John M - Observed 
Kath F 45 - 54 Observed / Interviewee 
Kev M 35 - 44 Interviewee 
Mark M 45 - 54 Interviewee 
Neil M 45 - 54 Interviewee 
Pete M 35 - 44 Interviewee 
Phil M 45 - 54 Interviewee 
Rach F 35 - 44 Interviewee 
Rich M 35 - 44 Interviewee 
Sadie F 35 - 44 Interviewee 
Seb M - Observed 
Sharon F 45 - 54 Interviewee 
Simon M - Observed 
Steve M 25 - 34 Interviewee 
Susan F 45 - 54 Interviewee 
Tom M 45 - 54 Interviewee 
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Table 3 Professionals’ participant numbers 
Participant Place of work 
P1 Commissioner 
P2 Commissioner 
P3 Commissioner 
P4 Commissioner 
P5 Commissioner 
P6 Alcohol service 
P7 Hepatitis C service 
P8 Hepatitis C service 
P9 Hepatitis C service 
P10 Alcohol service 
P11 Drug and alcohol service 
P12 Drug and alcohol service 
